
<html lang="en"     class="pb-page"  data-request-id="04c6f3d2-b8f6-4737-b96d-66e19cad08d0"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2015.58.issue-11;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.5b00217;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist" /></meta><meta name="dc.Creator" content="Yu  Yoshida" /></meta><meta name="dc.Creator" content="Yoshimitsu  Naoe" /></meta><meta name="dc.Creator" content="Taro  Terauchi" /></meta><meta name="dc.Creator" content="Fumihiro  Ozaki" /></meta><meta name="dc.Creator" content="Takashi  Doko" /></meta><meta name="dc.Creator" content="Ayumi  Takemura" /></meta><meta name="dc.Creator" content="Toshiaki  Tanaka" /></meta><meta name="dc.Creator" content="Keiichi  Sorimachi" /></meta><meta name="dc.Creator" content="Carsten T.  Beuckmann" /></meta><meta name="dc.Creator" content="Michiyuki  Suzuki" /></meta><meta name="dc.Creator" content="Takashi  Ueno" /></meta><meta name="dc.Creator" content="Shunsuke  Ozaki" /></meta><meta name="dc.Creator" content="Masahiro  Yonaga" /></meta><meta name="dc.Description" content="The orexin/hypocretin receptors are a family of G protein-coupled receptors and consist of orexin-1 (OX1) and orexin-2 (OX2) receptor subtypes. Orexin receptors are expressed throughout the central..." /></meta><meta name="Description" content="The orexin/hypocretin receptors are a family of G protein-coupled receptors and consist of orexin-1 (OX1) and orexin-2 (OX2) receptor subtypes. Orexin receptors are expressed throughout the central..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 22, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b00217" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00217" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b00217" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00217" /></link>
        
    
    

<title>Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b00217" /></meta><meta property="og:title" content="Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0016.jpeg" /></meta><meta property="og:description" content="The orexin/hypocretin receptors are a family of G protein-coupled receptors and consist of orexin-1 (OX1) and orexin-2 (OX2) receptor subtypes. Orexin receptors are expressed throughout the central nervous system and are involved in the regulation of the sleep/wake cycle. Because modulation of these receptors constitutes a promising target for novel treatments of disorders associated with the control of sleep and wakefulness, such as insomnia, the development of orexin receptor antagonists has emerged as an important focus in drug discovery research. Here, we report the design, synthesis, characterization, and structure–activity relationships (SARs) of novel orexin receptor antagonists. Various modifications made to the core structure of a previously developed compound (-)-5, the lead molecule, resulted in compounds with improved chemical and pharmacological profiles. The investigation afforded a potential therapeutic agent, (1R,2S)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006), an orally active, potent orexin antagonist. The efficacy was demonstrated in mice in an in vivo study by using sleep parameter measurements." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b00217"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00217">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b00217&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b00217&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b00217&amp;href=/doi/10.1021/acs.jmedchem.5b00217" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 4648-4664</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b00184" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b00220" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-<i>N</i>-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yu++Yoshida">Yu Yoshida</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yoshimitsu++Naoe">Yoshimitsu Naoe</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Taro++Terauchi">Taro Terauchi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fumihiro++Ozaki">Fumihiro Ozaki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Takashi++Doko">Takashi Doko</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ayumi++Takemura">Ayumi Takemura</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Toshiaki++Tanaka">Toshiaki Tanaka</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Keiichi++Sorimachi">Keiichi Sorimachi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carsten+T.++Beuckmann">Carsten T. Beuckmann</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michiyuki++Suzuki">Michiyuki Suzuki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Takashi++Ueno">Takashi Ueno</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shunsuke++Ozaki">Shunsuke Ozaki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Masahiro++Yonaga">Masahiro Yonaga</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Medicinal Chemistry, <sup>‡</sup>Biopharmacology, <sup>§</sup>Physical Chemistry, and <sup>∥</sup>Drug Metabolism and Pharmacokinetics, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan</span></div><div class="corresp-info"><strong>*</strong>Phone: +81 (0)29 847 7395. Fax: +81 (0)29 847 4952. E-mail: <a href="/cdn-cgi/l/email-protection#5f266e6e7226302c37363b3e1f37373c713a362c3e36713c3071352f"><span class="__cf_email__" data-cfemail="a0d991918dd9cfd3c8c9c4c1e0c8c8c38ec5c9d3c1c98ec3cf8ecad0">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00217&amp;href=/doi/10.1021%2Facs.jmedchem.5b00217" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 4648–4664</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 8, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 February 2015</li><li><span class="item_label"><b>Published</b> online</span>22 May 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 June 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b00217" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00217</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4648%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYu%2BYoshida%252C%2BYoshimitsu%2BNaoe%252C%2BTaro%2BTerauchi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D11%26contentID%3Dacs.jmedchem.5b00217%26title%3DDiscovery%2Bof%2B%25281R%252C2S%2529-2-%257B%255B%25282%252C4-Dimethylpyrimidin-5-yl%2529oxy%255Dmethyl%257D-2-%25283-fluorophenyl%2529-N-%25285-fluoropyridin-2-yl%2529cyclopropanecarboxamide%2B%2528E2006%2529%253A%2BA%2BPotent%2Band%2BEfficacious%2BOral%2BOrexin%2BReceptor%2BAntagonist%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4664%26publicationDate%3DJune%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b00217"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3294</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">43</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b00217" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yu&quot;,&quot;last_name&quot;:&quot;Yoshida&quot;},{&quot;first_name&quot;:&quot;Yoshimitsu&quot;,&quot;last_name&quot;:&quot;Naoe&quot;},{&quot;first_name&quot;:&quot;Taro&quot;,&quot;last_name&quot;:&quot;Terauchi&quot;},{&quot;first_name&quot;:&quot;Fumihiro&quot;,&quot;last_name&quot;:&quot;Ozaki&quot;},{&quot;first_name&quot;:&quot;Takashi&quot;,&quot;last_name&quot;:&quot;Doko&quot;},{&quot;first_name&quot;:&quot;Ayumi&quot;,&quot;last_name&quot;:&quot;Takemura&quot;},{&quot;first_name&quot;:&quot;Toshiaki&quot;,&quot;last_name&quot;:&quot;Tanaka&quot;},{&quot;first_name&quot;:&quot;Keiichi&quot;,&quot;last_name&quot;:&quot;Sorimachi&quot;},{&quot;first_name&quot;:&quot;Carsten&quot;,&quot;last_name&quot;:&quot;T. Beuckmann&quot;},{&quot;first_name&quot;:&quot;Michiyuki&quot;,&quot;last_name&quot;:&quot;Suzuki&quot;},{&quot;first_name&quot;:&quot;Takashi&quot;,&quot;last_name&quot;:&quot;Ueno&quot;},{&quot;first_name&quot;:&quot;Shunsuke&quot;,&quot;last_name&quot;:&quot;Ozaki&quot;},{&quot;first_name&quot;:&quot;Masahiro&quot;,&quot;last_name&quot;:&quot;Yonaga&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;4648-4664&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b00217&quot;},&quot;abstract&quot;:&quot;The orexin/hypocretin receptors are a family of G protein-coupled receptors and consist of orexin-1 (OX1) and orexin-2 (OX2) receptor subtypes. Orexin receptors are expressed throughout the central nervous system and are involved in the regulation of the sleep/wake cycle. Because modulation of these receptors constitutes a promising target for novel treatments of disorders associated with the control of sleep and wakefulness, such as insomnia, the development of orexin receptor antagonists has emerged as an important focus in drug discovery research. Here, we report the design, synthesis, characterization, and structure–activity relationships (SARs) of novel orexin receptor antagonists. Various modifications made to the core structure of a previously developed compound (-)-5, the lead molecule, resulted in compounds with improved chemical and pharmacological profiles. The investigation afforded a potential therapeutic agent, (1R,2S)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyr&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00217&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00217" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00217&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00217" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00217&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00217" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00217&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00217&amp;href=/doi/10.1021/acs.jmedchem.5b00217" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b00217" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b00217" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b00217%26sid%3Dliteratum%253Aachs%26pmid%3D25953512%26genre%3Darticle%26aulast%3DYoshida%26date%3D2015%26atitle%3DDiscovery%2Bof%2B%25281R%252C2S%2529-2-%257B%255B%25282%252C4-Dimethylpyrimidin-5-yl%2529oxy%255Dmethyl%257D-2-%25283-fluorophenyl%2529-N-%25285-fluoropyridin-2-yl%2529cyclopropanecarboxamide%2B%2528E2006%2529%253A%2BA%2BPotent%2Band%2BEfficacious%2BOral%2BOrexin%2BReceptor%2BAntagonist%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D11%26spage%3D4648%26epage%3D4664%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a>,</li><li><a href="/action/doSearch?ConceptID=291352" title="Screening assays">Screening assays</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/jmcmar.2015.58.issue-11/20150611/jmcmar.2015.58.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00217&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The orexin/hypocretin receptors are a family of G protein-coupled receptors and consist of orexin-1 (OX<sub>1</sub>) and orexin-2 (OX<sub>2</sub>) receptor subtypes. Orexin receptors are expressed throughout the central nervous system and are involved in the regulation of the sleep/wake cycle. Because modulation of these receptors constitutes a promising target for novel treatments of disorders associated with the control of sleep and wakefulness, such as insomnia, the development of orexin receptor antagonists has emerged as an important focus in drug discovery research. Here, we report the design, synthesis, characterization, and structure–activity relationships (SARs) of novel orexin receptor antagonists. Various modifications made to the core structure of a previously developed compound (<b>-</b>)-<b>5</b>, the lead molecule, resulted in compounds with improved chemical and pharmacological profiles. The investigation afforded a potential therapeutic agent, (1<i>R</i>,2<i>S</i>)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-<i>N</i>-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006), an orally active, potent orexin antagonist. The efficacy was demonstrated in mice in an in vivo study by using sleep parameter measurements.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31588" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31588" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Insomnia, a disorder in which the patient suffers from an inability to sleep or stay asleep for as long as desired, constitutes a widespread issue in today’s society, as approximately 30% of adults in the United States experience some symptoms of insomnia and approximately 10% describe their insomnia as chronic and/or severe. Despite the prevalence of this disorder, research regarding medical treatments for insomnia is relatively limited.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">The effects of insomnia are dramatic, as it leads to a reduction in the quality of life, poor productivity, and a high risk of traffic and work-related safety incidents. Additionally, insomnia is a costly disorder, as it is estimated to cost over $63 billion per year in the United States.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Commonly prescribed medications for the treatment of insomnia include agents that positively modulate GABA<sub>A</sub> receptors, with zolpidem, a nonbenzodiazepine sleep drug, being the current market leader. Nonbenzodiazepine sleep aids are structurally distinct from benzodiazepines, as reflected in their naming, and bind to benzodiazepine sites with high specificity. Additionally, their pharmacological profiles are believed to be better in comparison with those of benzodiazepines owing to the less severe side effects. Despite the availability of various sleep-modifying drugs, the prevalence of insomnia has not decreased substantially because of remaining concerns about the overall safety and efficacy of treatments that target the GABA signaling pathway.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Notably, two new non-GABA-related sleep drugs have recently been approved for the treatment of insomnia. Ramelteon, a melatonin (MT) receptor MT<sub>1</sub>/MT<sub>2</sub> agonist, was approved in 2005, and doxepin, a histamine H<sub>1</sub> receptor antagonist, received regulatory approval in 2010. In contrast to benzodiazepine and nonbenzodiazepine agents, these two sleep-aid drugs are nonscheduled drugs in the U.S.. However, questions remain about the effectiveness of ramelteon and doxepin, owing to the limited number of reports demonstrating their superiority to other sleep drugs, including those that positively modulate GABA<sub>A</sub>.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> The medical needs of patients with insomnia warrant the development of sleep medications with novel mechanisms of action.</div><div class="NLM_p">Toward that end, antagonism of the orexin receptor may serve as a promising route. Orexin A and orexin B, also known as hypocretin 1 and hypocretin 2, are endogenous neuropeptide ligands for orexin/hypocretin receptors (OXRs), which are G protein-coupled receptors (GPCRs). Orexin-1 receptor (OX<sub>1</sub>R) and orexin-2 receptor (OX<sub>2</sub>R) mediate the action of these ligands by postsynaptic neuronal signal transduction. OX<sub>1</sub>R and OX<sub>2</sub>R are expressed throughout the central nervous system and are involved in the regulation of the sleep/wake cycle.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7-9)</a> To date, the specific contribution of OXR to the regulation of the sleep/wake cycle has recently starting emerged. A number of genetic and pharmacological studies have suggested that the orexin pathway plays an important role in regulating the sleep/wake cycle.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19">(10-19)</a> Studies performed in <i>orexin/ataxin-3</i> transgenic mice and rats, which lack orexin peptide-producing neurons, and OXR-deficient mice have shown that both receptors are involved in the regulation of the sleep/wake cycle because the lack of activation of both receptors results in a narcolepsy–cataplexy phenotype, while the lack of activation of either receptor alone elicits an attenuated sleep phenotype.<a onclick="showRef(event, 'ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23">(20-23)</a> Furthermore, very low levels of orexin in cerebrospinal fluid (CSF), indicative of nearly complete or complete loss of orexinergic neurons, have been observed in humans suffering from narcolepsy–cataplexy syndrome.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24-26)</a></div><div class="NLM_p">A dual OXR antagonist, almorexant, evaluated by Actelion Pharmaceuticals/GlaxoSmithKline was found to significantly decrease the behavioral indices of wakefulness in animals and has shown effectiveness in clinical trials.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Recently, a number of orally active selective OX<sub>2</sub>R antagonists have been evaluated in animal studies.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(27, 28)</a> However, whether a dual receptor antagonist<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(29)</a> or an OX<sub>2</sub>R-selective antagonist<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(30)</a> will be better suited for use as a sleep aid is a topic of ongoing debate. We think that it is feasible to speculate that a sleep drug which promotes both non-REM and REM sleep would provide patients with a more natural sleep architecture, and we are providing animal data in this manuscript which suggest that a dual orexin antagonist is a potential candidate to fulfill this requirement.</div><div class="NLM_p">To date, a number of dual OXR antagonists have been described. Almorexant (<b>1</b>) and was tested in the treatment of insomnia,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(31)</a> but a phase III clinical trial was discontinued. SB-649868 (<b>2</b>) from GlaxoSmithKline proceeded to a phase II clinical trial.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(32)</a> Suvorexant (<b>3</b>), developed by Merck, received approval from the Pharmaceutical and Medical Devices Agency in Japan and the US Food and Drug Administration (FDA) in 2014 and is marketed for the treatment of insomnia.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(33, 34)</a> Merck has entered another dual OXR antagonist filorexant (<b>4</b>) into a phase II clinical trial for multiple indications, including the treatment of insomnia (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(35)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Orexin receptor dual antagonists that have advanced to clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00217&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In this paper, we report the synthesis, structure–activity relationships (SARs), optimization of drug-likeness parameters, and in vivo efficacy of a series of cyclopropane compounds reported previously.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a> Our efforts in this area led to the discovery of <b>34</b> (E2006) as a promising dual OXR antagonist that has advanced into clinical trials.</div><div class="NLM_p">A novel series of compounds containing a cyclopropane core structure were identified as promising orally active orexin receptor antagonists, as exemplified by (−)-<b>5</b><a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). (−)-<b>5</b> exhibits low-nanomolar affinity toward human OX<sub>2</sub>R, as measured by radio ligand-displacement binding assays. However, this compound exhibits a number of drawbacks in its drug-likeness parameters that need to be improved, such as its time-dependent inhibition (TDI) of cytochrome P450 3A (CYP3A) and low aqueous solubility under both acidic and neutral conditions (pH 1.2 and pH 7.4). (−)-<b>5</b> also demonstrated moderate reversible inhibition of CYPs (IC<sub>50</sub> values of 8 and 8.6 μM for CYP2C8 and CYP2C19, respectively, and >10 μM for CYP1A2, CYP2C9, and CYP2D6). In an effort to find a clinical candidate within the chemical series, the A, B, and C rings in the molecule were optimized through chemical modifications.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Properties of Compound (−)-<b>5</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0009.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">in vitro binding affinity (<i>K</i><sub>i</sub>, nM)</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">solubility<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> (μM)</th><th class="rowsep1 colsep0" align="center" char=".">TDI of CYP3A<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="rowsep1 colsep0" align="center" char=".">metabolic stability<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">OX<sub>2</sub>R</th><th class="colsep0 rowsep0" align="center" char=".">OX<sub>1</sub>R</th><th class="colsep0 rowsep0" align="center" char=".">pH 7.4<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">pH 1.2<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">(% of control at 10 μM)</th><th class="colsep0 rowsep0" align="center" char=".">(residual ratio %)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(−)-<b>5</b></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">106</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">49</td><td class="colsep0 rowsep0" align="char" char=".">80</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">DMSO solution precipitation method.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a></p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Dulbecco’s phosphate-buffered saline (PBS).</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Japanese Pharmacopoeia 1st fluid (aqueous HCl solution containing 34 mM NaCl).</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Time-dependent inhibition evaluated using a cocktail of probe substrates with human liver microsomes.</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last">Metabolism after incubation of compounds at 0.3 μM in 0.1% DMSO with human liver microsomes for 15 min.</p></div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70448" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70448" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">The general synthetic route used to produce the cyclopropane compounds is presented in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Chiral cyclopropane ring formation was carried out by the reaction of corresponding aryl acetonitriles <b>6</b>–<b>12</b> with (<i>R</i>)-epichlorohydrin to yield the desired lactones <b>13a</b>–<b>f</b>.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(37)</a> The reported racemic compounds<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a> can be obtained using racemic epichlorohydrin instead of (<i>R</i>)-epichlorohydrin by following a procedure similar to the one described in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Reduction of the lactone with sodium borohydride afforded diol products <b>14a</b>–<b>f</b> in excellent yields. Protection of the hydroxy group of <b>14a</b> with TBDPS-Cl gave the desired monoprotected compound <b>15a</b>. In the selective monoacylation of diols <b>14b</b>–<b>f</b>, enzymatic acylation with lipase acrylic resin from <i>Candida antarctica</i> was successfully applied in the presence of vinyl acetate to obtain compounds <b>15b</b>–<b>f</b> in good yields. The Mitsunobu reaction of the corresponding alcohols with various phenols led to the production of <b>16a</b>–<b>i</b>. Deprotection of <b>16a</b> and <b>16g</b>–<b>i</b> using TBAF, or hydrolysis of the acyl group of <b>16b</b>–<b>f</b> with sodium hydroxide, followed by Swern oxidation and Pinnick oxidation, afforded carboxylic acid intermediates <b>18a</b>–<b>i</b>. Subsequent amidation of <b>18a</b>–<b>i</b> with various amines yielded the desired products <b>19</b>–<b>38</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00217&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (1) NaHMDS, THF, 0 °C, 3 h, (2) KOH, EtOH, reflux, 8 h, (3) HCl, 0 °C–rt, 3 h; (b) NaBH<sub>4</sub>, MeOH–THF, 0 °C–rt; (c) TBDPS-Cl, imidazole, DMF, −10 °C–rt, or vinyl acetate, lipase acrylic resin from <i>Candida antarctica</i>, rt; (d) Ar<sub>1</sub>-OH, DIAD, PPh<sub>3</sub>, 0 °C–rt, overnight or (1) MsCl, TEA, DCM, (2) Ar<sub>1</sub>-OH, Cs<sub>2</sub>CO<sub>3</sub>, MeCN, 70 °C; (e) TBAF, THF, rt, 1 h or NaOH, EtOH–H<sub>2</sub>O, rt, 1 h (2 steps); (f) (COCl)<sub>2</sub>, DMSO, TEA, DCM, −78 °C–rt, 1 h; (g) 2-methyl-2-butene, NaClO<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>, acetone–H<sub>2</sub>O, rt, 2 h; (h) amine, HATU, DIPEA, DMF, 60 °C, overnight or (COCl)<sub>2</sub>, cat. DMF, DCM, rt, 1 h, then amine, DIPEA, THF, 60 °C.</p></p></figure><div class="NLM_p">Components of the heteroaromatic A ring were synthesized as outlined in Schemes <a class="ref internalNav" href="#sch2" aria-label="2">2</a> and <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Pyrazole derivatives <b>40a</b> and <b>40b</b> were synthesized from commercially available aldehydes <b>39a</b> and <b>39b</b> via Baeyer–Villiger oxidation (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). The Pd-catalyzed coupling of commercially available 2,4-dichloro-5-methoxy pyrimidine <b>41</b> with trimethylaluminum afforded <b>42</b> in a good yield. An analogous transformation yielded <b>45</b> from chloro intermediate <b>44</b>, which was accessed by iron-catalyzed ethylation of <b>41</b> with ethyl magnesium chloride (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). Deprotection of the methoxy group of <b>42</b> and <b>45</b> in the presence of BBr<sub>3</sub> produced hydroxypyrimidines <b>43</b> and <b>46</b>. Compound <b>49</b> was synthesized from <b>43</b>. Protection of the hydroxyl group with benzyl bromide followed by selective bromination of the methyl group in the 4 position yielded the crude bromomethyl-containing compound. Subsequent substitution of the alkyl bromide in the presence of sodium methoxide afforded methoxymethyl product <b>48</b>. Deprotection of the benzyl group gave desired product <b>49</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00217&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) <i>m</i>-CPBA, CHCl<sub>3</sub>, rt, overnight.</p></p></figure><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00217&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Me<sub>3</sub>Al, Pd(PPh<sub>3</sub>)<sub>4</sub>, THF, 75 °C, overnight; (b) BBr<sub>3</sub>, DCM, rt, 4 d; (c) EtMgCl, Fe(acac)<sub>3</sub>, THF, rt, overnight; (d) Me<sub>3</sub>Al, Pd(PPh<sub>3</sub>)<sub>4</sub>, THF, 70 °C, 2 d; (e) BBr<sub>3</sub>, DCM, rt, 4 d; (f) BnBr, NaH, THF, 0 °C to rt, overnight; (g) Br<sub>2</sub>, CHCl<sub>3</sub>, 0 °C to rt, overnight, then NaOMe, MeOH, 90 °C, 12 h; (h) Pd-C, H<sub>2</sub> gas, EtOAc, rt, 1 h.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Pharmacology</h3><div class="NLM_p">Our efforts were primarily aimed at reducing the TDI effect on CYP3A and improving the aqueous solubility. The TDI effect was believed to be related to the demethylation of the 4-OCH<sub>3</sub> or 3-OCH<sub>3</sub> groups on the A-ring, where a second oxidative metabolism step may produce quinone intermediates that can react with nucleophiles.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(38)</a> Therefore, to resolve the TDI and solubility issues, we tried to introduce a substituted hetero Ar into the A-ring position instead of 3,4-di-OMe-Ph. According to our previous work, the methoxy groups are critical pharmacophores; the orientations of the small lipophilic group and lone pair were shown to strongly influence in vitro binding affinity.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a> On the basis of the information regarding 3,4-di-OMe-Ph in the Cambridge Structural Database (CSD), the Me groups face opposite directions (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Therefore, two types of dimethylpyridines (<b>50</b> and <b>51</b>) were designed with the hope of imitating the pharmacophores of 3,4-di-OMe-Ph, the lone pair and small lipophilic group (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. A-Ring Modifications: Compounds <b>50</b>–<b>53</b> and <b>19</b>–<b>22</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0010.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0011.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last"><i>K</i><sub>i</sub> values are calculated from single experiments run in triplicate.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Measured in Dulbecco’s PBS by DMSO solution precipitation method.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a></p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Time-dependent inhibition using a cocktail of probe substrates with human liver microsomes.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">P-Glycoprotein (P-gp) transport assay.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a></p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">Derived from <i>rac</i>-epichlorohydrin.</p></div><div class="footnote" id="t2fn6"><sup>Table f</sup><p class="last">Derived from (<i>R</i>)-epichlorohydrin.</p></div></div><div></div></div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlay of (−)-<b>5</b> and <b>50</b> and <b>51</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00217&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Experimentally, dramatically different in vitro binding affinities were observed between <b>50</b> and <b>51</b>, as 3-pyridine-containing <b>50</b> exhibited a moderate affinity, whereas introduction of the 4-pyridine-containing <b>51</b> resulted in reduced in vitro binding affinity toward both OX<sub>1</sub>R and OX<sub>2</sub>R. From these results, computational simulations of superposition using Molecular Operating Environment (MOE, Ryoka System, Inc., Tokyo, Japan) were conducted with (−)-<b>5</b> and <b>50</b> or <b>51</b>, with a particular focus on the position of the three aromatic rings and the di-OMe substituents (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Accordingly, we considered the superposition of the aromatic rings of <b>50</b> and <b>51</b> with (−)-<b>5</b>, together with the overall molecular shape including directionality of the ether linker, the angle of the upper-left aromatic ring (C-ring), and the direction of the NH of amide bond. On the basis of these observations, it is reasonable to exhibit better in vitro binding affinity for <b>50</b> than <b>51</b>. We successfully converted 3,4-di-OMe-Ph to a hetero Ar group with reasonable activity, and <b>50</b> showed improved solubility. This finding encouraged us to further investigate hetero Ar rings other than dimethylpyridine to improve the parameters, although the compound did not show an improvement in the TDI.</div><div class="NLM_p">Dimethyl pyrazole <b>52</b>, which was expected to meet the structural requirements, was synthesized and it showed an affinity similar to that shown by <b>50</b> as well as a significant improvement in the TDI. To further increase the affinity, various substituents were installed at the 1-position of pyrazole <b>52</b>, owing to the results of the computational simulations. Ethyl-substituted <b>53</b> was thought to have more favorable interactions with the small lipophilic site, and it exhibited an in vitro binding affinity comparable to that of (−)-<b>5</b>. This racemic mixture could be resolved by chiral high-performance liquid chromatography (HPLC) to provide (+)-<b>53</b> and (−)-<b>53</b>. The two stereoisomers exhibited dramatically different receptor affinities; the (−)-<b>53</b> isomer exhibited potent affinity toward both OX<sub>2</sub>R and OX<sub>1</sub>R, while the (+)-<b>53</b> isomer did not. Notably, it was found that (−)-<b>53</b> could be synthesized stereoselectively from (<i>R</i>)-epichlorohydrin using the procedure shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a> suggesting that (−)-<b>53</b> had the chiral configuration of (1<i>R</i>,2<i>S</i>), which is the preferred configuration for OXR antagonist activity.</div><div class="NLM_p">Another approach for enhancing the in vitro receptor binding affinity was attempted in diazine derivatives, as exemplified by pyrimidine- or pyrazine-containing compounds <b>19</b> and <b>21</b>. Specifically, this approach was carried out to modulate the p<i>K</i><sub>a</sub> of the ring because the di-OMe phenyl moiety of (−)-5 is nonbasic. As a result, a 5-fold increase in the in vitro binding affinity was achieved with compound <b>19</b>. Compound <b>20</b>, which contained an Et group instead of the Me group in <b>19</b>, was synthesized with the same expectations as we had for Et substituted pyrazole (−)-<b>53</b>; it exhibited increased in vitro binding affinity compared to that shown by <b>19</b> and exhibited an affinity comparable to that of (−)-<b>5</b>. Moreover, the pyrazole and pyrimidine derivatives, especially <b>19</b>, showed some improved properties compared to those of (−)-<b>5</b>, namely a reduced TDI (96% for <b>19</b> vs 49% for (−)-<b>5</b>) and aqueous solubility: 80 μM for <b>19</b> vs 15 μM for (−)-<b>5</b>. Pyrazine <b>21</b> exhibited a similar affinity to those of the pyrimidine derivatives but exhibited a concomitant deterioration in certain aspects of its physicochemical and drug likeness such as its aqueous solubility and reversible inhibition of CYPs (data not shown). Further reduction of the lipophilicity by the introduction of an OMe group in the 4-position of the dimethyl pyrimidine, as exemplified in <b>22</b>, resulted in a stronger binding affinity than that of <b>19</b>. However, <b>22</b> served as a substrate for P-glycoprotein (P-gp) with a corrected flux ratio of 4.0. Evaluation of the SARs of the A ring revealed that dimethyl pyrimidine-containing <b>19</b> possessed the optimal profile in terms of overall balance because it exhibited a low lipophilicity (ClogP of 3.3 for <b>19</b> vs 3.9 for (−)-<b>5</b>) with acceptable affinity toward OX<sub>2</sub>R, improved TDI and solubility, and moderate liability in a P-gp transport assay. Therefore, compound <b>19</b> was selected for optimization of the B-ring moiety.</div><div class="NLM_p">First, 2-, 3-, and 4-pyridine were introduced to confirm the SAR regarding the position of nitrogen, as a comparison with our previous work (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a> As a consequence, increased P-gp susceptibility was observed in 3- and 4-pyridine-containing derivatives (<b>24</b> and <b>25</b>, respectively), with a close resemblance to previously identified SARs involving the derivatization of the di-OMe phenyl series.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a> Subsequently, we evaluated the SARs of 2-pyridine-containing moieties in the B-ring, with the aim of enhancing the in vitro binding affinity and in vivo efficacy without adversely affecting other parameters. Introduction of substituents in the 5-position, such as in compounds <b>26</b> and <b>28</b>, resulted in a greater in vitro binding affinity than that of <b>23</b>. In contrast, the introduction of an Me substituent in the 4- or 5-position (<b>29</b>, <b>30</b>) also resulted in increased in vitro binding affinity relative to that of <b>23</b> although the magnitude of the observed increase was smaller with an Me group than with a halogen. These results suggested that the basicity of the B-ring may influence the in vitro binding affinity. Accordingly, incorporation of fluorine in the 5-position and an Me substituent in the 4-position (<b>31</b>) resulted in increased in vitro binding affinity, which was more potent than that of compound <b>30</b>. However, <b>31</b> exhibited decreased solubility compared to that of <b>26</b> (<b>31</b>, 51 μM, vs <b>26</b>, 92 μM, at pH 7.4). Introduction of an OMe group in the 4-position (<b>32</b>) also elicited a strong increase in the in vitro binding affinity.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Results of B-Ring Exploration: Compounds <b>23</b>–<b>32</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0012.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0013.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last"><i>K</i><sub>i</sub> values are calculated from single experiments run in triplicate.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Time-dependent inhibition using a cocktail of probe substrates with human liver microsomes.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">P-gp transport assay.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a></p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Sleep measurements conducted using an established method.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a></p></div></div><div></div></div><div class="NLM_p">With highly potent compounds <b>26</b>, <b>28</b>, and <b>31</b> in hand, in vivo characterizations were performed. The effects of these three compounds on wakefulness were evaluated in sleep experiments with mice via electroencephalogram/electromyogram (EEG/EMG) recordings during the first 3 h of the dark phase, as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a> All compounds elicited a significant reduction in the time of wakefulness following an oral dose of 30 mg/kg (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Because of its well-balanced in vitro profiles taking into account the in vitro binding affinity, solubility, and other parameters, compound <b>26</b> was selected for optimization of the C ring.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Wakefulness time measured after oral administration of <b>26</b>, <b>28</b>, and <b>31</b>. The vehicle (10% Cremophor EL, 5% DMSO in saline; <i>n</i> = 4 for <b>26</b>, <i>n</i> = 7 for <b>28</b> and <b>31</b>), <b>26</b> (<i>n</i> = 4), <b>28</b> (<i>n</i> = 5), and <b>31</b> (<i>n</i> = 6) at 30 mg/kg doses were administered immediately prior to the beginning of the dark cycle; cumulative wakefulness times were measured during the first 3 h after administration. Values are mean ± SEM.* <i>P</i> < 0.05, ** <i>P</i> < 0.01, and *** <i>P</i> < 0.001 versus vehicle control (unpaired parametric two-tailed <i>t</i> test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00217&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Previous synthetic efforts regarding the cyclopropane series were focused on modifying the A- and B-rings, while modifications of the C-ring were not explored. To investigate the SARs owing to changes in this component, a fluorine scan was conducted to explore favorable positions for substitutions (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Substitution at the 3-position (<b>34</b>) slightly increased the in vitro binding affinity relative to that of <b>26</b> without altering other parameters, while 2- or 4-F derivatives (<b>33</b>, <b>35</b>) exhibited 2–3-fold decreases in the in vitro binding affinity or increased hERG inhibition. 3,5-Difluoro-containing derivative <b>36</b> and 3,4-difluoro-containing derivative <b>37</b> exhibited strong in vitro binding affinities, but <b>37</b> also exhibited increased hERG inhibitory activity. Compound <b>38</b> was derived from <b>31</b>, which exhibited strong in vivo efficacy and relatively weak hERG inhibitory activity (<b>31</b>: hERG IC<sub>50</sub> > 10 μM). Compound <b>38</b> exhibited an enhanced in vitro binding affinity compared to that of <b>26</b>, with reduced hERG inhibition, as expected. However, <b>38</b> exhibited decreased solubility (<b>34</b>, 74 μM, vs <b>38</b>, 46 μM at pH 7.4).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Exploration of C-Ring with Different Combinations of B and C-Rings in Compounds <b>33</b>–<b>38</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0014.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0015.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last"><i>K</i><sub>i</sub> values are calculated from single experiments run in triplicate.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Time-dependent inhibition using a cocktail of probe substrates with human liver microsomes.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">P-gp transport assay.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a></p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">Exploratory screening of inhibition of the human ether-a-go-go related gene (hERG) potassium channel.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(39)</a></p></div></div><div></div></div><div class="NLM_p">On the basis of the SAR studies, compound <b>34</b> showed the most promising balance of in vitro properties and was selected for further profiling (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). Compound <b>34</b> exhibited very weak reversible inhibition of CYP with IC<sub>50</sub> values of >20 μM for CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A. The aqueous solubility of <b>34</b> at room temperature was 74 μM at pH 7.4 and >100 μM at pH 1.2. Compound <b>34</b> showed weak TDI effects on CYP3A, measured as 76% of the control at 10 μM. Further evaluations of the possible risk of drug–drug interactions caused by CYP3A TDI are warranted, but the potential risk is expected to be marginal when the in vitro binding affinity and TDI screening data are considered.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro Properties of Selected Compound <b>34</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center"><b>34</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hOX2R RBA <i>K</i><sub>i</sub> (nM)</td><td class="colsep0 rowsep0" align="left">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hOX2R cell-based functional assay<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a><i>K</i><sub>i</sub> (nM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hOXIR RBA <i>K</i><sub>i</sub> (nM)</td><td class="colsep0 rowsep0" align="left">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hOXIR cell-based functional assay<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a><i>K</i><sub>i</sub> (nM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">5.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">corrected P-gp FR<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a> (MDR1 flux ratio/PK1 flux ratio)</td><td class="colsep0 rowsep0" align="left">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TDI<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a> (CYP3A) (%)</td><td class="colsep0 rowsep0" align="left">76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility (pM)<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pH 1.2<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pH 7.4<a class="ref internalNav" href="#t5fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">metabolic stability (residual ratio %)<a class="ref internalNav" href="#t5fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left">90</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">See cell-based functional assay section in <a class="ref internalNav" href="#sec3" aria-label="Experimental section">Experimental section</a>.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last"><i>K</i><sub>i</sub> values are calculated from single experiments run;</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">P-gp transport assay;<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a></p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Time-dependent inhibition using cocktail of probe substrates with human liver microsomes;</p></div><div class="footnote" id="t5fn5"><sup>e</sup><p class="last">DMSO solution precipitation method;<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a></p></div><div class="footnote" id="t5fn6"><sup>f</sup><p class="last">Japanese Pharmacopoeia 1st fluid;</p></div><div class="footnote" id="t5fn7"><sup>g</sup><p class="last">Dulbecco’s PBS;</p></div><div class="footnote" id="t5fn8"><sup>h</sup><p class="last">Metabolism after incubation at 0.1 μM in 0.1% DMSO with human liver microsomes for 15 min.</p></div></div></div><div class="NLM_p">The pharmacokinetic properties of <b>34</b> were evaluated in male mice after intravenous and oral administration at 3 mg/kg iv and 10 mg/kg po doses (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). The results at 10 mg/kg po dose exhibited a plasma clearance of 1060 mL/h/kg, a half-life of 2.16 h for iv and 2.20 h for po administration, a <i>T</i><sub>max</sub> of 0.25 h, and an oral bioavailability of 18.5%. A <i>C</i><sub>max</sub> exhibited 488 ng/mL for 10 mg/kg and 961 ng/mL for 30 mg/kg po administration. In addition, brain penetration of <b>34</b> was evaluated in mice after 1 and 3 h following a single oral administration of 10 mg/kg. After 1 h postdose, the concentration of <b>34</b> reached 32.8 nmol/L in CSF and 633.3 nmol/L in plasma and reached 7.6 nmol/L in CSF and 157.6 nmol/L in plasma at 3 h, with 85.2% of the compound bound to plasma protein, indicating that <b>34</b> had sufficient brain penetrability and exposure was clearly above <i>K</i><sub>i</sub> on the target (Tables <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a> and <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). Therefore, <b>34</b> was subjected to efficacy evaluations through measurements of its effects on sleep in mice.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Parameters for <b>34</b> (iv and po) in Mice</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="2" align="center" char=".">iv (1 mg/kg)</th><th class="colsep0 rowsep0" colspan="2" align="center" char=".">po (10 mg/kg)</th><th class="colsep0 rowsep0" colspan="2" align="center" char=".">po (30 mg/kg)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PK parameter<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">mean</th><th class="colsep0 rowsep0" align="center" char=".">SD</th><th class="colsep0 rowsep0" align="center" char=".">mean</th><th class="colsep0 rowsep0" align="center" char=".">SD</th><th class="colsep0 rowsep0" align="center" char=".">mean</th><th class="colsep0 rowsep0" align="center">SD</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/h/kg)</td><td class="colsep0 rowsep0" align="char" char=".">1060</td><td class="colsep0 rowsep0" align="char" char=".">375</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (mL/kg)</td><td class="colsep0 rowsep0" align="char" char=".">2710</td><td class="colsep0 rowsep0" align="char" char=".">1380</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>(0–inf)</sub> (ng·h/mL)</td><td class="colsep0 rowsep0" align="char" char=".">1030</td><td class="colsep0 rowsep0" align="char" char=".">368</td><td class="colsep0 rowsep0" align="char" char=".">1910</td><td class="colsep0 rowsep0" align="char" char=".">403</td><td class="colsep0 rowsep0" align="char" char=".">4130</td><td class="colsep0 rowsep0" align="left">555</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">2.16</td><td class="colsep0 rowsep0" align="char" char=".">0.289</td><td class="colsep0 rowsep0" align="char" char=".">2.20</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="char" char=".">1.94</td><td class="colsep0 rowsep0" align="left">0.585</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">(0.25–0.50)</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="left">(0.50–1.00)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">488</td><td class="colsep0 rowsep0" align="char" char=".">25.2</td><td class="colsep0 rowsep0" align="char" char=".">961</td><td class="colsep0 rowsep0" align="left">127</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">18.5</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">13.4</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">See the <a class="ref internalNav" href="#sec3" aria-label="Experimental section">Experimental section</a></p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last"><i>F</i> (%) = ((mean AUC<sub>(0–inf)</sub>, po/dose<sub>po</sub>)/(mean AUC<sub>(0–inf)</sub>, iv/dose<sub>iv</sub>)) × 100.</p></div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Mouse Brain Penetration Data of <b>34</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>34</b> (10 mg/kg)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CSF/plasma<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (nmol/L)</td><td class="colsep0 rowsep0" align="left">1 h</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">633.3 ± 67.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CSF</td><td class="colsep0 rowsep0" align="char" char=".">32.8 ± 22.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3 h</td><td class="colsep0 rowsep0" align="left">plasma</td><td class="colsep0 rowsep0" align="char" char=".">157.6 ± 22.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CSF</td><td class="colsep0 rowsep0" align="char" char=".">7.6 ± 2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PPB (%)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">C57BL/6N mice</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">85.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">See the <a class="ref internalNav" href="#sec3" aria-label="Experimental section">Experimental section</a>.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">See the <a class="ref internalNav" href="#sec3" aria-label="Experimental section">Experimental section</a>.</p></div></div></div><div class="NLM_p">Compound <b>34</b> was administered orally at 10 and 30 mg/kg in mice, and the effect on sleep was evaluated (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a> Accordingly, <b>34</b> resulted in a significant decrease in time of wakefulness during the first 3 h following administration of 10 and 30 mg/kg doses (77.1 and 75.3 min, respectively, for <b>34</b> vs 116.7 min for vehicle, <i>P</i> < 0.001, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>D). Both non-REM and REM sleep were increased following oral administration of 10 and 30 mg/kg doses (99.3 min at 10 mg/kg and 95.5 min at 30 mg/kg for <b>34</b> vs 62.6 min for vehicle, <i>P</i> < 0.01, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>E; 3.6 min at 10 mg/kg and 9.3 min at 30 mg/kg for <b>34</b> vs 0.6 min for vehicle, not significant and <i>P</i> < 0.001, respectively, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>F). Non-REM sleep-promoting effect in this sleep experiment was thought to be saturated at 10 and 30 mg/kg dose by taking of the PK results into consideration (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). These data suggested that the compound <b>34</b> possessed robust sleep-promoting effects<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a> and potential as a drug to treat sleep disorders such as insomnia.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Wake and sleep time measurements after administration of <b>34</b>. (A–C) Vehicle (10% Cremophor EL, 5% DMSO in saline; <i>n</i> = 7) or <b>34</b> (10 or 30 mg/kg; <i>n</i> = 6) were orally administered immediately prior to the dark cycle (lights off), and (A) wakefulness, (B) non-REM sleep, and (C) REM sleep were measured hourly. (D–F) Cumulative amounts of (D) wakefulness, (E) non-REM sleep, and (F) REM sleep times measured during the first 3 h following administration of vehicle or <b>34</b> (derived from the time courses shown in A–C). Values are mean ± SEM * <i>P</i> < 0.05, ** <i>P</i> < 0.01, *** <i>P</i> < 0.001 versus vehicle control (one-way ANOVA followed by Dunnett’s multiple comparison test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00217&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Interestingly, the effects on sleep architecture were different between lead compound (−)-<b>5</b><a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a> and lead optimized compound <b>34</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Especially, <b>34</b> caused a dose-dependent increase of REM sleep time, while (−)-<b>5</b> did not provoke REM-sleep even up to highest dose (100 mg/kg po).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a> The difference of the effects on REM sleep by these compounds probably can be explained by the difference of OXRs selectivity profiles, (−)-<b>5</b> is more OX<sub>2</sub>R selective antagonist than <b>34</b>, which is nearly dual antagonist (about 3-fold selective for OX<sub>2</sub>R). Our results strongly indicate that REM sleep increase is caused via OX<sub>1</sub>R antagonism. This result is in alignment with orexin receptor KO mouse studies,<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(40, 41)</a> which demonstrate that both receptors are involved in sleep/wake regulation, with OX<sub>2</sub>R more regulating non-REM sleep and OX<sub>1</sub>R more regulating REM sleep. In addition, another sleep study, where orexin receptors were functionally inabled by pharmacological intervention by applying OX<sub>2</sub>R selective or dual orexin receptor antagonists, has indicated similar results regarding the roles of OX<sub>1</sub>R and OX<sub>2</sub>R for sleep architecture.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(42)</a> Thus, in our humble opinion, the selectivity ratio for OX<sub>1</sub>R and OX<sub>2</sub>R can clearly explain the sleep architecture induced by both compounds. When clinical data using a SORA will become available in the future, it will be important for deepening our understanding of the predictability of rodent’s sleep architecture data for humans. Nonetheless, we believe that both receptors should be targeted to promote physiological sleep by increasing both non-REM and REM sleep. Therefore, compound <b>34</b> is thought to induce a more favorable sleep architecture than (−)-<b>5</b>.</div></div></div><div id="sec99" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16581" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16581" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, we optimized the structure of cyclopropane compounds based on (−)-<b>5</b> as a lead OXR antagonist compound. Modifications of the A, B, and C-ring, and appropriate combinations of these alterations, afforded several potentially valuable compounds. Compared to (−)-<b>5</b>, significant improvements in multiple aspects were achieved by our efforts. Specifically, <b>34</b> exhibited an overall improvement in other properties such as the TDI of CYP3A and aqueous solubility, which were previously recognized as the major drawbacks of (−)-<b>5</b>. Additionally, <b>34</b> exhibited high OXRs antagonist activity and sufficient brain penetration. Furthermore, <b>34</b> demonstrated high efficacy in preclinical sleep experiments. On the basis of these findings, it has been selected as a candidate compound, E2006, for further clinical evaluations toward the treatment of sleep disorders. Additional preclinical and clinical studies regarding this series will be reported in due course.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35314" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35314" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Chemistry</h3><div class="NLM_p"><sup>1</sup>H NMR spectra were recorded on a Bruker Avance spectrometer (operating at 600 MHz) or Varian Mercury 400 spectrometer (operating at 400 MHz). <sup>13</sup>C NMR spectra were recorded on a Bruker Avance spectrometer (operating at 150 MHz). Chemical shifts were calculated in ppm (δ) from the residual CHCl<sub>3</sub> signal at (δH) 7.26 ppm or DMSO signal at (δH) 2.50 and (δC) 77.0 ppm in CDCl<sub>3</sub>. Then 600 MHz <sup>1</sup>H or <sup>13</sup>C NMR data were processed using ACD Spectrus processor from ACD Laboratories. High-resolution mass spectra (HRMS) were recorded on a ThermoFisherScientific LTQ-Orbitrap XL spectrometer (using electrospray ionization).</div><div class="NLM_p">The purity of the tested biological compounds was determined by an analytical LC–MS or UPLC method and was found to be greater than or equal to 95%. LC–MS analyses were performed using a Shimadzu LCMS-2010 EV and UPLC analyses were performed using a ACQUITY UPLC. The tested biological compounds were not PAINS compound. Optical rotation(±) was measured by Shimadzu HPLC SCL-10A system with a corresponding chiral column and JASCO OR-2090 optical rotation detector. Column chromatography was carried out using a Hi-Flash column (40 μm, silica gel and NH-silica gel, Yamazen Corporation). Chemicals and solvents were purchased from commercial sources.</div><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> (1<i>S</i>,5<i>R</i>)-1-Phenyl-3-oxabicyclo[3.1.0]hexan-2-one (<b>13a</b>)</h4><div class="NLM_p last">NaHMDS (85 mL, 2.0 M) was added dropwise to a solution of 2-phenylacetonitrile (7.96g) in THF (300 mL) under cooling in an ice–salt bath. The mixture was stirred for 2 h, then <i>R</i>-(−)-epichlorohydrin (7.548 g) was added dropwise (3 h, 0 °C). Stirring was continued for 2 h at 0 °C then overnight at room temperature. The reaction solution was then cooled on ice, and a small amount of water was added. The resulting mixture was concentrated under reduced pressure, then ethanol (100 mL) and 1.5 N/KOH aqueous solution (100 mL) were added to the residue. The obtained mixture was heated to reflux for 8 h. The reaction solution was allowed to cool to room temperature, and concentrated hydrochloric acid was added to adjust the pH to <2. This mixture was stirred at 0 °C for 2 h then was concentrated under reduced pressure. Ethyl acetate and water were added to the concentrated solution to carry out liquid separation. The organic layer was washed successively with a saturated sodium bicarbonate aqueous solution and a saturated sodium chloride aqueous solution. The organic layer was dried over magnesium sulfate, the drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, giving the title compound (9.0 g). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 1.37 (t, <i>J</i> = 4.8 Hz, 1H), 1.65 (dd, <i>J</i> = 7.8, 4.4 Hz, 1H), 2.54–2.58 (m, 1H), 4.30 (d, <i>J</i> = 9.2 Hz, 1H), 4.47 (dd, <i>J</i> = 9.4, 4.4 Hz, 1H), 7.25–7.45 (m, 5H).</div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> (1<i>S</i>,5<i>R</i>)-1-(2-Fluorophenyl)-3-oxabicyclo[3.1.0]hexan-2-one (<b>13b</b>)</h4><div class="NLM_p last">The title compound was synthesized adapting the procedure described for compound <b>13a</b> (6.25 g, 67.5% yield) as a white solid. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.38 (t, <i>J</i> = 4.9 Hz, 1H), 1.73 (dd, <i>J</i> = 7.9, 4.9 Hz, 1H), 2.43–2.52 (m, 1H), 4.34 (d, <i>J</i> = 9.4 Hz, 1H), 4.57 (dd, <i>J</i> = 9.1, 4.5 Hz, 1H), 7.09 (t, <i>J</i> = 9.1 Hz, 1H), 7.14–7.18 (m, 1H), 7.31–7.42 (m, 2H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 17.2, 24.6, 27.9, 68.4, 115.6, 121.6, 124.3, 130.2, 131.6, 162.2, 175.5. HRMS (ESI(+)) calcd for C<sub>11</sub>H<sub>10</sub>FO<sub>2</sub> [M + H]<sup>+</sup>, 193.0659; found, 193.0660.</div></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> (1<i>S</i>,5<i>R</i>)-1-(3-Fluorophenyl)-3-oxabicyclo[3.1.0]hexan-2-one (<b>13c</b>)</h4><div class="NLM_p last">The title compound was synthesized adapting the procedure described for compound <b>13a</b> (9.96 g, 49.8% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 1.41 (t, <i>J</i> = 5.2 Hz, 1H), 1.64 (dd, <i>J</i> = 8.0, 5.2 Hz, 1H), 2.56–2.63 (m, 1H), 4.30 (d, <i>J</i> = 9.2 Hz, 1H), 4.47 (dd, <i>J</i> = 9.2, 4.8 Hz, 1H), 6.96–7.02 (m, 1H), 7.16–7.21 (m, 2H), 7.28–7.35 (m, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 20.7, 25.4, 31.2, 68.0, 114.7, 115.3, 123.6, 130.2, 136.6, 162.8, 175.3. HRMS (ESI(+)) calcd for C<sub>11</sub>H<sub>10</sub>FO<sub>2</sub> [M + H]<sup>+</sup>, 193.0659; found, 193.0659.</div></div><div id="sec3_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> (1<i>S</i>,5<i>R</i>)-1-(4-Fluorophenyl)-3-oxabicyclo[3.1.0]hexan-2-one (<b>13d</b>)</h4><div class="NLM_p last">The title compound was synthesized adapting the procedure described for compound <b>13a</b> (8.73g, 43.7% yield) as a colorless oil. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.39 (t, <i>J</i> = 4.7 Hz, 1H), 1.62 (dd, <i>J</i> = 7.9, 4.9 Hz, 1H), 2.54–2.58 (m, 1H), 4.31 (d, <i>J</i> = 9.1 Hz, 1H), 4.49 (dd, <i>J</i> = 9.4, 4.5 Hz, 1H), 7.06 (m, 2H), 7.39–7.43 (m, 2H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 20.2, 25.0, 31.2, 68.1, 115.6, 129.9, 130.2, 162.3, 175.8. HRMS (ESI(+)) calcd for C<sub>11</sub>H<sub>10</sub>FO<sub>2</sub> [M + H]<sup>+</sup>, 193.0659; found, 193.0658.</div></div><div id="sec3_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> (1<i>S</i>,5<i>R</i>)-1-(3,5-Difluorophenyl)-3-oxabicyclo[3.1.0]hexan-2-one (<b>13e</b>)</h4><div class="NLM_p last">The title compound was synthesized adapting the procedure described for compound <b>13a</b> (6.9 g, 50.3% yield). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.46 (t, <i>J</i> = 4.9 Hz, 1H), 1.64 (dd, <i>J</i> = 7.7, 5.1 Hz, 1H), 2.62 (dt, <i>J</i> = 8.1, 4.6 Hz, 1H), 4.32 (d, <i>J</i> = 9.4 Hz, 1H), 4.47 (dd, <i>J</i> = 9.4, 4.5 Hz, 1H), 6.76 (tt, <i>J</i> = 8.9, 2.3 Hz, 1H), 7.01 (m, 2H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 21.3, 25.7, 31.0, 67.8, 103.2, 110.9, 138.0, 162.2, 163.9, 174.6. HRMS (ESI(+)) calcd for C<sub>11</sub>H<sub>9</sub>F<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 211.0565; found, 211.0561.</div></div><div id="sec3_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> (1<i>S</i>,5<i>R</i>)-1-(3,4-Difluorophenyl)-3-oxabicyclo[3.1.0]hexan-2-one (<b>13f</b>)</h4><div class="NLM_p last">The title compound was synthesized adapting the procedure described for compound <b>13a</b> (7.1 g, 51.7% yield). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.42 (t, <i>J</i> = 4.9 Hz, 1H), 1.61 (dd, <i>J</i> = 7.7, 5.1 Hz, 1H), 2.57–2.61 (m, 1H), 4.31 (d, <i>J</i> = 9.4 Hz, 1H), 4.48 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.12–7.19 (m, 2H), 7.32 (m, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 20.7, 25.2, 30.9, 68.0, 117.5, 117.6, 124.2, 131.1, 149.2, 150.9, 175.2. HRMS (ESI(+)) calcd for C<sub>11</sub>H<sub>9</sub>F<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 211.0565; found, 211.0562.</div></div><div id="sec3_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> (1<i>S</i>,2<i>R</i>)-1-Phenylcyclopropan-1,2-dimethanol (<b>14a</b>)</h4><div class="NLM_p last">The title compound was synthesized as a colorless oil (340 mg, 67.7%) from (1<i>S</i>,5<i>R</i>)-1-phenyl-3-oxabicyclo[3.1.0]hexan-2-one by adapting a previously described procedure.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 0.78 (t, <i>J</i> = 5.2 Hz, 1H), 1.87 (dd, <i>J</i> = 8.6, 5.2, 1H), 1.60–1.76 (m, 1H), 3.42 (t, <i>J</i> = 11.6, 1H), 3.57 (dd, <i>J</i> = 9.4, 4.4 Hz, 1H), 4.14–4.28 (m, 2H) 7.22–7.44 (m, 5H).</div></div><div id="sec3_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (1<i>S</i>,2<i>R</i>)-1-(2-Fluorophenyl)cyclopropan-1,2-dimethanol (<b>14b</b>)</h4><div class="NLM_p last">The title compound was synthesized by adapting a previously described procedure<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a> to give <b>14b</b> (745 mg, 33.3% yield) as a colorless oil. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 0.88 (t, <i>J</i> = 5.5 Hz, 1H), 1.08 (dd, <i>J</i> = 8.7, 5.3 Hz, 1H), 1.67–1.75 (m, 1H), 2.50 (br s, 1H), 2.90 (br s, 1H), 3.46 (t, <i>J</i> = 11.3 Hz, 1H), 3.58 (d, <i>J</i> = 12.1 Hz, 1H), 4.15 (d, <i>J</i> = 12.1 Hz, 1H), 4.23 (dd, <i>J</i> = 11.3, 4.5 Hz, 1H), 7.04 (t, <i>J</i> = 9.3 Hz, 1H), 7.12 (t, <i>J</i> = 7.5 Hz, 1H), 7.22–7.27 (m, 1H), 7.42 (td, <i>J</i> = 7.6, 1.9 Hz, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 16.3, 24.8, 28.0, 63.4, 67.0, 115.6, 124.0, 128.8, 130.5, 132.7, 162.1. HRMS (ESI(+)) calcd for C<sub>11</sub>H<sub>14</sub>FO<sub>2</sub> [M + H]<sup>+</sup>, 197.0972; found, 197.0972.</div></div><div id="sec3_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (1<i>S</i>,2<i>R</i>)-1-(3-Fluorophenyl)cyclopropan-1,2-dimethanol (<b>14c</b>)</h4><div class="NLM_p last">The title compound was synthesized as a colorless oil (10.3 g, quant) from (1<i>S</i>,5<i>R</i>)-1-(3-fluorophenyl)-3-oxabicyclo[3.1.0]hexan-2-one by adapting a previously described procedure.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 0.80 (t, <i>J</i> = 5.0 Hz, 1H), 1.10 (dd, <i>J</i> = 8.6, 5.0 Hz, 1H), 1.62–1.71 (m, 1H), 3.41 (t, <i>J</i> =11.4 Hz, 1H), 3.58 (d, <i>J</i> = 12.0 Hz, 1H), 4.12–4.25 (m, 2H), 6.90–6.96 (m, 1H), 7.08–7.14 (m, 1H), 7.16–7.21 (m, 1H) 7.24–7.32 (m, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 17.1, 26.3, 32.1, 63.5, 67.3, 113.7, 116.0, 124.6, 129.8, 146.5, 162.8. HRMS (ESI(+)) calcd for C<sub>11</sub>H<sub>14</sub>FO<sub>2</sub> [M + H]<sup>+</sup>, 197.0972; found, 197.0970.</div></div><div id="sec3_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (1<i>S</i>,2<i>R</i>)-1-(4-Fluorophenyl)cyclopropan-1,2-dimethanol (<b>14d</b>)</h4><div class="NLM_p last">The title compound was synthesized as a colorless oil (8.56g, 96.1% yield) from (1<i>S</i>,5<i>R</i>)-1-(4-fluorophenyl)-3-oxabicyclo[3.1.0]hexan-2-one by adapting a previously described procedure.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a><sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 0.79 (t, <i>J</i> = 5.3 Hz, 1H), 1.08 (dd, <i>J</i> =8.7, 5.3 Hz, 1H), 1.63–1.69 (m, 1H), 2.50 (br s, 1H), 2.86 (d, <i>J</i> = 6.0 Hz, 1H), 3.43 (t, <i>J</i> = 11.3 Hz, 1H), 3.59 (dd, <i>J</i> = 12.1, 2.3 Hz, 1H), 4.13 (dd, <i>J</i> = 11.9, 4.7 Hz, 1H), 4.18–4.25 (m, 1H), 6.99–7.05 (m, 2H), 7.35–7.43 (m, 2H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 16.7, 25.9, 31.8, 63.6, 67.7, 115.2, 131.0, 139.6, 161.7. HRMS (ESI(+)) calcd for C<sub>11</sub>H<sub>14</sub>FO<sub>2</sub> [M + H]<sup>+</sup>, 197.0972; found, 197.0970.</div></div><div id="sec3_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (1<i>S</i>,2<i>R</i>)-1-(3,4-Difluorophenyl)cyclopropan-1,2-dimethanol (<b>14f</b>)</h4><div class="NLM_p last">The title compound was synthesized as a colorless oil (7.1 g, 98% yield) from (1<i>S</i>,5<i>R</i>)-1-(3,4-difluorophenyl)-3-oxabicyclo[3.1.0]hexan-2-one <b>13f</b> by adapting a previously described procedure.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a><sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 0.81 (t, <i>J</i> = 5.5 Hz, 1H), 1.10 (dd, <i>J</i> = 8.7, 5.3 Hz, 1H), 1.60–1.68 (m, 1H), 2.59–2.67 (m, 1H), 2.77 (d, <i>J</i> = 5.3 Hz, 1H), 3.43 (t, <i>J</i> = 11.3 Hz, 1H), 3.59 (dd, <i>J</i> = 11.9, 2.8 Hz, 1H), 4.13 (dd, <i>J</i> = 12.1, 6.4 Hz, 1H), 4.19–4.27 (m, 1H), 7.06–7.16 (m, 2H), 7.24 (ddd, <i>J</i> = 11.4, 7.8, 1.9 Hz, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 16.9, 26.3, 31.7, 63.4, 67.4, 117.0, 118.2, 125.0, 141.0, 149.3, 150.0. HRMS (ESI(+)) calcd for C<sub>11</sub>H<sub>13</sub>F<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 215.0878; found, 215.0875.</div></div><div id="sec3_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (1<i>S</i>,2<i>R</i>)-1-(3,5-Difluorophenyl)cyclopropan-1,2-dimethanol (<b>14e</b>)</h4><div class="NLM_p last">The title compound was synthesized as a colorless oil (3.2 g, 72.9% yield) from (1<i>S</i>,5<i>R</i>)-1-(3,5-difluorophenyl)-3-oxabicyclo[3.1.0]hexan-2-one <b>13e</b> by adapting a previously described procedure.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a><sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 0.84 (t, <i>J</i> = 5.5 Hz, 1H), 1.14 (dd, <i>J</i> = 8.7, 5.3 Hz, 1H), 1.61–1.72 (m, 1H), 2.70 (br s, 1H), 2.74 (br s, 1H), 3.44 (t, <i>J</i> = 11.5 Hz, 1H), 3.61 (d, <i>J</i> = 12.1 Hz, 1H), 4.16–4.31 (m, 2H), 6.65–6.73 (tt, <i>J</i> = 8.9, 2.3 Hz, 1H), 6.92–6.97 (m, 2H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 17.3, 26.7, 31.9, 63.4, 67.0, 102.2, 111.7, 148.0, 162.9. HRMS (ESI(+)) calcd for C<sub>11</sub>H<sub>13</sub>F<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 215.0878; found, 215.0875.</div></div><div id="sec3_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (1<i>S</i>,2<i>R</i>)-2-(<i>tert</i>-Butyldiphenylsilyloxymethyl)-1-phenylcyclopropylmethanol (<b>15a</b>)</h4><div class="NLM_p last">The title compound was synthesized as a colorless oil (340 mg, 67.7% yield)from (1<i>S</i>,2<i>R</i>)-1-phenylcyclopropan-1,2-dimethanol <b>14a</b> by adapting a previously described procedure.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 0.71 (t, <i>J</i> = 5.6 Hz, 1H), 1.04 (dd, <i>J</i> = 9.6, 5.2 Hz, 1H), 1.10 (s, 9H), 1.50–1.58 (m, 1H), 3.50 (dd, <i>J</i> = 12.4, 1.6 Hz, 1H), 3.53 (dd, <i>J</i> = 11.6, 1.6 Hz, 1H), 3.71 (dd, <i>J</i> = 12.4, 1.6 Hz, 1H), 4.10 (t, <i>J</i> = 12.0 Hz, 1H), 4.20 (dd, <i>J</i> = 12.0, 5.6 Hz, 1H), 7.21–7.46 (m, 10H). 7.7–7.76 (m, 5H).</div></div><div id="sec3_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> [(1<i>R</i>,2<i>S</i>)-2-(2-Fluorophenyl)-2-(hydroxymethyl)cyclopropyl]methyl Acetate (<b>15b</b>)</h4><div class="NLM_p last">Lipase acrylic resin from <i>Candida antarctica</i> was added to a THF (50 mL)–vinyl acetate (1.51 g, 17.6 mmol) solution of (1<i>S</i>,2<i>R</i>)-1-(2-fluorophenyl)cyclopropan-1,2-dimethanol (2.28 g, 11.7 mmol) under cooling on ice. This mixture was stirred at room temperature for 17 h, then was filtered, and filtrate was concentrated, so as to give the title compound (2.1 g, 82.6% yield). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 0.87 (t, <i>J</i> = 5.7 Hz, 1H), 1.15 (dd, <i>J</i> = 8.7, 5.3 Hz, 1H), 1.64 (ddd, <i>J</i> = 9.4, 5.7, 3.4 Hz, 1H), 2.08 (dd, <i>J</i> = 8.5, 3.6 Hz, 1H), 2.17 (s, 3H), 3.70 (dd, <i>J</i> = 12.1, 3.4 Hz, 1H), 3.96 (dd, <i>J</i> = 12.1, 8.7 Hz, 1H), 4.06 (dd, <i>J</i> = 11.9, 10.0 Hz, 1H), 4.65 (dd, <i>J</i> = 12.1, 5.7 Hz, 1H), 6.99–7.06 (m, 1H), 7.11 (td, <i>J</i> = 7.5, 0.9 Hz, 1H), 7.22–7.27 (m, 1H), 7.30 (td, <i>J</i> = 7.5, 1.7 Hz, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 15.1, 21.1, 22.1, 28.6, 64.5, 66.2, 115.6, 124.0, 128.9, 130.0, 132.1, 162.2, 171.1. HRMS (ESI(+)) calcd for C<sub>13</sub>H<sub>16</sub>FO<sub>3</sub> [M + H]<sup>+</sup>, 239.1078; found, 239.1075.</div></div><div id="sec3_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> [(1<i>R</i>,2<i>S</i>)-2-(3-Fluorophenyl)-2-(hydroxymethyl)cyclopropyl]methyl Acetate (<b>15c</b>)</h4><div class="NLM_p last">The title compound was synthesized as a light-yellow oil (1.21 g, quant) from (1<i>S</i>,2<i>R</i>)-1-(3-fluorophenyl)cyclopropan-1,2-dimethanol <b>14c</b> by adapting the procedure described for compound <b>15b</b>. HRMS (ESI(+)) calcd for C<sub>13</sub>H<sub>16</sub>FO<sub>3</sub> [M + H]<sup>+</sup>, 239.1078; found, 239.1074.</div></div><div id="sec3_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> [(1<i>R</i>,2<i>S</i>)-2-(4-Fluorophenyl)-2-(hydroxymethyl)cyclopropyl]methyl Acetate (<b>15d</b>)</h4><div class="NLM_p last">The title compound was synthesized as a colorless oil (2.8 g, 92.3% yield) from (1<i>S</i>,2<i>R</i>)-1-(4-fluorophenyl)cyclopropan-1,2-dimethanol by adapting the procedure described for compound <b>15b</b>. HRMS (ESI(+)) calcd for C<sub>13</sub>H<sub>16</sub>FO<sub>3</sub> [M + H]<sup>+</sup>, 239.1078; found, 239.1072.</div></div><div id="sec3_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> [(1<i>R</i>,2<i>S</i>)-2-(3,5-Difluorophenyl)-2-(hydroxymethyl)cyclopropyl]methyl Acetate (<b>15e</b>)</h4><div class="NLM_p last">The title compound was synthesized as a reddish oil (41.2 g, 99.2% yield) from (1<i>S</i>,2<i>R</i>)-1-(3,5-difluorophenyl)cyclopropan-1,2-dimethanol by adapting the procedure described for compound <b>15b</b>. HRMS (ESI(+)) calcd for C<sub>13</sub>H<sub>15</sub>F<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 257.0984; found, 257.0979.</div></div><div id="sec3_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> [(1<i>R</i>,2<i>S</i>)-2-(3,4-Difluorophenyl)-2-(hydroxymethyl)cyclopropyl]methyl Acetate (<b>15f</b>)</h4><div class="NLM_p last">The title compound was synthesized as a colorless oil (2.9 g, 81% yield) from (1<i>S</i>,2<i>R</i>)-1-(3,4-difluorophenyl)cyclopropan-1,2-dimethanolby adapting the procedure described for compound <b>15b</b>. HRMS (ESI(+)) calcd for C<sub>13</sub>H<sub>15</sub>F<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 257.0984; found, 257.0979.</div></div><div id="sec3_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 5-(((1<i>S</i>,2<i>R</i>)-2-(((<i>tert</i>-Butyldiphenylsilyl)oxy)methyl)-1-phenylcyclopropyl)methoxy)-2,4-dimethylpyrimidine (<b>16a</b>)</h4><div class="NLM_p last">The title compound was synthesized as a colorless oil (340 mg, 67.7% yield) from ((1<i>S</i>,2<i>R</i>)-2-(((<i>tert</i>-butyldiphenylsilyl)oxy)methyl)-1-phenylcyclopropyl)methanol (<b>15a</b>) and 2,4-dimethyl-5-hydroxypyrimidine by adapting a previously described procedure.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a><sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 0.95 (t, <i>J</i> = 5.7 Hz, 1H), 1.09 (s, 9H), 1.24 (dd, <i>J</i> = 8.7, 5.3 Hz, 1H), 1.64–1.70 (m, 1H), 2.30 (s, 3H), 2.61 (s, 3H), 3.80 (dd, <i>J</i> = 11.3, 8.3 Hz, 1H), 4.06 (dd, <i>J</i> = 11.3, 5.7 Hz, 1H), 4.18 (d, <i>J</i> = 9.8 Hz, 1H), 4.24 (d, <i>J</i> = 9.8 Hz, 1H), 7.24–7.28 (m, 1H), 7.31–7.39 (m, 6H), 7.41–7.45 (m, 4H), 7.66–7.70 (m, 4H), 7.89 (s, 1H). HRMS (ESI(+)) calcd for C<sub>33</sub>H<sub>39</sub>N<sub>2</sub>O<sub>2</sub>Si [M + H]<sup>+</sup>, 523.2775; found, 523.2783.</div></div><div id="sec3_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(2-fluorophenylcyclopropyl)methyl Acetate (<b>16b</b>)</h4><div class="NLM_p last">Diisopropyl azodicarboxylate (310 μL, 1.57 mmol) was added dropwise to a THF solution (10 mL) of the compound <b>15b</b> (300 mg, 1.26 mmol), triphenylphosphine (413 mg, 1.57 mmol), and 2,4-dimethyl-pyrimidin-5-ol <b>43</b> (195 mg, 1.57 mmol) at 0 °C. The reaction mixture was stirred at this temperature for 30 min, then allowed to warm to ambient temperatureand stirred overnight. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using <i>n</i>-heptane/ethyl acetate (4/1 to 0/1, v/v) to give <b>16b</b> (154 mg, 35.5% yield) as a colorless oil. HRMS (ESI(+)) calcd for C<sub>19</sub>H<sub>22</sub>FN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 345.1609; found, 345.1607.</div></div><div id="sec3_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(4-fluorophenylcyclopropyl)methyl Acetate (<b>16d</b>)</h4><div class="NLM_p last">The title compound was synthesized as a colorless oil (276 mg, 63.6% yield) from [(1<i>R</i>,2<i>S</i>)-2-(4-fluorophenyl)-2-(hydroxymethyl)cyclopropyl]methyl acetate <b>15d</b> by adapting the procedure described for compound <b>16b</b>. HRMS (ESI(+)) calcd for C<sub>19</sub>H<sub>22</sub>FN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 345.1609; found, 345.1606.</div></div><div id="sec3_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3,4-difluorophenylcyclopropyl)methyl Acetate (<b>16f</b>)</h4><div class="NLM_p last">The title compound was synthesized as a colorless oil (87 mg, 20.5% yield) from [(1<i>R</i>,2<i>S</i>)-2-(3,4-difluorophenyl)-2-(hydroxymethyl)cyclopropyl]methyl acetate <b>15f</b> by adapting the procedure described for compound <b>16b</b>. HRMS (ESI(+)) calcd for C<sub>19</sub>H<sub>21</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 363.1515; found, 363.1511.</div></div><div id="sec3_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> ((1<i>R</i>,2<i>S</i>)-2-(((2,4-Dimethylpyrimidin-5-yl)oxy)methyl)-2-phenylcyclopropyl)methanol (<b>17a</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white solid (155 mg, 83.9% yield) from 5-(((1<i>S</i>,2<i>R</i>)-2-(((<i>tert</i>-butyldiphenylsilyl)oxy)methyl)-1-phenylcyclopropyl)methoxy)-2,4-dimethylpyrimidine by adapting a previously described procedure.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a><sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 0.98 (t, <i>J</i> = 5.7 Hz, 1H), 1.29 (dd, <i>J</i> = 8.7, 5.3 Hz, 1H), 1.85 (ddd, <i>J</i> = 9.4, 5.6, 3.6 Hz, 1H), 2.25 (br s, 1H), 2.39 (s, 3H), 2.61 (s, 3H), 3.60 (t, <i>J</i> = 11.0 Hz, 1H), 4.06–4.15 (m, 2H), 4.46 (d, <i>J</i> = 10.2 Hz, 1H), 7.25–7.27 (m, 1H), 7.34 (m, 2H), 7.45 (m, 2H), 7.99 (s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 16.4, 19.0, 25.0, 26.9, 30.0, 63.2, 74.4, 127.1, 128.5, 129.4, 139.1, 143.0, 149.1, 157.1, 160.3. HRMS (ESI(+)) calcd for C<sub>17</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 285.1598; found, 285.1599.</div></div><div id="sec3_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(2-fluorophenylcyclopropyl)methanol (<b>17b</b>)</h4><div class="NLM_p last">The acetate <b>16b</b> was dissolved in EtOH–1N sodium hydroxide aqueous solution (5–0.34 mL). The reaction mixture was stirred for 1 h then was concentrated under reduced pressure. The residue was purified by NH–silica gel column chromatography using <i>n</i>-heptane/ethyl acetate (9/1 to 0/1, v/v) to give <b>17b</b> (84.5 mg, 62.5% yield) as a white solid. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.05 (t, <i>J</i> = 5.9 Hz, 1H), 1.26 (dd, <i>J</i> = 8.9, 5.5 Hz, 1H), 1.82–1.88 (m, 1H), 2.21 (dd, <i>J</i> = 9.3, 2.8 Hz, 1H), 2.35 (s, 3H), 2.60 (s, 3H), 3.60 (ddd, <i>J</i> = 12.2, 9.9, 2.8 Hz, 1H), 4.09–4.16 (m, 2H), 4.42 (d, <i>J</i> = 9.8 Hz, 1H), 7.05 (t, <i>J</i> =9.3 Hz, 1H), 7.13 (td, <i>J</i> = 7.6, 1.1 Hz, 1H), 7.25–7.29 (m, 1H), 7.46 (td, <i>J</i> = 7.6, 1.5 Hz, 1H), 7.98 (s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 15.9, 18.8, 25.0, 25.3, 25.9, 62.9, 73.3, 115.7, 124.1, 129.3, 129.7, 132.4, 139.0, 149.1, 157.2, 160.2, 162.1. HRMS (ESI(+)) calcd for C<sub>17</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 303.1503; found, 303.1500.</div></div><div id="sec3_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenylcyclopropyl)methanol (<b>17c</b>)</h4><div class="NLM_p last">Diisopropyl azodicarboxylate (45.8 mL, 217 mmol) was added dropwise to a THF solution (400 mL) of the compound <b>15c</b> (43.1 g, 181 mmol), triphenylphosphine (57 g, 217 mmol), and 2,4-dimethyl-pyrimidin-5-ol <b>43</b> (24.7 g, 199 mmol) at 0 °C. The reaction mixture was allowed to warm to ambient temperature and then was stirred overnight. The reaction mixture was partitioned between sat. NaHCO<sub>3</sub> aq and EtOAc. The organic layer was washed with brine and dried over MgSO<sub>4</sub>, filtered to remove the drying agent, then concentrated under reduced pressure. The residue was dissolved in EtOH–1N NaOH (200–200 mL), and this solution was stirred for 1 h at room temperature. Additional 5 N NaOH (100 mL) was added to the reaction mixture, which was then concentrated under reduced pressure. The residue was extracted with EtOAc. The organic layer was washed with brine and dried over with MgSO<sub>4</sub>, filtered to remove the drying agent, and then concentrated under reduced pressure. The residue was purified first by silica gel column chromatography using <i>n</i>-heptane/ethyl acetate/methanol (1/4/0 to 0/1/1, v/v) and thereafter by using a NH–silica gel pad with EtOAc as the eluent to give <b>17c</b> (39.3 g, 71.8% yield) as a light-red oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 1.00 (t, <i>J</i> = 5.2 Hz, 1H), 1.24–1.30 (m, 1H), 1.79–1.85 (m, 1H), 2.39 (s, 3H), 2.60 (s, 3H), 3.55–3.61 (m, 1H), 4.03–4.13 (m, 1H), 4.12 (d, <i>J</i> = 9.6 Hz, 1H), 4.43 (d, <i>J</i> = 9.6 Hz, 1H), 6.92–6.98 (m, 1H), 7.11–7.15 (m, 1H), 7.19–7.22 (m, 1H), 7.25–7.31 (m, 1H), 8.00 (s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 16.6, 19.0, 25.0, 27.2, 29.7, 63.0, 73.9, 114.1, 116.3, 124.8, 129.9, 139.1, 145.6, 149.0, 157.1, 160.4, 162.7. HRMS (ESI(+)) calcd for C<sub>17</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 303.1503; found, 303.1502.</div></div><div id="sec3_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(4-fluorophenylcyclopropyl)methanol (<b>17d</b>)</h4><div class="NLM_p last">The title compound was synthesized as a colorless oil (222 mg, 93% yield) from (1<i>R</i>,2<i>S</i>)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(4-fluorophenylcyclopropyl)methyl acetate by adapting the procedure described for compound <b>17b</b>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 0.98 (t, <i>J</i> = 5.5 Hz, 1H), 1.25 (dd, <i>J</i> = 8.7, 5.3 Hz, 1H), 1.76–1.83 (m, 1H), 2.22 (dd, <i>J</i> = 9.3, 2.8 Hz, 1H), 2.38 (s, 3H), 2.61 (s, 3H), 3.56–3.62 (m, 1H), 4.05–4.13 (m, 1H), 4.10 (d, 9.8 Hz, 1H), 4.39 (d, <i>J</i> = 9.8 Hz, 1H), 7.02 (m, 2H), 7.39–7.44 (m, 2H), 7.99 (s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 16.3, 19.0, 25.0, 26.9, 29.5, 63.0, 74.3, 115.3, 131.1, 138.8, 139.1, 149.0, 157.1, 160.4, 161.8. HRMS (ESI(+)) calcd for C<sub>17</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 303.1503; found, 303.1503.</div></div><div id="sec3_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3,5-difluorophenylcyclopropyl)methanol (<b>17e</b>)</h4><div class="NLM_p last">To a solution of acetate <b>15e</b> (597 mg, 2.33 mmol) was added triethyl amine (357 μL, 2.56 mmol) and methanesulfonyl chloride (180 μL, 2.33 mmol) at 0 °C. The reaction mixture was stirred for 1 h at this temperature, then water was added and the mixture was extracted with dichloromethane. The organic layer was dried over MgSO<sub>4</sub>, filtered to remove the drying agent, and concentrated under reduced pressure. The residue was dissolved in acetonitrile (20 mL), and to the solution were added 2,4-dimethylpyrimidin-5-ol <b>43</b> (347 mg, 2.8 mmol) and cesium carbonate (1.52 g, 4.66 mmol). The reaction mixture was stirred for 4 h at 70 °C, then was filtered through a glass filter. The filtrate was concentrated under reduced pressure. The residue was dissolved in EtOH–1N NaOH (2.45–2.45 mL), after which it was stirred for 1 h at 70 °C. After cooling the reaction mixture, it was extracted with EtOAc, washed with brine, and concentrated undwer reduced pressure. The residue was purified by silica gel column chromatography using <i>n</i>-heptane/AcOEt/MeOH (4/1/0 to 0/1/0 to 0/1/1, v/v) to give <b>17e</b> (520 mg, 69.7% yield) as a reddish oil. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.03 (t, <i>J</i> = 5.67 Hz, 1H), 1.31 (dd, <i>J</i> = 8.9, 5.5 Hz, 1H), 1.77–1.84 (m, 1H), 2.12 (dd, <i>J</i> = 8.9, 2.8 Hz, 1H), 2.41 (s, 3H), 2.63 (s, 3H), 3.57–3.63 (m, 1H), 4.04–4.10 (m, 1H), 4.13 (d, <i>J</i> = 10.2 Hz, 1H), 4.42 (d, <i>J</i> = 10.2 Hz, 1H), 6.72 (tt, <i>J</i> = 8.9, 2.3 Hz, 1H), 6.93–6.99 (m, 2H), 8.03 (s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 16.7, 19.0, 25.0, 27.4, 29.7, 62.7, 73.4, 102.7, 112.0, 139.0, 146.9, 148.9, 157.1, 160.5, 162.9. HRMS (ESI(+)) calcd for C<sub>17</sub>H<sub>19</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 321.1409; found, 321.1407.</div></div><div id="sec3_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3,4-difluorophenylcyclopropyl)methanol (<b>17f</b>)</h4><div class="NLM_p last">The title compound was synthesized as a colorless oil (70 mg, 97% yield) from [(1<i>R</i>,2<i>S</i>)-2-(3,4-fluorophenyl)-2-(hydroxymethyl)cyclopropyl]methyl acetate by adapting the procedure described for compound <b>17b</b>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.00 (t, <i>J</i> = 5.7 Hz, 1H), 1.27 (dd, <i>J</i> = 8.9, 5.5 Hz, 1H), 1.76–1.82 (m, 1H), 2.13 (dd, <i>J</i> = 9.1, 3.0 Hz, 1H), 2.40 (s, 3H), 2.62 (s, 3H), 3.59 (ddd, <i>J</i> = 12.3, 9.6, 3.0 Hz, 1H), 4.05–4.10 (m, 1H), 4.11(d, <i>J</i> = 9.8 Hz, 1H), 4.38 (d, <i>J</i> = 9.8 Hz, 1H), 7.09–7.19 (m, 2H), 7.24–7.28 (m, 1H), 8.01 (s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 16.4, 19.0, 25.0, 27.1, 29.4, 62.8, 73.8, 117.2, 118.5, 125.3, 139.0, 140.1, 148.9, 149.4, 150.0, 157.1, 160.5. HRMS (ESI(+)) calcd for C<sub>17</sub>H<sub>19</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>. 321.1409; found, 321.1408.</div></div><div id="sec3_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-phenylcyclopropanecarboxylic Acid (<b>18a</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white solid (569 mg, 60.4% yield) from ((1<i>R</i>,2<i>S</i>)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-phenylcyclopropyl)methanol (<b>17a</b>) by adapting a previously described procedure.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a><sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.57 (dd, <i>J</i> = 8.3, 4.9 Hz, 1H), 1.77 (t, <i>J</i> = 5.5 Hz, 1H), 2.28 (dd, <i>J</i> = 8.3, 6.0 Hz, 1H), 2.34 (s, 3H), 2.58 (s, 3H), 4.50 (q, <i>J</i> = 9.4 Hz, 2H), 7.28–7.33 (m, 1H), 7.37 (m, 2H), 7.51 (m, 2H), 8.20 (s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 18.8, 19.4, 24.0, 25.5, 35.0, 71.9, 127.5, 128.5, 129.3, 138.4, 141.8, 149.6, 158.7, 158.7, 174.1. HRMS (ESI(+)) calcd for C<sub>17</sub>H<sub>19</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 299.1390; found, 299.1388.</div></div><div id="sec3_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(2-fluorophenyl)cyclopropanecarboxylic Acid (<b>18b</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white solid by adapting the procedure previously described<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a> for compound <b>18a</b> (47 mg, 73.8% yield). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.49–1.55 (m, 1H), 1.74–1.81 (m, 1H), 2.21–2.30 (m, 4H), 2.53–2.60 (m, 3H), 4.47 (d, <i>J</i> = 9.4 Hz, 1H), 4.54 (d, <i>J</i> = 9.4 Hz, 1H), 7.02–7.18 (m, 2H), 7.28–7.33 (m, 1H), 7.45–7.54 (m, 1H), 8.20 (s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 18.6, 19.0, 24.0, 24.9, 30.0, 70.9, 115.7, 124.0, 128.6, 129.4, 132.3, 138.1, 149.6, 158.6, 158.7, 161.8, 174.3. HRMS (ESI(+)) calcd for C<sub>17</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 317.1296; found, 317.1293.</div></div><div id="sec3_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)cyclopropanecarboxylic Acid (<b>18c</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white solid (203 mg, 81.7% yield) from (1<i>R</i>,2<i>S</i>)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenylcyclopropyl)methanol by adapting a previously described procedure.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a><sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.58 (dd, <i>J</i> = 8.1, 5.1 Hz, 1H), 1.78 (t, <i>J</i> = 5.5 Hz, 1H), 2.28 (dd, <i>J</i> = 7.9, 6.0 Hz, 1H), 2.37 (s, 3H), 2.59 (s, 3H), 4.48–4.54 (m, 2H), 7.01 (td, <i>J</i> = 8.3, 2.3 Hz, 1H), 7.20–7.25 (m, 1H), 7.26–7.30 (m, 1H), 7.30–7.37 (m, 1H), 8.25 (s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 18.9, 19.4, 23.8, 25.7, 34.5, 71.7, 114.5, 116.4, 124.8, 130.0, 138.2, 144.2, 149.6, 158.7, 159.1, 162.7, 173.8. HRMS (ESI(+)) calcd for C<sub>17</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 317.1296; found, 317.1293.</div></div><div id="sec3_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(4-fluorophenyl)cyclopropanecarboxylic Acid (<b>18d</b>)</h4><div class="NLM_p last">The title compound was synthesized as an oil (223 mg, 92.5% yield) from (1<i>R</i>,2<i>S</i>)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(4-fluorophenylcyclopropyl)methanol by adapting a previously described procedure.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a><sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.54 (dd, <i>J</i> = 8.3, 4.9 Hz, 1H), 1.76 (t, <i>J</i> = 5.5 Hz, 1H), 2.24 (dd, <i>J</i> = 8.3, 6.0 Hz, 1H), 2.34 (s, 3H), 2.58 (s, 3H), 4.44–4.50 (m, 2H), 7.06 (m, 2H), 7.46–7.51 (m, 2H), 8.22 (s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 18.8, 19.4, 24.0, 25.5, 34.3, 71.9, 115.3, 131.1, 137.6, 138.6, 149.6, 158.8, 158.9, 162.1, 173.9. HRMS (ESI(+)) calcd for C<sub>17</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 317.1296; found, 317.1292.</div></div><div id="sec3_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3,5-difluorophenyl)cyclopropanecarboxylic Acid (<b>18e</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white solid (886 mg, 83.9% yield) from (1<i>R</i>,2<i>S</i>)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3,5-difluorophenylcyclopropyl)methanol by adapting a previously described procedure.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a><sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.57 (dd, <i>J</i> = 8.3, 5.3 Hz, 1H), 1.79 (t, <i>J</i> = 5.7 Hz, 1H), 2.26 (dd, <i>J</i> = 8.3, 6.0 Hz, 1H), 2.37 (s, 3H), 2.58 (s, 3H), 4.50 (s, 2H), 6.77 (tt, <i>J</i> = 8.8, 2.1 Hz, 1H), 7.00–7.09 (m, 2H), 8.26 (s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 18.9, 19.4, 23.9, 25.8, 34.2, 71.3, 103.1, 112.1, 138.6, 145.5, 149.5, 159.0, 159.0, 162.9, 173.4. HRMS (ESI(+)) calcd for C<sub>17</sub>H<sub>17</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 335.1202; found, 335.1198.</div></div><div id="sec3_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3,4-difluorophenyl)cyclopropanecarboxylic Acid (<b>18f</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white amorphous solid (662 mg, 63.1% yield) from (1<i>R</i>,2<i>S</i>)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3,4-difluorophenylcyclopropyl)methanol by adapting a previously described procedure.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a><sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.40 (br s, 1H), 1.65 (br s, 1H), 2.13 (br s, 1H), 2.28 (br s, 3H), 2.53 (s, 3H), 4.35–4.48 (m, 2H), 7.05–7.19 (m, 2H), 7.23–7.33 (m, 1H), 8.17 (br s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 18.8, 19.2, 24.1, 26.6, 33.7, 71.5, 117.2, 118.4, 125.2, 138.7, 138.9, 149.4, 149.6, 150.0, 158.5, 159.1, 175.3. HRMS (ESI(+)) calcd for C<sub>17</sub>H<sub>17</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 335.1202; found, 335.1198.</div></div><div id="sec3_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-<i>N</i>-(pyridin-2-yl)-2-phenylcyclopropanecarboxamide (<b>23</b>)</h4><div class="NLM_p last">To a solution of carboxylic acid <b>18a</b> (40 mg, 0.13 mmol) in DMF (1 mL) were added 2-aminopyridine (37.8 mg, 0.40 mmol), DIPEA (35.4 μL, 0.27 mmol), and HATU (56 mg, 0.15 mmol). The reaction mixture was stirred at room temperature for 5 h, then was warmed up to 50 °C and stirred overnight. The reaction mixture was concentrated under reduced pressure. The residue was purified first by silica gel column chromatography using chloroform/methanol (1/0 to 19/1, v/v) and subsequently by using Prep-TLC (SiO<sub>2</sub>, chloroform/methanol = 10/1 v/v) to give amide <b>23</b> (27.3 mg, 54.4% yield) as a white solid. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.63 (dd, <i>J</i> = 8.1, 5.1 Hz, 1H), 1.93 (t, <i>J</i> = 5.3 Hz, 1H), 2.13–2.19 (m, 1H), 2.22 (s, 3H), 2.56 (s, 3H), 4.43 (d, <i>J</i> = 9.4 Hz, 1H), 4.53 (d, <i>J</i> = 9.4 Hz, 1H), 7.02–7.06 (m, 1H), 7.30–7.34 (m, 1H), 7.38 (t, <i>J</i> = 7.4 Hz, 2H), 7.46–7.51 (m, 2H), 7.65–7.70 (m, 1H), 7.98 (s, 1H), 8.07 (d, <i>J</i> = 7.9 Hz, 1H), 8.27–8.30 (m, 1H), 8.37 (br s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 15.7, 15.9, 22.2, 26.2, 32.6, 68.3, 111.0, 117.1, 124.8, 125.9, 126.1, 135.7, 136.1, 139.0, 145.1, 146.4, 148.4, 154.3, 156.8, 165.7. HRMS (ESI(+)) calcd for C<sub>22</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 375.1816; found, 375.1810. Purity: >95%.</div></div><div id="sec3_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-<i>N</i>-(pyridin-3-yl)-2-phenylcyclopropanecarboxamide (<b>24</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white amorphous solid (28.6 mg, 57% yield) from (1<i>R</i>,2<i>S</i>)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-phenylcyclopropanecarboxylic acid <b>18a</b> by adapting the procedure described for compound <b>23</b>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.66 (dd, <i>J</i> = 7.7, 5.1 Hz, 1H), 1.93 (t, <i>J</i> = 5.5 Hz, 1H), 2.13 (dd, <i>J</i> = 7.9, 5.7 Hz, 1H), 2.24 (s, 3H), 2.57 (s, 3H), 4.47–4.51 (m, 1H), 4.53–4.57 (m, 1H), 7.25–7.27 (m, 1H), 7.29–7.34 (m, 1H), 7.38 (m, 2H), 7.47 (m, 2H), 7.69 (br s, 1H), 8.01 (s, 1H), 8.11 (d, <i>J</i> = 7.9 Hz, 1H), 8.36 (d, <i>J</i> = 4.2 Hz, 1H), 8.55 (br s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 18.7, 18.9, 25.0, 29.0, 35.2, 71.0, 123.8, 127.1, 127.6, 128.6, 128.7, 134.6, 139.1, 140.8, 141.7, 145.5, 149.2, 156.9, 159.7, 168.7. HRMS (ESI(+)) calcd for C<sub>22</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 375.1816; found, 375.1809. Purity: >95%.</div></div><div id="sec3_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-<i>N</i>-(pyridin-4-yl)-2-phenylcyclopropanecarboxamide (<b>25</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white amorphous solid (37.4 mg, 74.5% yield) from (1<i>R</i>,2<i>S</i>)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-phenylcyclopropanecarboxylic acid <b>18a</b> by adapting the procedure described for compound <b>23</b>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.68 (dd, <i>J</i> = 8.1, 5.1 Hz, 1H), 1.94 (t, <i>J</i> = 5.5 Hz, 1H), 2.11 (dd, <i>J</i> = 7.9, 6.0 Hz, 1H), 2.22 (s, 3H), 2.57 (s, 3H), 4.46 (d, <i>J</i> = 9.8 Hz, 1H), 4.55 (d, <i>J</i> = 9.4 Hz, 1H), 7.29–7.34 (m, 1H), 7.38 (m, 2H), 7.42–7.47 (m, 4H), 7.78 (br s, 1H), 8.01 (s, 1H), 8.50 (m, 2H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 18.7, 19.1, 25.0, 29.2, 35.5, 70.9, 113.36, 127.7, 128.5, 128.7, 139.2, 141.5, 144.7, 149.2, 150.9, 156.9, 159.8, 168.9. HRMS (ESI(+)) calcd for C<sub>22</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 375.1816; found, 375.1809. Purity: >95%.</div></div><div id="sec3_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-<i>N</i>-(5-fluoropyridin-2-yl)-2-phenylcyclopropanecarboxamide (<b>26</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white amorphous solid (30.5 mg, 46.3% yield) from (1<i>R</i>,2<i>S</i>)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-phenylcyclopropanecarboxylic acid <b>18a</b> by adapting the procedure described for compound <b>23</b>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.64 (dd, <i>J</i> = 8.1, 5.1 Hz, 1H), 1.92 (t, <i>J</i> = 5.3 Hz, 1H), 2.10–2.16 (m, 1H), 2.22 (s, 3H), 2.56 (s, 3H), 4.42 (d, <i>J</i> = 9.4 Hz, 1H), 4.52 (d, <i>J</i> = 9.4 Hz, 1H), 7.29–7.34 (m, 1H), 7.35–7.43 (m, 3H), 7.46–7.50 (m, 2H), 7.98 (s, 1H), 8.10 (dd, <i>J</i> = 9.1, 3.8 Hz, 1H), 8.14 (d, <i>J</i> = 3.0 Hz, 1H), 8.29 (br s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 18.6, 18.7, 25.0, 28.9, 35.4, 71.1, 114.5, 125.3, 127.7, 128.7, 128.8, 135.4, 138.8, 141.7, 147.4, 149.2, 156.4, 157.0, 159.6, 168.3. HRMS (ESI(+)) calcd for C<sub>22</sub>H<sub>22</sub>FN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 393.1721; found, 393.1716. Purity: >95%.</div></div><div id="sec3_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-<i>N</i>-(6-fluoropyridin-2-yl)-2-phenylcyclopropanecarboxamide (<b>27</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white solid (8.8 mg, 16.7% yield) from (1<i>R</i>,2<i>S</i>)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-phenylcyclopropanecarboxylic acid <b>18a</b> by adapting the procedure described for compound <b>23</b>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.64 (dd, <i>J</i> = 7.9, 5.5 Hz, 1H), 1.92 (t, <i>J</i> = 5.5 Hz, 1H), 2.09–2.16 (m, 1H), 2.22 (s, 3H), 2.56 (s, 3H), 4.41 (d, <i>J</i> = 9.4 Hz, 1H), 4.50 (d, <i>J</i> = 9.4 Hz, 1H), 6.66 (dd, <i>J</i> = 7.9, 2.3 Hz, 1H), 7.29–7.34 (m, 1H), 7.38 (m, 2H), 7.47 (m, 2H), 7.75 (q, <i>J</i> = 8.2 Hz, 1H), 7.94 (br d, <i>J</i> = 7.6 Hz, 1H), 7.98 (s, 1H), 8.23 (s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 18.7, 24.9, 28.8, 35.7, 71.1, 104.3, 104.5, 110.1, 127.7, 128.7, 128.9, 138.8, 141.6, 143.4, 149.2, 149.3, 157.0, 159.6, 161.9, 168.6. HRMS (ESI(+)) calcd for C<sub>22</sub>H<sub>22</sub>FN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 393.1721; found, 393.1717. Purity: >95%.</div></div><div id="sec3_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-<i>N</i>-(5-chloropyridin-2-yl)-2-phenylcyclopropanecarboxamide (<b>28</b>)</h4><div class="NLM_p last">The title compound was synthesized as a light-yellow solid (105.7 mg, 30.8% yield) from (1<i>R</i>,2<i>S</i>)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-phenylcyclopropanecarboxylic acid by adapting the procedure described for compound <b>23</b>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.64 (dd, <i>J</i> = 7.9, 4.9 Hz, 1H), 1.92 (t, <i>J</i> = 5.5 Hz, 1H), 2.11–2.16 (m, 1H), 2.22 (s, 3H), 2.56 (s, 3H), 4.41 (d, <i>J</i> = 9.4 Hz, 1H), 4.52 (d, <i>J</i> = 9.4 Hz, 1H), 7.29–7.34 (m, 1H), 7.38 (t, <i>J</i> = 7.4 Hz, 2H), 7.45–7.50 (m, 2H), 7.63 (dd, <i>J</i> = 9.1, 2.6 Hz, 1H), 7.98 (s, 1H), 8.06 (d, <i>J</i> = 8.7 Hz, 1H), 8.24 (d, <i>J</i> = 2.6 Hz, 1H), 8.29 g(s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 18.7, 18.7, 25.0, 28.9, 35.6, 71.0, 114.4, 126.9, 127.7, 128.7, 128.8, 138.1, 138.9, 141.6, 146.5, 149.2, 149.4, 157.0, 159.6, 168.5. HRMS (ESI(+)) calcd for C<sub>22</sub>H<sub>22</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 409.1426; found, 409.1422. Purity: >95%.</div></div><div id="sec3_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-<i>N</i>-(5-methylpyridin-2-yl)-2-phenylcyclopropanecarboxamide (<b>29</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white amorphous solid (5.5 mg, 44.9% yield) from (1<i>R</i>,2<i>S</i>)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-phenylcyclopropanecarboxylic acid <b>18a</b> by adapting the procedure described for compound <b>23</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 1.60 (dd, <i>J</i> = 8.0, 5.2 Hz, 1H), 1.90 (t, <i>J</i> = 5.2 Hz, 1H), 2.11 (br, 1H), 2.20 (s, 3H), 2.28 (s, 3H), 2.54 (s, 3H), 4.40 (d, <i>J</i> = 9.4 Hz, 1H), 4.51 (d, <i>J</i> = 9.4 Hz,1H), 7.27–7.38 (m, 3H), 7.45–7.48 (m, 3H), 7.94 (br, 1H), 7.96(s,1H), 8.08 (q, <i>J</i> = 0.8 Hz, 1H), 8.27 (br s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 17.8, 18.4, 18.7, 25.0, 28.9, 35.2, 71.1, 113.3, 127.6, 128.6, 128.9, 129.3, 138.8, 139.0, 141.9, 147.7, 149.0, 149.2, 157.1, 159.5, 168.3. HRMS (ESI(+)) calcd for C<sub>23</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 389.1972; found, 389.1965. Purity: >95%.</div></div><div id="sec3_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-<i>N</i>-(4-methylpyridin-2-yl)-2-phenylcyclopropanecarboxamide (<b>30</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white amorphous solid (6.5 mg, 53.0% yield) from (1<i>R</i>,2<i>S</i>)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-phenylcyclopropanecarboxylic acid <b>18a</b> by adapting the procedure described for compound <b>23</b>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.58–1.62 (m, 1H), 1.91 (t, <i>J</i> = 5.5 Hz, 1H), 2.11–2.16 (m, 1H), 2.22 (s, 3H), 2.32 (s, 3H), 2.56 (s, 3H), 4.43 (d, <i>J</i> = 9.4 Hz, 1H), 4.53 (d, <i>J</i> = 9.4 Hz, 1H), 6.85 (d, <i>J</i> = 5.3 Hz, 1H), 7.29–7.33 (m, 1H), 7.37 (m, 2H), 7.45–7.51 (m, 2H), 7.90 (br s, 1H), 7.99 (s, 1H), 8.11 (d, <i>J</i> = 5.3 Hz, 1H), 8.44 (br s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 18.5, 18.7, 21.4, 24.9, 29.0, 35.3, 71.0, 114.3, 121.1, 127.6, 128.6, 128.8, 138.8, 141.8, 147.4, 149.2, 150.0, 151.2, 157.1, 159.5, 168.5. HRMS (ESI(+)) calcd for C<sub>23</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 389.1972; found, 389.1966. Purity: >95%.</div></div><div id="sec3_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-<i>N</i>-(5-fluoro-4-methylpyridin-2-yl)-2-phenylcyclopropanecarboxamide (<b>31</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white amorphous solid (2.4 g, 61.7% yield) from (1<i>R</i>,2<i>S</i>)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-phenylcyclopropanecarboxylic acid by adapting the procedure described for compound <b>23</b>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.63 (dd, <i>J</i> = 8.1, 5.1 Hz, 1H), 1.91 (t, <i>J</i> = 5.5 Hz, 1H), 2.09–2.14 (m, 1H), 2.23 (s, 3H), 2.29 (s, 3H), 2.56 (s, 3H), 4.42 (d, <i>J</i> = 9.4 Hz, 1H), 4.52 (d, <i>J</i> = 9.4 Hz, 1H), 7.29–7.34 (m, 1H), 7.38 (m, 2H), 7.45–7.50 (m, 2H), 7.96 (d, <i>J</i> = 5.3 Hz, 1H), 7.98 (s, 1H), 8.02 (s, 1H), 8.23 (br s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 14.7, 18.5, 18.7, 25.0, 28.9, 35.4, 71.0, 115.8, 127.6, 128.7, 128.8, 134.5, 136.6, 138.8, 141.7, 147.1, 149.2, 155.8, 157.0, 159.5, 168.2. HRMS (ESI(+)) calcd for C<sub>23</sub>H<sub>24</sub>FN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 407.1878; found, 407.1871. Purity: >95%.</div></div><div id="sec3_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-<i>N</i>-(5-fluoro-4-methoxypyridin-2-yl)-2-phenylcyclopropanecarboxamide (<b>32</b>)</h4><div class="NLM_p last">To a solution of carboxylic acid <b>18a</b> (1 g, 3.35 mmol) was added oxalyl chloride (575 μL, 6.7 mmol). The reaction mixture was stirred for 2 h, then was concentrated under reduced pressure. The residue was dissolved in THF (15 mL), and 28% aqueous ammonia (4.08 mL, 67 mmol) was added at 0 °C. This mixture was stirred for 30 min, after which it was concentrated under reduced pressure to afford crude carboxamide. A mixture of this carboxamide (300 mg, 1.01 mmol), 2-chloro-5-fluoro-4-methoxypyridine (235 mg, 1.52 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (351 mg, 0.606 mmol), potassium triphosphate (429 mg, 2.02 mmol), and tris(dibenzylidene)dipalladium(0) (185 mg, 0.202 mmol) in 1,4-dioxane (20 mL) was heated to 95 °C. and stirred for 15 h. The reaction solution was cooled to room temperature and filtered using Celite. The filtrate was concentrated under reduced pressure, and the residue was partitioned between EtOAc and H<sub>2</sub>O. The organic layer was washed with brine and dried with MgSO<sub>4</sub>, filtered to remove the drying agent, and concentrated under reduced pressure. The residue was purified by silica gel chromatography using <i>n</i>-heptane/ethyl acetate (7/3 to ethyl acetate, v/v) then by NH–silica gel chromatography using <i>n</i>-heptane/ethyl acetate (4:1 to 2:3, v/v). The crude product obtained was dissolved in chloroform, and <i>n</i>-hexane was added. The precipitated solid was colected by filtration and dried to give compound (304 mg, 71.2% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 1.63 (dd, <i>J</i> = 8.0, 5.6 Hz, 1H), 1.89 (t, <i>J</i> = 5.6 Hz, 1H), 2.11 (dd, <i>J</i> = 8.0, 5.6 Hz, 1H), 2.23 (s, 3H), 2.55 (s, 3H), 3.88 (s, 3H), 4.41 (d, <i>J</i> = 9.6 Hz, 1H), 4.51 (d, <i>J</i> = 9.6 Hz, 1H), 7.28–7.39 (m, 3H), 7.45–7.48 (m, 2H), 7.82 (d, <i>J</i> = 6.4 Hz, 1H), 7.97 (d, <i>J</i> = 2.8 Hz, 1H), 7.98 (s, 1H), 8.30 (br s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 18.5, 18.7, 24.9, 29.0, 35.5, 56.1, 71.0, 98.4, 127.7, 128.7, 128.8, 134.7, 138.8, 141.6, 147.1, 148.6, 149.2, 155.2, 157.0, 159.6, 168.5. HRMS (ESI(+)) calcd for C<sub>23</sub>H<sub>24</sub>FN<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 423.1827; found, 423.1820. Purity: >95%.</div></div><div id="sec3_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(2-fluorophenyl)-<i>N</i>-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (<b>33</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white solid (1.7 mg, 8.74% yield) from (1<i>R</i>,2<i>S</i>)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(2-fluorophenyl)cyclopropanecarboxylic acid by adapting the procedure described for compound <b>23</b>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm): 1.53 (dd, <i>J</i> = 8.3, 5.3 Hz, 1H), 1.94 (t, <i>J</i> = 5.5 Hz, 1H), 2.15–2.27 (m, 4H), 2.55 (s, 3H), 4.34 (d, <i>J</i> = 9.8 Hz, 1H), 4.43 (d, <i>J</i> = 9.4 Hz, 1H), 7.08–7.14 (m, 1H), 7.17 (t, <i>J</i> = 7.4 Hz, 1H), 7.29–7.35 (m, 1H), 7.39–7.49 (m, 2H), 7.93 (s, 1H), 8.10–8.19 (m, 2H), 8.35 (br s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 17.6, 18.6, 24.9, 28.0, 30.3, 70.6, 114.5, 115.9, 124.4, 125.3, 128.5, 129.7, 131.9, 135.4, 138.5, 147.4, 149.2, 156.4, 157.1, 159.6, 161.9, 168.0. HRMS (ESI(+)) calcd for C<sub>22</sub>H<sub>21</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 411.1627; found, 411.1621. Purity: >95%.</div></div><div id="sec3_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-<i>N</i>-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (<b>34</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white solid (3.66 g, 56.4% yield) from (1<i>R</i>,2<i>S</i>)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)cyclopropanecarboxylic acid <b>18c</b> by adapting the procedure described for compound <b>23</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i>) δ (ppm): 1.46–1.50 (m, 1H), 1.68 (t, <i>J</i> = 6.0 Hz, 1H), 2.01 (s, 3H), 2.36 (s, 3H), 2.59–2.63 (m, 1H), 4.27 (d, <i>J</i> = 10.4 Hz, 1H), 4.66 (d, <i>J</i> = 10.4 Hz, 1H), 7.06–7.11 (m, 1H), 7.37–7.44 (m, 3H), 7.60–7.65 (m, 1H), 7.85–7.89 (m, 1H), 8.11 (s, 1H), 8.30 (d, <i>J</i> = 3.2 Hz, 1H), 11.20 (br s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 18.7, 18.7, 25.0, 29.0, 34.9, 70.7, 114.5, 114.7, 115.9, 124.2, 125.4, 130.2, 135.5, 138.9, 144.1, 147.3, 149.1, 156.4, 157.0, 159.8, 162.8, 167.9. HRMS (ESI(+)) calcd for C<sub>22</sub>H<sub>21</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 411.1627; found, 411.1622. Purity: >95%.</div></div><div id="sec3_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(4-fluorophenyl)-<i>N</i>-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (<b>35</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white solid (102 mg, 39.3% yield) from (1<i>R</i>,2<i>S</i>)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(4-fluorophenyl)cyclopropanecarboxylic acid by adapting the procedure described for compound <b>23</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i>) δ (ppm): 1.43–1.45 (m, 1H), 1.66 (t, <i>J</i> = 4.4 Hz, 1H), 2.02 (s, 3H), 2.36 (s, 3H), 2.55–2.58 (m, 1H), 4.26 (d, <i>J</i> = 10.4 Hz, 1H), 4.59 (d, <i>J</i> = 10.4 Hz, 1H), 7.15–7.20 (m, 2H), 7.57–7.65 (m, 3H), 7.86–7.89 (m, 1H), 8.09 (s, 1H), 8.30 (d, <i>J</i> = 3.2 Hz, 1H), 11.18 (br s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl3) δ (ppm): 18.6, 18.7, 24.9, 28.8, 34.8, 71.1, 114.5, 115.6, 125.4, 130.6, 135.4, 137.5, 138.9, 147.3, 149.1, 156.4, 157.0, 159.7, 162.1, 168.1. HRMS (ESI(+)) calcd for C<sub>22</sub>H<sub>21</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 411.1627; found, 411.1620. Purity: >95%.</div></div><div id="sec3_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3,4-difluorophenyl)-<i>N</i>-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (<b>37</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white amorphous solid (123 mg, 53.4% yield) from (1<i>R</i>,2<i>S</i>)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3,4-difluorophenyl)cyclopropanecarboxylic acid by adapting the procedure described for compound <b>23</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 1.58–1.61 (m, 1H), 1.91 (t, <i>J</i> = 5.2 Hz, 1H), 2.07 (br t, <i>J</i> = 8.0 Hz, 1H), 2.21 (s, 3H), 2.56 (s, 3H), 4.39 (d, <i>J</i> = 9.6 Hz, 1H), 4.45 (d, <i>J</i> = 9.6 Hz, 1H), 7.12–7.41 (m, 4H), 7.97 (s, 1H), 8.04–8.08 (m, 1H), 8.12 (d, <i>J</i> = 2.4 Hz, 1H), 8.30 (br s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 18.6, 18.7, 25.0, 28.9, 34.6, 70.7, 114.5, 117.5, 118.1, 124.8, 125.4, 135.5, 138.6, 138.9, 147.2, 149.0, 149.8, 150.1, 156.4, 156.87, 159.9, 167.7. HRMS (ESI(+)) calcd for C<sub>22</sub>H<sub>20</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 429.1533; found, 429.1527. Purity: >95%.</div></div><div id="sec3_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3,5-difluorophenyl)-<i>N</i>-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (<b>36</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white amorphous solid (140 mg, 60.7% yield) from (1<i>R</i>,2<i>S</i>)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3,5-difluorophenyl)cyclopropanecarboxylic acid by adapting the procedure described for compound <b>23</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ (ppm): 1.61–1.64 (m, 1H), 1.93 (t, <i>J</i> = 5.2 Hz, 1H), 2.09 (br t, <i>J</i> = 8.0 Hz, 1H), 2.22 (s, 3H), 2.56 (s, 3H), 4.40 (d, <i>J</i> = 9.6 Hz, 1H), 4.49 (d, <i>J</i> = 9.6 Hz, 1H), 6.74–6.79 (m, 1H), 6.98 (d, <i>J</i> = 6.0 Hz, 2H), 7.36–7.41 (m, 1H), 7.99 (s, 1H), 8.05 (dd, <i>J</i> = 3.6, 9.2 Hz, 1H), 8.11 (d, <i>J</i> = 2.8 Hz, 1H), 8.35 (br t, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 18.7, 18.7, 25.0, 29.1, 34.7, 70.3, 103.3, 111.7, 114.5, 125.4, 135.5, 138.9, 145.4, 147.2, 149.0, 156.5, 156.9, 160.0, 163.0, 167.4. HRMS (ESI(+)) calcd for C<sub>22</sub>H<sub>20</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 429.1533; found, 429.1526. Purity: >95%.</div></div><div id="sec3_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-<i>N</i>-(5-fluoro-4-methylpyridin-2-yl)-2-(3-fluorophenyl)cyclopropanecarboxamide (<b>38</b>)</h4><div class="NLM_p last">The title compound was synthesized as a white amorphous solid (289 mg, 55.4% yield) from (1<i>R</i>,2<i>S</i>)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)cyclopropanecarboxylic acid by adapting the procedure described for compound <b>23</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) d (ppm): 1.55–1.65 (m, 1H), 1.91 (t, <i>J</i> = 5.6 Hz, 1H), 2.05–2.13 (m, 1H), 2.22 (s, 3H), 2.27 (s, 3H), 2.56 (s, 3H), 4.41 (d, <i>J</i> = 10.0 Hz, 1H), 4.50 (d, <i>J</i> = 9.2 Hz, 1H), 6.97–7.04 (m, 1H), 7.14–7.20 (m, 1H), 7.22–7.28 (m, 1H), 7.33 (td, <i>J</i> = 8.0, 5.8 Hz, 1H), 7.93 (d, <i>J</i> = 5.2 Hz, 1H), 7.99 (s, 1H), 8.00 (s, 1H), 8.24 (br s, 1H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm): 14.7, 18.6, 18.7, 25.0, 29.0, 34.8, 70.6, 114.7,115.8, 115.8, 124.2, 130.2, 134.5, 136.7, 138.8, 144.1, 147.0, 149.1, 155.8, 157.0, 159.7, 162.8, 167.8. HRMS (ESI(+)) calcd for C<sub>23</sub>H<sub>23</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 425.1784; found, 425.1779. Purity: >95%.</div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Animals</h3><div class="NLM_p last">All animal experiments were approved by the Animal Care and Use Committee of Eisai Co., Ltd. Male C57BL/6NCrlCrlj mice (Charles River, Yokohama, Japan) were maintained under a 12 h light–dark cycle with food and water available ad libitum.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> In Vivo Sleep Experiments</h3><div id="sec3_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Recordings of Wake/Sleep Behavior</h4><div class="NLM_p">The sleep assay was quantitated using polysomnography in mice implanted with electrodes for recording EEG and EMG activity as previously described.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a></div><div class="NLM_p">In male mice (C57BL/6NCrlCrlj; Charles River Laboratories, Japan), compounds <b>26</b>, <b>28</b>, <b>31</b>, and <b>34</b> were formulated in 10% Cremophor EL, 5% DMSO in saline. The compounds or vehicle were administered prior to switching the lights off at ZT (zeitgeber time) 12:00, and EEG/EMG data were recorded from ZT 12:00 until ZT 20:00.</div><div class="NLM_p">After administration of compounds or vehicle, EEG/EMG activity recording results were analyzed by software (SleepSign 3.0, Kissei Comtech, Japan), followed up by visual confirmation by an experienced sleep researcher blinded as to treatment, to determine wakefulness, non-REM sleep, or REM sleep. The data were expressed as vigilance state time every hour (for time course) or for 3 h after lights out (for cumulative analysis).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(36)</a></div><div class="NLM_p last">Data were expressed as mean ± SEM. Unpaired parametric two-tailed <i>t</i> test for <b>26</b>, <b>28</b>, and <b>31</b> or one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test for <b>34</b> were applied to test the null hypothesis. A value of <i>p</i> < 0.05 was considered statistically significant. Statistical analyses were performed using GraphPad Prism version 6.02 (GraphPad Software, Inc.).</div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Cell-Based Calcium Accumulation Functional Assay</h3><div class="NLM_p last">HEK-293 cells expressing human OX<sub>1</sub>R or OX<sub>2</sub>R were cultured in Dulbecco’s Minimum Essential Medium (DMEM)/10% fetal bovine serum and frozen in aliquots until use. On the day before the experiment, cells were thawed and seeded at 16000 cells/well into poly-<span class="smallcaps smallerCapital">d</span>-lysine-coated 384-well plates (black walls with transparent bottom) in a culture medium and incubated overnight at 37 °C. On the day of the experiment, the cell supernatant medium was replaced with an assay buffer (115 mM NaCl, 5.4 nM KCl, 0.8 mM MgCl<sub>2</sub>, 1.8 mM CaCl<sub>2</sub>, 13.8 mM <span class="smallcaps smallerCapital">d</span>-glucose, 20 mM HEPES, 0.1% bovine serum albumin), containing Calcium 4 calcium-sensitive dye (FLIPR Calcium4 assay kit, Molecular Devices; Sunnyvale, CA, USA), and cells were subsequently incubated at 37 °C for 1 h, followed by 15 min at room temperature. After transfer to an FDSS6000 device (Hamamatsu Photonics; Hamamatsu, Japan), test compounds dissolved in the assay buffer were added to the cells and allowed to equilibrate for 30 min at room temperature. Baseline fluorescence was measured for approximately 10 s (9 measurements, 1.1 s each) before buffer alone or orexin-A in assay buffer were added in the 10th measurement, followed by 101 additional measurements (1.1 s each). All measurements were obtained using excitation and detection wavelengths of 480 and 540 nm, respectively. Calcium accumulation was expressed as the ratio of peak fluorescence intensity to fluorescence intensity at the baseline (9th measurement). In every experiment, the dose–response of orexin-A was measured to confirm the conditions of the cells and to calculate the half-maximal effective concentration (EC<sub>50</sub>). Test compounds were challenged with orexin-A at a concentration (<i>L</i>) equivalent to EC<sub>80</sub> on both receptors. The inhibition potential of the test compounds was expressed as the concentration necessary to reduce the orexin-A-elicited response by 50% (IC<sub>50</sub>), which was then converted to the inhibition constant, <i>K</i><sub>i</sub>, by using the Cheng–Prusoff formula: <i>K</i><sub>i</sub> = IC<sub>50</sub>/[1 + (<i>L</i>/EC<sub>50</sub>)].</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Evaluation of Pharmacokinetic Profile in Mice</h3><div class="NLM_p last">Compound <b>34</b> was formulated for intravenous (1 mg/kg) and oral (10 mg/kg) administrations in 10% DMSO in water and 10% Cremophor EL, 5% DMSO in saline, respectively, and adeministered to male C57BL/6NCrlCrlj mice. After administration, blood was collected from the tail vein at the designated time points and centrifuged to obtain the plasma sample. Plasma samples were precipitated with 20 volumes of acetonitrile containing the internal standard (10 ng/mL imipramine). Following vortex mixing and centrifugation, the supernatant was filtered, and the resulting filtrate was injected into the LC–MS/MS system. Detection was performed by multiple reaction monitoring in positive ionization mode. The standard curve was obtained from the ratios of the peak area responses relative to the internal standard using linear least-squares regression with a 1/<i>x</i><sup>2</sup> weighting. On the basis of the plasma concentrations, pharmacokinetic parameters were calculated using a software of Phoenix WinNonlin Ver. 6.3 (Certara USA, Inc., Missouri, US) via noncompartment analysis.</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Exploratory Determination of Plasma and CSF Concentrations in Mice</h3><div class="NLM_p">Compound <b>34</b> was formulated as a suspension in 0.5% aqueous methylcellulose and orally administered to male C57BL/6NCrlCrlj mice at a dose of 10 mg/kg. Subsequently, 1 or 3 h after administration, the mice were anesthetized with sodium pentobarbital and CSF was collected from the cisterna magna. Immediately after CSF sampling, a blood sample was collected from the abdominal aorta and centrifuged to obtain the plasma sample. The plasma and CSF samples were stored below −20 °C until analysis by liquid chromatography–tandem mass spectroscopy (LC–MS/MS).</div><div class="NLM_p last">Plasma samples were precipitated with 25 volumes of acetonitrile containing the internal standard (1 ng/mL deuterated <b>34</b>). Following vortex mixing and centrifugation, the supernatant was filtered and the resulting filtrate was injected into the LC–MS/MS system. CSF samples were mixed with 9 volumes of acetonitrile and 50 volumes of acetonitrile containing the internal standard. After vortex mixing, the mixture was injected onto the LC–MS/MS system. Plasma and CSF concentrations were determined by LC–MS/MS, and the values are reported as means ± SEM.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Exploratory Assessment of Plasma Protein Binding in Mice</h3><div class="NLM_p last">The plasma protein binding of compound <b>34</b> in C57BL/6N mice was determined by equilibrium dialysis. Blood was collected from the abdominal vein under anesthesia, and the plasma was obtained via centrifugation. Plasma samples spiked with <b>34</b> (1000 ng/mL) were dialyzed against an equal volume of PBS over a cellulose membrane with a 14000 Da molecular weight cutoff for 24 h at 37 °C. Following the dialysis, plasma and PBS fractions were collected and mixed with 4 volumes of acetonitrile containing the internal standard (100 ng/mL propranolol). After vortex mixing, the mixture was injected into the LC–MS/MS system. Plasma protein binding was calculated based on the concentrations measured in the plasma and PBS fractions using the following equation:<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/jm-2015-00217h_m001.gif" alt="" /></img></span></div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Metabolic Stability Screening in Liver Microsomes</h3><div class="NLM_p last">Test compounds were incubated with human liver microsomes (0.2 mg/mL) in the presence or absence of an NADPH-generating system (60 mM MgCl<sub>2</sub> solution containing 3.6 mM β-NADP<sup>+</sup>, 90 mM glucose-6-phosphate, and 1 unit/mL glucose-6-phosphate dehydrogenase, incubated for 5 min to generate NADPH) for 15 min at 37 °C. After the addition of an equal volume of acetonitrile/methanol (7:3) mixture containing 0.1 μM propranolol as the internal standard to the reaction mixture, the concentration of the test compound was measured using LC–MS. The residual ratio of the compound in the presence of NADPH relative to that in the absence of NADPH was evaluated.</div></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Screening for Time-Dependent CYP Inhibition in Liver Microsomes</h3><div class="NLM_p last">Test compounds were preincubated with human liver microsomes (0.2 mg/mL) in the presence or absence of the NADPH generating system for 30 min at 37 °C. After preincubation, a sample of the reaction solution was collected, diluted 10 times by mixing with a cocktail of CYP marker substrates (phenacetin for CYP1A2, rosiglitazone for CYP2C8, tolbutamide for CYP2C9, S-mephenytoin for CYP2C19, bufuralol for CYP2D6, and midazolam for CYP3A) and the NADPH generating system, and then incubated for 10 min at 37 °C. An equal volume of an acetonitrile/methanol (1:1) mixture containing 0.05 μM dextrorphan or 0.05 μM propranolol as an internal standard was added to the reaction mixtures, and the metabolites of the marker substrates were measured using LC–MS/MS. The ratio of residual activity in the presence of NADPH relative to that in the absence of NADPH was evaluated.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(43)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00217">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46555" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46555" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Synthesis and analytical data of all compounds and intermediates not described in the <a class="ref internalNav" href="#sec3" aria-label="Experimental Section">Experimental Section</a>. The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b00217" class="ext-link">10.1021/acs.jmedchem.5b00217</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00217/suppl_file/jm5b00217_si_001.pdf">jm5b00217_si_001.pdf (815.64 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b00217" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22168" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22168" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu Yoshida</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry, ‡Biopharmacology, §Physical Chemistry, and ∥Drug Metabolism and Pharmacokinetics, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#85fcb4b4a8fceaf6edece1e4c5edede6abe0ecf6e4ecabe6eaabeff5"><span class="__cf_email__" data-cfemail="b9c0888894c0d6cad1d0ddd8f9d1d1da97dcd0cad8d097dad697d3c9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yoshimitsu Naoe</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry, ‡Biopharmacology, §Physical Chemistry, and ∥Drug Metabolism and Pharmacokinetics, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Taro Terauchi</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry, ‡Biopharmacology, §Physical Chemistry, and ∥Drug Metabolism and Pharmacokinetics, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fumihiro Ozaki</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry, ‡Biopharmacology, §Physical Chemistry, and ∥Drug Metabolism and Pharmacokinetics, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takashi Doko</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry, ‡Biopharmacology, §Physical Chemistry, and ∥Drug Metabolism and Pharmacokinetics, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ayumi Takemura</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry, ‡Biopharmacology, §Physical Chemistry, and ∥Drug Metabolism and Pharmacokinetics, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Toshiaki Tanaka</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry, ‡Biopharmacology, §Physical Chemistry, and ∥Drug Metabolism and Pharmacokinetics, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keiichi Sorimachi</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry, ‡Biopharmacology, §Physical Chemistry, and ∥Drug Metabolism and Pharmacokinetics, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carsten T. Beuckmann</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry, ‡Biopharmacology, §Physical Chemistry, and ∥Drug Metabolism and Pharmacokinetics, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michiyuki Suzuki</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry, ‡Biopharmacology, §Physical Chemistry, and ∥Drug Metabolism and Pharmacokinetics, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takashi Ueno</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry, ‡Biopharmacology, §Physical Chemistry, and ∥Drug Metabolism and Pharmacokinetics, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shunsuke Ozaki</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry, ‡Biopharmacology, §Physical Chemistry, and ∥Drug Metabolism and Pharmacokinetics, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masahiro Yonaga</span> - <span class="hlFld-Affiliation affiliation">†Medicinal Chemistry, ‡Biopharmacology, §Physical Chemistry, and ∥Drug Metabolism and Pharmacokinetics, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba-shi, Ibaraki 300-2635, Japan</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1643e5593-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i75">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66502" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66502" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We express our gratitude to the colleagues who supported the generation of data reported in this manuscript. Special thanks to Makoto Nakagawa for in vivo experiment, Eri Ena, Satoko Naito, Masaki Kato, and Yumi Asai for NMR and HRMS analyses, and to Misako Watanabe and Kazuya Nagaoka for chemo-informatic support.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i76" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i76"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i77" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i77"> Abbreviations Used</h2><tr><td class="NLM_term">OX<sub>1</sub>R</td><td class="NLM_def"><p class="first last">orexin 1 receptor</p></td></tr><tr><td class="NLM_term">OX<sub>2</sub>R</td><td class="NLM_def"><p class="first last">orexin 2 receptor</p></td></tr><tr><td class="NLM_term">NaHMDS</td><td class="NLM_def"><p class="first last">sodium bis(trimethylsilyl)amide</p></td></tr><tr><td class="NLM_term">TBDPS</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldiphenylsilyl</p></td></tr><tr><td class="NLM_term">DIAD</td><td class="NLM_def"><p class="first last">diisopropyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>O</i>-(7-azabenzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term"><i>m</i>-CPBA</td><td class="NLM_def"><p class="first last"><i>m</i>-chloroperoxybenzoic acid</p></td></tr><tr><td class="NLM_term">acac</td><td class="NLM_def"><p class="first last">acetylacetone</p></td></tr><tr><td class="NLM_term">Bn</td><td class="NLM_def"><p class="first last">benzyl</p></td></tr><tr><td class="NLM_term">EMG</td><td class="NLM_def"><p class="first last">electromyogram</p></td></tr><tr><td class="NLM_term">ZT</td><td class="NLM_def"><p class="first last">zeitgeber time</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03355" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03355" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 43 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Ozminkowski, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, J. K.</span><span> </span><span class="NLM_article-title">The direct and indirect costs of untreated insomnia in adults in the United States</span> <span class="citation_source-journal">Sleep</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2007&pages=263-273&author=R.+J.+Ozminkowskiauthor=S.+Wangauthor=J.+K.+Walsh&title=The+direct+and+indirect+costs+of+untreated+insomnia+in+adults+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOzminkowski%26aufirst%3DR.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWalsh%26aufirst%3DJ.%2BK.%26atitle%3DThe%2520direct%2520and%2520indirect%2520costs%2520of%2520untreated%2520insomnia%2520in%2520adults%2520in%2520the%2520United%2520States%26jtitle%3DSleep%26date%3D2007%26volume%3D30%26spage%3D263%26epage%3D273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Kessler, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berglund, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coulouvrat, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahly, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shillington, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, J. K.</span><span> </span><span class="NLM_article-title">Insomnia and the Performance of US Workers: Results from the America Insomnia Survey</span> <span class="citation_source-journal">Sleep</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1161</span><span class="NLM_x">–</span> <span class="NLM_lpage">1171</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2011&pages=1161-1171&author=R.+C.+Kesslerauthor=P.+A.+Berglundauthor=C.+Coulouvratauthor=G.+Hajakauthor=T.+Rothauthor=V.+Shahlyauthor=A.+C.+Shillingtonauthor=J.+J.+Stephensonauthor=J.+K.+Walsh&title=Insomnia+and+the+Performance+of+US+Workers%3A+Results+from+the+America+Insomnia+Survey"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DR.%2BC.%26aulast%3DBerglund%26aufirst%3DP.%2BA.%26aulast%3DCoulouvrat%26aufirst%3DC.%26aulast%3DHajak%26aufirst%3DG.%26aulast%3DRoth%26aufirst%3DT.%26aulast%3DShahly%26aufirst%3DV.%26aulast%3DShillington%26aufirst%3DA.%2BC.%26aulast%3DStephenson%26aufirst%3DJ.%2BJ.%26aulast%3DWalsh%26aufirst%3DJ.%2BK.%26atitle%3DInsomnia%2520and%2520the%2520Performance%2520of%2520US%2520Workers%253A%2520Results%2520from%2520the%2520America%2520Insomnia%2520Survey%26jtitle%3DSleep%26date%3D2011%26volume%3D34%26spage%3D1161%26epage%3D1171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Sullivan, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guilleminault, C.</span><span> </span><span class="NLM_article-title">Emerging drugs for insomnia: new frontiers for old and new targets</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">411</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1517%2F14728210903171948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=19708818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVCgurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=411-422&author=S.+S.+Sullivanauthor=C.+Guilleminault&title=Emerging+drugs+for+insomnia%3A+new+frontiers+for+old+and+new+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging drugs for insomnia: new frontiers for old and novel targets</span></div><div class="casAuthors">Sullivan, Shannon S.; Guilleminault, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">411-422</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Insomnia is the most prevalent sleep disorder, with up to 50% of the US adult population reporting symptoms of insomnia on a weekly basis and ∼ 12% with insomnia disorder.  Comorbid conditions such as depression and anxiety are frequent.  Insomnia is more common with older age, female gender and socioeconomic status.  Traditionally, therapy has focused on GABAA receptor agonists, and off-label antidepressant and antihistamine use.  With increased understanding of complex neural networks involved in sleep and wake, hypnotics are being developed to target a broader variety of receptors with increasing selectivity.  This review summarizes promising compds. in Phase II and III trials with evidence supporting efficacy for treatment of insomnia.  5-HT2A and 5-HT2C antagonists, melatonergic (MT1/MT2) agonists, orexin receptor (OX1/OX2) antagonists, as well as GABAA receptor agonists are reviewed and summarized.  Data are collected from PubMed and Pharmaprojects database searches, company websites, recent scientific meeting presentations and abstrs.  A variety of drugs targeting several pathways, including GABAA agonism, MT1/MT2 agonism, 5-HT2A antagonism, OX1/OX2 antagonism and others, are in Phase II and III trials.  More work should be done to understand the impact of these drugs in certain populations and in the context of comorbid conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKfbmX3Dwh4LVg90H21EOLACvtfcHk0ljrNDhQgsJmNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVCgurbF&md5=33f28e611296310e8d3623290e20d7b3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1517%2F14728210903171948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728210903171948%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DS.%2BS.%26aulast%3DGuilleminault%26aufirst%3DC.%26atitle%3DEmerging%2520drugs%2520for%2520insomnia%253A%2520new%2520frontiers%2520for%2520old%2520and%2520new%2520targets%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2009%26volume%3D14%26spage%3D411%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Renger, J. J.</span><span> </span><span class="NLM_article-title">Overview of experimental and conventional pharmacological approaches in the treatment of sleep and wake disorders</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">937</span><span class="NLM_x">–</span> <span class="NLM_lpage">953</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.2174%2F156802608784936755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=18673164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1OhtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=937-953&author=J.+J.+Renger&title=Overview+of+experimental+and+conventional+pharmacological+approaches+in+the+treatment+of+sleep+and+wake+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of experimental and conventional pharmacological approaches in the treatment of sleep and wake disorders</span></div><div class="casAuthors">Renger, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">937-953</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The fundamental purpose of sleep remains one of the most compelling questions yet to be answered in the area of neuroscience, if not all of biol.  A pervasive behavior among members of the animal kingdom, the functional necessity of engaging regularly in sleep is best demonstrated by showing that failing to do so leads to a broad repertoire of pathol. outcomes including cognitive, immunol., hormonal, and metabolic outcomes, among others.  Indeed, an abs. requirement for sleep has been shown in studies that have demonstrated that continuous total deprivation of sleep for as short a period as 15 days is generally lethal in some species.  The most common clin. sleep disorder, insomnia, is both a principal disease (primary insomnia) as well as a co-morbidity of a large no. of other ostensibly unrelated diseases including chronic pain, attention deficit hyperactivity disorder, and depression.  From a treatment perspective, restoring normal healthy sleep delivers subsequent benefits in waking cognitive function and mood with the potential for beneficial therapeutic impact on daily functioning across multiple diseases for which restorative healthy sleep is compromised.  Our remarkable escalation in understanding the anatomy and physiol. of sleep/wake control mechanisms provides new opportunities to modify the neurobiol. of sleep and wake-related behaviors in novel and exciting ways.  In parallel, expansion of sleep research into novel interfaces between sleep-wake biol. and disease states is revealing addnl. extensive implications of lost sleep.  Current investigational and conventional pharmacol. approaches for the treatment of sleep and wake disorders are discussed based on their mechanism of action within the CNS and their effect on sleep and wake.  This review of recent sleep biol. and sleep pharmacol. peers into the future of sleep therapeutics to highlight both mechanistic safety and functional outcomes as key for differentiating and establishing success for the next generation of arousal modifying therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6GNzViXvCXbVg90H21EOLACvtfcHk0ljMzNOo7lOntA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1OhtLw%253D&md5=0f24539a5d8032bde88186f6df1a44a6</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F156802608784936755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608784936755%26sid%3Dliteratum%253Aachs%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26atitle%3DOverview%2520of%2520experimental%2520and%2520conventional%2520pharmacological%2520approaches%2520in%2520the%2520treatment%2520of%2520sleep%2520and%2520wake%2520disorders%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D937%26epage%3D953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Borja, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniel, K. L.</span><span> </span><span class="NLM_article-title">Ramelteon for the treatment of insomnia</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1540</span><span class="NLM_x">–</span> <span class="NLM_lpage">1555</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1016%2Fj.clinthera.2006.10.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=17157111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlartrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2006&pages=1540-1555&author=N.+L.+Borjaauthor=K.+L.+Daniel&title=Ramelteon+for+the+treatment+of+insomnia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Ramelteon for the treatment of insomnia</span></div><div class="casAuthors">Borja, Nancy L.; Daniel, Karen L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1540-1555</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Background: Insomnia is a common sleep disorder with a significant potential for deleterious effects on activities of daily living, productivity, and overall quality of life.  Ramelteon, a highly selective agonist for melatonin subtypes 1 and 2 receptors, is a hypnotic agent approved by the US Food and Drug Administration (FDA) for the treatment of insomnia characterized by difficulty falling asleep.  Objective: This article reviews the pharmacokinetic properties, efficacy, and tolerability of ramelteon in the treatment of insomnia characterized by difficulty falling asleep.  Methods: Relevant articles were identified through searches of MEDLINE (1966 to July 2006), International Pharmaceutical Abstrs. (Jan. 1970 to July 2006), EMBASE Drugs and Pharmacol. (1980 to third quarter 2006), and Current Contents/Clin. Medicine (2005 wk 32 to 2006 wk 31).  Search terms included ramelteon, TAK-375, melatonin agonist, melatonin receptor agonist, insomnia, and sleep disorders/drug therapy (MeSH).  Results: A literature search revealed 12 randomized, controlled clin. trials that examd. the efficacy or tolerability of ramelteon.  In addn., 17 studies were reviewed for pharmacol. and pharmacokinetic data.  The refs. of the clin. trials and recent review articles were examd. to ensure the comprehensiveness of the literature search.  In 2 trials of patients with primary insomnia, patients treated with ramelteon 4 to 32 mg had significant redns. in latency to persistent sleep (LPS) compared with placebo (P < 0.001).  Addnl., improvements in total sleep time (TST) were obsd. (P < 0.001), although increases in TST were noted only on nights 1-2 of the second study.  Similarly, improvement in sleep efficiency was reported only on nights 1-2 of the second trial (P < 0.001).  In elderly patients with primary insomnia, significant redns. in subjective LPS were obsd. with ramelteon 4 and 8 mg (P = 0.008); however, av. subjective LPS was >70 min.  Mean reported TST was significantly increased in the 4-mg group (P = 0.004).  A second study in elderly patients found decreases in LPS with ramelteon 4 mg (P < 0.001) and 8 mg (P < 0.01), as well as significant increases in TST (P < 0.05 and P < 0.01, resp.).  Sleep efficiency improved for patients treated with 4 mg (P < 0.05) and 8 mg (P < 0.01).  Overall, the mean decrease in LPS reported in trials of ramelteon ranged from 10 to 19 min, and the mean increase in TST was 8 to 22 min.  The most common adverse events obsd. with ramelteon included headache (7%), dizziness (5%), somnolence (5%), fatigue (4%), and nausea (3%).  No evidence of cognitive impairment, rebound insomnia, withdrawal effects, or abuse potential was noted.  Conclusions: Based on this review, ramelteon, the first FDA-approved melatonin receptor agonist, represents a pharmacol. option for the treatment of insomnia characterized by difficulty falling asleep.  In patients with insomnia, treatment with ramelteon was generally well tolerated and resulted in modest but statistically significant decreases in LPS.  In the absence of published trials comparing ramelteon with other sedative-hypnotic agents, it is not yet possible to det. its efficacy relative to other therapeutic options for insomnia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH8KOdHeFwbLVg90H21EOLACvtfcHk0ljMzNOo7lOntA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlartrzJ&md5=6c4c07814164db950f6de7c7d593972e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2006.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2006.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DBorja%26aufirst%3DN.%2BL.%26aulast%3DDaniel%26aufirst%3DK.%2BL.%26atitle%3DRamelteon%2520for%2520the%2520treatment%2520of%2520insomnia%26jtitle%3DClin.%2520Ther.%26date%3D2006%26volume%3D28%26spage%3D1540%26epage%3D1555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Sateia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby-Long, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, J. L.</span><span> </span><span class="NLM_article-title">Efficacy and clinical safety of ramelteon: an evidence-based review</span> <span class="citation_source-journal">Sleep Med. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">332</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1016%2Fj.smrv.2007.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=18603221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A280%3ADC%252BD1cvjsVektA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=319-332&author=M.+J.+Sateiaauthor=P.+Kirby-Longauthor=J.+L.+Taylor&title=Efficacy+and+clinical+safety+of+ramelteon%3A+an+evidence-based+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and clinical safety of ramelteon: an evidence-based review</span></div><div class="casAuthors">Sateia Michael J; Kirby-Long Paula; Taylor Jennifer L</div><div class="citationInfo"><span class="NLM_cas:title">Sleep medicine reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">319-32</span>
        ISSN:<span class="NLM_cas:issn">1087-0792</span>.
    </div><div class="casAbstract">Ramelteon is a novel hypnotic compound that is FDA-approved for the treatment of sleep-onset difficulty.  It is a melatonin 1/2 receptor agonist with rapid absorption, extensive first-pass metabolism and an elimination half-life of just over 1h.  Clinical efficacy data indicate moderate efficacy in reduction of sleep latency in adults of all ages with chronic insomnia, with estimated effect sizes roughly comparable to other standard hypnotic agents.  Objective studies show minimal increases in total sleep time and no significant impact on wake after sleep-onset or sleep-stage distribution.  Subjective reports demonstrate comparable, if slightly smaller, improvements.  The recommended dosage is 8mg but studies suggest a flat response across dosage ranges from 4 to 32mg.  Safety data indicate no evidence of clinically significant next-day performance effects and a reasonably low side effect profile.  Animal studies, and a single human study suggest low abuse potential.  Single-blind run-out from clinical trials have demonstrated no evidence of rebound insomnia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTao5mkhqwFD6Nc3HjJRoFAfW6udTcc2eatFKtWD63pP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvjsVektA%253D%253D&md5=7b94aef4c310eef9be12a54af296c001</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.smrv.2007.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.smrv.2007.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DSateia%26aufirst%3DM.%2BJ.%26aulast%3DKirby-Long%26aufirst%3DP.%26aulast%3DTaylor%26aufirst%3DJ.%2BL.%26atitle%3DEfficacy%2520and%2520clinical%2520safety%2520of%2520ramelteon%253A%2520an%2520evidence-based%2520review%26jtitle%3DSleep%2520Med.%2520Rev.%26date%3D2008%26volume%3D12%26spage%3D319%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Sakurai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amemiya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzaki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chemelli, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arch, J. R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckingham, R. E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haynes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annan, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNulty, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terrett, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elshourbagy, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergsma, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, M.</span><span> </span><span class="NLM_article-title">Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">585</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1016%2FS0092-8674%2800%2980949-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=9491897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADyaK1cXhsVKntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1998&pages=573-585&author=T.+Sakuraiauthor=A.+Amemiyaauthor=M.+Ishiiauthor=I.+Matsuzakiauthor=R.+M.+Chemelliauthor=H.+Tanakaauthor=S.+C.+Williamsauthor=J.+A.+Richardsonauthor=G.+P.+Kozlowskiauthor=S.+Wilsonauthor=J.+R.+S.+Archauthor=R.+E.+C.+Buckinghamauthor=A.+C.+Haynesauthor=S.+A.+Carrauthor=R.+S.+Annanauthor=D.+E.+McNultyauthor=W.+S.+Liuauthor=J.+A.+Terrettauthor=N.+A.+Elshourbagyauthor=D.+J.+Bergsmaauthor=M.+Yanagisawa&title=Orexins+and+orexin+receptors%3A+a+family+of+hypothalamic+neuropeptides+and+G+protein-coupled+receptors+that+regulate+feeding+behavior"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior</span></div><div class="casAuthors">Sakurai, Takeshi; Amemiya, Akira; Ishii, Makoto; Matsuzaki, Ichiyo; Chemelli, Richard M.; Tanaka, Hirokazu; Williams, S. Clay; Richardson, James A.; Kozlowski, Gerald P.; Wilson, Shelagh; Arch, Jonathan R. S.; Buckingham, Robin E.; Haynes, Andrea C.; Carr, Steven A.; Annan, Roland S.; Mcnulty, Dean E.; Liu, Wu-Schyong; Terrett, Jonathan A.; Elshourbagy, Nabil A.; Bergsma, Derk J.; Yanagisawa, Masashi</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">573-585</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The hypothalamus plays a central role in the integrated control of feeding and energy homeostasis.  The authors have identified two novel neuropeptides, both derived from the same precursor by proteolytic processing, that bind and activate two closely related (previously) orphan G protein-coupled receptors.  These peptides, termed orexin-A and -B, have no significant structural similarities to known families of regulatory peptides.  Prepro-orexin mRNA and immunoreactive orexin-A are localized in neurons within and around the lateral and posterior hypothalamus in the adult rat brain.  When administered centrally to rats, these peptides stimulate food consumption.  Prepro-orexin mRNA level is up-regulated upon fasting, suggesting a physiol. role for the peptides as mediators in the central feedback mechanism that regulates feeding behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA5y2uicTVlLVg90H21EOLACvtfcHk0liINd87By6LQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhsVKntr4%253D&md5=c0d02e69cd976521abfc5f88e8be7dda</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980949-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980949-6%26sid%3Dliteratum%253Aachs%26aulast%3DSakurai%26aufirst%3DT.%26aulast%3DAmemiya%26aufirst%3DA.%26aulast%3DIshii%26aufirst%3DM.%26aulast%3DMatsuzaki%26aufirst%3DI.%26aulast%3DChemelli%26aufirst%3DR.%2BM.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DS.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BA.%26aulast%3DKozlowski%26aufirst%3DG.%2BP.%26aulast%3DWilson%26aufirst%3DS.%26aulast%3DArch%26aufirst%3DJ.%2BR.%2BS.%26aulast%3DBuckingham%26aufirst%3DR.%2BE.%2BC.%26aulast%3DHaynes%26aufirst%3DA.%2BC.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DAnnan%26aufirst%3DR.%2BS.%26aulast%3DMcNulty%26aufirst%3DD.%2BE.%26aulast%3DLiu%26aufirst%3DW.%2BS.%26aulast%3DTerrett%26aufirst%3DJ.%2BA.%26aulast%3DElshourbagy%26aufirst%3DN.%2BA.%26aulast%3DBergsma%26aufirst%3DD.%2BJ.%26aulast%3DYanagisawa%26aufirst%3DM.%26atitle%3DOrexins%2520and%2520orexin%2520receptors%253A%2520a%2520family%2520of%2520hypothalamic%2520neuropeptides%2520and%2520G%2520protein-coupled%2520receptors%2520that%2520regulate%2520feeding%2520behavior%26jtitle%3DCell%26date%3D1998%26volume%3D92%26spage%3D573%26epage%3D585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">De Lecea, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilduff, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foye, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danielson, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuhara, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battenberg, E. L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gautvik, V. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartlett, F. S.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankel, W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Den Pol, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gautvik, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutcliffe, J. G.</span><span> </span><span class="NLM_article-title">The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">322</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1073%2Fpnas.95.1.322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=9419374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADyaK1cXjtl2hsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=322-327&author=L.+De+Leceaauthor=T.+S.+Kilduffauthor=C.+Peyronauthor=X.-B.+Gaoauthor=P.+E.+Foyeauthor=P.+E.+Danielsonauthor=C.+Fukuharaauthor=E.+L.+F.+Battenbergauthor=V.+T.+Gautvikauthor=F.+S.+Bartlettauthor=W.+N.+Frankelauthor=A.+N.+Van+Den+Polauthor=F.+E.+Bloomauthor=K.+M.+Gautvikauthor=J.+G.+Sutcliffe&title=The+hypocretins%3A+hypothalamus-specific+peptides+with+neuroexcitatory+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity</span></div><div class="casAuthors">De Lecea, L.; Kilduff, T. S.; Peyron, C.; Gao, X. -B.; Foye, P. E.; Danielson, P. E.; Fukuhara, C.; Battenberg, E. L. F.; Gautvik, V. T.; Bartlett, F. S., II; Frankel, W. N.; Van Den Pol, A. N.; Bloom, F. E.; Gautvik, K. M.; Sutcliffe, J. G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">322-327</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We describe a hypothalamus-specific mRNA that encodes preprohypocretin, the putative precursor of a pair of peptides that share substantial amino acid identities with the gut hormone secretin.  The hypocretin (Hcrt) protein products are restricted to neuronal cell bodies of the dorsal and lateral hypothalamic areas.  The fibers of these neurons are widespread throughout the posterior hypothalamus and project to multiple targets in other areas, including brainstem and thalamus.  Hcrt immunoreactivity is assocd. with large granular vesicles at synapses.  One of the Hcrt peptides was excitatory when applied to cultured, synaptically coupled hypothalamic neurons, but not hippocampal neurons.  These observations suggest that the hypocretins function within the CNS as neurotransmitters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAEQa5lFLKr7Vg90H21EOLACvtfcHk0lgCdp3oA9daaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtl2hsw%253D%253D&md5=52bde93a7933953f02930a6f57a0f1b1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.1.322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.1.322%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLecea%26aufirst%3DL.%26aulast%3DKilduff%26aufirst%3DT.%2BS.%26aulast%3DPeyron%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DX.-B.%26aulast%3DFoye%26aufirst%3DP.%2BE.%26aulast%3DDanielson%26aufirst%3DP.%2BE.%26aulast%3DFukuhara%26aufirst%3DC.%26aulast%3DBattenberg%26aufirst%3DE.%2BL.%2BF.%26aulast%3DGautvik%26aufirst%3DV.%2BT.%26aulast%3DBartlett%26aufirst%3DF.%2BS.%26aulast%3DFrankel%26aufirst%3DW.%2BN.%26aulast%3DVan%2BDen%2BPol%26aufirst%3DA.%2BN.%26aulast%3DBloom%26aufirst%3DF.%2BE.%26aulast%3DGautvik%26aufirst%3DK.%2BM.%26aulast%3DSutcliffe%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520hypocretins%253A%2520hypothalamus-specific%2520peptides%2520with%2520neuroexcitatory%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D322%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Van den Pol, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obrietan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilduff, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belousov, A. B.</span><span> </span><span class="NLM_article-title">Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">7962</span><span class="NLM_x">–</span> <span class="NLM_lpage">7971</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=9742163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADyaK1cXmtlequrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=7962-7971&author=A.+N.+Van+den+Polauthor=X.-B.+Gaoauthor=K.+Obrietanauthor=T.+S.+Kilduffauthor=A.+B.+Belousov&title=Presynaptic+and+postsynaptic+actions+and+modulation+of+neuroendocrine+neurons+by+a+new+hypothalamic+peptide%2C+hypocretin%2Forexin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin</span></div><div class="casAuthors">Van Den Pol, Anthony N.; Gao, Xiao-Bing; Obrietan, Karl; Kilduff, Thomas S.; Belousov, Andrei B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7962-7971</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">A new orexigenic peptide called hypocretin (orexin) has recently been described in neurons of the lateral hypothalamus and perifornical area.  The medial and lateral hypothalamus have been loosely called satiety and feeding centers of the brain, resp.  Approx. one-third of all medial and lateral hypothalamic neurons tested, but not hippocampal neurons, show a striking nanomolar sensitivity to hypocretin.  As studied with calcium digital imaging with fura-2, hypocretin raises cytoplasmic calcium via a mechanism based on G-protein enhancement of calcium influx through plasma membrane channels.  The peptide has a potent effect at both presynaptic and postsynaptic receptors.  Most synaptic activity in hypothalamic circuits is attributable to axonal release of GABA or glutamate.  With whole-cell patch-clamp recording, the authors show that hypocretin, acting directly at axon terminals, can increase the release of each of these amino acid transmitters.  Two hypocretin peptides, hypocretin-1 and hypocretin-2, are coded by a single gene; neurons that respond to one peptide also respond to the other.  In addn. to its effect on feeding, the authors find that this peptide also regulates the synaptic activity of physiol. identified neuroendocrine neurons studied in hypothalamic slices contg. the arcuate nucleus, suggesting a second function of hypocretin in hormone regulation.  The widespread distribution of hypocretin axons, coupled with the strong response to the peptide at both presynaptic and postsynaptic sites, suggests that the peptide probably modulates a variety of hypothalamic regulatory systems and could regulate the axonal input to these regions presynaptically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHi6BCCJkJnbVg90H21EOLACvtfcHk0ljrkdrQXiLXkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtlequrk%253D&md5=09608e3c2453416db5bdab5af3598479</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bden%2BPol%26aufirst%3DA.%2BN.%26aulast%3DGao%26aufirst%3DX.-B.%26aulast%3DObrietan%26aufirst%3DK.%26aulast%3DKilduff%26aufirst%3DT.%2BS.%26aulast%3DBelousov%26aufirst%3DA.%2BB.%26atitle%3DPresynaptic%2520and%2520postsynaptic%2520actions%2520and%2520modulation%2520of%2520neuroendocrine%2520neurons%2520by%2520a%2520new%2520hypothalamic%2520peptide%252C%2520hypocretin%252Forexin%26jtitle%3DJ.%2520Neurosci.%26date%3D1998%26volume%3D18%26spage%3D7962%26epage%3D7971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Beuckmann, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, M.</span><span> </span><span class="NLM_article-title">Orexins: from neuropeptides to energy homeostasis and sleep/wake regulation</span> <span class="citation_source-journal">J. Mol. Med. (Berlin, Ger.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1007%2Fs00109-002-0322-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=12072908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvV2msLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2002&pages=329-342&author=C.+T.+Beuckmannauthor=M.+Yanagisawa&title=Orexins%3A+from+neuropeptides+to+energy+homeostasis+and+sleep%2Fwake+regulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Orexins: From neuropeptides to energy homeostasis and sleep/wake regulation</span></div><div class="casAuthors">Beuckmann, Carsten T.; Yanagisawa, Masashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">329-342</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review.  The neuropeptides orexin A and orexin B (also called hypocretin 1 and 2) were recently discovered by a "reverse pharmacol." approach as ligands for two previously orphan G protein coupled receptors: orexin receptors 1 and 2.  Neurons producing orexins are located exclusively in the lateral hypothalamic area but project broadly to various parts of the brain, and they have been implicated in the control of energy homeostasis and arousal maintenance.  The orexin receptors are also broadly expressed in the central nervous system.  Murine and canine models suggest that defective signaling in the orexin system is responsible for the sleep/wake disorder narcolepsy.  Although narcoleptic patients rarely have genetic defects in the orexin system, they lack these neuropeptides in the brain and cerebrospinal fluid, indicating that human narcolepsy is an orexin deficiency syndrome in the majority of cases.  A connection between sleep/wake regulation and energy homeostasis is hypothesized with orexin neuropeptides as a mol. link.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGw06TNAJMLbVg90H21EOLACvtfcHk0ljrkdrQXiLXkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvV2msLw%253D&md5=8eceae17326204246280a2d7fe1e5381</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00109-002-0322-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-002-0322-x%26sid%3Dliteratum%253Aachs%26aulast%3DBeuckmann%26aufirst%3DC.%2BT.%26aulast%3DYanagisawa%26aufirst%3DM.%26atitle%3DOrexins%253A%2520from%2520neuropeptides%2520to%2520energy%2520homeostasis%2520and%2520sleep%252Fwake%2520regulation%26jtitle%3DJ.%2520Mol.%2520Med.%2520%2528Berlin%252C%2520Ger.%2529%26date%3D2002%26volume%3D80%26spage%3D329%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Brisbare-Roch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingemanse, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koberstein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoever, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aissaoui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gerven, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haas, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenck, F.</span><span> </span><span class="NLM_article-title">Promotion of sleep by targeting the orexin system in rats, dogs and humans</span> <span class="citation_source-journal">Nature Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">150</span><span class="NLM_x">–</span> <span class="NLM_lpage">155</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=150-155&author=C.+Brisbare-Rochauthor=J.+Dingemanseauthor=R.+Kobersteinauthor=P.+Hoeverauthor=H.+Aissaouiauthor=S.+Floresauthor=C.+Muellerauthor=O.+Naylerauthor=J.+van+Gervenauthor=S.+L.+de+Haasauthor=P.+Hessauthor=C.+Qiuauthor=S.+Buchmannauthor=M.+Scherzauthor=T.+Wellerauthor=W.+Fischliauthor=M.+Clozelauthor=F.+Jenck&title=Promotion+of+sleep+by+targeting+the+orexin+system+in+rats%2C+dogs+and+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrisbare-Roch%26aufirst%3DC.%26aulast%3DDingemanse%26aufirst%3DJ.%26aulast%3DKoberstein%26aufirst%3DR.%26aulast%3DHoever%26aufirst%3DP.%26aulast%3DAissaoui%26aufirst%3DH.%26aulast%3DFlores%26aufirst%3DS.%26aulast%3DMueller%26aufirst%3DC.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3Dvan%2BGerven%26aufirst%3DJ.%26aulast%3Dde%2BHaas%26aufirst%3DS.%2BL.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DQiu%26aufirst%3DC.%26aulast%3DBuchmann%26aufirst%3DS.%26aulast%3DScherz%26aufirst%3DM.%26aulast%3DWeller%26aufirst%3DT.%26aulast%3DFischli%26aufirst%3DW.%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DJenck%26aufirst%3DF.%26atitle%3DPromotion%2520of%2520sleep%2520by%2520targeting%2520the%2520orexin%2520system%2520in%2520rats%252C%2520dogs%2520and%2520humans%26jtitle%3DNature%2520Med.%26date%3D2007%26volume%3D13%26spage%3D150%26epage%3D155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Sato-Suzuki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kita, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oguri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, H.</span><span> </span><span class="NLM_article-title">Cortical arousal induced by microinjection of orexins into the paraventricular nucleus of the rat</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2002&pages=169-177&author=I.+Sato-Suzukiauthor=I.+Kitaauthor=Y.+Sekiauthor=M.+Oguriauthor=H.+Arita&title=Cortical+arousal+induced+by+microinjection+of+orexins+into+the+paraventricular+nucleus+of+the+rat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSato-Suzuki%26aufirst%3DI.%26aulast%3DKita%26aufirst%3DI.%26aulast%3DSeki%26aufirst%3DY.%26aulast%3DOguri%26aufirst%3DM.%26aulast%3DArita%26aufirst%3DH.%26atitle%3DCortical%2520arousal%2520induced%2520by%2520microinjection%2520of%2520orexins%2520into%2520the%2520paraventricular%2520nucleus%2520of%2520the%2520rat%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2002%26volume%3D128%26spage%3D169%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Akanmu, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honda, K.</span><span> </span><span class="NLM_article-title">Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1048</span><span class="NLM_x">, </span> <span class="NLM_fpage">138</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1016%2Fj.brainres.2005.04.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=15919057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt1Grtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1048&publication_year=2005&pages=138-145&author=M.+A.+Akanmuauthor=K.+Honda&title=Selective+stimulation+of+orexin+receptor+type+2+promotes+wakefulness+in+freely+behaving+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats</span></div><div class="casAuthors">Akanmu, Moses A.; Honda, Kazuki</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1048</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">138-145</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Orexins A and B are a pair of neuropeptides implicated in the regulation of feeding and arousal behavior mediated through two orexin receptors type 1 and type 2.  The authors have detd. the arousal effects of newly developed selective orexin receptor type 2 agonist, [Ala11]orexin-B, on the sleep-wake cycle in rats.  The effects of third ventricle intracerebroventricular (ICV) infusion of the novel orexin receptor type 2 selective agonist, [Ala11]orexin-B, on the sleep-wake cycle were investigated.  ICV infusion of [Ala11]orexin-B (1, 10 and 40 nmol) during the light period (11:00-16:00) dose-dependently resulted in a significant increase in wake duration by 46.9% (n = 5, P < 0.05), 159.2% (n = 4, P < 0.01) and 163.6% (n = 7, P < 0.01), resp., and a significant decrease in rapid eye movement (REM) (P < 0.01) and non-REM sleep (P < 0.01) for all doses.  In contrast, ICV infusion of orexin B at the same doses (1, 10 and 40 nmol) caused a 16.6% (n = 6, non-significant), 99.8% (n = 6, P < 0.05) and 72.0% (n = 4, P < 0.05) increase in wakefulness, resp.  Moreover, orexin-A, which exerts its effects through orexin receptor type 1 and orexin receptor type 2 with similar potency, resulted in a significant increase in wakefulness duration by 17.1% (n = 6, P < 0.05), 184.0% (n = 6, P < 0.01) and 228.6% (n = 6, P < 0.01) at doses of 0.1, 1 and 10 nmol, resp.  Further, the enhancement of wakefulness was accompanied by a marked redn. in REM and non-REM sleep.  These findings suggest that orexin receptor type 2 plays an important role in the modulation of sleep-wake state and behavioral responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxWQ0WqME6H7Vg90H21EOLACvtfcHk0lhHp3_j_M1f_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt1Grtr8%253D&md5=60ca1e78ee562eda40d65110a8b6ae7f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2005.04.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2005.04.064%26sid%3Dliteratum%253Aachs%26aulast%3DAkanmu%26aufirst%3DM.%2BA.%26aulast%3DHonda%26aufirst%3DK.%26atitle%3DSelective%2520stimulation%2520of%2520orexin%2520receptor%2520type%25202%2520promotes%2520wakefulness%2520in%2520freely%2520behaving%2520rats%26jtitle%3DBrain%2520Res.%26date%3D2005%26volume%3D1048%26spage%3D138%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Dugovic, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aluisio, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span> </span><span class="NLM_article-title">Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">142</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1124%2Fjpet.109.152009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=19363060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFeltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=142-151&author=C.+Dugovicauthor=J.+E.+Sheltonauthor=L.+E.+Aluisioauthor=I.+C.+Fraserauthor=X.+Jiangauthor=S.+W.+Suttonauthor=P.+Bonaventureauthor=S.+Yunauthor=X.+Liauthor=B.+Lordauthor=C.+A.+Dvorakauthor=N.+I.+Carruthersauthor=T.+W.+Lovenberg&title=Blockade+of+orexin-1+receptors+attenuates+orexin-2+receptor+antagonism-induced+sleep+promotion+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat</span></div><div class="casAuthors">Dugovic, Christine; Shelton, Jonathan E.; Aluisio, Leah E.; Fraser, Ian C.; Jiang, Xiaohui; Sutton, Steven W.; Bonaventure, Pascal; Yun, Sujin; Li, Xiaorong; Lord, Brian; Dvorak, Curt A.; Carruthers, Nicholas I.; Lovenberg, Timothy W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">142-151</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Orexins are peptides produced by lateral hypothalamic neurons that exert a prominent role in the maintenance of wakefulness by activating orexin-1 (OX1R) and orexin-2 (OX2R) receptor located in wake-active structures.  Pharmacol. blockade of both receptors by the dual OX1/2R antagonist (2R)-2-[(1S)-6,7-dimethoxy-1-{2-[4-(trifluoromethyl)phenyl]ethyl}-3,4-dihydroisoquinolin-2(1H)-yl]-N-methyl-2-phenylethanamide (almorexant) has been shown to promote sleep in animals and humans during their active period.  However, the selective distribution of OX1R and OX2R in distinct neuronal circuits may result in a differential impact of these receptors in sleep-wake modulation.  The resp. role of OX1R and OX2R on sleep in correlation with monoamine release was evaluated in rats treated with selective antagonists alone or in combination.  When administered in either phase of the light/dark cycle, the OX2R antagonist 1-(2,4-dibromophenyl)-3-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]urea (JNJ-10397049) decreased the latency for persistent sleep and increased nonrapid eye movement and rapid eye movement sleep time.  Almorexant produced less hypnotic activity, whereas the OX1R antagonist 1-(6,8-difluoro-2-methylquinolin-4-yl)-3-[4-(dimethylamino)phenyl]urea (SB-408124) had no effect.  Microdialysis studies showed that either OX2R or OX1/2R antagonism decreased extracellular histamine concn. in the lateral hypothalamus, whereas both OX1R and OX1/2R antagonists increased dopamine release in the prefrontal cortex.  Finally, coadministration of the OX1R with the OX2R antagonist greatly attenuated the sleep-promoting effects of the OX2R antagonist.  These results indicate that blockade of OX2R is sufficient to initiate and prolong sleep, consistent with the hypothesis of a deactivation of the histaminergic system.  In addn., it is suggested that simultaneous inhibition of OX1R attenuates the sleep-promoting effects mediated by selective OX2R blockade, possibly correlated with dopaminergic neurotransmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPXVs02jXOYLVg90H21EOLACvtfcHk0ljTiWVneAQhqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFeltLk%253D&md5=32a5fc48d949eef2a633187c274cec80</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.152009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.152009%26sid%3Dliteratum%253Aachs%26aulast%3DDugovic%26aufirst%3DC.%26aulast%3DShelton%26aufirst%3DJ.%2BE.%26aulast%3DAluisio%26aufirst%3DL.%2BE.%26aulast%3DFraser%26aufirst%3DI.%2BC.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DSutton%26aufirst%3DS.%2BW.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DYun%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DDvorak%26aufirst%3DC.%2BA.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26atitle%3DBlockade%2520of%2520orexin-1%2520receptors%2520attenuates%2520orexin-2%2520receptor%2520antagonism-induced%2520sleep%2520promotion%2520in%2520the%2520rat%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26spage%3D142%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Kummangal, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallick, H. N.</span><span> </span><span class="NLM_article-title">Intracerebroventricular injection of orexin-2 receptor antagonist promotes REM sleep</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">237</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=2013&pages=59-62&author=B.+A.+Kummangalauthor=D.+Kumarauthor=H.+N.+Mallick&title=Intracerebroventricular+injection+of+orexin-2+receptor+antagonist+promotes+REM+sleep"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKummangal%26aufirst%3DB.%2BA.%26aulast%3DKumar%26aufirst%3DD.%26aulast%3DMallick%26aufirst%3DH.%2BN.%26atitle%3DIntracerebroventricular%2520injection%2520of%2520orexin-2%2520receptor%2520antagonist%2520promotes%2520REM%2520sleep%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2013%26volume%3D237%26spage%3D59%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Boss, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roch-Brisbare, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietrich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenck, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Raumer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sifferlen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brotschi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aissaoui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegrist, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatfield, J.</span><span> </span><span class="NLM_article-title">Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonist</span> <span class="citation_source-journal">ChemMedChem. </span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2486</span><span class="NLM_x">–</span> <span class="NLM_lpage">2496</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1002%2Fcmdc.201402258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=25147058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSisLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2486-2496&author=C.+Bossauthor=C.+Roch-Brisbareauthor=M.+A.+Steinerauthor=A.+Treiberauthor=H.+Dietrichauthor=F.+Jenckauthor=M.+von+Raumerauthor=T.+Sifferlenauthor=C.+Brotschiauthor=B.+Heidmannauthor=J.+T.+Williamsauthor=H.+Aissaouiauthor=R.+Siegristauthor=J.+Gatfield&title=Structure-activity+relationship%2C+biological%2C+and+pharmacological+characterization+of+the+proline+sulfonamide+ACT-462206%3A+a+potent%2C+brain-penetrant+dual+orexin+1%2Forexin+2+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship, Biological, and Pharmacological Characterization of the Proline Sulfonamide ACT-462206: a Potent, Brain-Penetrant Dual Orexin 1/Orexin 2 Receptor Antagonist</span></div><div class="casAuthors">Boss, Christoph; Roch-Brisbare, Catherine; Steiner, Michel A.; Treiber, Alexander; Dietrich, Hendrik; Jenck, Francois; von Raumer, Markus; Sifferlen, Thierry; Brotschi, Christine; Heidmann, Bibia; Williams, Jodi; Aissaoui, Hamed; Siegrist, Romain; Gatfield, John</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2486-2496</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The orexin system consists of two G-protein-coupled receptors, the orexin 1 and orexin 2 receptors, widely expressed in diverse regions of the brain, and two peptide agonists, orexin A and orexin B, which are produced in a small assembly of neurons in the lateral hypothalamus.  The orexin system plays an important role in the maintenance of wakefulness.  Several compds. (almorexant, SB-649868, suvorexant) have been in advanced clin. trials for treating primary insomnia.  ACT-462206 is a new, potent, and selective dual orexin receptor antagonist (DORA) that inhibits the stimulating effects of the orexin peptides at both the orexin 1 and 2 receptors.  It decreases wakefulness and increases non-rapid eye movement (non-REM) and REM sleep while maintaining natural sleep architectures in rat and dog electroencephalog./electromyog. (EEG/EMG) expts.  ACT-462206 shows anxiolytic-like properties in rats without affecting cognition and motor function.  It is therefore a potential candidate for the treatment of insomnia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq058gWHsGWELVg90H21EOLACvtfcHk0ljTiWVneAQhqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSisLnJ&md5=2a9dca30961510eee24034a4524d441e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402258%26sid%3Dliteratum%253Aachs%26aulast%3DBoss%26aufirst%3DC.%26aulast%3DRoch-Brisbare%26aufirst%3DC.%26aulast%3DSteiner%26aufirst%3DM.%2BA.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DDietrich%26aufirst%3DH.%26aulast%3DJenck%26aufirst%3DF.%26aulast%3Dvon%2BRaumer%26aufirst%3DM.%26aulast%3DSifferlen%26aufirst%3DT.%26aulast%3DBrotschi%26aufirst%3DC.%26aulast%3DHeidmann%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DJ.%2BT.%26aulast%3DAissaoui%26aufirst%3DH.%26aulast%3DSiegrist%26aufirst%3DR.%26aulast%3DGatfield%26aufirst%3DJ.%26atitle%3DStructure-activity%2520relationship%252C%2520biological%252C%2520and%2520pharmacological%2520characterization%2520of%2520the%2520proline%2520sulfonamide%2520ACT-462206%253A%2520a%2520potent%252C%2520brain-penetrant%2520dual%2520orexin%25201%252Forexin%25202%2520receptor%2520antagonist%26jtitle%3DChemMedChem.%2520%26date%3D2014%26volume%3D9%26spage%3D2486%26epage%3D2496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Boss, C.</span><span> </span><span class="NLM_article-title">Orexin receptor antagonists - a patent review</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1367</span><span class="NLM_x">–</span> <span class="NLM_lpage">1381</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1517%2F13543776.2014.978859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=25407283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFejsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=1367-1381&author=C.+Boss&title=Orexin+receptor+antagonists+-+a+patent+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Orexin receptor antagonists - a patent review (2010 to August 2014)</span></div><div class="casAuthors">Boss, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1367-1381</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: The orexin (hypocretin) system is an evolutionarily conserved neuropeptide-G-protein-coupled receptor system, consisting of two neuropeptides the orexin-A and the orexin-B peptides as well as two receptors the orexin-1 and the orexin-2 receptors.  The orexin system is crucially involved in the regulation of the circadian rhythm, states of wakefulness and arousal and the modulation of emotions and has attracted the interest of many researchers which resulted in an enormous amt. of insight, mainly in the field of antagonists.  Clin. proof of concept was obtained with dual orexin receptor antagonists in primary insomnia.  Merck's suvorexant got FDA approval on 13 August 2014 for the treatment of insomnia.  Areas covered: The patent applications from Thomson Reuters Integrity Database (covering 2010 - August 2014) are summarized, analyzed and discussed in the review.  Expert opinion: Intense patenting activities have been obsd. over the past 3 years in the field of orexin antagonists.  Several compds. have been investigated in clin. trials mainly for the treatment of primary insomnia.  The advantage of orexin antagonists, based on animal pharmacol. results, is the promotion and maintenance of physiol. sleep which should avoid hangover phenomena reported as side effects of approved treatments.  Many other potential treatment options are mentioned for orexin antagonists of different selectivity profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_El4j7cEx47Vg90H21EOLACvtfcHk0liSoxVE1BOvSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFejsr%252FO&md5=560c906cf24a15310f9f1a2ae1dbc92a</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.978859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.978859%26sid%3Dliteratum%253Aachs%26aulast%3DBoss%26aufirst%3DC.%26atitle%3DOrexin%2520receptor%2520antagonists%2520-%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D1367%26epage%3D1381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Christopher, J. A.</span><span> </span><span class="NLM_article-title">Small-molecule antagonists of the orexin receptors</span> <span class="citation_source-journal">Pharm. Pat. Anal.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">625</span><span class="NLM_x">–</span> <span class="NLM_lpage">638</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.4155%2Fppa.14.46" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=25489915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCrs7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=625-638&author=J.+A.+Christopher&title=Small-molecule+antagonists+of+the+orexin+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule antagonists of the orexin receptors</span></div><div class="casAuthors">Christopher, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Patent Analyst</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">625-638</span>CODEN:
                <span class="NLM_cas:coden">PPAHCN</span>;
        ISSN:<span class="NLM_cas:issn">2046-8954</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The orexin-1 and orexin-2 receptors are two G protein-coupled receptors that bind the neuropeptides orexin-A and orexin-B.  Dual antagonism of the receptors by small mols. is clin. efficacious in the treatment of insomnia, where the most advanced mol. suvorexant has recently been approved.  The scope of this article is to review the small mol. orexin receptor antagonist patent literature between Jan. 2012 and Jan. 2014.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopenQpzY9wD7Vg90H21EOLACvtfcHk0liSoxVE1BOvSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCrs7vF&md5=e5b05ee60ec2568410395bf20c26b588</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.4155%2Fppa.14.46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fppa.14.46%26sid%3Dliteratum%253Aachs%26aulast%3DChristopher%26aufirst%3DJ.%2BA.%26atitle%3DSmall-molecule%2520antagonists%2520of%2520the%2520orexin%2520receptors%26jtitle%3DPharm.%2520Pat.%2520Anal.%26date%3D2014%26volume%3D3%26spage%3D625%26epage%3D638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Bingham, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deehan, M. R.</span><span> </span><span class="NLM_article-title">Eating, sleeping and rewarding: Orexin receptors and their antagonists</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">–</span> <span class="NLM_lpage">559</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=551-559&author=M.+J.+Binghamauthor=J.+Caiauthor=M.+R.+Deehan&title=Eating%2C+sleeping+and+rewarding%3A+Orexin+receptors+and+their+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBingham%26aufirst%3DM.%2BJ.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DDeehan%26aufirst%3DM.%2BR.%26atitle%3DEating%252C%2520sleeping%2520and%2520rewarding%253A%2520Orexin%2520receptors%2520and%2520their%2520antagonists%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2006%26volume%3D9%26spage%3D551%26epage%3D559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Sakurai, T.</span><span> </span><span class="NLM_article-title">The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness</span> <span class="citation_source-journal">Nature Rev. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1038%2Fnrn2092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=17299454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=171-181&author=T.+Sakurai&title=The+neural+circuit+of+orexin+%28hypocretin%29%3A+maintaining+sleep+and+wakefulness"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness</span></div><div class="casAuthors">Sakurai, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-181</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Sleep and wakefulness are regulated to occur at appropriate times that are in accordance with our internal and external environments.  Avoiding danger and finding food, which are life-essential activities that are regulated by emotion, reward and energy balance, require vigilance and therefore, by definition, wakefulness.  The orexin (hypocretin) system regulates sleep and wakefulness through interactions with systems that regulate emotion, reward and energy homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopn63To7y5mLVg90H21EOLACvtfcHk0ljmNvPHwIavkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyqu7s%253D&md5=8d3c4c98d3c725b34bc59bc455f44615</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrn2092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn2092%26sid%3Dliteratum%253Aachs%26aulast%3DSakurai%26aufirst%3DT.%26atitle%3DThe%2520neural%2520circuit%2520of%2520orexin%2520%2528hypocretin%2529%253A%2520maintaining%2520sleep%2520and%2520wakefulness%26jtitle%3DNature%2520Rev.%2520Neurosci.%26date%3D2007%26volume%3D8%26spage%3D171%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Hara, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beuckmann, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willie, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chemelli, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinton, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yagami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, T.</span><span> </span><span class="NLM_article-title">Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1016%2FS0896-6273%2801%2900293-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=11394998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktFeisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2001&pages=345-354&author=J.+Haraauthor=C.+T.+Beuckmannauthor=T.+Nambuauthor=J.+T.+Willieauthor=R.+M.+Chemelliauthor=C.+M.+Sintonauthor=F.+Sugiyamaauthor=K.+Yagamiauthor=K.+Gotoauthor=M.+Yanagisawaauthor=T.+Sakurai&title=Genetic+ablation+of+orexin+neurons+in+mice+results+in+narcolepsy%2C+hypophagia%2C+and+obesity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity</span></div><div class="casAuthors">Hara, Junko; Beuckmann, Carsten T.; Nambu, Tadahiro; Willie, Jon T.; Chemelli, Richard M.; Sinton, Christopher M.; Sugiyama, Fumihiro; Yagami, Ken-Ichi; Goto, Katsutoshi; Yanagisawa, Masashi; Sakurai, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">345-354</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Orexins (hypocretins) are a pair of neuropeptides implicated in energy homeostasis and arousal.  Recent reports suggest that loss of orexin-contg. neurons occurs in human patients with narcolepsy.  We generated transgenic mice in which orexin-contg. neurons are ablated by orexinergic-specific expression of a truncated Machado-Joseph disease gene product (ataxin-3) with an expanded polyglutamine stretch.  These mice showed a phenotype strikingly similar to human narcolepsy, including behavioral arrests, premature entry into rapid eye movement (REM) sleep, poorly consolidated sleep patterns, and a late-onset obesity, despite eating less than nontransgenic littermates.  These results provide evidence that orexin-contg. neurons play important roles in regulating vigilance states and energy homeostasis.  Orexin/ataxin-3 mice provide a valuable model for studying the pathophysiol. and treatment of narcolepsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW-IREBtcUCbVg90H21EOLACvtfcHk0ljmNvPHwIavkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktFeisbc%253D&md5=5e30da52fb8a0446e7a1b5eb33e11e97</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0896-6273%2801%2900293-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0896-6273%252801%252900293-8%26sid%3Dliteratum%253Aachs%26aulast%3DHara%26aufirst%3DJ.%26aulast%3DBeuckmann%26aufirst%3DC.%2BT.%26aulast%3DNambu%26aufirst%3DT.%26aulast%3DWillie%26aufirst%3DJ.%2BT.%26aulast%3DChemelli%26aufirst%3DR.%2BM.%26aulast%3DSinton%26aufirst%3DC.%2BM.%26aulast%3DSugiyama%26aufirst%3DF.%26aulast%3DYagami%26aufirst%3DK.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DYanagisawa%26aufirst%3DM.%26aulast%3DSakurai%26aufirst%3DT.%26atitle%3DGenetic%2520ablation%2520of%2520orexin%2520neurons%2520in%2520mice%2520results%2520in%2520narcolepsy%252C%2520hypophagia%252C%2520and%2520obesity%26jtitle%3DNeuron%26date%3D2001%26volume%3D30%26spage%3D345%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Beuckmann, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinton, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammer, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, M.</span><span> </span><span class="NLM_article-title">Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy–cataplexy in the rat</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4469</span><span class="NLM_x">–</span> <span class="NLM_lpage">4477</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1523%2FJNEUROSCI.5560-03.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=15128861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktFCjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=4469-4477&author=C.+T.+Beuckmannauthor=C.+M.+Sintonauthor=S.+C.+Williamsauthor=J.+A.+Richardsonauthor=R.+E.+Hammerauthor=T.+Sakuraiauthor=M.+Yanagisawa&title=Expression+of+a+poly-glutamine-ataxin-3+transgene+in+orexin+neurons+induces+narcolepsy%E2%80%93cataplexy+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat</span></div><div class="casAuthors">Beuckmann, Carsten T.; Sinton, Christopher M.; Williams, S. Clay; Richardson, James A.; Hammer, Robert E.; Sakurai, Takeshi; Yanagisawa, Masashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4469-4477</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The sleep disorder narcolepsy has been linked to loss of hypothalamic neurons producing the orexin (hypocretin) neuropeptides.  Here, we report the generation of transgenic rats expressing a human ataxin-3 fragment with an elongated polyglutamyl stretch under control of the human prepro-orexin promoter (orexin/ataxin-3 rats).  At 17 wk of age, the transgenic rats exhibited postnatal loss of orexin-pos. neurons in the lateral hypothalamus, and orexin-contg. projections were essentially undetectable.  The loss of orexin prodn. resulted in the expression of a phenotype with fragmented vigilance states, a decreased latency to rapid eye movement (REM) sleep and increased REM sleep time during the dark active phase.  Wakefulness time was also reduced during the dark phase, and this effect was concd. at the photoperiod boundaries.  Direct transitions from wakefulness to REM sleep, a defining characteristic of narcolepsy, occurred frequently.  Brief episodes of muscle atonia and postural collapse resembling cataplexy were also noted while rats maintained the electroencephalog. characteristics of wakefulness.  These findings indicate that the orexin/ataxin-3 transgenic rat could provide a useful model of human narcolepsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyrvMTyDBXMLVg90H21EOLACvtfcHk0lhq7dXr0-noTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktFCjtbo%253D&md5=43ccade5d2e22fe42afd9048084b30d9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.5560-03.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.5560-03.2004%26sid%3Dliteratum%253Aachs%26aulast%3DBeuckmann%26aufirst%3DC.%2BT.%26aulast%3DSinton%26aufirst%3DC.%2BM.%26aulast%3DWilliams%26aufirst%3DS.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BA.%26aulast%3DHammer%26aufirst%3DR.%2BE.%26aulast%3DSakurai%26aufirst%3DT.%26aulast%3DYanagisawa%26aufirst%3DM.%26atitle%3DExpression%2520of%2520a%2520poly-glutamine-ataxin-3%2520transgene%2520in%2520orexin%2520neurons%2520induces%2520narcolepsy%25E2%2580%2593cataplexy%2520in%2520the%2520rat%26jtitle%3DJ.%2520Neurosci.%26date%3D2004%26volume%3D24%26spage%3D4469%26epage%3D4477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Chemelli, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willie, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinton, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmquist, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammell, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisanuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitch, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakazato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammer, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saper, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, M.</span><span> </span><span class="NLM_article-title">Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1016%2FS0092-8674%2800%2981973-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10481909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADyaK1MXlslWmsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1999&pages=437-451&author=R.+M.+Chemelliauthor=J.+T.+Willieauthor=C.+M.+Sintonauthor=J.+K.+Elmquistauthor=T.+Scammellauthor=C.+Leeauthor=J.+A.+Richardsonauthor=S.+C.+Williamsauthor=Y.+Xiongauthor=Y.+Kisanukiauthor=T.+E.+Fitchauthor=M.+Nakazatoauthor=R.+E.+Hammerauthor=C.+B.+Saperauthor=M.+Yanagisawa&title=Narcolepsy+in+orexin+knockout+mice%3A+molecular+genetics+of+sleep+regulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation</span></div><div class="casAuthors">Chemelli, Richard M.; Willie, Jon T.; Sinton, Christopher M.; Elmquist, Joel K.; Scammell, Thomas; Lee, Charlotte; Richardson, James A.; Williams, S. Clay; Xiong, Yumei; Kisanuki, Yaz; Fitch, Thomas E.; Nakazato, Masamitsu; Hammer, Robert E.; Saper, Clifford B.; Yanagisawa, Masashi</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">437-451</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Neurons contg. the neuropeptide orexin (hypocretin) are located exclusively in the lateral hypothalamus and send axons to numerous regions throughout the central nervous system, including the major nuclei implicated in sleep regulation.  Here, we report that, by behavioral and electroencephalog. criteria, orexin knockout mice exhibit a phenotype strikingly similar to human narcolepsy patients, as well as canarc-1 mutant dogs, the only known monogenic model of narcolepsy.  Moreover, modafinil, an anti-narcoleptic drug with ill-defined mechanisms of action, activates orexin-contg. neurons.  We propose that orexin regulates sleep/wakefulness states, and that orexin knockout mice are a model of human narcolepsy, a disorder characterized primarily by rapid eye movement (REM) sleep dysregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomTMUcvI3kgbVg90H21EOLACvtfcHk0lhaxfo1gzYrNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlslWmsbo%253D&md5=71290ef78fe300cfe3c61b4f3fcf7e6f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981973-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981973-X%26sid%3Dliteratum%253Aachs%26aulast%3DChemelli%26aufirst%3DR.%2BM.%26aulast%3DWillie%26aufirst%3DJ.%2BT.%26aulast%3DSinton%26aufirst%3DC.%2BM.%26aulast%3DElmquist%26aufirst%3DJ.%2BK.%26aulast%3DScammell%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DRichardson%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DS.%2BC.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DKisanuki%26aufirst%3DY.%26aulast%3DFitch%26aufirst%3DT.%2BE.%26aulast%3DNakazato%26aufirst%3DM.%26aulast%3DHammer%26aufirst%3DR.%2BE.%26aulast%3DSaper%26aufirst%3DC.%2BB.%26aulast%3DYanagisawa%26aufirst%3DM.%26atitle%3DNarcolepsy%2520in%2520orexin%2520knockout%2520mice%253A%2520molecular%2520genetics%2520of%2520sleep%2520regulation%26jtitle%3DCell%26date%3D1999%26volume%3D98%26spage%3D437%26epage%3D451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Willie, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chemelli, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinton, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisanuki, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcus, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmquist, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlmeier, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammer, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, M.</span><span> </span><span class="NLM_article-title">Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">715</span><span class="NLM_x">–</span> <span class="NLM_lpage">730</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1016%2FS0896-6273%2803%2900330-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=12797957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkslOls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=715-730&author=J.+T.+Willieauthor=R.+M.+Chemelliauthor=C.+M.+Sintonauthor=S.+Tokitaauthor=S.+C.+Williamsauthor=Y.+Y.+Kisanukiauthor=J.+N.+Marcusauthor=C.+Leeauthor=J.+K.+Elmquistauthor=K.+A.+Kohlmeierauthor=C.+S.+Leonardauthor=J.+A.+Richardsonauthor=R.+E.+Hammerauthor=M.+Yanagisawa&title=Distinct+narcolepsy+syndromes+in+Orexin+receptor-2+and+Orexin+null+mice%3A+molecular+genetic+dissection+of+non-REM+and+REM+sleep+regulatory+processes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: Molecular genetic dissection of non-REM and REM sleep regulatory processes</span></div><div class="casAuthors">Willie, Jon T.; Chemelli, Richard M.; Sinton, Christopher M.; Tokita, Shigeru; Williams, S. Clay; Kisanuki, Yaz Y.; Marcus, Jacob N.; Lee, Charlotte; Elmquist, Joel K.; Kohlmeier, Kristi A.; Leonard, Christopher S.; Richardson, James A.; Hammer, Robert E.; Yanagisawa, Masashi</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">715-730</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Narcolepsy-cataplexy, a neurol. disorder assocd. with the absence of hypothalamic orexin (hypocretin) neuropeptides, consists of two underlying problems: inability to maintain wakefulness and intrusion of rapid eye movement (REM) sleep into wakefulness.  Here the authors document, using behavioral, electrophysiol., and pharmacol. criteria, two distinct classes of behavioral arrests exhibited by mice deficient in orexin-mediated signaling.  Both OX2R-/- and orexin-/- mice are similarly affected with behaviorally abnormal attacks of non-REM sleep ("sleep attacks") and show similar degrees of disrupted wakefulness.  In contrast, OX2R-/- mice are only mildly affected with cataplexy-like attacks of REM sleep, whereas orexin-/- mice are severely affected.  Absence of OX2Rs eliminates orexin-evoked excitation of histaminergic neurons in the hypothalamus, which gate non-REM sleep onset.  While normal regulation of wake/non-REM sleep transitions depends critically upon OX2R activation, the profound dysregulation of REM sleep control unique to the narcolepsy-cataplexy syndrome emerges from loss of signaling through both OX2R-dependent and OX2R-independent pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0vge4IjIe2bVg90H21EOLACvtfcHk0liM1xjpcaTAYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkslOls74%253D&md5=0b63a1ad633b8688d182badead136898</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0896-6273%2803%2900330-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0896-6273%252803%252900330-1%26sid%3Dliteratum%253Aachs%26aulast%3DWillie%26aufirst%3DJ.%2BT.%26aulast%3DChemelli%26aufirst%3DR.%2BM.%26aulast%3DSinton%26aufirst%3DC.%2BM.%26aulast%3DTokita%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DS.%2BC.%26aulast%3DKisanuki%26aufirst%3DY.%2BY.%26aulast%3DMarcus%26aufirst%3DJ.%2BN.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DElmquist%26aufirst%3DJ.%2BK.%26aulast%3DKohlmeier%26aufirst%3DK.%2BA.%26aulast%3DLeonard%26aufirst%3DC.%2BS.%26aulast%3DRichardson%26aufirst%3DJ.%2BA.%26aulast%3DHammer%26aufirst%3DR.%2BE.%26aulast%3DYanagisawa%26aufirst%3DM.%26atitle%3DDistinct%2520narcolepsy%2520syndromes%2520in%2520Orexin%2520receptor-2%2520and%2520Orexin%2520null%2520mice%253A%2520molecular%2520genetic%2520dissection%2520of%2520non-REM%2520and%2520REM%2520sleep%2520regulatory%2520processes%26jtitle%3DNeuron%26date%3D2003%26volume%3D38%26spage%3D715%26epage%3D730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Thannickal, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, R. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nienhuis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulyani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldrich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornford, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, J. M.</span><span> </span><span class="NLM_article-title">Reduced number of hypocretin neurons in human narcolepsy</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">474</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2000&pages=469-474&author=T.+C.+Thannickalauthor=R.+Y.+Mooreauthor=R.+Nienhuisauthor=L.+Ramanathanauthor=S.+Gulyaniauthor=M.+Aldrichauthor=M.+Cornfordauthor=J.+M.+Siegel&title=Reduced+number+of+hypocretin+neurons+in+human+narcolepsy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThannickal%26aufirst%3DT.%2BC.%26aulast%3DMoore%26aufirst%3DR.%2BY.%26aulast%3DNienhuis%26aufirst%3DR.%26aulast%3DRamanathan%26aufirst%3DL.%26aulast%3DGulyani%26aufirst%3DS.%26aulast%3DAldrich%26aufirst%3DM.%26aulast%3DCornford%26aufirst%3DM.%26aulast%3DSiegel%26aufirst%3DJ.%2BM.%26atitle%3DReduced%2520number%2520of%2520hypocretin%2520neurons%2520in%2520human%2520narcolepsy%26jtitle%3DNeuron%26date%3D2000%26volume%3D27%26spage%3D469%26epage%3D474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Peyron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overeem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charnay, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevsimalova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldrich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hungs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedrazzoli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padigaru, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kucherlapati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lammers, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouras, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kucherlapati, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mignot, E.</span><span> </span><span class="NLM_article-title">A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains</span> <span class="citation_source-journal">Nature Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">991</span><span class="NLM_x">–</span> <span class="NLM_lpage">997</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=991-997&author=C.+Peyronauthor=J.+Faracoauthor=W.+Rogersauthor=B.+Ripleyauthor=S.+Overeemauthor=Y.+Charnayauthor=S.+Nevsimalovaauthor=M.+Aldrichauthor=D.+Reynoldsauthor=R.+Albinauthor=R.+Liauthor=M.+Hungsauthor=M.+Pedrazzoliauthor=M.+Padigaruauthor=M.+Kucherlapatiauthor=J.+Fanauthor=R.+Makiauthor=G.+J.+Lammersauthor=C.+Bourasauthor=R.+Kucherlapatiauthor=S.+Nishinoauthor=E.+Mignot&title=A+mutation+in+a+case+of+early+onset+narcolepsy+and+a+generalized+absence+of+hypocretin+peptides+in+human+narcoleptic+brains"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeyron%26aufirst%3DC.%26aulast%3DFaraco%26aufirst%3DJ.%26aulast%3DRogers%26aufirst%3DW.%26aulast%3DRipley%26aufirst%3DB.%26aulast%3DOvereem%26aufirst%3DS.%26aulast%3DCharnay%26aufirst%3DY.%26aulast%3DNevsimalova%26aufirst%3DS.%26aulast%3DAldrich%26aufirst%3DM.%26aulast%3DReynolds%26aufirst%3DD.%26aulast%3DAlbin%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DHungs%26aufirst%3DM.%26aulast%3DPedrazzoli%26aufirst%3DM.%26aulast%3DPadigaru%26aufirst%3DM.%26aulast%3DKucherlapati%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DMaki%26aufirst%3DR.%26aulast%3DLammers%26aufirst%3DG.%2BJ.%26aulast%3DBouras%26aufirst%3DC.%26aulast%3DKucherlapati%26aufirst%3DR.%26aulast%3DNishino%26aufirst%3DS.%26aulast%3DMignot%26aufirst%3DE.%26atitle%3DA%2520mutation%2520in%2520a%2520case%2520of%2520early%2520onset%2520narcolepsy%2520and%2520a%2520generalized%2520absence%2520of%2520hypocretin%2520peptides%2520in%2520human%2520narcoleptic%2520brains%26jtitle%3DNature%2520Med.%26date%3D2000%26volume%3D6%26spage%3D991%26epage%3D997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Nishino, S.</span><span> </span><span class="NLM_article-title">Chapter 47: Hypothalamus, hypocretins/orexin, and vigilance control</span> <span class="citation_source-journal">Handb. Clin. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">765</span><span class="NLM_x">–</span> <span class="NLM_lpage">782</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1016%2FB978-0-444-52007-4.00006-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=21056227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A280%3ADC%252BC3cblsVOgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2011&pages=765-782&author=S.+Nishino&title=Chapter+47%3A+Hypothalamus%2C+hypocretins%2Forexin%2C+and+vigilance+control"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Hypothalamus, hypocretins/orexin, and vigilance control</span></div><div class="casAuthors">Nishino Seiji</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of clinical neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">765-82</span>
        ISSN:<span class="NLM_cas:issn">0072-9752</span>.
    </div><div class="casAbstract">The hypothalamus has re-emerged as a key regulator of sleep and wakefulness, shifting the focus away from the brainstem and thalamocortical systems (ascending reticular activating systems).  Several new sleep control systems in the hypothalamus and their interaction with the circadian pacemaker in the suprachiasmatic nucleus have been identified recently.  More recently, deficiency of the hypothalamic peptide, hypocretin/orexin, has been found to be the major pathophysiological factor in human narcolepsy-cataplexy, the sleep disorder characterized by excessive daytime sleepiness and rapid eye movement sleep abnormalities.  The results from a series of experiments suggest that the hypocretin system is involved in the maintenance of wakefulness and stabilizes the vigilance states.  The hypocretin system also plays a role in the link between sleep and other fundamental hypothalamic functions, such as the regulation of food intake, metabolism, hormone release, and temperature.  Sleep deprivation is known to alter hormone release, increase body temperature, stimulate appetite, and activate the sympathetic nervous system.  Sleep control systems within the hypothalamus may therefore be closely integrated with homeostatic systems needed for survival.  In this chapter, the role of the hypothalamus in vigilance control is discussed, with a particular emphasis on the hypocretins/orexin system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjXRjpDLSqHe-MdeMhXAHkfW6udTcc2ea-DPGat5X4Q7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cblsVOgug%253D%253D&md5=e61c97a255da6ca31f3d0527ba707df4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FB978-0-444-52007-4.00006-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-444-52007-4.00006-0%26sid%3Dliteratum%253Aachs%26aulast%3DNishino%26aufirst%3DS.%26atitle%3DChapter%252047%253A%2520Hypothalamus%252C%2520hypocretins%252Forexin%252C%2520and%2520vigilance%2520control%26jtitle%3DHandb.%2520Clin.%2520Neurol.%26date%3D2011%26volume%3D99%26spage%3D765%26epage%3D782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Roecker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercer, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreier, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraley, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steen, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotter, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tannenbaum, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabalu, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stellabott, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winrow, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renger, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span> </span><span class="NLM_article-title">Discovery of 5″-chloro-<i>N</i>-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2′:5′,3″-terpyridine-3′-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">322</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=311-322&author=A.+J.+Roeckerauthor=S.+P.+Mercerauthor=J.+D.+Schreierauthor=C.+D.+Coxauthor=M.+E.+Fraleyauthor=J.+T.+Steenauthor=W.+Lemaireauthor=J.+G.+Brunoauthor=C.+M.+Harrellauthor=S.+L.+Garsonauthor=A.+L.+Gotterauthor=S.+V.+Foxauthor=J.+Stevensauthor=P.+L.+Tannenbaumauthor=T.+Prueksaritanontauthor=T.+D.+Cabaluauthor=D.+Cuiauthor=J.+Stellabottauthor=G.+D.+Hartmanauthor=S.+D.+Youngauthor=C.+J.+Winrowauthor=J.+J.+Rengerauthor=P.+J.+Coleman&title=Discovery+of+5%E2%80%B3-chloro-N-%5B%285%2C6-dimethoxypyridin-2-yl%29methyl%5D-2%2C2%E2%80%B2%3A5%E2%80%B2%2C3%E2%80%B3-terpyridine-3%E2%80%B2-carboxamide+%28MK-1064%29%3A+a+selective+orexin+2+receptor+antagonist+%282-SORA%29+for+the+treatment+of+insomnia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoecker%26aufirst%3DA.%2BJ.%26aulast%3DMercer%26aufirst%3DS.%2BP.%26aulast%3DSchreier%26aufirst%3DJ.%2BD.%26aulast%3DCox%26aufirst%3DC.%2BD.%26aulast%3DFraley%26aufirst%3DM.%2BE.%26aulast%3DSteen%26aufirst%3DJ.%2BT.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DBruno%26aufirst%3DJ.%2BG.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DGarson%26aufirst%3DS.%2BL.%26aulast%3DGotter%26aufirst%3DA.%2BL.%26aulast%3DFox%26aufirst%3DS.%2BV.%26aulast%3DStevens%26aufirst%3DJ.%26aulast%3DTannenbaum%26aufirst%3DP.%2BL.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DCabalu%26aufirst%3DT.%2BD.%26aulast%3DCui%26aufirst%3DD.%26aulast%3DStellabott%26aufirst%3DJ.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DYoung%26aufirst%3DS.%2BD.%26aulast%3DWinrow%26aufirst%3DC.%2BJ.%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%2520of%25205%25E2%2580%25B3-chloro-N-%255B%25285%252C6-dimethoxypyridin-2-yl%2529methyl%255D-2%252C2%25E2%2580%25B2%253A5%25E2%2580%25B2%252C3%25E2%2580%25B3-terpyridine-3%25E2%2580%25B2-carboxamide%2520%2528MK-1064%2529%253A%2520a%2520selective%2520orexin%25202%2520receptor%2520antagonist%2520%25282-SORA%2529%2520for%2520the%2520treatment%2520of%2520insomnia%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D311%26epage%3D322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Betschart, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hintermann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotesta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gee, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laue, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ofner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhari, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badiger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandit, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoyer, D.</span><span> </span><span class="NLM_article-title">Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7590</span><span class="NLM_x">–</span> <span class="NLM_lpage">7607</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm4007627" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7590-7607&author=C.+Betschartauthor=S.+Hintermannauthor=D.+Behnkeauthor=S.+Cotestaauthor=M.+Fendtauthor=C.+E.+Geeauthor=L.+H.+Jacobsonauthor=G.+Laueauthor=S.+Ofnerauthor=V.+Chaudhariauthor=S.+Badigerauthor=C.+Panditauthor=J.+Wagnerauthor=D.+Hoyer&title=Identification+of+a+Novel+Series+of+Orexin+Receptor+Antagonists+with+a+Distinct+Effect+on+Sleep+Architecture+for+the+Treatment+of+Insomnia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm4007627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4007627%26sid%3Dliteratum%253Aachs%26aulast%3DBetschart%26aufirst%3DC.%26aulast%3DHintermann%26aufirst%3DS.%26aulast%3DBehnke%26aufirst%3DD.%26aulast%3DCotesta%26aufirst%3DS.%26aulast%3DFendt%26aufirst%3DM.%26aulast%3DGee%26aufirst%3DC.%2BE.%26aulast%3DJacobson%26aufirst%3DL.%2BH.%26aulast%3DLaue%26aufirst%3DG.%26aulast%3DOfner%26aufirst%3DS.%26aulast%3DChaudhari%26aufirst%3DV.%26aulast%3DBadiger%26aufirst%3DS.%26aulast%3DPandit%26aufirst%3DC.%26aulast%3DWagner%26aufirst%3DJ.%26aulast%3DHoyer%26aufirst%3DD.%26atitle%3DIdentification%2520of%2520a%2520Novel%2520Series%2520of%2520Orexin%2520Receptor%2520Antagonists%2520with%2520a%2520Distinct%2520Effect%2520on%2520Sleep%2520Architecture%2520for%2520the%2520Treatment%2520of%2520Insomnia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7590%26epage%3D7607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Morairty, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Revel, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malherbe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valladao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wettstein, J.G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilduff, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borroni, E.</span><span> </span><span class="NLM_article-title">Dual Hypocretin Receptor Antagonism Is More Effective for Sleep Promotion than Antagonism of Either Receptor Alone</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e39131</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1371%2Fjournal.pone.0039131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=22768296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvF2is74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e39131&author=S.+R.+Morairtyauthor=F.+G.+Revelauthor=P.+Malherbeauthor=J.-L.+Moreauauthor=D.+Valladaoauthor=J.G.+Wettsteinauthor=T.+S.+Kilduffauthor=E.+Borroni&title=Dual+Hypocretin+Receptor+Antagonism+Is+More+Effective+for+Sleep+Promotion+than+Antagonism+of+Either+Receptor+Alone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone</span></div><div class="casAuthors">Morairty, Stephen R.; Revel, Florent G.; Malherbe, Pari; Moreau, Jean-Luc; Valladao, Daniel; Wettstein, Joseph G.; Kilduff, Thomas S.; Borroni, Edilio</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e39131</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The hypocretin (orexin) system is involved in sleep/wake regulation, and antagonists of both hypocretin receptor type 1 (HCRTR1) and/or HCRTR2 are considered to be potential hypnotic medications.  It is currently unclear whether blockade of either or both receptors is more effective for promoting sleep with minimal side effects.  Accordingly, we compared the properties of selective HCRTR1 (SB-408124 and SB-334867) and HCRTR2 (EMPA) antagonists with that of the dual HCRTR1/R2 antagonist almorexant in the rat.  All 4 antagonists bound to their resp. receptors with high affinity and selectivity in vitro.  Since in vivo pharmacokinetic expts. revealed poor brain penetration for SB-408124, SB-334867 was selected for subsequent in vivo studies.  When injected in the mid-active phase, SB-334867 produced small increases in rapid-eye-movement (REM) and non-REM (NR) sleep.  EMPA produced a significant increase in NR only at the highest dose studied.  In contrast, almorexant decreased NR latency and increased both NR and REM proportionally throughout the subsequent 6 h without rebound wakefulness.  The increased NR was due to a greater no. of NR bouts; NR bout duration was unchanged.  At the highest dose tested (100 mg/kg), almorexant fragmented sleep architecture by increasing the no. of waking and REM bouts.  No evidence of cataplexy was obsd.  HCRTR1 occupancy by almorexant declined 4-6 h post-administration while HCRTR2 occupancy was still elevated after 12 h, revealing a complex relationship between occupancy of HCRT receptors and sleep promotion.  We conclude that dual HCRTR1/R2 blockade is more effective in promoting sleep than blockade of either HCRTR alone.  In contrast to GABA receptor agonists which induce sleep by generalized inhibition, HCRTR antagonists seem to facilitate sleep by reducing waking "drive".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojj3qSrI1XLrVg90H21EOLACvtfcHk0lgPmJhZwfhXCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvF2is74%253D&md5=f250e9f2430fe055cf189a7713c5e2ba</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0039131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0039131%26sid%3Dliteratum%253Aachs%26aulast%3DMorairty%26aufirst%3DS.%2BR.%26aulast%3DRevel%26aufirst%3DF.%2BG.%26aulast%3DMalherbe%26aufirst%3DP.%26aulast%3DMoreau%26aufirst%3DJ.-L.%26aulast%3DValladao%26aufirst%3DD.%26aulast%3DWettstein%26aufirst%3DJ.G.%26aulast%3DKilduff%26aufirst%3DT.%2BS.%26aulast%3DBorroni%26aufirst%3DE.%26atitle%3DDual%2520Hypocretin%2520Receptor%2520Antagonism%2520Is%2520More%2520Effective%2520for%2520Sleep%2520Promotion%2520than%2520Antagonism%2520of%2520Either%2520Receptor%2520Alone%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De39131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Dugovic, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alusio, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span> </span><span class="NLM_article-title">Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">142</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1124%2Fjpet.109.152009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=19363060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFeltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=142-151&author=C.+Dugovicauthor=J.+E.+Sheltonauthor=L.+E.+Alusioauthor=I.+C.+Fraserauthor=X.+Jiangauthor=S.+W.+Suttonauthor=P.+Bonaventureauthor=S.+Yunauthor=X.+Liauthor=B.+Lordauthor=C.+A.+Dvorakauthor=N.+I.+Carruthersauthor=T.+W.+Lovenberg&title=Blockade+of+orexin-1+receptors+attenuates+orexin-2+receptor+antagonism-induced+sleep+promotion+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat</span></div><div class="casAuthors">Dugovic, Christine; Shelton, Jonathan E.; Aluisio, Leah E.; Fraser, Ian C.; Jiang, Xiaohui; Sutton, Steven W.; Bonaventure, Pascal; Yun, Sujin; Li, Xiaorong; Lord, Brian; Dvorak, Curt A.; Carruthers, Nicholas I.; Lovenberg, Timothy W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">142-151</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Orexins are peptides produced by lateral hypothalamic neurons that exert a prominent role in the maintenance of wakefulness by activating orexin-1 (OX1R) and orexin-2 (OX2R) receptor located in wake-active structures.  Pharmacol. blockade of both receptors by the dual OX1/2R antagonist (2R)-2-[(1S)-6,7-dimethoxy-1-{2-[4-(trifluoromethyl)phenyl]ethyl}-3,4-dihydroisoquinolin-2(1H)-yl]-N-methyl-2-phenylethanamide (almorexant) has been shown to promote sleep in animals and humans during their active period.  However, the selective distribution of OX1R and OX2R in distinct neuronal circuits may result in a differential impact of these receptors in sleep-wake modulation.  The resp. role of OX1R and OX2R on sleep in correlation with monoamine release was evaluated in rats treated with selective antagonists alone or in combination.  When administered in either phase of the light/dark cycle, the OX2R antagonist 1-(2,4-dibromophenyl)-3-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]urea (JNJ-10397049) decreased the latency for persistent sleep and increased nonrapid eye movement and rapid eye movement sleep time.  Almorexant produced less hypnotic activity, whereas the OX1R antagonist 1-(6,8-difluoro-2-methylquinolin-4-yl)-3-[4-(dimethylamino)phenyl]urea (SB-408124) had no effect.  Microdialysis studies showed that either OX2R or OX1/2R antagonism decreased extracellular histamine concn. in the lateral hypothalamus, whereas both OX1R and OX1/2R antagonists increased dopamine release in the prefrontal cortex.  Finally, coadministration of the OX1R with the OX2R antagonist greatly attenuated the sleep-promoting effects of the OX2R antagonist.  These results indicate that blockade of OX2R is sufficient to initiate and prolong sleep, consistent with the hypothesis of a deactivation of the histaminergic system.  In addn., it is suggested that simultaneous inhibition of OX1R attenuates the sleep-promoting effects mediated by selective OX2R blockade, possibly correlated with dopaminergic neurotransmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPXVs02jXOYLVg90H21EOLACvtfcHk0lj8bFa9yejlLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFeltLk%253D&md5=32a5fc48d949eef2a633187c274cec80</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.152009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.152009%26sid%3Dliteratum%253Aachs%26aulast%3DDugovic%26aufirst%3DC.%26aulast%3DShelton%26aufirst%3DJ.%2BE.%26aulast%3DAlusio%26aufirst%3DL.%2BE.%26aulast%3DFraser%26aufirst%3DI.%2BC.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DSutton%26aufirst%3DS.%2BW.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DYun%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DDvorak%26aufirst%3DC.%2BA.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26atitle%3DBlockade%2520of%2520orexin-1%2520receptors%2520attenuates%2520orexin-2%2520receptor%2520antagonism-induced%2520sleep%2520promotion%2520in%2520the%2520rat%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26spage%3D142%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Hoever, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoemaker, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiossi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gerven, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingemanse, J.</span><span> </span><span class="NLM_article-title">Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant</span> <span class="citation_source-journal">Clin. Pharmacol. Ther. (N. Y., NY, U. S.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">593</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1038%2Fclpt.2010.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=20376002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFCntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=593-600&author=P.+Hoeverauthor=S.+de+Haasauthor=J.+Winklerauthor=R.+C.+Schoemakerauthor=E.+Chiossiauthor=J.+van+Gervenauthor=J.+Dingemanse&title=Orexin+receptor+antagonism%2C+a+new+sleep-promoting+paradigm%3A+an+ascending+single-dose+study+with+almorexant"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Orexin Receptor Antagonism, a New Sleep-Promoting Paradigm: An Ascending Single-Dose Study With Almorexant</span></div><div class="casAuthors">Hoever, P.; de Haas, S.; Winkler, J.; Schoemaker, R. C.; Chiossi, E.; van Gerven, J.; Dingemanse, J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">593-600</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Almorexant, a dual orexin receptor antagonist potentially representing a new class of sleep-promoting compds., was administered in an ascending single-dose study to evaluate tolerability, pharmacokinetics, and pharmacodynamics.  Seventy healthy male subjects were enrolled in this double-blind, placebo- and active-controlled study.  Each dose level (1-1,000 mg) was investigated in a sep. group of 10 subjects (6 on almorexant, 2 on placebo, 2 on zolpidem 10 mg).  Almorexant was well tolerated with no signs of cataplexy.  Peak plasma concn. (Cmax) was quickly attained (median time to max. concn. (tmax) ranged from 0.7 to 2.3 h), and plasma concns. subsequently decreased quickly to ∼20% of Cmax over the course of 8 h.  Vigilance, alertness, and visuomotor and motor coordination were reduced following daytime administration of zolpidem or almorexant at doses of ≥400 mg.  Population pharmacokinetic/pharmacodynamic modeling suggested that doses of ∼500 mg almorexant and 10 mg zolpidem are equiv. with respect to subjectively assessed alertness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ9nYFrp8FEbVg90H21EOLACvtfcHk0liGAluqRe3q2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFCntLk%253D&md5=528965794ed9ae22a832f66b8047ed7b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2010.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2010.19%26sid%3Dliteratum%253Aachs%26aulast%3DHoever%26aufirst%3DP.%26aulast%3Dde%2BHaas%26aufirst%3DS.%26aulast%3DWinkler%26aufirst%3DJ.%26aulast%3DSchoemaker%26aufirst%3DR.%2BC.%26aulast%3DChiossi%26aufirst%3DE.%26aulast%3Dvan%2BGerven%26aufirst%3DJ.%26aulast%3DDingemanse%26aufirst%3DJ.%26atitle%3DOrexin%2520receptor%2520antagonism%252C%2520a%2520new%2520sleep-promoting%2520paradigm%253A%2520an%2520ascending%2520single-dose%2520study%2520with%2520almorexant%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2010%26volume%3D87%26spage%3D593%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Bettica, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nucci, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pyke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squassante, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamuner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomeni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, R.</span><span> </span><span class="NLM_article-title">Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist</span> <span class="citation_source-journal">J. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1058</span><span class="NLM_x">–</span> <span class="NLM_lpage">1070</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1177%2F0269881111408954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=21730017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A280%3ADC%252BC38zkslGmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1058-1070&author=P.+Betticaauthor=G.+Nucciauthor=C.+Pykeauthor=L.+Squassanteauthor=S.+Zamunerauthor=E.+Rattiauthor=R.+Gomeniauthor=R.+Alexander&title=Phase+I+studies+on+the+safety%2C+tolerability%2C+pharmacokinetics+and+pharmacodynamics+of+SB-649868%2C+a+novel+dual+orexin+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist</span></div><div class="casAuthors">Bettica Paolo; Nucci Gianluca; Pyke Caroline; Squassante Lisa; Zamuner Stefano; Ratti Emiliangelo; Gomeni Roberto; Alexander Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychopharmacology (Oxford, England)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1058-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The orexin system plays a major role in the integration of metabolic and circadian influences that drive wakefulness.  This paper describes initial Phase I trials of a novel dual orexin receptor antagonist SB-649868 that has demonstrated preclinical potential for treatment of sleep disorders.  The trial designs included a single ascending dose escalation study (dose range: 10-80 mg in the fed and fasted states) and a multiple repeat dose study (dose range: 5-30 mg in the fed state) enrolling a total of 103 male volunteer subjects.  SB-649868 was well tolerated at all doses in this study population, with mechanism-related adverse events (e.g. somnolence and fatigue) observed in a majority of subjects after 60 and 80 mg single doses.  Although total drug exposure was similar in the fed and fasted states, the rate, but not the extent, of absorption increased in the fed state, resulting in an increased C(max).  The typical estimated half-life of SB-649868 was 3-6 h - comparable with currently used hypnotic agents.  Repeated administration of SB-649868 dose-dependently increased exposure to simvastatin (10 mg), suggesting CYP3A4 inhibition ranging from very mild (5 mg) to strong (30 mg).  Evening dosing resulted in significant dose-dependent improvement in latency to persistent sleep, total sleep time and wake after sleep onset as measured by polysomnography.  Next-morning testing did not detect evidence of residual cognitive effects.  Results of these trials support further investigation of SB-649868 and other dual orexin receptor antagonists as potentially effective and well-tolerated treatments for patients with sleep disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRpW1wEDRIs7INpW7w2tapOfW6udTcc2eY2Jtv9v2C-OLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zkslGmsA%253D%253D&md5=5428764a9d43dc08ef56b4e5990e1c4d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1177%2F0269881111408954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881111408954%26sid%3Dliteratum%253Aachs%26aulast%3DBettica%26aufirst%3DP.%26aulast%3DNucci%26aufirst%3DG.%26aulast%3DPyke%26aufirst%3DC.%26aulast%3DSquassante%26aufirst%3DL.%26aulast%3DZamuner%26aufirst%3DS.%26aulast%3DRatti%26aufirst%3DE.%26aulast%3DGomeni%26aufirst%3DR.%26aulast%3DAlexander%26aufirst%3DR.%26atitle%3DPhase%2520I%2520studies%2520on%2520the%2520safety%252C%2520tolerability%252C%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520SB-649868%252C%2520a%2520novel%2520dual%2520orexin%2520receptor%2520antagonist%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2012%26volume%3D26%26spage%3D1058%26epage%3D1070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Winrow, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotter, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doran, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tannenbaum, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renger, J. J.</span><span> </span><span class="NLM_article-title">Promotion of sleep by suvorexant—a novel dual orexin receptor antagonist</span> <span class="citation_source-journal">J. Neurogenet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">52</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.3109%2F01677063.2011.566953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=21473737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVWlsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=52-61&author=C.+J.+Winrowauthor=A.+L.+Gotterauthor=C.+D.+Coxauthor=S.+M.+Doranauthor=P.+L.+Tannenbaumauthor=M.+J.+Breslinauthor=S.+L.+Garsonauthor=S.+V.+Foxauthor=C.+M.+Harrellauthor=J.+Stevensauthor=D.+R.+Reissauthor=D.+Cuiauthor=P.+J.+Colemanauthor=J.+J.+Renger&title=Promotion+of+sleep+by+suvorexant%E2%80%94a+novel+dual+orexin+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Promotion of Sleep by Suvorexant--A Novel Dual Orexin Receptor Antagonist</span></div><div class="casAuthors">Winrow, Christopher J.; Gotter, Anthony L.; Cox, Christopher D.; Doran, Scott M.; Tannenbaum, Pamela L.; Breslin, Michael J.; Garson, Susan L.; Fox, Steven V.; Harrell, Charles M.; Stevens, Joanne; Reiss, Duane R.; Cui, Donghui; Coleman, Paul J.; Renger, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurogenetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">52-61</span>CODEN:
                <span class="NLM_cas:coden">JLNEDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-7063</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Orexins/hypocretins are key neuropeptides responsible for regulating central arousal and reward circuits.  Two receptors respond to orexin signaling, orexin 1 receptor (OX1R) and orexin 2 receptor (OX2R) with partially overlapping nervous system distributions.  Genetic studies suggest orexin receptor antagonists could be therapeutic for insomnia and other disorders with disruptions of sleep and wake.  Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX1R and OX2R currently under clin. investigation as a novel therapy for insomnia.  Examn. of Suvorexant in radioligand binding assays using tissue from transgenic rats expressing the human OX2R found nearly full receptor occupancy (>90%) at plasma exposures of 1.1 μμM.  Dosed orally Suvorexant significantly and dose-dependently reduced locomotor activity and promoted sleep in rats (10, 30, and 100 mg/kg), dogs (1 and 3 mg/kg), and rhesus monkeys (10 mg/kg).  Consistent cross-species sleep/wake architecture changes produced by Suvorexant highlight a unique opportunity to develop dual orexin antagonists as a novel therapy for insomnia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN-4uWCwpZ8bVg90H21EOLACvtfcHk0ljscm9uZ_Rn8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVWlsrg%253D&md5=ed9c4d09d1944557c41ca0c62d6e71a6</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3109%2F01677063.2011.566953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F01677063.2011.566953%26sid%3Dliteratum%253Aachs%26aulast%3DWinrow%26aufirst%3DC.%2BJ.%26aulast%3DGotter%26aufirst%3DA.%2BL.%26aulast%3DCox%26aufirst%3DC.%2BD.%26aulast%3DDoran%26aufirst%3DS.%2BM.%26aulast%3DTannenbaum%26aufirst%3DP.%2BL.%26aulast%3DBreslin%26aufirst%3DM.%2BJ.%26aulast%3DGarson%26aufirst%3DS.%2BL.%26aulast%3DFox%26aufirst%3DS.%2BV.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DStevens%26aufirst%3DJ.%26aulast%3DReiss%26aufirst%3DD.%2BR.%26aulast%3DCui%26aufirst%3DD.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26atitle%3DPromotion%2520of%2520sleep%2520by%2520suvorexant%25E2%2580%2594a%2520novel%2520dual%2520orexin%2520receptor%2520antagonist%26jtitle%3DJ.%2520Neurogenet.%26date%3D2011%26volume%3D25%26spage%3D52%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Cox, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitman, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreier, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGaughey, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogusky, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roecker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercer, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednar, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doran, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabalu, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koblan, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winrow, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renger, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span> </span><span class="NLM_article-title">Discovery of the dual orexin receptor antagonist [(7<i>R</i>)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5320</span><span class="NLM_x">–</span> <span class="NLM_lpage">5332</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100541c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5320-5332&author=C.+D.+Coxauthor=M.+J.+Breslinauthor=D.+B.+Whitmanauthor=J.+D.+Schreierauthor=G.+B.+McGaugheyauthor=M.+J.+Boguskyauthor=A.+J.+Roeckerauthor=S.+P.+Mercerauthor=R.+A.+Bednarauthor=W.+Lemaireauthor=J.+G.+Brunoauthor=D.+R.+Reissauthor=C.+M.+Harrellauthor=K.+L.+Murphyauthor=S.+L.+Garsonauthor=S.+M.+Doranauthor=T.+Prueksaritanontauthor=W.+B.+Andersonauthor=C.+Tangauthor=S.+Rollerauthor=T.+D.+Cabaluauthor=D.+Cuiauthor=G.+D.+Hartmanauthor=S.+D.+Youngauthor=K.+S.+Koblanauthor=C.+J.+Winrowauthor=J.+J.+Rengerauthor=P.+J.+Coleman&title=Discovery+of+the+dual+orexin+receptor+antagonist+%5B%287R%29-4-%285-chloro-1%2C3-benzoxazol-2-yl%29-7-methyl-1%2C4-diazepan-1-yl%5D%5B5-methyl-2-%282H-1%2C2%2C3-triazol-2-yl%29phenyl%5Dmethanone+%28MK-4305%29+for+the+treatment+of+insomnia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm100541c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100541c%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DC.%2BD.%26aulast%3DBreslin%26aufirst%3DM.%2BJ.%26aulast%3DWhitman%26aufirst%3DD.%2BB.%26aulast%3DSchreier%26aufirst%3DJ.%2BD.%26aulast%3DMcGaughey%26aufirst%3DG.%2BB.%26aulast%3DBogusky%26aufirst%3DM.%2BJ.%26aulast%3DRoecker%26aufirst%3DA.%2BJ.%26aulast%3DMercer%26aufirst%3DS.%2BP.%26aulast%3DBednar%26aufirst%3DR.%2BA.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DBruno%26aufirst%3DJ.%2BG.%26aulast%3DReiss%26aufirst%3DD.%2BR.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DGarson%26aufirst%3DS.%2BL.%26aulast%3DDoran%26aufirst%3DS.%2BM.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DAnderson%26aufirst%3DW.%2BB.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DRoller%26aufirst%3DS.%26aulast%3DCabalu%26aufirst%3DT.%2BD.%26aulast%3DCui%26aufirst%3DD.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DYoung%26aufirst%3DS.%2BD.%26aulast%3DKoblan%26aufirst%3DK.%2BS.%26aulast%3DWinrow%26aufirst%3DC.%2BJ.%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%2520of%2520the%2520dual%2520orexin%2520receptor%2520antagonist%2520%255B%25287R%2529-4-%25285-chloro-1%252C3-benzoxazol-2-yl%2529-7-methyl-1%252C4-diazepan-1-yl%255D%255B5-methyl-2-%25282H-1%252C2%252C3-triazol-2-yl%2529phenyl%255Dmethanone%2520%2528MK-4305%2529%2520for%2520the%2520treatment%2520of%2520insomnia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5320%26epage%3D5332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreier, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitman, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogusky, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGaughey, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednar, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doran, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotter, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabalu, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tannenbaum, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stellabott, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winrow, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renger, J. J.</span><span> </span><span class="NLM_article-title">Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=415-424&author=P.+J.+Colemanauthor=J.+D.+Schreierauthor=C.+D.+Coxauthor=M.+J.+Breslinauthor=D.+B.+Whitmanauthor=M.+J.+Boguskyauthor=G.+B.+McGaugheyauthor=R.+A.+Bednarauthor=W.+Lemaireauthor=S.+M.+Doranauthor=S.+V.+Foxauthor=S.+L.+Garsonauthor=A.+L.+Gotterauthor=C.+M.+Harrellauthor=D.+R.+Reissauthor=T.+D.+Cabaluauthor=D.+Cuiauthor=T.+Prueksaritanontauthor=J.+Stevensauthor=P.+L.+Tannenbaumauthor=R.+G.+Ballauthor=J.+Stellabottauthor=S.+D.+Youngauthor=G.+D.+Hartmanauthor=C.+J.+Winrowauthor=J.+J.+Renger&title=Discovery+of+%5B%282R%2C5R%29-5-%7B%5B%285-fluoropyridin-2-yl%29oxy%5Dmethyl%7D-2-methylpiperidin-1-yl%5D%5B5-methyl-2-%28pyrimidin-2-yl%29phenyl%5Dmethanone+%28MK-6096%29%3A+a+dual+orexin+receptor+antagonist+with+potent+sleep-promoting+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DSchreier%26aufirst%3DJ.%2BD.%26aulast%3DCox%26aufirst%3DC.%2BD.%26aulast%3DBreslin%26aufirst%3DM.%2BJ.%26aulast%3DWhitman%26aufirst%3DD.%2BB.%26aulast%3DBogusky%26aufirst%3DM.%2BJ.%26aulast%3DMcGaughey%26aufirst%3DG.%2BB.%26aulast%3DBednar%26aufirst%3DR.%2BA.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DDoran%26aufirst%3DS.%2BM.%26aulast%3DFox%26aufirst%3DS.%2BV.%26aulast%3DGarson%26aufirst%3DS.%2BL.%26aulast%3DGotter%26aufirst%3DA.%2BL.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DReiss%26aufirst%3DD.%2BR.%26aulast%3DCabalu%26aufirst%3DT.%2BD.%26aulast%3DCui%26aufirst%3DD.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DStevens%26aufirst%3DJ.%26aulast%3DTannenbaum%26aufirst%3DP.%2BL.%26aulast%3DBall%26aufirst%3DR.%2BG.%26aulast%3DStellabott%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DS.%2BD.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DWinrow%26aufirst%3DC.%2BJ.%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26atitle%3DDiscovery%2520of%2520%255B%25282R%252C5R%2529-5-%257B%255B%25285-fluoropyridin-2-yl%2529oxy%255Dmethyl%257D-2-methylpiperidin-1-yl%255D%255B5-methyl-2-%2528pyrimidin-2-yl%2529phenyl%255Dmethanone%2520%2528MK-6096%2529%253A%2520a%2520dual%2520orexin%2520receptor%2520antagonist%2520with%2520potent%2520sleep-promoting%2520properties%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D415%26epage%3D424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Yoshida, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terauchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazuta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozaki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beuckmann, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kushida, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takenaka, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonaga, M.</span><span> </span><span class="NLM_article-title">Design, synthesis, and structure–activity relationships of a series of novel <i>N</i>-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6071</span><span class="NLM_x">–</span> <span class="NLM_lpage">6088</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=6071-6088&author=Y.+Yoshidaauthor=T.+Terauchiauthor=Y.+Naoeauthor=Y.+Kazutaauthor=F.+Ozakiauthor=C.+T.+Beuckmannauthor=M.+Nakagawaauthor=M.+Suzukiauthor=I.+Kushidaauthor=O.+Takenakaauthor=T.+Uenoauthor=M.+Yonaga&title=Design%2C+synthesis%2C+and+structure%E2%80%93activity+relationships+of+a+series+of+novel+N-aryl-2-phenylcyclopropanecarboxamide+that+are+potent+and+orally+active+orexin+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DY.%26aulast%3DTerauchi%26aufirst%3DT.%26aulast%3DNaoe%26aufirst%3DY.%26aulast%3DKazuta%26aufirst%3DY.%26aulast%3DOzaki%26aufirst%3DF.%26aulast%3DBeuckmann%26aufirst%3DC.%2BT.%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DKushida%26aufirst%3DI.%26aulast%3DTakenaka%26aufirst%3DO.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DYonaga%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520a%2520series%2520of%2520novel%2520N-aryl-2-phenylcyclopropanecarboxamide%2520that%2520are%2520potent%2520and%2520orally%2520active%2520orexin%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D6071%26epage%3D6088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Shuto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hase, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, A.</span><span> </span><span class="NLM_article-title">Conformational restriction by repulsion between adjacent substituents on a cyclopropane ring: design and enantioselective synthesis of 1-phenyl-2-(1-aminoalkyl)-<i>N</i>,<i>N</i>-diethylcyclopropanecarboxamides as potent NMDA receptor antagonists</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">915</span><span class="NLM_x">–</span> <span class="NLM_lpage">923</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo9518056" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1996&pages=915-923&author=S.+Shutoauthor=S.+Onoauthor=Y.+Haseauthor=N.+Kamiyamaauthor=H.+Takadaauthor=K.+Yamashitaauthor=A.+Matsuda&title=Conformational+restriction+by+repulsion+between+adjacent+substituents+on+a+cyclopropane+ring%3A+design+and+enantioselective+synthesis+of+1-phenyl-2-%281-aminoalkyl%29-N%2CN-diethylcyclopropanecarboxamides+as+potent+NMDA+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjo9518056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo9518056%26sid%3Dliteratum%253Aachs%26aulast%3DShuto%26aufirst%3DS.%26aulast%3DOno%26aufirst%3DS.%26aulast%3DHase%26aufirst%3DY.%26aulast%3DKamiyama%26aufirst%3DN.%26aulast%3DTakada%26aufirst%3DH.%26aulast%3DYamashita%26aufirst%3DK.%26aulast%3DMatsuda%26aufirst%3DA.%26atitle%3DConformational%2520restriction%2520by%2520repulsion%2520between%2520adjacent%2520substituents%2520on%2520a%2520cyclopropane%2520ring%253A%2520design%2520and%2520enantioselective%2520synthesis%2520of%25201-phenyl-2-%25281-aminoalkyl%2529-N%252CN-diethylcyclopropanecarboxamides%2520as%2520potent%2520NMDA%2520receptor%2520antagonists%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1996%26volume%3D61%26spage%3D915%26epage%3D923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Zhao, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soglia, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span> </span><span class="NLM_article-title">NADPH-dependent covalent binding of [<sup>3</sup>H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1649</span><span class="NLM_x">–</span> <span class="NLM_lpage">1657</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx700132x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSkurrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=1649-1657&author=S.+X.+Zhaoauthor=D.+K.+Dalvieauthor=J.+M.+Kellyauthor=J.+R.+Sogliaauthor=K.+S.+Frederickauthor=E.+B.+Smithauthor=R.+S.+Obachauthor=A.+S.+Kalgutkar&title=NADPH-dependent+covalent+binding+of+%5B3H%5Dparoxetine+to+human+liver+microsomes+and+S-9+fractions%3A+identification+of+an+electrophilic+quinone+metabolite+of+paroxetine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">NADPH-Dependent Covalent Binding of [3H]Paroxetine to Human Liver Microsomes and S-9 Fractions: Identification of an Electrophilic Quinone Metabolite of Paroxetine</span></div><div class="casAuthors">Zhao, Sabrina X.; Dalvie, Deepak K.; Kelly, Joan M.; Soglia, John R.; Frederick, Kosea S.; Smith, Evan B.; Obach, R. Scott; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1649-1657</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The primary pathway of clearance of the methylenedioxyphenyl-contg. compd. and selective serotonin reuptake inhibitor paroxetine in humans involves P 450 2D6-mediated demethylenation to a catechol intermediate.  The process of demethylenation also results in the mechanism-based inactivation of the P 450 isoenzyme.  While the link between P 450 2D6 inactivation and pharmacokinetic interactions of paroxetine with P 450 2D6 substrates has been firmly established, there is a disconnect in terms of paroxetine's excellent safety record despite the potential for bioactivation.  In the present study, the authors have systematically assessed the NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 prepns. in the absence and presence of cofactors of the various phase II drug-metabolizing enzymes involved in the downstream metab./detoxification of the putative paroxetine-catechol intermediate.  Incubation of [3H]paroxetine with human liver microsomes and S-9 prepns. resulted in irreversible binding of radioactive material to macromols. by a process that was NADPH-dependent.  The addn. of reduced glutathione (GSH) to the microsomal and S-9 incubations resulted in a dramatic redn. of covalent binding.  Following incubations with NADPH- and GSH-supplemented human liver microsomes and S-9, three sulfhydryl conjugates with MH+ ions at 623 Da (GS1), 779 Da (GS2), and 928 Da (GS3), resp., were detected by LC-MS/MS.  The collision-induced dissocn. spectra allowed an insight into the structure of the GSH conjugates, based on which, bioactivation pathways were proposed.  The formation of GS1 was consistent with Michael addn. of GSH to the quinone derived from two-electron oxidn. of paroxetine-catechol.  GS3 was formed by the addn. of a second mol. of GSH to the quinone species obtained via the two-electron oxidn. of GS1.  The mechanism of formation of GS2 can be rationalized via (i) further two-electron oxidn. of the catechol motif in GS3 to the ortho-quinone, (ii) loss of a glutamic acid residue from one of the adducted GSH mols., and (iii) condensation of a cysteine-NH2 with an adjacent carbonyl of the ortho-quinone to yield an ortho-benzoquinoneimine structure.  Inclusion of the catechol-O-methyltransferase cofactor S-adenosylmethionine (SAM) in S-9 incubations also dramatically reduced the covalent binding of [3H]paroxetine, a finding that was consistent with O-methylation of the paroxetine-catechol metabolite to the corresponding guaiacol regioisomers in S-9 incubations.  While the NADPH-dependent covalent binding was attenuated by GSH and SAM, these reagents did not alter paroxetine's ability to inactivate P 450 2D6, suggesting that the reactive intermediate responsible for P 450 inactivation did not leave the active site to react with other proteins.  The results of the studies indicate that in addn. to the low once-a-day dosing regimen (20 mg) of paroxetine, efficient scavenging of the catechol and quinone metabolites by SAM and GSH, resp., serves as an explanation for the excellent safety record of paroxetine despite the fact that it undergoes bioactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOXUHMcbZnN7Vg90H21EOLACvtfcHk0lgetP99WXkdjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSkurrK&md5=e7d3aa749a419cc87340271eb9b839a0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Ftx700132x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700132x%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DKelly%26aufirst%3DJ.%2BM.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DFrederick%26aufirst%3DK.%2BS.%26aulast%3DSmith%26aufirst%3DE.%2BB.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DNADPH-dependent%2520covalent%2520binding%2520of%2520%255B3H%255Dparoxetine%2520to%2520human%2520liver%2520microsomes%2520and%2520S-9%2520fractions%253A%2520identification%2520of%2520an%2520electrophilic%2520quinone%2520metabolite%2520of%2520paroxetine%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D1649%26epage%3D1657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Takashi, Y.; Toru, A.</span><span> </span><span class="NLM_article-title">hERG Channel-Expressing Cell</span>. U.S. Patent 7,935,526 B2,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=Y.+Takashi&author=A.+Toru&title=hERG+Channel-Expressing+Cell"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTakashi%26aufirst%3DY.%26atitle%3DhERG%2520Channel-Expressing%2520Cell%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Mieda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasegawa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisanuki, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinton, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, T.</span><span> </span><span class="NLM_article-title">Differential Roles of Orexin Receptor-1 and -2 in the Regulation of non-REM and REM Sleep</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">6518</span><span class="NLM_x">–</span> <span class="NLM_lpage">6526</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1523%2FJNEUROSCI.6506-10.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=21525292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Oltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=6518-6526&author=M.+Miedaauthor=E.+Hasegawaauthor=Y.+Y.+Kisanukiauthor=M.+C.+Sintonauthor=M.+Yanagisawaauthor=T.+Sakurai&title=Differential+Roles+of+Orexin+Receptor-1+and+-2+in+the+Regulation+of+non-REM+and+REM+Sleep"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep</span></div><div class="casAuthors">Mieda, Michihiro; Hasegawa, Emi; Kisanuki, Yaz Y.; Sinton, Christopher M.; Yanagisawa, Masashi; Sakurai, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6518-6526</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Orexin-A and orexin-B are hypothalamic neuropeptides that play crit. roles in the maintenance of wakefulness.  Intracerebroventricular (ICV) administration of orexin-A has been shown to promote wakefulness and suppress both rapid eye movement (REM) sleep and non-REM (NREM) sleep through the orexin receptor-1 (OX1R) and orexin receptor-2 (OX2R).  Here, we elucidated the differential roles of orexin receptors in the regulation of sleep and wakefulness by comparing the effects of ICV orexin-A administration in wild-type, OX1R-/-, and OX2R-/- mice.  The effects of orexin-A on wakefulness and NREM sleep were significantly attenuated in both knock-out mice as compared with wild-type mice, with substantially larger attenuation in OX2R-/- mice than in OX1R-/- mice.  These results suggest that although the OX2R-mediated pathway has a pivotal role in the promotion of wakefulness, OX1R also plays addnl. roles in promoting arousal.  In contrast, suppression of REM sleep by orexin-A administration was slightly and similarly attenuated in both OX1R-/- and OX2R-/- mice, suggesting a comparable contribution of the two receptors to REM sleep suppression.  Histol. studies demonstrated differential distributions of each receptor subtype in distinct neuronal populations with specific neurotransmitter identities in brainstem cholinergic/monoaminergic neurons.  In the laterodorsal tegmental and pedunculopontine tegmental nuclei esp., cholinergic neurons exclusively expressed OX1R mRNA, but OX2R mRNA was expressed mainly in GABAergic putative interneurons.  Thus, each orexin receptor subtype plays differential roles in gating NREM and REM sleep through distinct neuronal pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH-GjaYHZNmLVg90H21EOLACvtfcHk0ljnx6kWXVb5-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Oltrs%253D&md5=e0892147bb9e9380cc4cc13a6708746c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.6506-10.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.6506-10.2011%26sid%3Dliteratum%253Aachs%26aulast%3DMieda%26aufirst%3DM.%26aulast%3DHasegawa%26aufirst%3DE.%26aulast%3DKisanuki%26aufirst%3DY.%2BY.%26aulast%3DSinton%26aufirst%3DM.%2BC.%26aulast%3DYanagisawa%26aufirst%3DM.%26aulast%3DSakurai%26aufirst%3DT.%26atitle%3DDifferential%2520Roles%2520of%2520Orexin%2520Receptor-1%2520and%2520-2%2520in%2520the%2520Regulation%2520of%2520non-REM%2520and%2520REM%2520Sleep%26jtitle%3DJ.%2520Neurosci.%26date%3D2011%26volume%3D31%26spage%3D6518%26epage%3D6526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonson, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shekhar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitz, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shireman, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebold, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nepomuceno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wnnerholm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugovic, C.</span><span> </span><span class="NLM_article-title">A Selective Origin-1 Receptor Antagonist Attenuates Stress-Induced Hyperarousal without Hypnotic Effects</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">590</span><span class="NLM_x">–</span> <span class="NLM_lpage">601</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1124%2Fjpet.114.220392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=25583879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Omuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=590-601&author=P.+Bonaventureauthor=S.+Yunauthor=P.+L.+Jonsonauthor=A.+Shekharauthor=S.+D.+Fitzauthor=B.+T.+Shiremanauthor=T.+P.+Leboldauthor=D.+Nepomucenoauthor=B.+Lordauthor=M.+Wnnerholmauthor=J.+Sheltonauthor=N.+Carruthersauthor=T.+Lovenbergauthor=C.+Dugovic&title=A+Selective+Origin-1+Receptor+Antagonist+Attenuates+Stress-Induced+Hyperarousal+without+Hypnotic+Effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects</span></div><div class="casAuthors">Bonaventure, Pascal; Yun, Sujin; Johnson, Philip L.; Shekhar, Anantha; Fitz, Stephanie D.; Shireman, Brock T.; Lebold, Terry P.; Nepomuceno, Diane; Lord, Brian; Wennerholm, Michelle; Shelton, Jonathan; Carruthers, Nicholas; Lovenberg, Timothy; Dugovic, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">590-601, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Orexins (OXs) are peptides produced by perifornical (PeF) and lateral hypothalamic neurons that exert a prominent role in arousal-related processes, including stress.  A crit. role for the orexin-1 receptor (OX1R) in complex emotional behavior is emerging, such as overactivation of the OX1R pathway being assocd. with panic or anxiety states.  Here we characterize a brain-penetrant, selective, and high-affinity OX1R antagonist, compd. 56 [N-({3-[(3-ethoxy-6-methylpyridin-2-yl)carbonyl]-3-azabicyclo[4.1.0]hept-4-yl}methyl)-5-(trifluoromethyl)pyrimidin-2-amine].  Ex vivo receptor binding studies demonstrated that, after s.c. administration, compd. 56 crossed the blood-brain barrier and occupied OX1Rs in the rat brain at lower doses than std. OX1R antagonists GSK-1059865 [5-bromo-N-({1-[(3-fluoro-2-methoxyphenyl)carbonyl]-5-methylpiperidin-2-yl}methyl)pyridin-2-amine], SB-334867 [1-(2-methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea], and SB-408124 [1-(6,8-difluoro-2-methylquinolin-4-yl)-3-[4-(dimethylamino)phenyl]urea].  Although compd. 56 did not alter spontaneous sleep in rats and in wild-type mice, its administration in orexin-2 receptor knockout mice selectively promoted rapid eye movement sleep, demonstrating target engagement and specific OX1R blockade.  In a rat model of psychol. stress induced by cage exchange, the OX1R antagonist prevented the prolongation of sleep onset without affecting sleep duration.  In a rat model of panic vulnerability (involving disinhibition of the PeF OX region) to threatening internal state changes (i.e., i.v. sodium lactate infusion), compd. 56 attenuated sodium lactate-induced panic-like behaviors and cardiovascular responses without altering baseline locomotor or autonomic activity.  In conclusion, OX1R antagonism represents a novel therapeutic strategy for the treatment of various psychiatric disorders assocd. with stress or hyperarousal states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobTtYJtwsEh7Vg90H21EOLACvtfcHk0ljnx6kWXVb5-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Omuro%253D&md5=0793591a77a5bf93b9e448cb1381da2a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220392%26sid%3Dliteratum%253Aachs%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DYun%26aufirst%3DS.%26aulast%3DJonson%26aufirst%3DP.%2BL.%26aulast%3DShekhar%26aufirst%3DA.%26aulast%3DFitz%26aufirst%3DS.%2BD.%26aulast%3DShireman%26aufirst%3DB.%2BT.%26aulast%3DLebold%26aufirst%3DT.%2BP.%26aulast%3DNepomuceno%26aufirst%3DD.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DWnnerholm%26aufirst%3DM.%26aulast%3DShelton%26aufirst%3DJ.%26aulast%3DCarruthers%26aufirst%3DN.%26aulast%3DLovenberg%26aufirst%3DT.%26aulast%3DDugovic%26aufirst%3DC.%26atitle%3DA%2520Selective%2520Origin-1%2520Receptor%2520Antagonist%2520Attenuates%2520Stress-Induced%2520Hyperarousal%2520without%2520Hypnotic%2520Effects%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D590%26epage%3D601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Etori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujino, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, T.</span><span> </span><span class="NLM_article-title">Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice</span> <span class="citation_source-journal">Front. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.3389%2Ffnins.2014.00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=24550770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A280%3ADC%252BC2cvmt1ynuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=8&author=K.+Etoriauthor=C.+Y.+Saitoauthor=N.+Tsujinoauthor=T.+Sakurai&title=Effects+of+a+newly+developed+potent+orexin-2+receptor-selective+antagonist%2C+compound+1+m%2C+on+sleep%2Fwakefulness+states+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice</span></div><div class="casAuthors">Etori Keishi; Saito Yuki C; Tsujino Natsuko; Sakurai Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">Orexins (also known as hypocretins) play critical roles in the regulation of sleep/wakefulness states by activating two G-protein coupled receptors (GPCRs), orexin 1 (OX1R) and orexin 2 receptors (OX2R).  In order to understand the differential contribution of both receptors in regulating sleep/wakefulness states we compared the pharmacological effects of a newly developed OX2R antagonist (2-SORA), Compound 1 m (C1 m), with those of a dual orexin receptor antagonist (DORA), suvorexant, in C57BL/6J mice.  After oral administration in the dark period, both C1m and suvorexant decreased wakefulness time with similar efficacy in a dose-dependent manner.  While C1m primarily increased total non-rapid eye movement (NREM) sleep time without affecting episode durations and with minimal effects on REM sleep, suvorexant increased both total NREM and REM sleep time and episode durations with predominant effects on REM sleep.  Fos-immunostaining showed that both compounds affected the activities of arousal-related neurons with different patterns.  The number of Fos-IR noradrenergic neurons in the locus coeruleus was lower in the suvorexant group as compared with the control and C1m-treated groups.  In contrast, the numbers of Fos-IR neurons in histaminergic neurons in the tuberomamillary nucleus and serotonergic neurons in the dorsal raphe were reduced to a similar extent in the suvorexant and C1m groups as compared with the vehicle-treated group.  Together, these results suggest that an orexin-mediated suppression of REM sleep via potential activation of OX1Rs in the locus coeruleus may possibly contribute to the differential effects on sleep/wakefulness exerted by a DORA as compared to a 2-SORA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQakzy_Ia1EjwaK-_ZudimnfW6udTcc2eYn44zy0EWSObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvmt1ynuw%253D%253D&md5=d7bc4732cd4e8c93eaf65b7bd4a9a84e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2014.00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2014.00008%26sid%3Dliteratum%253Aachs%26aulast%3DEtori%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DC.%2BY.%26aulast%3DTsujino%26aufirst%3DN.%26aulast%3DSakurai%26aufirst%3DT.%26atitle%3DEffects%2520of%2520a%2520newly%2520developed%2520potent%2520orexin-2%2520receptor-selective%2520antagonist%252C%2520compound%25201%2520m%252C%2520on%2520sleep%252Fwakefulness%2520states%2520in%2520mice%26jtitle%3DFront.%2520Neurosci.%26date%3D2014%26volume%3D8%26spage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Mori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takatsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuda-Tsukimoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kume, T.</span><span> </span><span class="NLM_article-title">Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=415-422&author=K.+Moriauthor=H.+Hashimotoauthor=H.+Takatsuauthor=M.+Tsuda-Tsukimotoauthor=T.+Kume&title=Cocktail-substrate+assay+system+for+mechanism-based+inhibition+of+CYP2C9%2C+CYP2D6%2C+and+CYP3A+using+human+liver+microsomes+at+an+early+stage+of+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DK.%26aulast%3DHashimoto%26aufirst%3DH.%26aulast%3DTakatsu%26aufirst%3DH.%26aulast%3DTsuda-Tsukimoto%26aufirst%3DM.%26aulast%3DKume%26aufirst%3DT.%26atitle%3DCocktail-substrate%2520assay%2520system%2520for%2520mechanism-based%2520inhibition%2520of%2520CYP2C9%252C%2520CYP2D6%252C%2520and%2520CYP3A%2520using%2520human%2520liver%2520microsomes%2520at%2520an%2520early%2520stage%2520of%2520drug%2520development%26jtitle%3DXenobiotica%26date%3D2009%26volume%3D39%26spage%3D415%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 43 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Subham Mahapatra, Daniel W. Carney, Erick A. Lindsey, Jacob C. DeForest, Scott P. France, Simon Berritt, Simone V. Bigi-Botterill, Tony S. Gibson, Yiyang Liu, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to the New Drugs Approved during 2019. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3604-3657. <a href="https://doi.org/10.1021/acs.jmedchem.1c00208" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00208</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00208%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252Bthe%252BNew%252BDrugs%252BApproved%252Bduring%252B2019%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D03022021%26date%3D30032021%26volume%3D64%26issue%3D7%26spage%3D3604%26epage%3D3657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Antonin Clemenceau, Pierre Thesmar, Maxime Gicquel, Alexandre Le Flohic, <span class="NLM_string-name hlFld-ContribAuthor">Olivier Baudoin</span>. </span><span class="cited-content_cbyCitation_article-title">Direct Synthesis of Cyclopropanes from gem-Dialkyl Groups through Double C–H Activation. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (36)
                                     , 15355-15361. <a href="https://doi.org/10.1021/jacs.0c05887" title="DOI URL">https://doi.org/10.1021/jacs.0c05887</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c05887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c05887%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DDirect%252BSynthesis%252Bof%252BCyclopropanes%252Bfrom%252Bgem-Dialkyl%252BGroups%252Bthrough%252BDouble%252BC%2525E2%252580%252593H%252BActivation%26aulast%3DClemenceau%26aufirst%3DAntonin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D30052020%26date%3D26082020%26date%3D12082020%26volume%3D142%26issue%3D36%26spage%3D15355%26epage%3D15361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mathieu Rappas, Ammar A. E. Ali, Kirstie A. Bennett, Jason D. Brown, Sarah J. Bucknell, Miles Congreve, Robert M. Cooke, Gabriella Cseke, Chris de Graaf, Andrew S. Doré, James C. Errey, Ali Jazayeri, Fiona H. Marshall, Jonathan S. Mason, Richard Mould, Jayesh C. Patel, Benjamin G. Tehan, Malcolm Weir, <span class="NLM_string-name hlFld-ContribAuthor">John A. Christopher</span>. </span><span class="cited-content_cbyCitation_article-title">Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (4)
                                     , 1528-1543. <a href="https://doi.org/10.1021/acs.jmedchem.9b01787" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01787</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01787%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DComparison%252Bof%252BOrexin%252B1%252Band%252BOrexin%252B2%252BLigand%252BBinding%252BModes%252BUsing%252BX-ray%252BCrystallography%252Band%252BComputational%252BAnalysis%26aulast%3DRappas%26aufirst%3DMathieu%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D28102019%26date%3D19012020%26date%3D20122019%26volume%3D63%26issue%3D4%26spage%3D1528%26epage%3D1543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tanaji T.  Talele</span>  . </span><span class="cited-content_cbyCitation_article-title">The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (19)
                                     , 8712-8756. <a href="https://doi.org/10.1021/acs.jmedchem.6b00472" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00472%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252B%2525E2%252580%25259CCyclopropyl%252BFragment%2525E2%252580%25259D%252Bis%252Ba%252BVersatile%252BPlayer%252Bthat%252BFrequently%252BAppears%252Bin%252BPreclinical%25252FClinical%252BDrug%252BMolecules%26aulast%3DTalele%26aufirst%3DTanaji%2BT.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D30032016%26date%3D30062016%26date%3D13102016%26date%3D14062016%26volume%3D59%26issue%3D19%26spage%3D8712%26epage%3D8756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony J.  Roecker</span>, <span class="hlFld-ContribAuthor ">Christopher D.  Cox</span>, and <span class="hlFld-ContribAuthor ">Paul J.  Coleman</span>  . </span><span class="cited-content_cbyCitation_article-title">Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (2)
                                     , 504-530. <a href="https://doi.org/10.1021/acs.jmedchem.5b00832" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00832</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00832%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOrexin%252BReceptor%252BAntagonists%25253A%252BNew%252BTherapeutic%252BAgents%252Bfor%252Bthe%252BTreatment%252Bof%252BInsomnia%26aulast%3DRoecker%26aufirst%3DAnthony%2BJ.%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D30052015%26date%3D15092015%26date%3D28012016%26date%3D28082015%26volume%3D59%26issue%3D2%26spage%3D504%26epage%3D530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dehua  Yang</span>, <span class="hlFld-ContribAuthor ">Qingtong  Zhou</span>, <span class="hlFld-ContribAuthor ">Viktorija  Labroska</span>, <span class="hlFld-ContribAuthor ">Shanshan  Qin</span>, <span class="hlFld-ContribAuthor ">Sanaz  Darbalaei</span>, <span class="hlFld-ContribAuthor ">Yiran  Wu</span>, <span class="hlFld-ContribAuthor ">Elita  Yuliantie</span>, <span class="hlFld-ContribAuthor ">Linshan  Xie</span>, <span class="hlFld-ContribAuthor ">Houchao  Tao</span>, <span class="hlFld-ContribAuthor ">Jianjun  Cheng</span>, <span class="hlFld-ContribAuthor ">Qing  Liu</span>, <span class="hlFld-ContribAuthor ">Suwen  Zhao</span>, <span class="hlFld-ContribAuthor ">Wenqing  Shui</span>, <span class="hlFld-ContribAuthor ">Yi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ming-Wei  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">G protein-coupled receptors: structure- and function-based drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-020-00435-w" title="DOI URL">https://doi.org/10.1038/s41392-020-00435-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-020-00435-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-020-00435-w%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DG%252Bprotein-coupled%252Breceptors%25253A%252Bstructure-%252Band%252Bfunction-based%252Bdrug%252Bdiscovery%26aulast%3DYang%26aufirst%3DDehua%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gary  Zammit</span>, <span class="hlFld-ContribAuthor ">Andrew  Krystal</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluating lemborexant for the treatment of insomnia. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2021,</strong> <em>22 </em>
                                    (10)
                                     , 1235-1243. <a href="https://doi.org/10.1080/14656566.2021.1902987" title="DOI URL">https://doi.org/10.1080/14656566.2021.1902987</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2021.1902987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2021.1902987%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DEvaluating%252Blemborexant%252Bfor%252Bthe%252Btreatment%252Bof%252Binsomnia%26aulast%3DZammit%26aufirst%3DGary%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D10%26spage%3D1235%26epage%3D1243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carsten T.  Beuckmann</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Suzuki</span>, <span class="hlFld-ContribAuthor ">Erik S.  Musiek</span>, <span class="hlFld-ContribAuthor ">Takashi  Ueno</span>, <span class="hlFld-ContribAuthor ">Toshitaka  Sato</span>, <span class="hlFld-ContribAuthor ">Masahiro  Bando</span>, <span class="hlFld-ContribAuthor ">Yoshihide  Osada</span>, <span class="hlFld-ContribAuthor ">Margaret  Moline</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of SAMP8 Mice as a Model for Sleep-Wake and Rhythm Disturbances Associated with Alzheimer’s Disease: Impact of Treatment with the Dual Orexin (Hypocretin) Receptor Antagonist Lemborexant. </span><span class="cited-content_cbyCitation_journal-name">Journal of Alzheimer's Disease</span><span> <strong>2021,</strong> <em>81 </em>
                                    (3)
                                     , 1151-1167. <a href="https://doi.org/10.3233/JAD-201054" title="DOI URL">https://doi.org/10.3233/JAD-201054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3233/JAD-201054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3233%2FJAD-201054%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Alzheimer%2527s%2520Disease%26atitle%3DEvaluation%252Bof%252BSAMP8%252BMice%252Bas%252Ba%252BModel%252Bfor%252BSleep-Wake%252Band%252BRhythm%252BDisturbances%252BAssociated%252Bwith%252BAlzheimer%2525E2%252580%252599s%252BDisease%25253A%252BImpact%252Bof%252BTreatment%252Bwith%252Bthe%252BDual%252BOrexin%252B%252528Hypocretin%252529%252BReceptor%252BAntagonist%252BLemborexant%26aulast%3DBeuckmann%26aufirst%3DCarsten%2BT.%26date%3D2021%26volume%3D81%26issue%3D3%26spage%3D1151%26epage%3D1167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ishani  Landry</span>, <span class="hlFld-ContribAuthor ">Jagadeesh  Aluri</span>, <span class="hlFld-ContribAuthor ">Kenya  Nakai</span>, <span class="hlFld-ContribAuthor ">Nancy  Hall</span>, <span class="hlFld-ContribAuthor ">Yukiko  Miyajima</span>, <span class="hlFld-ContribAuthor ">Takashi  Ueno</span>, <span class="hlFld-ContribAuthor ">Satish  Dayal</span>, <span class="hlFld-ContribAuthor ">Gleb  Filippov</span>, <span class="hlFld-ContribAuthor ">Bojan  Lalovic</span>, <span class="hlFld-ContribAuthor ">Margaret  Moline</span>, <span class="hlFld-ContribAuthor ">Larisa  Reyderman</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacology in Drug Development</span><span> <strong>2021,</strong> <em>10 </em>
                                    (6)
                                     , 681-690. <a href="https://doi.org/10.1002/cpdd.915" title="DOI URL">https://doi.org/10.1002/cpdd.915</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpdd.915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpdd.915%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacology%2520in%2520Drug%2520Development%26atitle%3DEvaluation%252Bof%252Bthe%252BCYP3A%252Band%252BCYP2B6%252BDrug%2525E2%252580%252590Drug%252BInteraction%252BPotential%252Bof%252BLemborexant%26aulast%3DLandry%26aufirst%3DIshani%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D6%26spage%3D681%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ishani  Landry</span>, <span class="hlFld-ContribAuthor ">Kenya  Nakai</span>, <span class="hlFld-ContribAuthor ">Jim  Ferry</span>, <span class="hlFld-ContribAuthor ">Jagadeesh  Aluri</span>, <span class="hlFld-ContribAuthor ">Nancy  Hall</span>, <span class="hlFld-ContribAuthor ">Bojan  Lalovic</span>, <span class="hlFld-ContribAuthor ">Margaret L.  Moline</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacology in Drug Development</span><span> <strong>2021,</strong> <em>10 </em>
                                    (2)
                                     , 153-165. <a href="https://doi.org/10.1002/cpdd.817" title="DOI URL">https://doi.org/10.1002/cpdd.817</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpdd.817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpdd.817%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacology%2520in%2520Drug%2520Development%26atitle%3DPharmacokinetics%25252C%252BPharmacodynamics%25252C%252Band%252BSafety%252Bof%252Bthe%252BDual%252BOrexin%252BReceptor%252BAntagonist%252BLemborexant%25253A%252BFindings%252BFrom%252BSingle%2525E2%252580%252590Dose%252Band%252BMultiple%2525E2%252580%252590Ascending%2525E2%252580%252590Dose%252BPhase%252B1%252BStudies%252Bin%252BHealthy%252BAdults%26aulast%3DLandry%26aufirst%3DIshani%26date%3D2021%26date%3D2020%26volume%3D10%26issue%3D2%26spage%3D153%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takashi  Ueno</span>, <span class="hlFld-ContribAuthor ">Tomomi  Ishida</span>, <span class="hlFld-ContribAuthor ">Jagadeesh  Aluri</span>, <span class="hlFld-ContribAuthor ">Michiyuki  Suzuki</span>, <span class="hlFld-ContribAuthor ">Carsten T.  Beuckmann</span>, <span class="hlFld-ContribAuthor ">Takaaki  Kameyama</span>, <span class="hlFld-ContribAuthor ">Shoji  Asakura</span>, <span class="hlFld-ContribAuthor ">Kazutomi  Kusano</span>. </span><span class="cited-content_cbyCitation_article-title">Disposition and Metabolism of [
              14
              C]Lemborexant in Healthy Human Subjects and Characterization of Its Circulating Metabolites. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2021,</strong> <em>49 </em>
                                    (1)
                                     , 31-38. <a href="https://doi.org/10.1124/dmd.120.000229" title="DOI URL">https://doi.org/10.1124/dmd.120.000229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.120.000229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.120.000229%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DDisposition%252Band%252BMetabolism%252Bof%252B%25255B%252B14%252BC%25255DLemborexant%252Bin%252BHealthy%252BHuman%252BSubjects%252Band%252BCharacterization%252Bof%252BIts%252BCirculating%252BMetabolites%26aulast%3DUeno%26aufirst%3DTakashi%26date%3D2021%26date%3D2020%26volume%3D49%26issue%3D1%26spage%3D31%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christoph  Boss</span>, <span class="hlFld-ContribAuthor ">John  Gatfield</span>, <span class="hlFld-ContribAuthor ">Christine  Brotschi</span>, <span class="hlFld-ContribAuthor ">Bibia  Heidmann</span>, <span class="hlFld-ContribAuthor ">Thierry  Sifferlen</span>, <span class="hlFld-ContribAuthor ">Markus  Raumer</span>, <span class="hlFld-ContribAuthor ">Gunther  Schmidt</span>, <span class="hlFld-ContribAuthor ">Jodi T.  Williams</span>, <span class="hlFld-ContribAuthor ">Alexander  Treiber</span>, <span class="hlFld-ContribAuthor ">Catherine  Roch</span>. </span><span class="cited-content_cbyCitation_article-title">The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (23)
                                     , 2286-2305. <a href="https://doi.org/10.1002/cmdc.202000453" title="DOI URL">https://doi.org/10.1002/cmdc.202000453</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000453%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DThe%252BQuest%252Bfor%252Bthe%252BBest%252BDual%252BOrexin%252BReceptor%252BAntagonist%252B%252528Daridorexant%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BInsomnia%252BDisorders%26aulast%3DBoss%26aufirst%3DChristoph%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D23%26spage%3D2286%26epage%3D2305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ishani  Landry</span>, <span class="hlFld-ContribAuthor ">Jagadeesh  Aluri</span>, <span class="hlFld-ContribAuthor ">Nancy  Hall</span>, <span class="hlFld-ContribAuthor ">Dinesh  Kumar</span>, <span class="hlFld-ContribAuthor ">Satish  Dayal</span>, <span class="hlFld-ContribAuthor ">Margaret  Moline</span>, <span class="hlFld-ContribAuthor ">Larisa  Reyderman</span>. </span><span class="cited-content_cbyCitation_article-title">Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology Research & Perspectives</span><span> <strong>2020,</strong> <em>8 </em>
                                    (6)
                                     <a href="https://doi.org/10.1002/prp2.678" title="DOI URL">https://doi.org/10.1002/prp2.678</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/prp2.678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fprp2.678%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520Research%2520%2526%2520Perspectives%26atitle%3DEffect%252Bof%252Bgastric%252Bacid%2525E2%252580%252590reducing%252Bagents%252Bon%252Bthe%252Bpharmacokinetics%252Band%252Befficacy%252Bof%252Blemborexant%26aulast%3DLandry%26aufirst%3DIshani%26date%3D2020%26date%3D2020%26volume%3D8%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">New drug approvals for 2019: Synthesis and clinical applications. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>205 </em>, 112667. <a href="https://doi.org/10.1016/j.ejmech.2020.112667" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112667%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252Bdrug%252Bapprovals%252Bfor%252B2019%25253A%252BSynthesis%252Band%252Bclinical%252Bapplications%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2020%26volume%3D205%26spage%3D112667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hannah A.  Blair</span>. </span><span class="cited-content_cbyCitation_article-title">Lemborexant in insomnia disorder: a profile of its use. </span><span class="cited-content_cbyCitation_journal-name">Drugs & Therapy Perspectives</span><span> <strong>2020,</strong> <em>36 </em>
                                    (10)
                                     , 427-434. <a href="https://doi.org/10.1007/s40267-020-00771-5" title="DOI URL">https://doi.org/10.1007/s40267-020-00771-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40267-020-00771-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40267-020-00771-5%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%2520%2526%2520Therapy%2520Perspectives%26atitle%3DLemborexant%252Bin%252Binsomnia%252Bdisorder%25253A%252Ba%252Bprofile%252Bof%252Bits%252Buse%26aulast%3DBlair%26aufirst%3DHannah%2BA.%26date%3D2020%26date%3D2020%26volume%3D36%26issue%3D10%26spage%3D427%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haibo  Mei</span>, <span class="hlFld-ContribAuthor ">Attila Márió  Remete</span>, <span class="hlFld-ContribAuthor ">Yupiao  Zou</span>, <span class="hlFld-ContribAuthor ">Hiroki  Moriwaki</span>, <span class="hlFld-ContribAuthor ">Santos  Fustero</span>, <span class="hlFld-ContribAuthor ">Lorand  Kiss</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>, <span class="hlFld-ContribAuthor ">Jianlin  Han</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorine-containing drugs approved by the FDA in 2019. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2020,</strong> <em>31 </em>
                                    (9)
                                     , 2401-2413. <a href="https://doi.org/10.1016/j.cclet.2020.03.050" title="DOI URL">https://doi.org/10.1016/j.cclet.2020.03.050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2020.03.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2020.03.050%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DFluorine-containing%252Bdrugs%252Bapproved%252Bby%252Bthe%252BFDA%252Bin%252B2019%26aulast%3DMei%26aufirst%3DHaibo%26date%3D2020%26volume%3D31%26issue%3D9%26spage%3D2401%26epage%3D2413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin  Guo</span>, <span class="hlFld-ContribAuthor ">Jingya  Xiu</span>, <span class="hlFld-ContribAuthor ">Yi  Shen</span>, <span class="hlFld-ContribAuthor ">Qingeng  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological activity evaluation of azacycloheptane sulfonamide derivatives as potential orexin receptor antagonists. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2020,</strong> <em>10 </em>
                                    (51)
                                     , 30683-30691. <a href="https://doi.org/10.1039/D0RA05068G" title="DOI URL">https://doi.org/10.1039/D0RA05068G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0RA05068G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0RA05068G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DSynthesis%252Band%252Bbiological%252Bactivity%252Bevaluation%252Bof%252Bazacycloheptane%252Bsulfonamide%252Bderivatives%252Bas%252Bpotential%252Borexin%252Breceptor%252Bantagonists%26aulast%3DGuo%26aufirst%3DBin%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D51%26spage%3D30683%26epage%3D30691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aya  Futamura</span>, <span class="hlFld-ContribAuthor ">Ryo  Suzuki</span>, <span class="hlFld-ContribAuthor ">Yunoshin  Tamura</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Kawamoto</span>, <span class="hlFld-ContribAuthor ">Mari  Ohmichi</span>, <span class="hlFld-ContribAuthor ">Noriko  Hino</span>, <span class="hlFld-ContribAuthor ">Yuichi  Tokumaru</span>, <span class="hlFld-ContribAuthor ">Sora  Kirinuki</span>, <span class="hlFld-ContribAuthor ">Tetsuaki  Hiyoshi</span>, <span class="hlFld-ContribAuthor ">Takeshi  Aoki</span>, <span class="hlFld-ContribAuthor ">Daiji  Kambe</span>, <span class="hlFld-ContribAuthor ">Dai  Nozawa</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (13)
                                     , 115489. <a href="https://doi.org/10.1016/j.bmc.2020.115489" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115489</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115489%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BORN0829%25252C%252Ba%252Bpotent%252Bdual%252Borexin%252B1%25252F2%252Breceptor%252Bantagonist%252Bfor%252Bthe%252Btreatment%252Bof%252Binsomnia%26aulast%3DFutamura%26aufirst%3DAya%26date%3D2020%26volume%3D28%26issue%3D13%26spage%3D115489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samaresh  Jana</span>, <span class="hlFld-ContribAuthor ">Sohini  Sarkar</span>, <span class="hlFld-ContribAuthor ">Scott A.  Morris</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments towards the synthesis of paroxetine: A 3,4-disubstituted piperidine. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2020,</strong> <em>76 </em>
                                    (25)
                                     , 131215. <a href="https://doi.org/10.1016/j.tet.2020.131215" title="DOI URL">https://doi.org/10.1016/j.tet.2020.131215</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.131215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.131215%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DRecent%252Bdevelopments%252Btowards%252Bthe%252Bsynthesis%252Bof%252Bparoxetine%25253A%252BA%252B3%25252C4-disubstituted%252Bpiperidine%26aulast%3DJana%26aufirst%3DSamaresh%26date%3D2020%26volume%3D76%26issue%3D25%26spage%3D131215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karol  Biernacki</span>, <span class="hlFld-ContribAuthor ">Mateusz  Daśko</span>, <span class="hlFld-ContribAuthor ">Olga  Ciupak</span>, <span class="hlFld-ContribAuthor ">Konrad  Kubiński</span>, <span class="hlFld-ContribAuthor ">Janusz  Rachon</span>, <span class="hlFld-ContribAuthor ">Sebastian  Demkowicz</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 1,2,4-Oxadiazole Derivatives in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (6)
                                     , 111. <a href="https://doi.org/10.3390/ph13060111" title="DOI URL">https://doi.org/10.3390/ph13060111</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13060111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13060111%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DNovel%252B1%25252C2%25252C4-Oxadiazole%252BDerivatives%252Bin%252BDrug%252BDiscovery%26aulast%3DBiernacki%26aufirst%3DKarol%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D6%26spage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying  Han</span>, <span class="hlFld-ContribAuthor ">Kai  Yuan</span>, <span class="hlFld-ContribAuthor ">Yongbo  Zheng</span>, <span class="hlFld-ContribAuthor ">Lin  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. </span><span class="cited-content_cbyCitation_journal-name">Neuroscience Bulletin</span><span> <strong>2020,</strong> <em>36 </em>
                                    (4)
                                     , 432-448. <a href="https://doi.org/10.1007/s12264-019-00447-9" title="DOI URL">https://doi.org/10.1007/s12264-019-00447-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12264-019-00447-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12264-019-00447-9%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuroscience%2520Bulletin%26atitle%3DOrexin%252BReceptor%252BAntagonists%252Bas%252BEmerging%252BTreatments%252Bfor%252BPsychiatric%252BDisorders%26aulast%3DHan%26aufirst%3DYing%26date%3D2020%26date%3D2019%26volume%3D36%26issue%3D4%26spage%3D432%26epage%3D448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christine  Brotschi</span>, <span class="hlFld-ContribAuthor ">Martin H.  Bolli</span>, <span class="hlFld-ContribAuthor ">John  Gatfield</span>, <span class="hlFld-ContribAuthor ">Bibia  Heidmann</span>, <span class="hlFld-ContribAuthor ">Francois  Jenck</span>, <span class="hlFld-ContribAuthor ">Catherine  Roch</span>, <span class="hlFld-ContribAuthor ">Thierry  Sifferlen</span>, <span class="hlFld-ContribAuthor ">Alexander  Treiber</span>, <span class="hlFld-ContribAuthor ">Jodi T.  Williams</span>, <span class="hlFld-ContribAuthor ">Christoph  Boss</span>. </span><span class="cited-content_cbyCitation_article-title">From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (5)
                                     , 430-448. <a href="https://doi.org/10.1002/cmdc.201900618" title="DOI URL">https://doi.org/10.1002/cmdc.201900618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900618%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DFrom%252BOxadiazole%252Bto%252BTriazole%252BAnalogues%25253A%252BOptimization%252Btoward%252Ba%252BDual%252BOrexin%252BReceptor%252BAntagonist%252Bwith%252BImproved%252Bin%2525E2%252580%252585vivo%252BEfficacy%252Bin%252BDogs%26aulast%3DBrotschi%26aufirst%3DChristine%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D5%26spage%3D430%26epage%3D448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lesley J.  Scott</span>. </span><span class="cited-content_cbyCitation_article-title">Lemborexant: First Approval. </span><span class="cited-content_cbyCitation_journal-name">Drugs</span><span> <strong>2020,</strong> <em>80 </em>
                                    (4)
                                     , 425-432. <a href="https://doi.org/10.1007/s40265-020-01276-1" title="DOI URL">https://doi.org/10.1007/s40265-020-01276-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40265-020-01276-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40265-020-01276-1%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%26atitle%3DLemborexant%25253A%252BFirst%252BApproval%26aulast%3DScott%26aufirst%3DLesley%2BJ.%26date%3D2020%26date%3D2020%26volume%3D80%26issue%3D4%26spage%3D425%26epage%3D432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel  Hoyer</span>, <span class="hlFld-ContribAuthor ">Andrew  Allen</span>, <span class="hlFld-ContribAuthor ">Laura H.  Jacobson</span>. </span><span class="cited-content_cbyCitation_article-title">Hypnotics with novel modes of action. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Clinical Pharmacology</span><span> <strong>2020,</strong> <em>86 </em>
                                    (2)
                                     , 244-249. <a href="https://doi.org/10.1111/bcp.14180" title="DOI URL">https://doi.org/10.1111/bcp.14180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bcp.14180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbcp.14180%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DHypnotics%252Bwith%252Bnovel%252Bmodes%252Bof%252Baction%26aulast%3DHoyer%26aufirst%3DDaniel%26date%3D2020%26date%3D2020%26volume%3D86%26issue%3D2%26spage%3D244%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adrielle P.  Maximiano</span>, <span class="hlFld-ContribAuthor ">Marcus M.  Sá</span>. </span><span class="cited-content_cbyCitation_article-title">Stereoselective Synthesis of Cyclopropylidene Iminolactones and Functionalized Cyclopropanecarboxamides Mediated by Triflic Acid. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>2019 </em>
                                    (38)
                                     , 6515-6524. <a href="https://doi.org/10.1002/ejoc.201900931" title="DOI URL">https://doi.org/10.1002/ejoc.201900931</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201900931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201900931%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DStereoselective%252BSynthesis%252Bof%252BCyclopropylidene%252BIminolactones%252Band%252BFunctionalized%252BCyclopropanecarboxamides%252BMediated%252Bby%252BTriflic%252BAcid%26aulast%3DMaximiano%26aufirst%3DAdrielle%2BP.%26date%3D2019%26date%3D2019%26volume%3D2019%26issue%3D38%26spage%3D6515%26epage%3D6524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christine  Brotschi</span>, <span class="hlFld-ContribAuthor ">Catherine  Roch</span>, <span class="hlFld-ContribAuthor ">John  Gatfield</span>, <span class="hlFld-ContribAuthor ">Alexander  Treiber</span>, <span class="hlFld-ContribAuthor ">Jodi T.  Williams</span>, <span class="hlFld-ContribAuthor ">Thierry  Sifferlen</span>, <span class="hlFld-ContribAuthor ">Bibia  Heidmann</span>, <span class="hlFld-ContribAuthor ">Francois  Jenck</span>, <span class="hlFld-ContribAuthor ">Martin H.  Bolli</span>, <span class="hlFld-ContribAuthor ">Christoph  Boss</span>. </span><span class="cited-content_cbyCitation_article-title">Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure–Activity Relationships, and Sleep‐Promoting Properties in Rats. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2019,</strong> <em>14 </em>
                                    (13)
                                     , 1257-1270. <a href="https://doi.org/10.1002/cmdc.201900242" title="DOI URL">https://doi.org/10.1002/cmdc.201900242</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900242%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DOxadiazole%252BDerivatives%252Bas%252BDual%252BOrexin%252BReceptor%252BAntagonists%25253A%252BSynthesis%25252C%252BStructure%2525E2%252580%252593Activity%252BRelationships%25252C%252Band%252BSleep%2525E2%252580%252590Promoting%252BProperties%252Bin%252BRats%26aulast%3DBrotschi%26aufirst%3DChristine%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D13%26spage%3D1257%26epage%3D1270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carsten Theodor  Beuckmann</span>, <span class="hlFld-ContribAuthor ">Takashi  Ueno</span>, <span class="hlFld-ContribAuthor ">Makoto  Nakagawa</span>, <span class="hlFld-ContribAuthor ">Michiyuki  Suzuki</span>, <span class="hlFld-ContribAuthor ">Shigeru  Akasofu</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation. </span><span class="cited-content_cbyCitation_journal-name">Sleep</span><span> <strong>2019,</strong> <em>42 </em>
                                    (6)
                                     <a href="https://doi.org/10.1093/sleep/zsz076" title="DOI URL">https://doi.org/10.1093/sleep/zsz076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/sleep/zsz076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fsleep%2Fzsz076%26sid%3Dliteratum%253Aachs%26jtitle%3DSleep%26atitle%3DPreclinical%252Bin%252Bvivo%252Bcharacterization%252Bof%252Blemborexant%252B%252528E2006%252529%25252C%252Ba%252Bnovel%252Bdual%252Borexin%252Breceptor%252Bantagonist%252Bfor%252Bsleep%25252Fwake%252Bregulation%26aulast%3DBeuckmann%26aufirst%3DCarsten%2BTheodor%26date%3D2019%26date%3D2019%26volume%3D42%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takashi  Ueno</span>, <span class="hlFld-ContribAuthor ">Tomomi  Ishida</span>, <span class="hlFld-ContribAuthor ">Kazutomi  Kusano</span>. </span><span class="cited-content_cbyCitation_article-title">Disposition and metabolism of [
              14
              C]lemborexant, a novel dual orexin receptor antagonist, in rats and monkeys. </span><span class="cited-content_cbyCitation_journal-name">Xenobiotica</span><span> <strong>2019,</strong> <em>49 </em>
                                    (6)
                                     , 688-697. <a href="https://doi.org/10.1080/00498254.2018.1482509" title="DOI URL">https://doi.org/10.1080/00498254.2018.1482509</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00498254.2018.1482509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00498254.2018.1482509%26sid%3Dliteratum%253Aachs%26jtitle%3DXenobiotica%26atitle%3DDisposition%252Band%252Bmetabolism%252Bof%252B%25255B%252B14%252BC%25255Dlemborexant%25252C%252Ba%252Bnovel%252Bdual%252Borexin%252Breceptor%252Bantagonist%25252C%252Bin%252Brats%252Band%252Bmonkeys%26aulast%3DUeno%26aufirst%3DTakashi%26date%3D2019%26date%3D2018%26volume%3D49%26issue%3D6%26spage%3D688%26epage%3D697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Annemiek  Vermeeren</span>, <span class="hlFld-ContribAuthor ">Stefan  Jongen</span>, <span class="hlFld-ContribAuthor ">Patricia  Murphy</span>, <span class="hlFld-ContribAuthor ">Margaret  Moline</span>, <span class="hlFld-ContribAuthor ">Gleb  Filippov</span>, <span class="hlFld-ContribAuthor ">Kate  Pinner</span>, <span class="hlFld-ContribAuthor ">Carlos  Perdomo</span>, <span class="hlFld-ContribAuthor ">Ishani  Landry</span>, <span class="hlFld-ContribAuthor ">Oneeb  Majid</span>, <span class="hlFld-ContribAuthor ">Anita C M  Van Oers</span>, <span class="hlFld-ContribAuthor ">Cees J  Van Leeuwen</span>, <span class="hlFld-ContribAuthor ">Johannes G  Ramaekers</span>, <span class="hlFld-ContribAuthor ">Eric F P M  Vuurman</span>. </span><span class="cited-content_cbyCitation_article-title">On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. </span><span class="cited-content_cbyCitation_journal-name">Sleep</span><span> <strong>2019,</strong> <em>42 </em>
                                    (4)
                                     <a href="https://doi.org/10.1093/sleep/zsy260" title="DOI URL">https://doi.org/10.1093/sleep/zsy260</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/sleep/zsy260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fsleep%2Fzsy260%26sid%3Dliteratum%253Aachs%26jtitle%3DSleep%26atitle%3DOn-the-road%252Bdriving%252Bperformance%252Bthe%252Bmorning%252Bafter%252Bbedtime%252Badministration%252Bof%252Blemborexant%252Bin%252Bhealthy%252Badult%252Band%252Belderly%252Bvolunteers%26aulast%3DVermeeren%26aufirst%3DAnnemiek%26date%3D2019%26date%3D2018%26volume%3D42%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">W. Joseph  Herring</span>, <span class="hlFld-ContribAuthor ">Thomas  Roth</span>, <span class="hlFld-ContribAuthor ">Andrew D.  Krystal</span>, <span class="hlFld-ContribAuthor ">David  Michelson</span>. </span><span class="cited-content_cbyCitation_article-title">Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. </span><span class="cited-content_cbyCitation_journal-name">Journal of Sleep Research</span><span> <strong>2019,</strong> <em>28 </em>
                                    (2)
                                     <a href="https://doi.org/10.1111/jsr.12782" title="DOI URL">https://doi.org/10.1111/jsr.12782</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jsr.12782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjsr.12782%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Sleep%2520Research%26atitle%3DOrexin%252Breceptor%252Bantagonists%252Bfor%252Bthe%252Btreatment%252Bof%252Binsomnia%252Band%252Bpotential%252Btreatment%252Bof%252Bother%252Bneuropsychiatric%252Bindications%26aulast%3DHerring%26aufirst%3DW.%2BJoseph%26date%3D2019%26date%3D2018%26volume%3D28%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hannah E.  Thomasy</span>, <span class="hlFld-ContribAuthor ">Mark R.  Opp</span>. </span><span class="cited-content_cbyCitation_article-title">Hypocretin Mediates Sleep and Wake Disturbances in a Mouse Model of Traumatic Brain Injury. </span><span class="cited-content_cbyCitation_journal-name">Journal of Neurotrauma</span><span> <strong>2019,</strong> <em>36 </em>
                                    (5)
                                     , 802-814. <a href="https://doi.org/10.1089/neu.2018.5810" title="DOI URL">https://doi.org/10.1089/neu.2018.5810</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1089/neu.2018.5810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1089%2Fneu.2018.5810%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Neurotrauma%26atitle%3DHypocretin%252BMediates%252BSleep%252Band%252BWake%252BDisturbances%252Bin%252Ba%252BMouse%252BModel%252Bof%252BTraumatic%252BBrain%252BInjury%26aulast%3DThomasy%26aufirst%3DHannah%2BE.%26date%3D2019%26volume%3D36%26issue%3D5%26spage%3D802%26epage%3D814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marie-Laure  Boof</span>, <span class="hlFld-ContribAuthor ">Abir  Alatrach</span>, <span class="hlFld-ContribAuthor ">Mike  Ufer</span>, <span class="hlFld-ContribAuthor ">Jasper  Dingemanse</span>. </span><span class="cited-content_cbyCitation_article-title">Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Clinical Pharmacology</span><span> <strong>2019,</strong> <em>75 </em>
                                    (2)
                                     , 195-205. <a href="https://doi.org/10.1007/s00228-018-2559-5" title="DOI URL">https://doi.org/10.1007/s00228-018-2559-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00228-018-2559-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00228-018-2559-5%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DInteraction%252Bpotential%252Bof%252Bthe%252Bdual%252Borexin%252Breceptor%252Bantagonist%252BACT-541468%252Bwith%252BCYP3A4%252Band%252Bfood%25253A%252Bresults%252Bfrom%252Btwo%252Binteraction%252Bstudies%26aulast%3DBoof%26aufirst%3DMarie-Laure%26date%3D2019%26date%3D2018%26volume%3D75%26issue%3D2%26spage%3D195%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel  Hoyer</span>, <span class="hlFld-ContribAuthor ">Laura H.  Jacobson</span>. </span><span class="cited-content_cbyCitation_article-title">Orexin Receptor Antagonists. </span><span class="cited-content_cbyCitation_journal-name">Current Sleep Medicine Reports</span><span> <strong>2017,</strong> <em>3 </em>
                                    (4)
                                     , 342-353. <a href="https://doi.org/10.1007/s40675-017-0099-7" title="DOI URL">https://doi.org/10.1007/s40675-017-0099-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40675-017-0099-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40675-017-0099-7%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Sleep%2520Medicine%2520Reports%26atitle%3DOrexin%252BReceptor%252BAntagonists%26aulast%3DHoyer%26aufirst%3DDaniel%26date%3D2017%26date%3D2017%26volume%3D3%26issue%3D4%26spage%3D342%26epage%3D353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christoph  Boss</span>, <span class="hlFld-ContribAuthor ">Catherine  Roch</span>. </span><span class="cited-content_cbyCitation_article-title">Orexin research: patent news from 2016. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2017,</strong> <em>27 </em>
                                    (10)
                                     , 1123-1133. <a href="https://doi.org/10.1080/13543776.2017.1344221" title="DOI URL">https://doi.org/10.1080/13543776.2017.1344221</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2017.1344221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2017.1344221%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DOrexin%252Bresearch%25253A%252Bpatent%252Bnews%252Bfrom%252B2016%26aulast%3DBoss%26aufirst%3DChristoph%26date%3D2017%26date%3D2017%26volume%3D27%26issue%3D10%26spage%3D1123%26epage%3D1133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander  Treiber</span>, <span class="hlFld-ContribAuthor ">Ruben  de Kanter</span>, <span class="hlFld-ContribAuthor ">Catherine  Roch</span>, <span class="hlFld-ContribAuthor ">John  Gatfield</span>, <span class="hlFld-ContribAuthor ">Christoph  Boss</span>, <span class="hlFld-ContribAuthor ">Markus  von Raumer</span>, <span class="hlFld-ContribAuthor ">Benno  Schindelholz</span>, <span class="hlFld-ContribAuthor ">Clemens  Muehlan</span>, <span class="hlFld-ContribAuthor ">Joop  van Gerven</span>, <span class="hlFld-ContribAuthor ">Francois  Jenck</span>. </span><span class="cited-content_cbyCitation_article-title">The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2017,</strong> <em>362 </em>
                                    (3)
                                     , 489-503. <a href="https://doi.org/10.1124/jpet.117.241596" title="DOI URL">https://doi.org/10.1124/jpet.117.241596</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.117.241596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.117.241596%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DThe%252BUse%252Bof%252BPhysiology-Based%252BPharmacokinetic%252Band%252BPharmacodynamic%252BModeling%252Bin%252Bthe%252BDiscovery%252Bof%252Bthe%252BDual%252BOrexin%252BReceptor%252BAntagonist%252BACT-541468%26aulast%3DTreiber%26aufirst%3DAlexander%26date%3D2017%26date%3D2017%26volume%3D362%26issue%3D3%26spage%3D489%26epage%3D503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carsten Theodor  Beuckmann</span>, <span class="hlFld-ContribAuthor ">Michiyuki  Suzuki</span>, <span class="hlFld-ContribAuthor ">Takashi  Ueno</span>, <span class="hlFld-ContribAuthor ">Kazuya  Nagaoka</span>, <span class="hlFld-ContribAuthor ">Tohru  Arai</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Higashiyama</span>. </span><span class="cited-content_cbyCitation_article-title">In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2017,</strong> <em>362 </em>
                                    (2)
                                     , 287-295. <a href="https://doi.org/10.1124/jpet.117.241422" title="DOI URL">https://doi.org/10.1124/jpet.117.241422</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.117.241422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.117.241422%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DIn%252BVitro%252Band%252BIn%252BSilico%252BCharacterization%252Bof%252BLemborexant%252B%252528E2006%252529%25252C%252Ba%252BNovel%252BDual%252BOrexin%252BReceptor%252BAntagonist%26aulast%3DBeuckmann%26aufirst%3DCarsten%2BTheodor%26date%3D2017%26date%3D2017%26volume%3D362%26issue%3D2%26spage%3D287%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter J.  Lindsay-Scott</span>, <span class="hlFld-ContribAuthor ">Peter T.  Gallagher</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of heterocycles from arylacetonitriles: Powerful tools for medicinal chemists. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2017,</strong> <em>58 </em>
                                    (27)
                                     , 2629-2635. <a href="https://doi.org/10.1016/j.tetlet.2017.05.089" title="DOI URL">https://doi.org/10.1016/j.tetlet.2017.05.089</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2017.05.089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2017.05.089%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DSynthesis%252Bof%252Bheterocycles%252Bfrom%252Barylacetonitriles%25253A%252BPowerful%252Btools%252Bfor%252Bmedicinal%252Bchemists%26aulast%3DLindsay-Scott%26aufirst%3DPeter%2BJ.%26date%3D2017%26volume%3D58%26issue%3D27%26spage%3D2629%26epage%3D2635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michihiro  Mieda</span>. </span><span class="cited-content_cbyCitation_article-title">The roles of orexins in sleep/wake regulation. </span><span class="cited-content_cbyCitation_journal-name">Neuroscience Research</span><span> <strong>2017,</strong> <em>118 </em>, 56-65. <a href="https://doi.org/10.1016/j.neures.2017.03.015" title="DOI URL">https://doi.org/10.1016/j.neures.2017.03.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neures.2017.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neures.2017.03.015%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuroscience%2520Research%26atitle%3DThe%252Broles%252Bof%252Borexins%252Bin%252Bsleep%25252Fwake%252Bregulation%26aulast%3DMieda%26aufirst%3DMichihiro%26date%3D2017%26volume%3D118%26spage%3D56%26epage%3D65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul J.  Coleman</span>, <span class="hlFld-ContribAuthor ">Anthony L.  Gotter</span>, <span class="hlFld-ContribAuthor ">W. Joseph  Herring</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Winrow</span>, <span class="hlFld-ContribAuthor ">John J.  Renger</span>. </span><span class="cited-content_cbyCitation_article-title">The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Pharmacology and Toxicology</span><span> <strong>2017,</strong> <em>57 </em>
                                    (1)
                                     , 509-533. <a href="https://doi.org/10.1146/annurev-pharmtox-010716-104837" title="DOI URL">https://doi.org/10.1146/annurev-pharmtox-010716-104837</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-pharmtox-010716-104837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-pharmtox-010716-104837%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Pharmacology%2520and%2520Toxicology%26atitle%3DThe%252BDiscovery%252Bof%252BSuvorexant%25252C%252Bthe%252BFirst%252BOrexin%252BReceptor%252BDrug%252Bfor%252BInsomnia%26aulast%3DColeman%26aufirst%3DPaul%2BJ.%26date%3D2017%26volume%3D57%26issue%3D1%26spage%3D509%26epage%3D533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">B.T.  Shireman</span>, <span class="hlFld-ContribAuthor ">M.A.  Letavic</span>. </span><span class="cited-content_cbyCitation_article-title">Orexin Receptor Antagonists. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 225-279. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12442-4" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12442-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12442-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12442-4%26sid%3Dliteratum%253Aachs%26atitle%3DOrexin%252BReceptor%252BAntagonists%26aulast%3DShireman%26aufirst%3DB.T.%26date%3D2017%26spage%3D225%26epage%3D279%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seijiro  Takada</span>, <span class="hlFld-ContribAuthor ">Taichi  Saito</span>, <span class="hlFld-ContribAuthor ">Kiitsu  Iwata</span>, <span class="hlFld-ContribAuthor ">Yoshinori  Nishii</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-Catalyzed 1,5-Addition of Grignard reagents to Enantioenriched Donor-Acceptor Cyclopropanes with Inversion. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>5 </em>
                                    (10)
                                     , 1225-1229. <a href="https://doi.org/10.1002/ajoc.201600313" title="DOI URL">https://doi.org/10.1002/ajoc.201600313</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201600313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201600313%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DCopper-Catalyzed%252B1%25252C5-Addition%252Bof%252BGrignard%252Breagents%252Bto%252BEnantioenriched%252BDonor-Acceptor%252BCyclopropanes%252Bwith%252BInversion%26aulast%3DTakada%26aufirst%3DSeijiro%26date%3D2016%26date%3D2016%26volume%3D5%26issue%3D10%26spage%3D1225%26epage%3D1229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christoph  Boss</span>, <span class="hlFld-ContribAuthor ">Catherine  Roch</span>. </span><span class="cited-content_cbyCitation_article-title">Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2016,</strong> <em>26 </em>
                                    (3)
                                     , 409-415. <a href="https://doi.org/10.1517/13543776.2016.1124087" title="DOI URL">https://doi.org/10.1517/13543776.2016.1124087</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2016.1124087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2016.1124087%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSubstituted%252Bcyclopentanes%25252C%252Btetrahydrofurans%252Band%252Bpyrrolidines%252Bas%252Borexin-1-receptor%252Bantagonists%252Bfor%252Btreatment%252Bof%252Bvarious%252BCNS%252Bdisorders%252B%252528WO2015%25252F055994%25253B%252BWO2015%25252F124932%25253B%252BWO2015%25252F124934%252529%26aulast%3DBoss%26aufirst%3DChristoph%26date%3D2016%26date%3D2015%26volume%3D26%26issue%3D3%26spage%3D409%26epage%3D415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura H.  Jacobson</span>, <span class="hlFld-ContribAuthor ">Sui  Chen</span>, <span class="hlFld-ContribAuthor ">Sanjida  Mir</span>, <span class="hlFld-ContribAuthor ">Daniel  Hoyer</span>. </span><span class="cited-content_cbyCitation_article-title">Orexin OX2 Receptor Antagonists as Sleep Aids. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 105-136. <a href="https://doi.org/10.1007/7854_2016_47" title="DOI URL">https://doi.org/10.1007/7854_2016_47</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7854_2016_47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7854_2016_47%26sid%3Dliteratum%253Aachs%26atitle%3DOrexin%252BOX2%252BReceptor%252BAntagonists%252Bas%252BSleep%252BAids%26aulast%3DJacobson%26aufirst%3DLaura%2BH.%26date%3D2016%26date%3D2016%26spage%3D105%26epage%3D136%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DBehavioral%252BNeuroscience%252Bof%252BOrexin%25252FHypocretin%26aulast%3DLawrence%26aufirst%3DAndrew%2BJ%26date%3D2017%26volume%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00217&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Orexin receptor dual antagonists that have advanced to clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00217&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00217&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (1) NaHMDS, THF, 0 °C, 3 h, (2) KOH, EtOH, reflux, 8 h, (3) HCl, 0 °C–rt, 3 h; (b) NaBH<sub>4</sub>, MeOH–THF, 0 °C–rt; (c) TBDPS-Cl, imidazole, DMF, −10 °C–rt, or vinyl acetate, lipase acrylic resin from <i>Candida antarctica</i>, rt; (d) Ar<sub>1</sub>-OH, DIAD, PPh<sub>3</sub>, 0 °C–rt, overnight or (1) MsCl, TEA, DCM, (2) Ar<sub>1</sub>-OH, Cs<sub>2</sub>CO<sub>3</sub>, MeCN, 70 °C; (e) TBAF, THF, rt, 1 h or NaOH, EtOH–H<sub>2</sub>O, rt, 1 h (2 steps); (f) (COCl)<sub>2</sub>, DMSO, TEA, DCM, −78 °C–rt, 1 h; (g) 2-methyl-2-butene, NaClO<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>, acetone–H<sub>2</sub>O, rt, 2 h; (h) amine, HATU, DIPEA, DMF, 60 °C, overnight or (COCl)<sub>2</sub>, cat. DMF, DCM, rt, 1 h, then amine, DIPEA, THF, 60 °C.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00217&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) <i>m</i>-CPBA, CHCl<sub>3</sub>, rt, overnight.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00217&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Me<sub>3</sub>Al, Pd(PPh<sub>3</sub>)<sub>4</sub>, THF, 75 °C, overnight; (b) BBr<sub>3</sub>, DCM, rt, 4 d; (c) EtMgCl, Fe(acac)<sub>3</sub>, THF, rt, overnight; (d) Me<sub>3</sub>Al, Pd(PPh<sub>3</sub>)<sub>4</sub>, THF, 70 °C, 2 d; (e) BBr<sub>3</sub>, DCM, rt, 4 d; (f) BnBr, NaH, THF, 0 °C to rt, overnight; (g) Br<sub>2</sub>, CHCl<sub>3</sub>, 0 °C to rt, overnight, then NaOMe, MeOH, 90 °C, 12 h; (h) Pd-C, H<sub>2</sub> gas, EtOAc, rt, 1 h.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overlay of (−)-<b>5</b> and <b>50</b> and <b>51</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00217&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Wakefulness time measured after oral administration of <b>26</b>, <b>28</b>, and <b>31</b>. The vehicle (10% Cremophor EL, 5% DMSO in saline; <i>n</i> = 4 for <b>26</b>, <i>n</i> = 7 for <b>28</b> and <b>31</b>), <b>26</b> (<i>n</i> = 4), <b>28</b> (<i>n</i> = 5), and <b>31</b> (<i>n</i> = 6) at 30 mg/kg doses were administered immediately prior to the beginning of the dark cycle; cumulative wakefulness times were measured during the first 3 h after administration. Values are mean ± SEM.* <i>P</i> < 0.05, ** <i>P</i> < 0.01, and *** <i>P</i> < 0.001 versus vehicle control (unpaired parametric two-tailed <i>t</i> test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00217&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/medium/jm-2015-00217h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Wake and sleep time measurements after administration of <b>34</b>. (A–C) Vehicle (10% Cremophor EL, 5% DMSO in saline; <i>n</i> = 7) or <b>34</b> (10 or 30 mg/kg; <i>n</i> = 6) were orally administered immediately prior to the dark cycle (lights off), and (A) wakefulness, (B) non-REM sleep, and (C) REM sleep were measured hourly. (D–F) Cumulative amounts of (D) wakefulness, (E) non-REM sleep, and (F) REM sleep times measured during the first 3 h following administration of vehicle or <b>34</b> (derived from the time courses shown in A–C). Values are mean ± SEM * <i>P</i> < 0.05, ** <i>P</i> < 0.01, *** <i>P</i> < 0.001 versus vehicle control (one-way ANOVA followed by Dunnett’s multiple comparison test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-11/acs.jmedchem.5b00217/20150605/images/large/jm-2015-00217h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00217&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i78">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06455" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06455" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 43 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Ozminkowski, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, J. K.</span><span> </span><span class="NLM_article-title">The direct and indirect costs of untreated insomnia in adults in the United States</span> <span class="citation_source-journal">Sleep</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2007&pages=263-273&author=R.+J.+Ozminkowskiauthor=S.+Wangauthor=J.+K.+Walsh&title=The+direct+and+indirect+costs+of+untreated+insomnia+in+adults+in+the+United+States"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOzminkowski%26aufirst%3DR.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWalsh%26aufirst%3DJ.%2BK.%26atitle%3DThe%2520direct%2520and%2520indirect%2520costs%2520of%2520untreated%2520insomnia%2520in%2520adults%2520in%2520the%2520United%2520States%26jtitle%3DSleep%26date%3D2007%26volume%3D30%26spage%3D263%26epage%3D273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Kessler, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berglund, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coulouvrat, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajak, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahly, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shillington, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, J. K.</span><span> </span><span class="NLM_article-title">Insomnia and the Performance of US Workers: Results from the America Insomnia Survey</span> <span class="citation_source-journal">Sleep</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1161</span><span class="NLM_x">–</span> <span class="NLM_lpage">1171</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2011&pages=1161-1171&author=R.+C.+Kesslerauthor=P.+A.+Berglundauthor=C.+Coulouvratauthor=G.+Hajakauthor=T.+Rothauthor=V.+Shahlyauthor=A.+C.+Shillingtonauthor=J.+J.+Stephensonauthor=J.+K.+Walsh&title=Insomnia+and+the+Performance+of+US+Workers%3A+Results+from+the+America+Insomnia+Survey"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKessler%26aufirst%3DR.%2BC.%26aulast%3DBerglund%26aufirst%3DP.%2BA.%26aulast%3DCoulouvrat%26aufirst%3DC.%26aulast%3DHajak%26aufirst%3DG.%26aulast%3DRoth%26aufirst%3DT.%26aulast%3DShahly%26aufirst%3DV.%26aulast%3DShillington%26aufirst%3DA.%2BC.%26aulast%3DStephenson%26aufirst%3DJ.%2BJ.%26aulast%3DWalsh%26aufirst%3DJ.%2BK.%26atitle%3DInsomnia%2520and%2520the%2520Performance%2520of%2520US%2520Workers%253A%2520Results%2520from%2520the%2520America%2520Insomnia%2520Survey%26jtitle%3DSleep%26date%3D2011%26volume%3D34%26spage%3D1161%26epage%3D1171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Sullivan, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guilleminault, C.</span><span> </span><span class="NLM_article-title">Emerging drugs for insomnia: new frontiers for old and new targets</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">411</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1517%2F14728210903171948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=19708818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVCgurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=411-422&author=S.+S.+Sullivanauthor=C.+Guilleminault&title=Emerging+drugs+for+insomnia%3A+new+frontiers+for+old+and+new+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging drugs for insomnia: new frontiers for old and novel targets</span></div><div class="casAuthors">Sullivan, Shannon S.; Guilleminault, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">411-422</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Insomnia is the most prevalent sleep disorder, with up to 50% of the US adult population reporting symptoms of insomnia on a weekly basis and ∼ 12% with insomnia disorder.  Comorbid conditions such as depression and anxiety are frequent.  Insomnia is more common with older age, female gender and socioeconomic status.  Traditionally, therapy has focused on GABAA receptor agonists, and off-label antidepressant and antihistamine use.  With increased understanding of complex neural networks involved in sleep and wake, hypnotics are being developed to target a broader variety of receptors with increasing selectivity.  This review summarizes promising compds. in Phase II and III trials with evidence supporting efficacy for treatment of insomnia.  5-HT2A and 5-HT2C antagonists, melatonergic (MT1/MT2) agonists, orexin receptor (OX1/OX2) antagonists, as well as GABAA receptor agonists are reviewed and summarized.  Data are collected from PubMed and Pharmaprojects database searches, company websites, recent scientific meeting presentations and abstrs.  A variety of drugs targeting several pathways, including GABAA agonism, MT1/MT2 agonism, 5-HT2A antagonism, OX1/OX2 antagonism and others, are in Phase II and III trials.  More work should be done to understand the impact of these drugs in certain populations and in the context of comorbid conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKfbmX3Dwh4LVg90H21EOLACvtfcHk0ljR6Cyu1NeUIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVCgurbF&md5=33f28e611296310e8d3623290e20d7b3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1517%2F14728210903171948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728210903171948%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DS.%2BS.%26aulast%3DGuilleminault%26aufirst%3DC.%26atitle%3DEmerging%2520drugs%2520for%2520insomnia%253A%2520new%2520frontiers%2520for%2520old%2520and%2520new%2520targets%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2009%26volume%3D14%26spage%3D411%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Renger, J. J.</span><span> </span><span class="NLM_article-title">Overview of experimental and conventional pharmacological approaches in the treatment of sleep and wake disorders</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">937</span><span class="NLM_x">–</span> <span class="NLM_lpage">953</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.2174%2F156802608784936755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=18673164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1OhtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=937-953&author=J.+J.+Renger&title=Overview+of+experimental+and+conventional+pharmacological+approaches+in+the+treatment+of+sleep+and+wake+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of experimental and conventional pharmacological approaches in the treatment of sleep and wake disorders</span></div><div class="casAuthors">Renger, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">937-953</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The fundamental purpose of sleep remains one of the most compelling questions yet to be answered in the area of neuroscience, if not all of biol.  A pervasive behavior among members of the animal kingdom, the functional necessity of engaging regularly in sleep is best demonstrated by showing that failing to do so leads to a broad repertoire of pathol. outcomes including cognitive, immunol., hormonal, and metabolic outcomes, among others.  Indeed, an abs. requirement for sleep has been shown in studies that have demonstrated that continuous total deprivation of sleep for as short a period as 15 days is generally lethal in some species.  The most common clin. sleep disorder, insomnia, is both a principal disease (primary insomnia) as well as a co-morbidity of a large no. of other ostensibly unrelated diseases including chronic pain, attention deficit hyperactivity disorder, and depression.  From a treatment perspective, restoring normal healthy sleep delivers subsequent benefits in waking cognitive function and mood with the potential for beneficial therapeutic impact on daily functioning across multiple diseases for which restorative healthy sleep is compromised.  Our remarkable escalation in understanding the anatomy and physiol. of sleep/wake control mechanisms provides new opportunities to modify the neurobiol. of sleep and wake-related behaviors in novel and exciting ways.  In parallel, expansion of sleep research into novel interfaces between sleep-wake biol. and disease states is revealing addnl. extensive implications of lost sleep.  Current investigational and conventional pharmacol. approaches for the treatment of sleep and wake disorders are discussed based on their mechanism of action within the CNS and their effect on sleep and wake.  This review of recent sleep biol. and sleep pharmacol. peers into the future of sleep therapeutics to highlight both mechanistic safety and functional outcomes as key for differentiating and establishing success for the next generation of arousal modifying therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6GNzViXvCXbVg90H21EOLACvtfcHk0lg3d7OW8REKyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1OhtLw%253D&md5=0f24539a5d8032bde88186f6df1a44a6</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F156802608784936755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608784936755%26sid%3Dliteratum%253Aachs%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26atitle%3DOverview%2520of%2520experimental%2520and%2520conventional%2520pharmacological%2520approaches%2520in%2520the%2520treatment%2520of%2520sleep%2520and%2520wake%2520disorders%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D937%26epage%3D953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Borja, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniel, K. L.</span><span> </span><span class="NLM_article-title">Ramelteon for the treatment of insomnia</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1540</span><span class="NLM_x">–</span> <span class="NLM_lpage">1555</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1016%2Fj.clinthera.2006.10.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=17157111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlartrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2006&pages=1540-1555&author=N.+L.+Borjaauthor=K.+L.+Daniel&title=Ramelteon+for+the+treatment+of+insomnia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Ramelteon for the treatment of insomnia</span></div><div class="casAuthors">Borja, Nancy L.; Daniel, Karen L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1540-1555</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Background: Insomnia is a common sleep disorder with a significant potential for deleterious effects on activities of daily living, productivity, and overall quality of life.  Ramelteon, a highly selective agonist for melatonin subtypes 1 and 2 receptors, is a hypnotic agent approved by the US Food and Drug Administration (FDA) for the treatment of insomnia characterized by difficulty falling asleep.  Objective: This article reviews the pharmacokinetic properties, efficacy, and tolerability of ramelteon in the treatment of insomnia characterized by difficulty falling asleep.  Methods: Relevant articles were identified through searches of MEDLINE (1966 to July 2006), International Pharmaceutical Abstrs. (Jan. 1970 to July 2006), EMBASE Drugs and Pharmacol. (1980 to third quarter 2006), and Current Contents/Clin. Medicine (2005 wk 32 to 2006 wk 31).  Search terms included ramelteon, TAK-375, melatonin agonist, melatonin receptor agonist, insomnia, and sleep disorders/drug therapy (MeSH).  Results: A literature search revealed 12 randomized, controlled clin. trials that examd. the efficacy or tolerability of ramelteon.  In addn., 17 studies were reviewed for pharmacol. and pharmacokinetic data.  The refs. of the clin. trials and recent review articles were examd. to ensure the comprehensiveness of the literature search.  In 2 trials of patients with primary insomnia, patients treated with ramelteon 4 to 32 mg had significant redns. in latency to persistent sleep (LPS) compared with placebo (P < 0.001).  Addnl., improvements in total sleep time (TST) were obsd. (P < 0.001), although increases in TST were noted only on nights 1-2 of the second study.  Similarly, improvement in sleep efficiency was reported only on nights 1-2 of the second trial (P < 0.001).  In elderly patients with primary insomnia, significant redns. in subjective LPS were obsd. with ramelteon 4 and 8 mg (P = 0.008); however, av. subjective LPS was >70 min.  Mean reported TST was significantly increased in the 4-mg group (P = 0.004).  A second study in elderly patients found decreases in LPS with ramelteon 4 mg (P < 0.001) and 8 mg (P < 0.01), as well as significant increases in TST (P < 0.05 and P < 0.01, resp.).  Sleep efficiency improved for patients treated with 4 mg (P < 0.05) and 8 mg (P < 0.01).  Overall, the mean decrease in LPS reported in trials of ramelteon ranged from 10 to 19 min, and the mean increase in TST was 8 to 22 min.  The most common adverse events obsd. with ramelteon included headache (7%), dizziness (5%), somnolence (5%), fatigue (4%), and nausea (3%).  No evidence of cognitive impairment, rebound insomnia, withdrawal effects, or abuse potential was noted.  Conclusions: Based on this review, ramelteon, the first FDA-approved melatonin receptor agonist, represents a pharmacol. option for the treatment of insomnia characterized by difficulty falling asleep.  In patients with insomnia, treatment with ramelteon was generally well tolerated and resulted in modest but statistically significant decreases in LPS.  In the absence of published trials comparing ramelteon with other sedative-hypnotic agents, it is not yet possible to det. its efficacy relative to other therapeutic options for insomnia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH8KOdHeFwbLVg90H21EOLACvtfcHk0lg3d7OW8REKyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlartrzJ&md5=6c4c07814164db950f6de7c7d593972e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2006.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2006.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DBorja%26aufirst%3DN.%2BL.%26aulast%3DDaniel%26aufirst%3DK.%2BL.%26atitle%3DRamelteon%2520for%2520the%2520treatment%2520of%2520insomnia%26jtitle%3DClin.%2520Ther.%26date%3D2006%26volume%3D28%26spage%3D1540%26epage%3D1555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Sateia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirby-Long, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, J. L.</span><span> </span><span class="NLM_article-title">Efficacy and clinical safety of ramelteon: an evidence-based review</span> <span class="citation_source-journal">Sleep Med. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">332</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1016%2Fj.smrv.2007.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=18603221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A280%3ADC%252BD1cvjsVektA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2008&pages=319-332&author=M.+J.+Sateiaauthor=P.+Kirby-Longauthor=J.+L.+Taylor&title=Efficacy+and+clinical+safety+of+ramelteon%3A+an+evidence-based+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and clinical safety of ramelteon: an evidence-based review</span></div><div class="casAuthors">Sateia Michael J; Kirby-Long Paula; Taylor Jennifer L</div><div class="citationInfo"><span class="NLM_cas:title">Sleep medicine reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">319-32</span>
        ISSN:<span class="NLM_cas:issn">1087-0792</span>.
    </div><div class="casAbstract">Ramelteon is a novel hypnotic compound that is FDA-approved for the treatment of sleep-onset difficulty.  It is a melatonin 1/2 receptor agonist with rapid absorption, extensive first-pass metabolism and an elimination half-life of just over 1h.  Clinical efficacy data indicate moderate efficacy in reduction of sleep latency in adults of all ages with chronic insomnia, with estimated effect sizes roughly comparable to other standard hypnotic agents.  Objective studies show minimal increases in total sleep time and no significant impact on wake after sleep-onset or sleep-stage distribution.  Subjective reports demonstrate comparable, if slightly smaller, improvements.  The recommended dosage is 8mg but studies suggest a flat response across dosage ranges from 4 to 32mg.  Safety data indicate no evidence of clinically significant next-day performance effects and a reasonably low side effect profile.  Animal studies, and a single human study suggest low abuse potential.  Single-blind run-out from clinical trials have demonstrated no evidence of rebound insomnia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTao5mkhqwFD6Nc3HjJRoFAfW6udTcc2eaeCLHyh6WGbrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvjsVektA%253D%253D&md5=7b94aef4c310eef9be12a54af296c001</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.smrv.2007.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.smrv.2007.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DSateia%26aufirst%3DM.%2BJ.%26aulast%3DKirby-Long%26aufirst%3DP.%26aulast%3DTaylor%26aufirst%3DJ.%2BL.%26atitle%3DEfficacy%2520and%2520clinical%2520safety%2520of%2520ramelteon%253A%2520an%2520evidence-based%2520review%26jtitle%3DSleep%2520Med.%2520Rev.%26date%3D2008%26volume%3D12%26spage%3D319%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Sakurai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amemiya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzaki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chemelli, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozlowski, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arch, J. R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckingham, R. E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haynes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annan, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNulty, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terrett, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elshourbagy, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergsma, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, M.</span><span> </span><span class="NLM_article-title">Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">585</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1016%2FS0092-8674%2800%2980949-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=9491897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADyaK1cXhsVKntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1998&pages=573-585&author=T.+Sakuraiauthor=A.+Amemiyaauthor=M.+Ishiiauthor=I.+Matsuzakiauthor=R.+M.+Chemelliauthor=H.+Tanakaauthor=S.+C.+Williamsauthor=J.+A.+Richardsonauthor=G.+P.+Kozlowskiauthor=S.+Wilsonauthor=J.+R.+S.+Archauthor=R.+E.+C.+Buckinghamauthor=A.+C.+Haynesauthor=S.+A.+Carrauthor=R.+S.+Annanauthor=D.+E.+McNultyauthor=W.+S.+Liuauthor=J.+A.+Terrettauthor=N.+A.+Elshourbagyauthor=D.+J.+Bergsmaauthor=M.+Yanagisawa&title=Orexins+and+orexin+receptors%3A+a+family+of+hypothalamic+neuropeptides+and+G+protein-coupled+receptors+that+regulate+feeding+behavior"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior</span></div><div class="casAuthors">Sakurai, Takeshi; Amemiya, Akira; Ishii, Makoto; Matsuzaki, Ichiyo; Chemelli, Richard M.; Tanaka, Hirokazu; Williams, S. Clay; Richardson, James A.; Kozlowski, Gerald P.; Wilson, Shelagh; Arch, Jonathan R. S.; Buckingham, Robin E.; Haynes, Andrea C.; Carr, Steven A.; Annan, Roland S.; Mcnulty, Dean E.; Liu, Wu-Schyong; Terrett, Jonathan A.; Elshourbagy, Nabil A.; Bergsma, Derk J.; Yanagisawa, Masashi</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">573-585</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The hypothalamus plays a central role in the integrated control of feeding and energy homeostasis.  The authors have identified two novel neuropeptides, both derived from the same precursor by proteolytic processing, that bind and activate two closely related (previously) orphan G protein-coupled receptors.  These peptides, termed orexin-A and -B, have no significant structural similarities to known families of regulatory peptides.  Prepro-orexin mRNA and immunoreactive orexin-A are localized in neurons within and around the lateral and posterior hypothalamus in the adult rat brain.  When administered centrally to rats, these peptides stimulate food consumption.  Prepro-orexin mRNA level is up-regulated upon fasting, suggesting a physiol. role for the peptides as mediators in the central feedback mechanism that regulates feeding behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA5y2uicTVlLVg90H21EOLACvtfcHk0lirRGt-6rZdZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhsVKntr4%253D&md5=c0d02e69cd976521abfc5f88e8be7dda</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980949-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980949-6%26sid%3Dliteratum%253Aachs%26aulast%3DSakurai%26aufirst%3DT.%26aulast%3DAmemiya%26aufirst%3DA.%26aulast%3DIshii%26aufirst%3DM.%26aulast%3DMatsuzaki%26aufirst%3DI.%26aulast%3DChemelli%26aufirst%3DR.%2BM.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DWilliams%26aufirst%3DS.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BA.%26aulast%3DKozlowski%26aufirst%3DG.%2BP.%26aulast%3DWilson%26aufirst%3DS.%26aulast%3DArch%26aufirst%3DJ.%2BR.%2BS.%26aulast%3DBuckingham%26aufirst%3DR.%2BE.%2BC.%26aulast%3DHaynes%26aufirst%3DA.%2BC.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DAnnan%26aufirst%3DR.%2BS.%26aulast%3DMcNulty%26aufirst%3DD.%2BE.%26aulast%3DLiu%26aufirst%3DW.%2BS.%26aulast%3DTerrett%26aufirst%3DJ.%2BA.%26aulast%3DElshourbagy%26aufirst%3DN.%2BA.%26aulast%3DBergsma%26aufirst%3DD.%2BJ.%26aulast%3DYanagisawa%26aufirst%3DM.%26atitle%3DOrexins%2520and%2520orexin%2520receptors%253A%2520a%2520family%2520of%2520hypothalamic%2520neuropeptides%2520and%2520G%2520protein-coupled%2520receptors%2520that%2520regulate%2520feeding%2520behavior%26jtitle%3DCell%26date%3D1998%26volume%3D92%26spage%3D573%26epage%3D585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">De Lecea, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilduff, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foye, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danielson, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuhara, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battenberg, E. L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gautvik, V. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartlett, F. S.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankel, W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Den Pol, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gautvik, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutcliffe, J. G.</span><span> </span><span class="NLM_article-title">The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">322</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1073%2Fpnas.95.1.322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=9419374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADyaK1cXjtl2hsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=322-327&author=L.+De+Leceaauthor=T.+S.+Kilduffauthor=C.+Peyronauthor=X.-B.+Gaoauthor=P.+E.+Foyeauthor=P.+E.+Danielsonauthor=C.+Fukuharaauthor=E.+L.+F.+Battenbergauthor=V.+T.+Gautvikauthor=F.+S.+Bartlettauthor=W.+N.+Frankelauthor=A.+N.+Van+Den+Polauthor=F.+E.+Bloomauthor=K.+M.+Gautvikauthor=J.+G.+Sutcliffe&title=The+hypocretins%3A+hypothalamus-specific+peptides+with+neuroexcitatory+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity</span></div><div class="casAuthors">De Lecea, L.; Kilduff, T. S.; Peyron, C.; Gao, X. -B.; Foye, P. E.; Danielson, P. E.; Fukuhara, C.; Battenberg, E. L. F.; Gautvik, V. T.; Bartlett, F. S., II; Frankel, W. N.; Van Den Pol, A. N.; Bloom, F. E.; Gautvik, K. M.; Sutcliffe, J. G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">322-327</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We describe a hypothalamus-specific mRNA that encodes preprohypocretin, the putative precursor of a pair of peptides that share substantial amino acid identities with the gut hormone secretin.  The hypocretin (Hcrt) protein products are restricted to neuronal cell bodies of the dorsal and lateral hypothalamic areas.  The fibers of these neurons are widespread throughout the posterior hypothalamus and project to multiple targets in other areas, including brainstem and thalamus.  Hcrt immunoreactivity is assocd. with large granular vesicles at synapses.  One of the Hcrt peptides was excitatory when applied to cultured, synaptically coupled hypothalamic neurons, but not hippocampal neurons.  These observations suggest that the hypocretins function within the CNS as neurotransmitters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAEQa5lFLKr7Vg90H21EOLACvtfcHk0lirRGt-6rZdZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtl2hsw%253D%253D&md5=52bde93a7933953f02930a6f57a0f1b1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.1.322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.1.322%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLecea%26aufirst%3DL.%26aulast%3DKilduff%26aufirst%3DT.%2BS.%26aulast%3DPeyron%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DX.-B.%26aulast%3DFoye%26aufirst%3DP.%2BE.%26aulast%3DDanielson%26aufirst%3DP.%2BE.%26aulast%3DFukuhara%26aufirst%3DC.%26aulast%3DBattenberg%26aufirst%3DE.%2BL.%2BF.%26aulast%3DGautvik%26aufirst%3DV.%2BT.%26aulast%3DBartlett%26aufirst%3DF.%2BS.%26aulast%3DFrankel%26aufirst%3DW.%2BN.%26aulast%3DVan%2BDen%2BPol%26aufirst%3DA.%2BN.%26aulast%3DBloom%26aufirst%3DF.%2BE.%26aulast%3DGautvik%26aufirst%3DK.%2BM.%26aulast%3DSutcliffe%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520hypocretins%253A%2520hypothalamus-specific%2520peptides%2520with%2520neuroexcitatory%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D322%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Van den Pol, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obrietan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilduff, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belousov, A. B.</span><span> </span><span class="NLM_article-title">Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">7962</span><span class="NLM_x">–</span> <span class="NLM_lpage">7971</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=9742163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADyaK1cXmtlequrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=7962-7971&author=A.+N.+Van+den+Polauthor=X.-B.+Gaoauthor=K.+Obrietanauthor=T.+S.+Kilduffauthor=A.+B.+Belousov&title=Presynaptic+and+postsynaptic+actions+and+modulation+of+neuroendocrine+neurons+by+a+new+hypothalamic+peptide%2C+hypocretin%2Forexin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin</span></div><div class="casAuthors">Van Den Pol, Anthony N.; Gao, Xiao-Bing; Obrietan, Karl; Kilduff, Thomas S.; Belousov, Andrei B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7962-7971</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">A new orexigenic peptide called hypocretin (orexin) has recently been described in neurons of the lateral hypothalamus and perifornical area.  The medial and lateral hypothalamus have been loosely called satiety and feeding centers of the brain, resp.  Approx. one-third of all medial and lateral hypothalamic neurons tested, but not hippocampal neurons, show a striking nanomolar sensitivity to hypocretin.  As studied with calcium digital imaging with fura-2, hypocretin raises cytoplasmic calcium via a mechanism based on G-protein enhancement of calcium influx through plasma membrane channels.  The peptide has a potent effect at both presynaptic and postsynaptic receptors.  Most synaptic activity in hypothalamic circuits is attributable to axonal release of GABA or glutamate.  With whole-cell patch-clamp recording, the authors show that hypocretin, acting directly at axon terminals, can increase the release of each of these amino acid transmitters.  Two hypocretin peptides, hypocretin-1 and hypocretin-2, are coded by a single gene; neurons that respond to one peptide also respond to the other.  In addn. to its effect on feeding, the authors find that this peptide also regulates the synaptic activity of physiol. identified neuroendocrine neurons studied in hypothalamic slices contg. the arcuate nucleus, suggesting a second function of hypocretin in hormone regulation.  The widespread distribution of hypocretin axons, coupled with the strong response to the peptide at both presynaptic and postsynaptic sites, suggests that the peptide probably modulates a variety of hypothalamic regulatory systems and could regulate the axonal input to these regions presynaptically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHi6BCCJkJnbVg90H21EOLACvtfcHk0lhFSfHeXNI3gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtlequrk%253D&md5=09608e3c2453416db5bdab5af3598479</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bden%2BPol%26aufirst%3DA.%2BN.%26aulast%3DGao%26aufirst%3DX.-B.%26aulast%3DObrietan%26aufirst%3DK.%26aulast%3DKilduff%26aufirst%3DT.%2BS.%26aulast%3DBelousov%26aufirst%3DA.%2BB.%26atitle%3DPresynaptic%2520and%2520postsynaptic%2520actions%2520and%2520modulation%2520of%2520neuroendocrine%2520neurons%2520by%2520a%2520new%2520hypothalamic%2520peptide%252C%2520hypocretin%252Forexin%26jtitle%3DJ.%2520Neurosci.%26date%3D1998%26volume%3D18%26spage%3D7962%26epage%3D7971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Beuckmann, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, M.</span><span> </span><span class="NLM_article-title">Orexins: from neuropeptides to energy homeostasis and sleep/wake regulation</span> <span class="citation_source-journal">J. Mol. Med. (Berlin, Ger.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1007%2Fs00109-002-0322-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=12072908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvV2msLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2002&pages=329-342&author=C.+T.+Beuckmannauthor=M.+Yanagisawa&title=Orexins%3A+from+neuropeptides+to+energy+homeostasis+and+sleep%2Fwake+regulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Orexins: From neuropeptides to energy homeostasis and sleep/wake regulation</span></div><div class="casAuthors">Beuckmann, Carsten T.; Yanagisawa, Masashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Berlin, Germany)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">329-342</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review.  The neuropeptides orexin A and orexin B (also called hypocretin 1 and 2) were recently discovered by a "reverse pharmacol." approach as ligands for two previously orphan G protein coupled receptors: orexin receptors 1 and 2.  Neurons producing orexins are located exclusively in the lateral hypothalamic area but project broadly to various parts of the brain, and they have been implicated in the control of energy homeostasis and arousal maintenance.  The orexin receptors are also broadly expressed in the central nervous system.  Murine and canine models suggest that defective signaling in the orexin system is responsible for the sleep/wake disorder narcolepsy.  Although narcoleptic patients rarely have genetic defects in the orexin system, they lack these neuropeptides in the brain and cerebrospinal fluid, indicating that human narcolepsy is an orexin deficiency syndrome in the majority of cases.  A connection between sleep/wake regulation and energy homeostasis is hypothesized with orexin neuropeptides as a mol. link.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGw06TNAJMLbVg90H21EOLACvtfcHk0lhFSfHeXNI3gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvV2msLw%253D&md5=8eceae17326204246280a2d7fe1e5381</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00109-002-0322-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-002-0322-x%26sid%3Dliteratum%253Aachs%26aulast%3DBeuckmann%26aufirst%3DC.%2BT.%26aulast%3DYanagisawa%26aufirst%3DM.%26atitle%3DOrexins%253A%2520from%2520neuropeptides%2520to%2520energy%2520homeostasis%2520and%2520sleep%252Fwake%2520regulation%26jtitle%3DJ.%2520Mol.%2520Med.%2520%2528Berlin%252C%2520Ger.%2529%26date%3D2002%26volume%3D80%26spage%3D329%26epage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Brisbare-Roch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingemanse, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koberstein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoever, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aissaoui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nayler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gerven, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haas, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clozel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenck, F.</span><span> </span><span class="NLM_article-title">Promotion of sleep by targeting the orexin system in rats, dogs and humans</span> <span class="citation_source-journal">Nature Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">150</span><span class="NLM_x">–</span> <span class="NLM_lpage">155</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=150-155&author=C.+Brisbare-Rochauthor=J.+Dingemanseauthor=R.+Kobersteinauthor=P.+Hoeverauthor=H.+Aissaouiauthor=S.+Floresauthor=C.+Muellerauthor=O.+Naylerauthor=J.+van+Gervenauthor=S.+L.+de+Haasauthor=P.+Hessauthor=C.+Qiuauthor=S.+Buchmannauthor=M.+Scherzauthor=T.+Wellerauthor=W.+Fischliauthor=M.+Clozelauthor=F.+Jenck&title=Promotion+of+sleep+by+targeting+the+orexin+system+in+rats%2C+dogs+and+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrisbare-Roch%26aufirst%3DC.%26aulast%3DDingemanse%26aufirst%3DJ.%26aulast%3DKoberstein%26aufirst%3DR.%26aulast%3DHoever%26aufirst%3DP.%26aulast%3DAissaoui%26aufirst%3DH.%26aulast%3DFlores%26aufirst%3DS.%26aulast%3DMueller%26aufirst%3DC.%26aulast%3DNayler%26aufirst%3DO.%26aulast%3Dvan%2BGerven%26aufirst%3DJ.%26aulast%3Dde%2BHaas%26aufirst%3DS.%2BL.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DQiu%26aufirst%3DC.%26aulast%3DBuchmann%26aufirst%3DS.%26aulast%3DScherz%26aufirst%3DM.%26aulast%3DWeller%26aufirst%3DT.%26aulast%3DFischli%26aufirst%3DW.%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DJenck%26aufirst%3DF.%26atitle%3DPromotion%2520of%2520sleep%2520by%2520targeting%2520the%2520orexin%2520system%2520in%2520rats%252C%2520dogs%2520and%2520humans%26jtitle%3DNature%2520Med.%26date%3D2007%26volume%3D13%26spage%3D150%26epage%3D155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Sato-Suzuki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kita, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oguri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, H.</span><span> </span><span class="NLM_article-title">Cortical arousal induced by microinjection of orexins into the paraventricular nucleus of the rat</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2002&pages=169-177&author=I.+Sato-Suzukiauthor=I.+Kitaauthor=Y.+Sekiauthor=M.+Oguriauthor=H.+Arita&title=Cortical+arousal+induced+by+microinjection+of+orexins+into+the+paraventricular+nucleus+of+the+rat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSato-Suzuki%26aufirst%3DI.%26aulast%3DKita%26aufirst%3DI.%26aulast%3DSeki%26aufirst%3DY.%26aulast%3DOguri%26aufirst%3DM.%26aulast%3DArita%26aufirst%3DH.%26atitle%3DCortical%2520arousal%2520induced%2520by%2520microinjection%2520of%2520orexins%2520into%2520the%2520paraventricular%2520nucleus%2520of%2520the%2520rat%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2002%26volume%3D128%26spage%3D169%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Akanmu, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honda, K.</span><span> </span><span class="NLM_article-title">Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1048</span><span class="NLM_x">, </span> <span class="NLM_fpage">138</span><span class="NLM_x">–</span> <span class="NLM_lpage">145</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1016%2Fj.brainres.2005.04.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=15919057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt1Grtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1048&publication_year=2005&pages=138-145&author=M.+A.+Akanmuauthor=K.+Honda&title=Selective+stimulation+of+orexin+receptor+type+2+promotes+wakefulness+in+freely+behaving+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats</span></div><div class="casAuthors">Akanmu, Moses A.; Honda, Kazuki</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1048</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">138-145</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Orexins A and B are a pair of neuropeptides implicated in the regulation of feeding and arousal behavior mediated through two orexin receptors type 1 and type 2.  The authors have detd. the arousal effects of newly developed selective orexin receptor type 2 agonist, [Ala11]orexin-B, on the sleep-wake cycle in rats.  The effects of third ventricle intracerebroventricular (ICV) infusion of the novel orexin receptor type 2 selective agonist, [Ala11]orexin-B, on the sleep-wake cycle were investigated.  ICV infusion of [Ala11]orexin-B (1, 10 and 40 nmol) during the light period (11:00-16:00) dose-dependently resulted in a significant increase in wake duration by 46.9% (n = 5, P < 0.05), 159.2% (n = 4, P < 0.01) and 163.6% (n = 7, P < 0.01), resp., and a significant decrease in rapid eye movement (REM) (P < 0.01) and non-REM sleep (P < 0.01) for all doses.  In contrast, ICV infusion of orexin B at the same doses (1, 10 and 40 nmol) caused a 16.6% (n = 6, non-significant), 99.8% (n = 6, P < 0.05) and 72.0% (n = 4, P < 0.05) increase in wakefulness, resp.  Moreover, orexin-A, which exerts its effects through orexin receptor type 1 and orexin receptor type 2 with similar potency, resulted in a significant increase in wakefulness duration by 17.1% (n = 6, P < 0.05), 184.0% (n = 6, P < 0.01) and 228.6% (n = 6, P < 0.01) at doses of 0.1, 1 and 10 nmol, resp.  Further, the enhancement of wakefulness was accompanied by a marked redn. in REM and non-REM sleep.  These findings suggest that orexin receptor type 2 plays an important role in the modulation of sleep-wake state and behavioral responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxWQ0WqME6H7Vg90H21EOLACvtfcHk0lidBt3aCJ5qlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt1Grtr8%253D&md5=60ca1e78ee562eda40d65110a8b6ae7f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2005.04.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2005.04.064%26sid%3Dliteratum%253Aachs%26aulast%3DAkanmu%26aufirst%3DM.%2BA.%26aulast%3DHonda%26aufirst%3DK.%26atitle%3DSelective%2520stimulation%2520of%2520orexin%2520receptor%2520type%25202%2520promotes%2520wakefulness%2520in%2520freely%2520behaving%2520rats%26jtitle%3DBrain%2520Res.%26date%3D2005%26volume%3D1048%26spage%3D138%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Dugovic, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aluisio, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span> </span><span class="NLM_article-title">Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">142</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1124%2Fjpet.109.152009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=19363060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFeltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=142-151&author=C.+Dugovicauthor=J.+E.+Sheltonauthor=L.+E.+Aluisioauthor=I.+C.+Fraserauthor=X.+Jiangauthor=S.+W.+Suttonauthor=P.+Bonaventureauthor=S.+Yunauthor=X.+Liauthor=B.+Lordauthor=C.+A.+Dvorakauthor=N.+I.+Carruthersauthor=T.+W.+Lovenberg&title=Blockade+of+orexin-1+receptors+attenuates+orexin-2+receptor+antagonism-induced+sleep+promotion+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat</span></div><div class="casAuthors">Dugovic, Christine; Shelton, Jonathan E.; Aluisio, Leah E.; Fraser, Ian C.; Jiang, Xiaohui; Sutton, Steven W.; Bonaventure, Pascal; Yun, Sujin; Li, Xiaorong; Lord, Brian; Dvorak, Curt A.; Carruthers, Nicholas I.; Lovenberg, Timothy W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">142-151</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Orexins are peptides produced by lateral hypothalamic neurons that exert a prominent role in the maintenance of wakefulness by activating orexin-1 (OX1R) and orexin-2 (OX2R) receptor located in wake-active structures.  Pharmacol. blockade of both receptors by the dual OX1/2R antagonist (2R)-2-[(1S)-6,7-dimethoxy-1-{2-[4-(trifluoromethyl)phenyl]ethyl}-3,4-dihydroisoquinolin-2(1H)-yl]-N-methyl-2-phenylethanamide (almorexant) has been shown to promote sleep in animals and humans during their active period.  However, the selective distribution of OX1R and OX2R in distinct neuronal circuits may result in a differential impact of these receptors in sleep-wake modulation.  The resp. role of OX1R and OX2R on sleep in correlation with monoamine release was evaluated in rats treated with selective antagonists alone or in combination.  When administered in either phase of the light/dark cycle, the OX2R antagonist 1-(2,4-dibromophenyl)-3-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]urea (JNJ-10397049) decreased the latency for persistent sleep and increased nonrapid eye movement and rapid eye movement sleep time.  Almorexant produced less hypnotic activity, whereas the OX1R antagonist 1-(6,8-difluoro-2-methylquinolin-4-yl)-3-[4-(dimethylamino)phenyl]urea (SB-408124) had no effect.  Microdialysis studies showed that either OX2R or OX1/2R antagonism decreased extracellular histamine concn. in the lateral hypothalamus, whereas both OX1R and OX1/2R antagonists increased dopamine release in the prefrontal cortex.  Finally, coadministration of the OX1R with the OX2R antagonist greatly attenuated the sleep-promoting effects of the OX2R antagonist.  These results indicate that blockade of OX2R is sufficient to initiate and prolong sleep, consistent with the hypothesis of a deactivation of the histaminergic system.  In addn., it is suggested that simultaneous inhibition of OX1R attenuates the sleep-promoting effects mediated by selective OX2R blockade, possibly correlated with dopaminergic neurotransmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPXVs02jXOYLVg90H21EOLACvtfcHk0lgpAvTGdrSH2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFeltLk%253D&md5=32a5fc48d949eef2a633187c274cec80</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.152009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.152009%26sid%3Dliteratum%253Aachs%26aulast%3DDugovic%26aufirst%3DC.%26aulast%3DShelton%26aufirst%3DJ.%2BE.%26aulast%3DAluisio%26aufirst%3DL.%2BE.%26aulast%3DFraser%26aufirst%3DI.%2BC.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DSutton%26aufirst%3DS.%2BW.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DYun%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DDvorak%26aufirst%3DC.%2BA.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26atitle%3DBlockade%2520of%2520orexin-1%2520receptors%2520attenuates%2520orexin-2%2520receptor%2520antagonism-induced%2520sleep%2520promotion%2520in%2520the%2520rat%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26spage%3D142%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Kummangal, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallick, H. N.</span><span> </span><span class="NLM_article-title">Intracerebroventricular injection of orexin-2 receptor antagonist promotes REM sleep</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">237</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=2013&pages=59-62&author=B.+A.+Kummangalauthor=D.+Kumarauthor=H.+N.+Mallick&title=Intracerebroventricular+injection+of+orexin-2+receptor+antagonist+promotes+REM+sleep"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKummangal%26aufirst%3DB.%2BA.%26aulast%3DKumar%26aufirst%3DD.%26aulast%3DMallick%26aufirst%3DH.%2BN.%26atitle%3DIntracerebroventricular%2520injection%2520of%2520orexin-2%2520receptor%2520antagonist%2520promotes%2520REM%2520sleep%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2013%26volume%3D237%26spage%3D59%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Boss, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roch-Brisbare, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietrich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenck, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Raumer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sifferlen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brotschi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidmann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aissaoui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegrist, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatfield, J.</span><span> </span><span class="NLM_article-title">Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonist</span> <span class="citation_source-journal">ChemMedChem. </span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2486</span><span class="NLM_x">–</span> <span class="NLM_lpage">2496</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1002%2Fcmdc.201402258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=25147058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSisLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=2486-2496&author=C.+Bossauthor=C.+Roch-Brisbareauthor=M.+A.+Steinerauthor=A.+Treiberauthor=H.+Dietrichauthor=F.+Jenckauthor=M.+von+Raumerauthor=T.+Sifferlenauthor=C.+Brotschiauthor=B.+Heidmannauthor=J.+T.+Williamsauthor=H.+Aissaouiauthor=R.+Siegristauthor=J.+Gatfield&title=Structure-activity+relationship%2C+biological%2C+and+pharmacological+characterization+of+the+proline+sulfonamide+ACT-462206%3A+a+potent%2C+brain-penetrant+dual+orexin+1%2Forexin+2+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship, Biological, and Pharmacological Characterization of the Proline Sulfonamide ACT-462206: a Potent, Brain-Penetrant Dual Orexin 1/Orexin 2 Receptor Antagonist</span></div><div class="casAuthors">Boss, Christoph; Roch-Brisbare, Catherine; Steiner, Michel A.; Treiber, Alexander; Dietrich, Hendrik; Jenck, Francois; von Raumer, Markus; Sifferlen, Thierry; Brotschi, Christine; Heidmann, Bibia; Williams, Jodi; Aissaoui, Hamed; Siegrist, Romain; Gatfield, John</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2486-2496</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The orexin system consists of two G-protein-coupled receptors, the orexin 1 and orexin 2 receptors, widely expressed in diverse regions of the brain, and two peptide agonists, orexin A and orexin B, which are produced in a small assembly of neurons in the lateral hypothalamus.  The orexin system plays an important role in the maintenance of wakefulness.  Several compds. (almorexant, SB-649868, suvorexant) have been in advanced clin. trials for treating primary insomnia.  ACT-462206 is a new, potent, and selective dual orexin receptor antagonist (DORA) that inhibits the stimulating effects of the orexin peptides at both the orexin 1 and 2 receptors.  It decreases wakefulness and increases non-rapid eye movement (non-REM) and REM sleep while maintaining natural sleep architectures in rat and dog electroencephalog./electromyog. (EEG/EMG) expts.  ACT-462206 shows anxiolytic-like properties in rats without affecting cognition and motor function.  It is therefore a potential candidate for the treatment of insomnia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq058gWHsGWELVg90H21EOLACvtfcHk0lgSNXY4asRDpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSisLnJ&md5=2a9dca30961510eee24034a4524d441e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201402258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201402258%26sid%3Dliteratum%253Aachs%26aulast%3DBoss%26aufirst%3DC.%26aulast%3DRoch-Brisbare%26aufirst%3DC.%26aulast%3DSteiner%26aufirst%3DM.%2BA.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DDietrich%26aufirst%3DH.%26aulast%3DJenck%26aufirst%3DF.%26aulast%3Dvon%2BRaumer%26aufirst%3DM.%26aulast%3DSifferlen%26aufirst%3DT.%26aulast%3DBrotschi%26aufirst%3DC.%26aulast%3DHeidmann%26aufirst%3DB.%26aulast%3DWilliams%26aufirst%3DJ.%2BT.%26aulast%3DAissaoui%26aufirst%3DH.%26aulast%3DSiegrist%26aufirst%3DR.%26aulast%3DGatfield%26aufirst%3DJ.%26atitle%3DStructure-activity%2520relationship%252C%2520biological%252C%2520and%2520pharmacological%2520characterization%2520of%2520the%2520proline%2520sulfonamide%2520ACT-462206%253A%2520a%2520potent%252C%2520brain-penetrant%2520dual%2520orexin%25201%252Forexin%25202%2520receptor%2520antagonist%26jtitle%3DChemMedChem.%2520%26date%3D2014%26volume%3D9%26spage%3D2486%26epage%3D2496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Boss, C.</span><span> </span><span class="NLM_article-title">Orexin receptor antagonists - a patent review</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1367</span><span class="NLM_x">–</span> <span class="NLM_lpage">1381</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1517%2F13543776.2014.978859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=25407283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFejsr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=1367-1381&author=C.+Boss&title=Orexin+receptor+antagonists+-+a+patent+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Orexin receptor antagonists - a patent review (2010 to August 2014)</span></div><div class="casAuthors">Boss, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1367-1381</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: The orexin (hypocretin) system is an evolutionarily conserved neuropeptide-G-protein-coupled receptor system, consisting of two neuropeptides the orexin-A and the orexin-B peptides as well as two receptors the orexin-1 and the orexin-2 receptors.  The orexin system is crucially involved in the regulation of the circadian rhythm, states of wakefulness and arousal and the modulation of emotions and has attracted the interest of many researchers which resulted in an enormous amt. of insight, mainly in the field of antagonists.  Clin. proof of concept was obtained with dual orexin receptor antagonists in primary insomnia.  Merck's suvorexant got FDA approval on 13 August 2014 for the treatment of insomnia.  Areas covered: The patent applications from Thomson Reuters Integrity Database (covering 2010 - August 2014) are summarized, analyzed and discussed in the review.  Expert opinion: Intense patenting activities have been obsd. over the past 3 years in the field of orexin antagonists.  Several compds. have been investigated in clin. trials mainly for the treatment of primary insomnia.  The advantage of orexin antagonists, based on animal pharmacol. results, is the promotion and maintenance of physiol. sleep which should avoid hangover phenomena reported as side effects of approved treatments.  Many other potential treatment options are mentioned for orexin antagonists of different selectivity profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_El4j7cEx47Vg90H21EOLACvtfcHk0lgSNXY4asRDpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFejsr%252FO&md5=560c906cf24a15310f9f1a2ae1dbc92a</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.978859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.978859%26sid%3Dliteratum%253Aachs%26aulast%3DBoss%26aufirst%3DC.%26atitle%3DOrexin%2520receptor%2520antagonists%2520-%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D1367%26epage%3D1381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Christopher, J. A.</span><span> </span><span class="NLM_article-title">Small-molecule antagonists of the orexin receptors</span> <span class="citation_source-journal">Pharm. Pat. Anal.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">625</span><span class="NLM_x">–</span> <span class="NLM_lpage">638</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.4155%2Fppa.14.46" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=25489915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCrs7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=625-638&author=J.+A.+Christopher&title=Small-molecule+antagonists+of+the+orexin+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule antagonists of the orexin receptors</span></div><div class="casAuthors">Christopher, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Patent Analyst</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">625-638</span>CODEN:
                <span class="NLM_cas:coden">PPAHCN</span>;
        ISSN:<span class="NLM_cas:issn">2046-8954</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The orexin-1 and orexin-2 receptors are two G protein-coupled receptors that bind the neuropeptides orexin-A and orexin-B.  Dual antagonism of the receptors by small mols. is clin. efficacious in the treatment of insomnia, where the most advanced mol. suvorexant has recently been approved.  The scope of this article is to review the small mol. orexin receptor antagonist patent literature between Jan. 2012 and Jan. 2014.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopenQpzY9wD7Vg90H21EOLACvtfcHk0lgSNXY4asRDpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCrs7vF&md5=e5b05ee60ec2568410395bf20c26b588</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.4155%2Fppa.14.46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fppa.14.46%26sid%3Dliteratum%253Aachs%26aulast%3DChristopher%26aufirst%3DJ.%2BA.%26atitle%3DSmall-molecule%2520antagonists%2520of%2520the%2520orexin%2520receptors%26jtitle%3DPharm.%2520Pat.%2520Anal.%26date%3D2014%26volume%3D3%26spage%3D625%26epage%3D638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Bingham, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deehan, M. R.</span><span> </span><span class="NLM_article-title">Eating, sleeping and rewarding: Orexin receptors and their antagonists</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">–</span> <span class="NLM_lpage">559</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=551-559&author=M.+J.+Binghamauthor=J.+Caiauthor=M.+R.+Deehan&title=Eating%2C+sleeping+and+rewarding%3A+Orexin+receptors+and+their+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBingham%26aufirst%3DM.%2BJ.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DDeehan%26aufirst%3DM.%2BR.%26atitle%3DEating%252C%2520sleeping%2520and%2520rewarding%253A%2520Orexin%2520receptors%2520and%2520their%2520antagonists%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2006%26volume%3D9%26spage%3D551%26epage%3D559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Sakurai, T.</span><span> </span><span class="NLM_article-title">The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness</span> <span class="citation_source-journal">Nature Rev. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1038%2Fnrn2092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=17299454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=171-181&author=T.+Sakurai&title=The+neural+circuit+of+orexin+%28hypocretin%29%3A+maintaining+sleep+and+wakefulness"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness</span></div><div class="casAuthors">Sakurai, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-181</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Sleep and wakefulness are regulated to occur at appropriate times that are in accordance with our internal and external environments.  Avoiding danger and finding food, which are life-essential activities that are regulated by emotion, reward and energy balance, require vigilance and therefore, by definition, wakefulness.  The orexin (hypocretin) system regulates sleep and wakefulness through interactions with systems that regulate emotion, reward and energy homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopn63To7y5mLVg90H21EOLACvtfcHk0lj-gvWGSY0E2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyqu7s%253D&md5=8d3c4c98d3c725b34bc59bc455f44615</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrn2092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn2092%26sid%3Dliteratum%253Aachs%26aulast%3DSakurai%26aufirst%3DT.%26atitle%3DThe%2520neural%2520circuit%2520of%2520orexin%2520%2528hypocretin%2529%253A%2520maintaining%2520sleep%2520and%2520wakefulness%26jtitle%3DNature%2520Rev.%2520Neurosci.%26date%3D2007%26volume%3D8%26spage%3D171%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Hara, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beuckmann, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willie, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chemelli, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinton, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yagami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, T.</span><span> </span><span class="NLM_article-title">Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1016%2FS0896-6273%2801%2900293-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=11394998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktFeisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2001&pages=345-354&author=J.+Haraauthor=C.+T.+Beuckmannauthor=T.+Nambuauthor=J.+T.+Willieauthor=R.+M.+Chemelliauthor=C.+M.+Sintonauthor=F.+Sugiyamaauthor=K.+Yagamiauthor=K.+Gotoauthor=M.+Yanagisawaauthor=T.+Sakurai&title=Genetic+ablation+of+orexin+neurons+in+mice+results+in+narcolepsy%2C+hypophagia%2C+and+obesity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity</span></div><div class="casAuthors">Hara, Junko; Beuckmann, Carsten T.; Nambu, Tadahiro; Willie, Jon T.; Chemelli, Richard M.; Sinton, Christopher M.; Sugiyama, Fumihiro; Yagami, Ken-Ichi; Goto, Katsutoshi; Yanagisawa, Masashi; Sakurai, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">345-354</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Orexins (hypocretins) are a pair of neuropeptides implicated in energy homeostasis and arousal.  Recent reports suggest that loss of orexin-contg. neurons occurs in human patients with narcolepsy.  We generated transgenic mice in which orexin-contg. neurons are ablated by orexinergic-specific expression of a truncated Machado-Joseph disease gene product (ataxin-3) with an expanded polyglutamine stretch.  These mice showed a phenotype strikingly similar to human narcolepsy, including behavioral arrests, premature entry into rapid eye movement (REM) sleep, poorly consolidated sleep patterns, and a late-onset obesity, despite eating less than nontransgenic littermates.  These results provide evidence that orexin-contg. neurons play important roles in regulating vigilance states and energy homeostasis.  Orexin/ataxin-3 mice provide a valuable model for studying the pathophysiol. and treatment of narcolepsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW-IREBtcUCbVg90H21EOLACvtfcHk0lj-gvWGSY0E2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktFeisbc%253D&md5=5e30da52fb8a0446e7a1b5eb33e11e97</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0896-6273%2801%2900293-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0896-6273%252801%252900293-8%26sid%3Dliteratum%253Aachs%26aulast%3DHara%26aufirst%3DJ.%26aulast%3DBeuckmann%26aufirst%3DC.%2BT.%26aulast%3DNambu%26aufirst%3DT.%26aulast%3DWillie%26aufirst%3DJ.%2BT.%26aulast%3DChemelli%26aufirst%3DR.%2BM.%26aulast%3DSinton%26aufirst%3DC.%2BM.%26aulast%3DSugiyama%26aufirst%3DF.%26aulast%3DYagami%26aufirst%3DK.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DYanagisawa%26aufirst%3DM.%26aulast%3DSakurai%26aufirst%3DT.%26atitle%3DGenetic%2520ablation%2520of%2520orexin%2520neurons%2520in%2520mice%2520results%2520in%2520narcolepsy%252C%2520hypophagia%252C%2520and%2520obesity%26jtitle%3DNeuron%26date%3D2001%26volume%3D30%26spage%3D345%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Beuckmann, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinton, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammer, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, M.</span><span> </span><span class="NLM_article-title">Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy–cataplexy in the rat</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4469</span><span class="NLM_x">–</span> <span class="NLM_lpage">4477</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1523%2FJNEUROSCI.5560-03.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=15128861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktFCjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=4469-4477&author=C.+T.+Beuckmannauthor=C.+M.+Sintonauthor=S.+C.+Williamsauthor=J.+A.+Richardsonauthor=R.+E.+Hammerauthor=T.+Sakuraiauthor=M.+Yanagisawa&title=Expression+of+a+poly-glutamine-ataxin-3+transgene+in+orexin+neurons+induces+narcolepsy%E2%80%93cataplexy+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat</span></div><div class="casAuthors">Beuckmann, Carsten T.; Sinton, Christopher M.; Williams, S. Clay; Richardson, James A.; Hammer, Robert E.; Sakurai, Takeshi; Yanagisawa, Masashi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4469-4477</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The sleep disorder narcolepsy has been linked to loss of hypothalamic neurons producing the orexin (hypocretin) neuropeptides.  Here, we report the generation of transgenic rats expressing a human ataxin-3 fragment with an elongated polyglutamyl stretch under control of the human prepro-orexin promoter (orexin/ataxin-3 rats).  At 17 wk of age, the transgenic rats exhibited postnatal loss of orexin-pos. neurons in the lateral hypothalamus, and orexin-contg. projections were essentially undetectable.  The loss of orexin prodn. resulted in the expression of a phenotype with fragmented vigilance states, a decreased latency to rapid eye movement (REM) sleep and increased REM sleep time during the dark active phase.  Wakefulness time was also reduced during the dark phase, and this effect was concd. at the photoperiod boundaries.  Direct transitions from wakefulness to REM sleep, a defining characteristic of narcolepsy, occurred frequently.  Brief episodes of muscle atonia and postural collapse resembling cataplexy were also noted while rats maintained the electroencephalog. characteristics of wakefulness.  These findings indicate that the orexin/ataxin-3 transgenic rat could provide a useful model of human narcolepsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyrvMTyDBXMLVg90H21EOLACvtfcHk0ljkrvzedLDQEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktFCjtbo%253D&md5=43ccade5d2e22fe42afd9048084b30d9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.5560-03.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.5560-03.2004%26sid%3Dliteratum%253Aachs%26aulast%3DBeuckmann%26aufirst%3DC.%2BT.%26aulast%3DSinton%26aufirst%3DC.%2BM.%26aulast%3DWilliams%26aufirst%3DS.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BA.%26aulast%3DHammer%26aufirst%3DR.%2BE.%26aulast%3DSakurai%26aufirst%3DT.%26aulast%3DYanagisawa%26aufirst%3DM.%26atitle%3DExpression%2520of%2520a%2520poly-glutamine-ataxin-3%2520transgene%2520in%2520orexin%2520neurons%2520induces%2520narcolepsy%25E2%2580%2593cataplexy%2520in%2520the%2520rat%26jtitle%3DJ.%2520Neurosci.%26date%3D2004%26volume%3D24%26spage%3D4469%26epage%3D4477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Chemelli, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willie, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinton, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmquist, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammell, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisanuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitch, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakazato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammer, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saper, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, M.</span><span> </span><span class="NLM_article-title">Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1016%2FS0092-8674%2800%2981973-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10481909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADyaK1MXlslWmsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=1999&pages=437-451&author=R.+M.+Chemelliauthor=J.+T.+Willieauthor=C.+M.+Sintonauthor=J.+K.+Elmquistauthor=T.+Scammellauthor=C.+Leeauthor=J.+A.+Richardsonauthor=S.+C.+Williamsauthor=Y.+Xiongauthor=Y.+Kisanukiauthor=T.+E.+Fitchauthor=M.+Nakazatoauthor=R.+E.+Hammerauthor=C.+B.+Saperauthor=M.+Yanagisawa&title=Narcolepsy+in+orexin+knockout+mice%3A+molecular+genetics+of+sleep+regulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation</span></div><div class="casAuthors">Chemelli, Richard M.; Willie, Jon T.; Sinton, Christopher M.; Elmquist, Joel K.; Scammell, Thomas; Lee, Charlotte; Richardson, James A.; Williams, S. Clay; Xiong, Yumei; Kisanuki, Yaz; Fitch, Thomas E.; Nakazato, Masamitsu; Hammer, Robert E.; Saper, Clifford B.; Yanagisawa, Masashi</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">437-451</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Neurons contg. the neuropeptide orexin (hypocretin) are located exclusively in the lateral hypothalamus and send axons to numerous regions throughout the central nervous system, including the major nuclei implicated in sleep regulation.  Here, we report that, by behavioral and electroencephalog. criteria, orexin knockout mice exhibit a phenotype strikingly similar to human narcolepsy patients, as well as canarc-1 mutant dogs, the only known monogenic model of narcolepsy.  Moreover, modafinil, an anti-narcoleptic drug with ill-defined mechanisms of action, activates orexin-contg. neurons.  We propose that orexin regulates sleep/wakefulness states, and that orexin knockout mice are a model of human narcolepsy, a disorder characterized primarily by rapid eye movement (REM) sleep dysregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomTMUcvI3kgbVg90H21EOLACvtfcHk0ljkrvzedLDQEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlslWmsbo%253D&md5=71290ef78fe300cfe3c61b4f3fcf7e6f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981973-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981973-X%26sid%3Dliteratum%253Aachs%26aulast%3DChemelli%26aufirst%3DR.%2BM.%26aulast%3DWillie%26aufirst%3DJ.%2BT.%26aulast%3DSinton%26aufirst%3DC.%2BM.%26aulast%3DElmquist%26aufirst%3DJ.%2BK.%26aulast%3DScammell%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DRichardson%26aufirst%3DJ.%2BA.%26aulast%3DWilliams%26aufirst%3DS.%2BC.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DKisanuki%26aufirst%3DY.%26aulast%3DFitch%26aufirst%3DT.%2BE.%26aulast%3DNakazato%26aufirst%3DM.%26aulast%3DHammer%26aufirst%3DR.%2BE.%26aulast%3DSaper%26aufirst%3DC.%2BB.%26aulast%3DYanagisawa%26aufirst%3DM.%26atitle%3DNarcolepsy%2520in%2520orexin%2520knockout%2520mice%253A%2520molecular%2520genetics%2520of%2520sleep%2520regulation%26jtitle%3DCell%26date%3D1999%26volume%3D98%26spage%3D437%26epage%3D451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Willie, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chemelli, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinton, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisanuki, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcus, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmquist, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlmeier, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammer, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, M.</span><span> </span><span class="NLM_article-title">Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">715</span><span class="NLM_x">–</span> <span class="NLM_lpage">730</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1016%2FS0896-6273%2803%2900330-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=12797957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkslOls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=715-730&author=J.+T.+Willieauthor=R.+M.+Chemelliauthor=C.+M.+Sintonauthor=S.+Tokitaauthor=S.+C.+Williamsauthor=Y.+Y.+Kisanukiauthor=J.+N.+Marcusauthor=C.+Leeauthor=J.+K.+Elmquistauthor=K.+A.+Kohlmeierauthor=C.+S.+Leonardauthor=J.+A.+Richardsonauthor=R.+E.+Hammerauthor=M.+Yanagisawa&title=Distinct+narcolepsy+syndromes+in+Orexin+receptor-2+and+Orexin+null+mice%3A+molecular+genetic+dissection+of+non-REM+and+REM+sleep+regulatory+processes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: Molecular genetic dissection of non-REM and REM sleep regulatory processes</span></div><div class="casAuthors">Willie, Jon T.; Chemelli, Richard M.; Sinton, Christopher M.; Tokita, Shigeru; Williams, S. Clay; Kisanuki, Yaz Y.; Marcus, Jacob N.; Lee, Charlotte; Elmquist, Joel K.; Kohlmeier, Kristi A.; Leonard, Christopher S.; Richardson, James A.; Hammer, Robert E.; Yanagisawa, Masashi</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">715-730</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Narcolepsy-cataplexy, a neurol. disorder assocd. with the absence of hypothalamic orexin (hypocretin) neuropeptides, consists of two underlying problems: inability to maintain wakefulness and intrusion of rapid eye movement (REM) sleep into wakefulness.  Here the authors document, using behavioral, electrophysiol., and pharmacol. criteria, two distinct classes of behavioral arrests exhibited by mice deficient in orexin-mediated signaling.  Both OX2R-/- and orexin-/- mice are similarly affected with behaviorally abnormal attacks of non-REM sleep ("sleep attacks") and show similar degrees of disrupted wakefulness.  In contrast, OX2R-/- mice are only mildly affected with cataplexy-like attacks of REM sleep, whereas orexin-/- mice are severely affected.  Absence of OX2Rs eliminates orexin-evoked excitation of histaminergic neurons in the hypothalamus, which gate non-REM sleep onset.  While normal regulation of wake/non-REM sleep transitions depends critically upon OX2R activation, the profound dysregulation of REM sleep control unique to the narcolepsy-cataplexy syndrome emerges from loss of signaling through both OX2R-dependent and OX2R-independent pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0vge4IjIe2bVg90H21EOLACvtfcHk0ljkrvzedLDQEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkslOls74%253D&md5=0b63a1ad633b8688d182badead136898</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0896-6273%2803%2900330-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0896-6273%252803%252900330-1%26sid%3Dliteratum%253Aachs%26aulast%3DWillie%26aufirst%3DJ.%2BT.%26aulast%3DChemelli%26aufirst%3DR.%2BM.%26aulast%3DSinton%26aufirst%3DC.%2BM.%26aulast%3DTokita%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DS.%2BC.%26aulast%3DKisanuki%26aufirst%3DY.%2BY.%26aulast%3DMarcus%26aufirst%3DJ.%2BN.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DElmquist%26aufirst%3DJ.%2BK.%26aulast%3DKohlmeier%26aufirst%3DK.%2BA.%26aulast%3DLeonard%26aufirst%3DC.%2BS.%26aulast%3DRichardson%26aufirst%3DJ.%2BA.%26aulast%3DHammer%26aufirst%3DR.%2BE.%26aulast%3DYanagisawa%26aufirst%3DM.%26atitle%3DDistinct%2520narcolepsy%2520syndromes%2520in%2520Orexin%2520receptor-2%2520and%2520Orexin%2520null%2520mice%253A%2520molecular%2520genetic%2520dissection%2520of%2520non-REM%2520and%2520REM%2520sleep%2520regulatory%2520processes%26jtitle%3DNeuron%26date%3D2003%26volume%3D38%26spage%3D715%26epage%3D730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Thannickal, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, R. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nienhuis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulyani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldrich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornford, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, J. M.</span><span> </span><span class="NLM_article-title">Reduced number of hypocretin neurons in human narcolepsy</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">474</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2000&pages=469-474&author=T.+C.+Thannickalauthor=R.+Y.+Mooreauthor=R.+Nienhuisauthor=L.+Ramanathanauthor=S.+Gulyaniauthor=M.+Aldrichauthor=M.+Cornfordauthor=J.+M.+Siegel&title=Reduced+number+of+hypocretin+neurons+in+human+narcolepsy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThannickal%26aufirst%3DT.%2BC.%26aulast%3DMoore%26aufirst%3DR.%2BY.%26aulast%3DNienhuis%26aufirst%3DR.%26aulast%3DRamanathan%26aufirst%3DL.%26aulast%3DGulyani%26aufirst%3DS.%26aulast%3DAldrich%26aufirst%3DM.%26aulast%3DCornford%26aufirst%3DM.%26aulast%3DSiegel%26aufirst%3DJ.%2BM.%26atitle%3DReduced%2520number%2520of%2520hypocretin%2520neurons%2520in%2520human%2520narcolepsy%26jtitle%3DNeuron%26date%3D2000%26volume%3D27%26spage%3D469%26epage%3D474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Peyron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ripley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overeem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charnay, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevsimalova, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldrich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hungs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedrazzoli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padigaru, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kucherlapati, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lammers, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouras, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kucherlapati, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishino, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mignot, E.</span><span> </span><span class="NLM_article-title">A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains</span> <span class="citation_source-journal">Nature Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">991</span><span class="NLM_x">–</span> <span class="NLM_lpage">997</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=991-997&author=C.+Peyronauthor=J.+Faracoauthor=W.+Rogersauthor=B.+Ripleyauthor=S.+Overeemauthor=Y.+Charnayauthor=S.+Nevsimalovaauthor=M.+Aldrichauthor=D.+Reynoldsauthor=R.+Albinauthor=R.+Liauthor=M.+Hungsauthor=M.+Pedrazzoliauthor=M.+Padigaruauthor=M.+Kucherlapatiauthor=J.+Fanauthor=R.+Makiauthor=G.+J.+Lammersauthor=C.+Bourasauthor=R.+Kucherlapatiauthor=S.+Nishinoauthor=E.+Mignot&title=A+mutation+in+a+case+of+early+onset+narcolepsy+and+a+generalized+absence+of+hypocretin+peptides+in+human+narcoleptic+brains"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeyron%26aufirst%3DC.%26aulast%3DFaraco%26aufirst%3DJ.%26aulast%3DRogers%26aufirst%3DW.%26aulast%3DRipley%26aufirst%3DB.%26aulast%3DOvereem%26aufirst%3DS.%26aulast%3DCharnay%26aufirst%3DY.%26aulast%3DNevsimalova%26aufirst%3DS.%26aulast%3DAldrich%26aufirst%3DM.%26aulast%3DReynolds%26aufirst%3DD.%26aulast%3DAlbin%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DR.%26aulast%3DHungs%26aufirst%3DM.%26aulast%3DPedrazzoli%26aufirst%3DM.%26aulast%3DPadigaru%26aufirst%3DM.%26aulast%3DKucherlapati%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DMaki%26aufirst%3DR.%26aulast%3DLammers%26aufirst%3DG.%2BJ.%26aulast%3DBouras%26aufirst%3DC.%26aulast%3DKucherlapati%26aufirst%3DR.%26aulast%3DNishino%26aufirst%3DS.%26aulast%3DMignot%26aufirst%3DE.%26atitle%3DA%2520mutation%2520in%2520a%2520case%2520of%2520early%2520onset%2520narcolepsy%2520and%2520a%2520generalized%2520absence%2520of%2520hypocretin%2520peptides%2520in%2520human%2520narcoleptic%2520brains%26jtitle%3DNature%2520Med.%26date%3D2000%26volume%3D6%26spage%3D991%26epage%3D997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Nishino, S.</span><span> </span><span class="NLM_article-title">Chapter 47: Hypothalamus, hypocretins/orexin, and vigilance control</span> <span class="citation_source-journal">Handb. Clin. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">765</span><span class="NLM_x">–</span> <span class="NLM_lpage">782</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1016%2FB978-0-444-52007-4.00006-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=21056227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A280%3ADC%252BC3cblsVOgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2011&pages=765-782&author=S.+Nishino&title=Chapter+47%3A+Hypothalamus%2C+hypocretins%2Forexin%2C+and+vigilance+control"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Hypothalamus, hypocretins/orexin, and vigilance control</span></div><div class="casAuthors">Nishino Seiji</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of clinical neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">765-82</span>
        ISSN:<span class="NLM_cas:issn">0072-9752</span>.
    </div><div class="casAbstract">The hypothalamus has re-emerged as a key regulator of sleep and wakefulness, shifting the focus away from the brainstem and thalamocortical systems (ascending reticular activating systems).  Several new sleep control systems in the hypothalamus and their interaction with the circadian pacemaker in the suprachiasmatic nucleus have been identified recently.  More recently, deficiency of the hypothalamic peptide, hypocretin/orexin, has been found to be the major pathophysiological factor in human narcolepsy-cataplexy, the sleep disorder characterized by excessive daytime sleepiness and rapid eye movement sleep abnormalities.  The results from a series of experiments suggest that the hypocretin system is involved in the maintenance of wakefulness and stabilizes the vigilance states.  The hypocretin system also plays a role in the link between sleep and other fundamental hypothalamic functions, such as the regulation of food intake, metabolism, hormone release, and temperature.  Sleep deprivation is known to alter hormone release, increase body temperature, stimulate appetite, and activate the sympathetic nervous system.  Sleep control systems within the hypothalamus may therefore be closely integrated with homeostatic systems needed for survival.  In this chapter, the role of the hypothalamus in vigilance control is discussed, with a particular emphasis on the hypocretins/orexin system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQjXRjpDLSqHe-MdeMhXAHkfW6udTcc2eZ9Jq3ufJAxALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cblsVOgug%253D%253D&md5=e61c97a255da6ca31f3d0527ba707df4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FB978-0-444-52007-4.00006-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-444-52007-4.00006-0%26sid%3Dliteratum%253Aachs%26aulast%3DNishino%26aufirst%3DS.%26atitle%3DChapter%252047%253A%2520Hypothalamus%252C%2520hypocretins%252Forexin%252C%2520and%2520vigilance%2520control%26jtitle%3DHandb.%2520Clin.%2520Neurol.%26date%3D2011%26volume%3D99%26spage%3D765%26epage%3D782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Roecker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercer, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreier, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraley, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steen, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotter, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tannenbaum, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabalu, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stellabott, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winrow, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renger, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span> </span><span class="NLM_article-title">Discovery of 5″-chloro-<i>N</i>-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2′:5′,3″-terpyridine-3′-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">322</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=311-322&author=A.+J.+Roeckerauthor=S.+P.+Mercerauthor=J.+D.+Schreierauthor=C.+D.+Coxauthor=M.+E.+Fraleyauthor=J.+T.+Steenauthor=W.+Lemaireauthor=J.+G.+Brunoauthor=C.+M.+Harrellauthor=S.+L.+Garsonauthor=A.+L.+Gotterauthor=S.+V.+Foxauthor=J.+Stevensauthor=P.+L.+Tannenbaumauthor=T.+Prueksaritanontauthor=T.+D.+Cabaluauthor=D.+Cuiauthor=J.+Stellabottauthor=G.+D.+Hartmanauthor=S.+D.+Youngauthor=C.+J.+Winrowauthor=J.+J.+Rengerauthor=P.+J.+Coleman&title=Discovery+of+5%E2%80%B3-chloro-N-%5B%285%2C6-dimethoxypyridin-2-yl%29methyl%5D-2%2C2%E2%80%B2%3A5%E2%80%B2%2C3%E2%80%B3-terpyridine-3%E2%80%B2-carboxamide+%28MK-1064%29%3A+a+selective+orexin+2+receptor+antagonist+%282-SORA%29+for+the+treatment+of+insomnia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoecker%26aufirst%3DA.%2BJ.%26aulast%3DMercer%26aufirst%3DS.%2BP.%26aulast%3DSchreier%26aufirst%3DJ.%2BD.%26aulast%3DCox%26aufirst%3DC.%2BD.%26aulast%3DFraley%26aufirst%3DM.%2BE.%26aulast%3DSteen%26aufirst%3DJ.%2BT.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DBruno%26aufirst%3DJ.%2BG.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DGarson%26aufirst%3DS.%2BL.%26aulast%3DGotter%26aufirst%3DA.%2BL.%26aulast%3DFox%26aufirst%3DS.%2BV.%26aulast%3DStevens%26aufirst%3DJ.%26aulast%3DTannenbaum%26aufirst%3DP.%2BL.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DCabalu%26aufirst%3DT.%2BD.%26aulast%3DCui%26aufirst%3DD.%26aulast%3DStellabott%26aufirst%3DJ.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DYoung%26aufirst%3DS.%2BD.%26aulast%3DWinrow%26aufirst%3DC.%2BJ.%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%2520of%25205%25E2%2580%25B3-chloro-N-%255B%25285%252C6-dimethoxypyridin-2-yl%2529methyl%255D-2%252C2%25E2%2580%25B2%253A5%25E2%2580%25B2%252C3%25E2%2580%25B3-terpyridine-3%25E2%2580%25B2-carboxamide%2520%2528MK-1064%2529%253A%2520a%2520selective%2520orexin%25202%2520receptor%2520antagonist%2520%25282-SORA%2529%2520for%2520the%2520treatment%2520of%2520insomnia%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D311%26epage%3D322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Betschart, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hintermann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cotesta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gee, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laue, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ofner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhari, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badiger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandit, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoyer, D.</span><span> </span><span class="NLM_article-title">Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7590</span><span class="NLM_x">–</span> <span class="NLM_lpage">7607</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm4007627" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7590-7607&author=C.+Betschartauthor=S.+Hintermannauthor=D.+Behnkeauthor=S.+Cotestaauthor=M.+Fendtauthor=C.+E.+Geeauthor=L.+H.+Jacobsonauthor=G.+Laueauthor=S.+Ofnerauthor=V.+Chaudhariauthor=S.+Badigerauthor=C.+Panditauthor=J.+Wagnerauthor=D.+Hoyer&title=Identification+of+a+Novel+Series+of+Orexin+Receptor+Antagonists+with+a+Distinct+Effect+on+Sleep+Architecture+for+the+Treatment+of+Insomnia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm4007627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4007627%26sid%3Dliteratum%253Aachs%26aulast%3DBetschart%26aufirst%3DC.%26aulast%3DHintermann%26aufirst%3DS.%26aulast%3DBehnke%26aufirst%3DD.%26aulast%3DCotesta%26aufirst%3DS.%26aulast%3DFendt%26aufirst%3DM.%26aulast%3DGee%26aufirst%3DC.%2BE.%26aulast%3DJacobson%26aufirst%3DL.%2BH.%26aulast%3DLaue%26aufirst%3DG.%26aulast%3DOfner%26aufirst%3DS.%26aulast%3DChaudhari%26aufirst%3DV.%26aulast%3DBadiger%26aufirst%3DS.%26aulast%3DPandit%26aufirst%3DC.%26aulast%3DWagner%26aufirst%3DJ.%26aulast%3DHoyer%26aufirst%3DD.%26atitle%3DIdentification%2520of%2520a%2520Novel%2520Series%2520of%2520Orexin%2520Receptor%2520Antagonists%2520with%2520a%2520Distinct%2520Effect%2520on%2520Sleep%2520Architecture%2520for%2520the%2520Treatment%2520of%2520Insomnia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7590%26epage%3D7607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Morairty, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Revel, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malherbe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valladao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wettstein, J.G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilduff, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borroni, E.</span><span> </span><span class="NLM_article-title">Dual Hypocretin Receptor Antagonism Is More Effective for Sleep Promotion than Antagonism of Either Receptor Alone</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e39131</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1371%2Fjournal.pone.0039131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=22768296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvF2is74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e39131&author=S.+R.+Morairtyauthor=F.+G.+Revelauthor=P.+Malherbeauthor=J.-L.+Moreauauthor=D.+Valladaoauthor=J.G.+Wettsteinauthor=T.+S.+Kilduffauthor=E.+Borroni&title=Dual+Hypocretin+Receptor+Antagonism+Is+More+Effective+for+Sleep+Promotion+than+Antagonism+of+Either+Receptor+Alone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone</span></div><div class="casAuthors">Morairty, Stephen R.; Revel, Florent G.; Malherbe, Pari; Moreau, Jean-Luc; Valladao, Daniel; Wettstein, Joseph G.; Kilduff, Thomas S.; Borroni, Edilio</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e39131</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The hypocretin (orexin) system is involved in sleep/wake regulation, and antagonists of both hypocretin receptor type 1 (HCRTR1) and/or HCRTR2 are considered to be potential hypnotic medications.  It is currently unclear whether blockade of either or both receptors is more effective for promoting sleep with minimal side effects.  Accordingly, we compared the properties of selective HCRTR1 (SB-408124 and SB-334867) and HCRTR2 (EMPA) antagonists with that of the dual HCRTR1/R2 antagonist almorexant in the rat.  All 4 antagonists bound to their resp. receptors with high affinity and selectivity in vitro.  Since in vivo pharmacokinetic expts. revealed poor brain penetration for SB-408124, SB-334867 was selected for subsequent in vivo studies.  When injected in the mid-active phase, SB-334867 produced small increases in rapid-eye-movement (REM) and non-REM (NR) sleep.  EMPA produced a significant increase in NR only at the highest dose studied.  In contrast, almorexant decreased NR latency and increased both NR and REM proportionally throughout the subsequent 6 h without rebound wakefulness.  The increased NR was due to a greater no. of NR bouts; NR bout duration was unchanged.  At the highest dose tested (100 mg/kg), almorexant fragmented sleep architecture by increasing the no. of waking and REM bouts.  No evidence of cataplexy was obsd.  HCRTR1 occupancy by almorexant declined 4-6 h post-administration while HCRTR2 occupancy was still elevated after 12 h, revealing a complex relationship between occupancy of HCRT receptors and sleep promotion.  We conclude that dual HCRTR1/R2 blockade is more effective in promoting sleep than blockade of either HCRTR alone.  In contrast to GABA receptor agonists which induce sleep by generalized inhibition, HCRTR antagonists seem to facilitate sleep by reducing waking "drive".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojj3qSrI1XLrVg90H21EOLACvtfcHk0lg_LNxtXLNSCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvF2is74%253D&md5=f250e9f2430fe055cf189a7713c5e2ba</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0039131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0039131%26sid%3Dliteratum%253Aachs%26aulast%3DMorairty%26aufirst%3DS.%2BR.%26aulast%3DRevel%26aufirst%3DF.%2BG.%26aulast%3DMalherbe%26aufirst%3DP.%26aulast%3DMoreau%26aufirst%3DJ.-L.%26aulast%3DValladao%26aufirst%3DD.%26aulast%3DWettstein%26aufirst%3DJ.G.%26aulast%3DKilduff%26aufirst%3DT.%2BS.%26aulast%3DBorroni%26aufirst%3DE.%26atitle%3DDual%2520Hypocretin%2520Receptor%2520Antagonism%2520Is%2520More%2520Effective%2520for%2520Sleep%2520Promotion%2520than%2520Antagonism%2520of%2520Either%2520Receptor%2520Alone%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De39131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Dugovic, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alusio, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dvorak, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T. W.</span><span> </span><span class="NLM_article-title">Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">330</span><span class="NLM_x">, </span> <span class="NLM_fpage">142</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1124%2Fjpet.109.152009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=19363060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFeltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=142-151&author=C.+Dugovicauthor=J.+E.+Sheltonauthor=L.+E.+Alusioauthor=I.+C.+Fraserauthor=X.+Jiangauthor=S.+W.+Suttonauthor=P.+Bonaventureauthor=S.+Yunauthor=X.+Liauthor=B.+Lordauthor=C.+A.+Dvorakauthor=N.+I.+Carruthersauthor=T.+W.+Lovenberg&title=Blockade+of+orexin-1+receptors+attenuates+orexin-2+receptor+antagonism-induced+sleep+promotion+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat</span></div><div class="casAuthors">Dugovic, Christine; Shelton, Jonathan E.; Aluisio, Leah E.; Fraser, Ian C.; Jiang, Xiaohui; Sutton, Steven W.; Bonaventure, Pascal; Yun, Sujin; Li, Xiaorong; Lord, Brian; Dvorak, Curt A.; Carruthers, Nicholas I.; Lovenberg, Timothy W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">142-151</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Orexins are peptides produced by lateral hypothalamic neurons that exert a prominent role in the maintenance of wakefulness by activating orexin-1 (OX1R) and orexin-2 (OX2R) receptor located in wake-active structures.  Pharmacol. blockade of both receptors by the dual OX1/2R antagonist (2R)-2-[(1S)-6,7-dimethoxy-1-{2-[4-(trifluoromethyl)phenyl]ethyl}-3,4-dihydroisoquinolin-2(1H)-yl]-N-methyl-2-phenylethanamide (almorexant) has been shown to promote sleep in animals and humans during their active period.  However, the selective distribution of OX1R and OX2R in distinct neuronal circuits may result in a differential impact of these receptors in sleep-wake modulation.  The resp. role of OX1R and OX2R on sleep in correlation with monoamine release was evaluated in rats treated with selective antagonists alone or in combination.  When administered in either phase of the light/dark cycle, the OX2R antagonist 1-(2,4-dibromophenyl)-3-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]urea (JNJ-10397049) decreased the latency for persistent sleep and increased nonrapid eye movement and rapid eye movement sleep time.  Almorexant produced less hypnotic activity, whereas the OX1R antagonist 1-(6,8-difluoro-2-methylquinolin-4-yl)-3-[4-(dimethylamino)phenyl]urea (SB-408124) had no effect.  Microdialysis studies showed that either OX2R or OX1/2R antagonism decreased extracellular histamine concn. in the lateral hypothalamus, whereas both OX1R and OX1/2R antagonists increased dopamine release in the prefrontal cortex.  Finally, coadministration of the OX1R with the OX2R antagonist greatly attenuated the sleep-promoting effects of the OX2R antagonist.  These results indicate that blockade of OX2R is sufficient to initiate and prolong sleep, consistent with the hypothesis of a deactivation of the histaminergic system.  In addn., it is suggested that simultaneous inhibition of OX1R attenuates the sleep-promoting effects mediated by selective OX2R blockade, possibly correlated with dopaminergic neurotransmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPXVs02jXOYLVg90H21EOLACvtfcHk0lgg7yjG6BDtFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFeltLk%253D&md5=32a5fc48d949eef2a633187c274cec80</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.152009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.152009%26sid%3Dliteratum%253Aachs%26aulast%3DDugovic%26aufirst%3DC.%26aulast%3DShelton%26aufirst%3DJ.%2BE.%26aulast%3DAlusio%26aufirst%3DL.%2BE.%26aulast%3DFraser%26aufirst%3DI.%2BC.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DSutton%26aufirst%3DS.%2BW.%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DYun%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DDvorak%26aufirst%3DC.%2BA.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26aulast%3DLovenberg%26aufirst%3DT.%2BW.%26atitle%3DBlockade%2520of%2520orexin-1%2520receptors%2520attenuates%2520orexin-2%2520receptor%2520antagonism-induced%2520sleep%2520promotion%2520in%2520the%2520rat%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26spage%3D142%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Hoever, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoemaker, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiossi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gerven, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingemanse, J.</span><span> </span><span class="NLM_article-title">Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant</span> <span class="citation_source-journal">Clin. Pharmacol. Ther. (N. Y., NY, U. S.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">593</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1038%2Fclpt.2010.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=20376002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFCntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=593-600&author=P.+Hoeverauthor=S.+de+Haasauthor=J.+Winklerauthor=R.+C.+Schoemakerauthor=E.+Chiossiauthor=J.+van+Gervenauthor=J.+Dingemanse&title=Orexin+receptor+antagonism%2C+a+new+sleep-promoting+paradigm%3A+an+ascending+single-dose+study+with+almorexant"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Orexin Receptor Antagonism, a New Sleep-Promoting Paradigm: An Ascending Single-Dose Study With Almorexant</span></div><div class="casAuthors">Hoever, P.; de Haas, S.; Winkler, J.; Schoemaker, R. C.; Chiossi, E.; van Gerven, J.; Dingemanse, J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">593-600</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Almorexant, a dual orexin receptor antagonist potentially representing a new class of sleep-promoting compds., was administered in an ascending single-dose study to evaluate tolerability, pharmacokinetics, and pharmacodynamics.  Seventy healthy male subjects were enrolled in this double-blind, placebo- and active-controlled study.  Each dose level (1-1,000 mg) was investigated in a sep. group of 10 subjects (6 on almorexant, 2 on placebo, 2 on zolpidem 10 mg).  Almorexant was well tolerated with no signs of cataplexy.  Peak plasma concn. (Cmax) was quickly attained (median time to max. concn. (tmax) ranged from 0.7 to 2.3 h), and plasma concns. subsequently decreased quickly to ∼20% of Cmax over the course of 8 h.  Vigilance, alertness, and visuomotor and motor coordination were reduced following daytime administration of zolpidem or almorexant at doses of ≥400 mg.  Population pharmacokinetic/pharmacodynamic modeling suggested that doses of ∼500 mg almorexant and 10 mg zolpidem are equiv. with respect to subjectively assessed alertness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ9nYFrp8FEbVg90H21EOLACvtfcHk0lgg7yjG6BDtFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFCntLk%253D&md5=528965794ed9ae22a832f66b8047ed7b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2010.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2010.19%26sid%3Dliteratum%253Aachs%26aulast%3DHoever%26aufirst%3DP.%26aulast%3Dde%2BHaas%26aufirst%3DS.%26aulast%3DWinkler%26aufirst%3DJ.%26aulast%3DSchoemaker%26aufirst%3DR.%2BC.%26aulast%3DChiossi%26aufirst%3DE.%26aulast%3Dvan%2BGerven%26aufirst%3DJ.%26aulast%3DDingemanse%26aufirst%3DJ.%26atitle%3DOrexin%2520receptor%2520antagonism%252C%2520a%2520new%2520sleep-promoting%2520paradigm%253A%2520an%2520ascending%2520single-dose%2520study%2520with%2520almorexant%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2010%26volume%3D87%26spage%3D593%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Bettica, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nucci, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pyke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squassante, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamuner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomeni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, R.</span><span> </span><span class="NLM_article-title">Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist</span> <span class="citation_source-journal">J. Psychopharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1058</span><span class="NLM_x">–</span> <span class="NLM_lpage">1070</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1177%2F0269881111408954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=21730017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A280%3ADC%252BC38zkslGmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1058-1070&author=P.+Betticaauthor=G.+Nucciauthor=C.+Pykeauthor=L.+Squassanteauthor=S.+Zamunerauthor=E.+Rattiauthor=R.+Gomeniauthor=R.+Alexander&title=Phase+I+studies+on+the+safety%2C+tolerability%2C+pharmacokinetics+and+pharmacodynamics+of+SB-649868%2C+a+novel+dual+orexin+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist</span></div><div class="casAuthors">Bettica Paolo; Nucci Gianluca; Pyke Caroline; Squassante Lisa; Zamuner Stefano; Ratti Emiliangelo; Gomeni Roberto; Alexander Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychopharmacology (Oxford, England)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1058-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The orexin system plays a major role in the integration of metabolic and circadian influences that drive wakefulness.  This paper describes initial Phase I trials of a novel dual orexin receptor antagonist SB-649868 that has demonstrated preclinical potential for treatment of sleep disorders.  The trial designs included a single ascending dose escalation study (dose range: 10-80 mg in the fed and fasted states) and a multiple repeat dose study (dose range: 5-30 mg in the fed state) enrolling a total of 103 male volunteer subjects.  SB-649868 was well tolerated at all doses in this study population, with mechanism-related adverse events (e.g. somnolence and fatigue) observed in a majority of subjects after 60 and 80 mg single doses.  Although total drug exposure was similar in the fed and fasted states, the rate, but not the extent, of absorption increased in the fed state, resulting in an increased C(max).  The typical estimated half-life of SB-649868 was 3-6 h - comparable with currently used hypnotic agents.  Repeated administration of SB-649868 dose-dependently increased exposure to simvastatin (10 mg), suggesting CYP3A4 inhibition ranging from very mild (5 mg) to strong (30 mg).  Evening dosing resulted in significant dose-dependent improvement in latency to persistent sleep, total sleep time and wake after sleep onset as measured by polysomnography.  Next-morning testing did not detect evidence of residual cognitive effects.  Results of these trials support further investigation of SB-649868 and other dual orexin receptor antagonists as potentially effective and well-tolerated treatments for patients with sleep disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRpW1wEDRIs7INpW7w2tapOfW6udTcc2eYu0T_bP-vuI7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zkslGmsA%253D%253D&md5=5428764a9d43dc08ef56b4e5990e1c4d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1177%2F0269881111408954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881111408954%26sid%3Dliteratum%253Aachs%26aulast%3DBettica%26aufirst%3DP.%26aulast%3DNucci%26aufirst%3DG.%26aulast%3DPyke%26aufirst%3DC.%26aulast%3DSquassante%26aufirst%3DL.%26aulast%3DZamuner%26aufirst%3DS.%26aulast%3DRatti%26aufirst%3DE.%26aulast%3DGomeni%26aufirst%3DR.%26aulast%3DAlexander%26aufirst%3DR.%26atitle%3DPhase%2520I%2520studies%2520on%2520the%2520safety%252C%2520tolerability%252C%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520SB-649868%252C%2520a%2520novel%2520dual%2520orexin%2520receptor%2520antagonist%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2012%26volume%3D26%26spage%3D1058%26epage%3D1070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Winrow, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotter, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doran, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tannenbaum, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renger, J. J.</span><span> </span><span class="NLM_article-title">Promotion of sleep by suvorexant—a novel dual orexin receptor antagonist</span> <span class="citation_source-journal">J. Neurogenet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">52</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.3109%2F01677063.2011.566953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=21473737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVWlsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=52-61&author=C.+J.+Winrowauthor=A.+L.+Gotterauthor=C.+D.+Coxauthor=S.+M.+Doranauthor=P.+L.+Tannenbaumauthor=M.+J.+Breslinauthor=S.+L.+Garsonauthor=S.+V.+Foxauthor=C.+M.+Harrellauthor=J.+Stevensauthor=D.+R.+Reissauthor=D.+Cuiauthor=P.+J.+Colemanauthor=J.+J.+Renger&title=Promotion+of+sleep+by+suvorexant%E2%80%94a+novel+dual+orexin+receptor+antagonist"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Promotion of Sleep by Suvorexant--A Novel Dual Orexin Receptor Antagonist</span></div><div class="casAuthors">Winrow, Christopher J.; Gotter, Anthony L.; Cox, Christopher D.; Doran, Scott M.; Tannenbaum, Pamela L.; Breslin, Michael J.; Garson, Susan L.; Fox, Steven V.; Harrell, Charles M.; Stevens, Joanne; Reiss, Duane R.; Cui, Donghui; Coleman, Paul J.; Renger, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurogenetics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">52-61</span>CODEN:
                <span class="NLM_cas:coden">JLNEDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-7063</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Orexins/hypocretins are key neuropeptides responsible for regulating central arousal and reward circuits.  Two receptors respond to orexin signaling, orexin 1 receptor (OX1R) and orexin 2 receptor (OX2R) with partially overlapping nervous system distributions.  Genetic studies suggest orexin receptor antagonists could be therapeutic for insomnia and other disorders with disruptions of sleep and wake.  Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX1R and OX2R currently under clin. investigation as a novel therapy for insomnia.  Examn. of Suvorexant in radioligand binding assays using tissue from transgenic rats expressing the human OX2R found nearly full receptor occupancy (>90%) at plasma exposures of 1.1 μμM.  Dosed orally Suvorexant significantly and dose-dependently reduced locomotor activity and promoted sleep in rats (10, 30, and 100 mg/kg), dogs (1 and 3 mg/kg), and rhesus monkeys (10 mg/kg).  Consistent cross-species sleep/wake architecture changes produced by Suvorexant highlight a unique opportunity to develop dual orexin antagonists as a novel therapy for insomnia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN-4uWCwpZ8bVg90H21EOLACvtfcHk0ljNMbo0YjOr7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVWlsrg%253D&md5=ed9c4d09d1944557c41ca0c62d6e71a6</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3109%2F01677063.2011.566953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F01677063.2011.566953%26sid%3Dliteratum%253Aachs%26aulast%3DWinrow%26aufirst%3DC.%2BJ.%26aulast%3DGotter%26aufirst%3DA.%2BL.%26aulast%3DCox%26aufirst%3DC.%2BD.%26aulast%3DDoran%26aufirst%3DS.%2BM.%26aulast%3DTannenbaum%26aufirst%3DP.%2BL.%26aulast%3DBreslin%26aufirst%3DM.%2BJ.%26aulast%3DGarson%26aufirst%3DS.%2BL.%26aulast%3DFox%26aufirst%3DS.%2BV.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DStevens%26aufirst%3DJ.%26aulast%3DReiss%26aufirst%3DD.%2BR.%26aulast%3DCui%26aufirst%3DD.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26atitle%3DPromotion%2520of%2520sleep%2520by%2520suvorexant%25E2%2580%2594a%2520novel%2520dual%2520orexin%2520receptor%2520antagonist%26jtitle%3DJ.%2520Neurogenet.%26date%3D2011%26volume%3D25%26spage%3D52%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Cox, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitman, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreier, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGaughey, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogusky, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roecker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercer, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednar, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doran, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabalu, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koblan, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winrow, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renger, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coleman, P. J.</span><span> </span><span class="NLM_article-title">Discovery of the dual orexin receptor antagonist [(7<i>R</i>)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2<i>H</i>-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5320</span><span class="NLM_x">–</span> <span class="NLM_lpage">5332</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100541c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5320-5332&author=C.+D.+Coxauthor=M.+J.+Breslinauthor=D.+B.+Whitmanauthor=J.+D.+Schreierauthor=G.+B.+McGaugheyauthor=M.+J.+Boguskyauthor=A.+J.+Roeckerauthor=S.+P.+Mercerauthor=R.+A.+Bednarauthor=W.+Lemaireauthor=J.+G.+Brunoauthor=D.+R.+Reissauthor=C.+M.+Harrellauthor=K.+L.+Murphyauthor=S.+L.+Garsonauthor=S.+M.+Doranauthor=T.+Prueksaritanontauthor=W.+B.+Andersonauthor=C.+Tangauthor=S.+Rollerauthor=T.+D.+Cabaluauthor=D.+Cuiauthor=G.+D.+Hartmanauthor=S.+D.+Youngauthor=K.+S.+Koblanauthor=C.+J.+Winrowauthor=J.+J.+Rengerauthor=P.+J.+Coleman&title=Discovery+of+the+dual+orexin+receptor+antagonist+%5B%287R%29-4-%285-chloro-1%2C3-benzoxazol-2-yl%29-7-methyl-1%2C4-diazepan-1-yl%5D%5B5-methyl-2-%282H-1%2C2%2C3-triazol-2-yl%29phenyl%5Dmethanone+%28MK-4305%29+for+the+treatment+of+insomnia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm100541c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100541c%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DC.%2BD.%26aulast%3DBreslin%26aufirst%3DM.%2BJ.%26aulast%3DWhitman%26aufirst%3DD.%2BB.%26aulast%3DSchreier%26aufirst%3DJ.%2BD.%26aulast%3DMcGaughey%26aufirst%3DG.%2BB.%26aulast%3DBogusky%26aufirst%3DM.%2BJ.%26aulast%3DRoecker%26aufirst%3DA.%2BJ.%26aulast%3DMercer%26aufirst%3DS.%2BP.%26aulast%3DBednar%26aufirst%3DR.%2BA.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DBruno%26aufirst%3DJ.%2BG.%26aulast%3DReiss%26aufirst%3DD.%2BR.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DGarson%26aufirst%3DS.%2BL.%26aulast%3DDoran%26aufirst%3DS.%2BM.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DAnderson%26aufirst%3DW.%2BB.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DRoller%26aufirst%3DS.%26aulast%3DCabalu%26aufirst%3DT.%2BD.%26aulast%3DCui%26aufirst%3DD.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DYoung%26aufirst%3DS.%2BD.%26aulast%3DKoblan%26aufirst%3DK.%2BS.%26aulast%3DWinrow%26aufirst%3DC.%2BJ.%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%2520of%2520the%2520dual%2520orexin%2520receptor%2520antagonist%2520%255B%25287R%2529-4-%25285-chloro-1%252C3-benzoxazol-2-yl%2529-7-methyl-1%252C4-diazepan-1-yl%255D%255B5-methyl-2-%25282H-1%252C2%252C3-triazol-2-yl%2529phenyl%255Dmethanone%2520%2528MK-4305%2529%2520for%2520the%2520treatment%2520of%2520insomnia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5320%26epage%3D5332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Coleman, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreier, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitman, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogusky, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGaughey, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednar, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaire, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doran, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotter, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrell, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabalu, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tannenbaum, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stellabott, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winrow, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renger, J. J.</span><span> </span><span class="NLM_article-title">Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=415-424&author=P.+J.+Colemanauthor=J.+D.+Schreierauthor=C.+D.+Coxauthor=M.+J.+Breslinauthor=D.+B.+Whitmanauthor=M.+J.+Boguskyauthor=G.+B.+McGaugheyauthor=R.+A.+Bednarauthor=W.+Lemaireauthor=S.+M.+Doranauthor=S.+V.+Foxauthor=S.+L.+Garsonauthor=A.+L.+Gotterauthor=C.+M.+Harrellauthor=D.+R.+Reissauthor=T.+D.+Cabaluauthor=D.+Cuiauthor=T.+Prueksaritanontauthor=J.+Stevensauthor=P.+L.+Tannenbaumauthor=R.+G.+Ballauthor=J.+Stellabottauthor=S.+D.+Youngauthor=G.+D.+Hartmanauthor=C.+J.+Winrowauthor=J.+J.+Renger&title=Discovery+of+%5B%282R%2C5R%29-5-%7B%5B%285-fluoropyridin-2-yl%29oxy%5Dmethyl%7D-2-methylpiperidin-1-yl%5D%5B5-methyl-2-%28pyrimidin-2-yl%29phenyl%5Dmethanone+%28MK-6096%29%3A+a+dual+orexin+receptor+antagonist+with+potent+sleep-promoting+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DSchreier%26aufirst%3DJ.%2BD.%26aulast%3DCox%26aufirst%3DC.%2BD.%26aulast%3DBreslin%26aufirst%3DM.%2BJ.%26aulast%3DWhitman%26aufirst%3DD.%2BB.%26aulast%3DBogusky%26aufirst%3DM.%2BJ.%26aulast%3DMcGaughey%26aufirst%3DG.%2BB.%26aulast%3DBednar%26aufirst%3DR.%2BA.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DDoran%26aufirst%3DS.%2BM.%26aulast%3DFox%26aufirst%3DS.%2BV.%26aulast%3DGarson%26aufirst%3DS.%2BL.%26aulast%3DGotter%26aufirst%3DA.%2BL.%26aulast%3DHarrell%26aufirst%3DC.%2BM.%26aulast%3DReiss%26aufirst%3DD.%2BR.%26aulast%3DCabalu%26aufirst%3DT.%2BD.%26aulast%3DCui%26aufirst%3DD.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DStevens%26aufirst%3DJ.%26aulast%3DTannenbaum%26aufirst%3DP.%2BL.%26aulast%3DBall%26aufirst%3DR.%2BG.%26aulast%3DStellabott%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DS.%2BD.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DWinrow%26aufirst%3DC.%2BJ.%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26atitle%3DDiscovery%2520of%2520%255B%25282R%252C5R%2529-5-%257B%255B%25285-fluoropyridin-2-yl%2529oxy%255Dmethyl%257D-2-methylpiperidin-1-yl%255D%255B5-methyl-2-%2528pyrimidin-2-yl%2529phenyl%255Dmethanone%2520%2528MK-6096%2529%253A%2520a%2520dual%2520orexin%2520receptor%2520antagonist%2520with%2520potent%2520sleep-promoting%2520properties%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D415%26epage%3D424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Yoshida, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terauchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazuta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozaki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beuckmann, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kushida, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takenaka, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonaga, M.</span><span> </span><span class="NLM_article-title">Design, synthesis, and structure–activity relationships of a series of novel <i>N</i>-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">6071</span><span class="NLM_x">–</span> <span class="NLM_lpage">6088</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=6071-6088&author=Y.+Yoshidaauthor=T.+Terauchiauthor=Y.+Naoeauthor=Y.+Kazutaauthor=F.+Ozakiauthor=C.+T.+Beuckmannauthor=M.+Nakagawaauthor=M.+Suzukiauthor=I.+Kushidaauthor=O.+Takenakaauthor=T.+Uenoauthor=M.+Yonaga&title=Design%2C+synthesis%2C+and+structure%E2%80%93activity+relationships+of+a+series+of+novel+N-aryl-2-phenylcyclopropanecarboxamide+that+are+potent+and+orally+active+orexin+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DY.%26aulast%3DTerauchi%26aufirst%3DT.%26aulast%3DNaoe%26aufirst%3DY.%26aulast%3DKazuta%26aufirst%3DY.%26aulast%3DOzaki%26aufirst%3DF.%26aulast%3DBeuckmann%26aufirst%3DC.%2BT.%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DKushida%26aufirst%3DI.%26aulast%3DTakenaka%26aufirst%3DO.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DYonaga%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520a%2520series%2520of%2520novel%2520N-aryl-2-phenylcyclopropanecarboxamide%2520that%2520are%2520potent%2520and%2520orally%2520active%2520orexin%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D6071%26epage%3D6088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Shuto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hase, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamiyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, A.</span><span> </span><span class="NLM_article-title">Conformational restriction by repulsion between adjacent substituents on a cyclopropane ring: design and enantioselective synthesis of 1-phenyl-2-(1-aminoalkyl)-<i>N</i>,<i>N</i>-diethylcyclopropanecarboxamides as potent NMDA receptor antagonists</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">915</span><span class="NLM_x">–</span> <span class="NLM_lpage">923</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo9518056" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1996&pages=915-923&author=S.+Shutoauthor=S.+Onoauthor=Y.+Haseauthor=N.+Kamiyamaauthor=H.+Takadaauthor=K.+Yamashitaauthor=A.+Matsuda&title=Conformational+restriction+by+repulsion+between+adjacent+substituents+on+a+cyclopropane+ring%3A+design+and+enantioselective+synthesis+of+1-phenyl-2-%281-aminoalkyl%29-N%2CN-diethylcyclopropanecarboxamides+as+potent+NMDA+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjo9518056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo9518056%26sid%3Dliteratum%253Aachs%26aulast%3DShuto%26aufirst%3DS.%26aulast%3DOno%26aufirst%3DS.%26aulast%3DHase%26aufirst%3DY.%26aulast%3DKamiyama%26aufirst%3DN.%26aulast%3DTakada%26aufirst%3DH.%26aulast%3DYamashita%26aufirst%3DK.%26aulast%3DMatsuda%26aufirst%3DA.%26atitle%3DConformational%2520restriction%2520by%2520repulsion%2520between%2520adjacent%2520substituents%2520on%2520a%2520cyclopropane%2520ring%253A%2520design%2520and%2520enantioselective%2520synthesis%2520of%25201-phenyl-2-%25281-aminoalkyl%2529-N%252CN-diethylcyclopropanecarboxamides%2520as%2520potent%2520NMDA%2520receptor%2520antagonists%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1996%26volume%3D61%26spage%3D915%26epage%3D923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Zhao, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soglia, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frederick, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalgutkar, A. S.</span><span> </span><span class="NLM_article-title">NADPH-dependent covalent binding of [<sup>3</sup>H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1649</span><span class="NLM_x">–</span> <span class="NLM_lpage">1657</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx700132x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSkurrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=1649-1657&author=S.+X.+Zhaoauthor=D.+K.+Dalvieauthor=J.+M.+Kellyauthor=J.+R.+Sogliaauthor=K.+S.+Frederickauthor=E.+B.+Smithauthor=R.+S.+Obachauthor=A.+S.+Kalgutkar&title=NADPH-dependent+covalent+binding+of+%5B3H%5Dparoxetine+to+human+liver+microsomes+and+S-9+fractions%3A+identification+of+an+electrophilic+quinone+metabolite+of+paroxetine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">NADPH-Dependent Covalent Binding of [3H]Paroxetine to Human Liver Microsomes and S-9 Fractions: Identification of an Electrophilic Quinone Metabolite of Paroxetine</span></div><div class="casAuthors">Zhao, Sabrina X.; Dalvie, Deepak K.; Kelly, Joan M.; Soglia, John R.; Frederick, Kosea S.; Smith, Evan B.; Obach, R. Scott; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1649-1657</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The primary pathway of clearance of the methylenedioxyphenyl-contg. compd. and selective serotonin reuptake inhibitor paroxetine in humans involves P 450 2D6-mediated demethylenation to a catechol intermediate.  The process of demethylenation also results in the mechanism-based inactivation of the P 450 isoenzyme.  While the link between P 450 2D6 inactivation and pharmacokinetic interactions of paroxetine with P 450 2D6 substrates has been firmly established, there is a disconnect in terms of paroxetine's excellent safety record despite the potential for bioactivation.  In the present study, the authors have systematically assessed the NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 prepns. in the absence and presence of cofactors of the various phase II drug-metabolizing enzymes involved in the downstream metab./detoxification of the putative paroxetine-catechol intermediate.  Incubation of [3H]paroxetine with human liver microsomes and S-9 prepns. resulted in irreversible binding of radioactive material to macromols. by a process that was NADPH-dependent.  The addn. of reduced glutathione (GSH) to the microsomal and S-9 incubations resulted in a dramatic redn. of covalent binding.  Following incubations with NADPH- and GSH-supplemented human liver microsomes and S-9, three sulfhydryl conjugates with MH+ ions at 623 Da (GS1), 779 Da (GS2), and 928 Da (GS3), resp., were detected by LC-MS/MS.  The collision-induced dissocn. spectra allowed an insight into the structure of the GSH conjugates, based on which, bioactivation pathways were proposed.  The formation of GS1 was consistent with Michael addn. of GSH to the quinone derived from two-electron oxidn. of paroxetine-catechol.  GS3 was formed by the addn. of a second mol. of GSH to the quinone species obtained via the two-electron oxidn. of GS1.  The mechanism of formation of GS2 can be rationalized via (i) further two-electron oxidn. of the catechol motif in GS3 to the ortho-quinone, (ii) loss of a glutamic acid residue from one of the adducted GSH mols., and (iii) condensation of a cysteine-NH2 with an adjacent carbonyl of the ortho-quinone to yield an ortho-benzoquinoneimine structure.  Inclusion of the catechol-O-methyltransferase cofactor S-adenosylmethionine (SAM) in S-9 incubations also dramatically reduced the covalent binding of [3H]paroxetine, a finding that was consistent with O-methylation of the paroxetine-catechol metabolite to the corresponding guaiacol regioisomers in S-9 incubations.  While the NADPH-dependent covalent binding was attenuated by GSH and SAM, these reagents did not alter paroxetine's ability to inactivate P 450 2D6, suggesting that the reactive intermediate responsible for P 450 inactivation did not leave the active site to react with other proteins.  The results of the studies indicate that in addn. to the low once-a-day dosing regimen (20 mg) of paroxetine, efficient scavenging of the catechol and quinone metabolites by SAM and GSH, resp., serves as an explanation for the excellent safety record of paroxetine despite the fact that it undergoes bioactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOXUHMcbZnN7Vg90H21EOLACvtfcHk0lh29Ju_GP4QlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSkurrK&md5=e7d3aa749a419cc87340271eb9b839a0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Ftx700132x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700132x%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DS.%2BX.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DKelly%26aufirst%3DJ.%2BM.%26aulast%3DSoglia%26aufirst%3DJ.%2BR.%26aulast%3DFrederick%26aufirst%3DK.%2BS.%26aulast%3DSmith%26aufirst%3DE.%2BB.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DNADPH-dependent%2520covalent%2520binding%2520of%2520%255B3H%255Dparoxetine%2520to%2520human%2520liver%2520microsomes%2520and%2520S-9%2520fractions%253A%2520identification%2520of%2520an%2520electrophilic%2520quinone%2520metabolite%2520of%2520paroxetine%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2007%26volume%3D20%26spage%3D1649%26epage%3D1657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Takashi, Y.; Toru, A.</span><span> </span><span class="NLM_article-title">hERG Channel-Expressing Cell</span>. U.S. Patent 7,935,526 B2,<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=Y.+Takashi&author=A.+Toru&title=hERG+Channel-Expressing+Cell"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTakashi%26aufirst%3DY.%26atitle%3DhERG%2520Channel-Expressing%2520Cell%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Mieda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasegawa, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisanuki, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinton, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagisawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, T.</span><span> </span><span class="NLM_article-title">Differential Roles of Orexin Receptor-1 and -2 in the Regulation of non-REM and REM Sleep</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">6518</span><span class="NLM_x">–</span> <span class="NLM_lpage">6526</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1523%2FJNEUROSCI.6506-10.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=21525292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Oltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=6518-6526&author=M.+Miedaauthor=E.+Hasegawaauthor=Y.+Y.+Kisanukiauthor=M.+C.+Sintonauthor=M.+Yanagisawaauthor=T.+Sakurai&title=Differential+Roles+of+Orexin+Receptor-1+and+-2+in+the+Regulation+of+non-REM+and+REM+Sleep"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep</span></div><div class="casAuthors">Mieda, Michihiro; Hasegawa, Emi; Kisanuki, Yaz Y.; Sinton, Christopher M.; Yanagisawa, Masashi; Sakurai, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6518-6526</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Orexin-A and orexin-B are hypothalamic neuropeptides that play crit. roles in the maintenance of wakefulness.  Intracerebroventricular (ICV) administration of orexin-A has been shown to promote wakefulness and suppress both rapid eye movement (REM) sleep and non-REM (NREM) sleep through the orexin receptor-1 (OX1R) and orexin receptor-2 (OX2R).  Here, we elucidated the differential roles of orexin receptors in the regulation of sleep and wakefulness by comparing the effects of ICV orexin-A administration in wild-type, OX1R-/-, and OX2R-/- mice.  The effects of orexin-A on wakefulness and NREM sleep were significantly attenuated in both knock-out mice as compared with wild-type mice, with substantially larger attenuation in OX2R-/- mice than in OX1R-/- mice.  These results suggest that although the OX2R-mediated pathway has a pivotal role in the promotion of wakefulness, OX1R also plays addnl. roles in promoting arousal.  In contrast, suppression of REM sleep by orexin-A administration was slightly and similarly attenuated in both OX1R-/- and OX2R-/- mice, suggesting a comparable contribution of the two receptors to REM sleep suppression.  Histol. studies demonstrated differential distributions of each receptor subtype in distinct neuronal populations with specific neurotransmitter identities in brainstem cholinergic/monoaminergic neurons.  In the laterodorsal tegmental and pedunculopontine tegmental nuclei esp., cholinergic neurons exclusively expressed OX1R mRNA, but OX2R mRNA was expressed mainly in GABAergic putative interneurons.  Thus, each orexin receptor subtype plays differential roles in gating NREM and REM sleep through distinct neuronal pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH-GjaYHZNmLVg90H21EOLACvtfcHk0li5jYH7lOPwUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Oltrs%253D&md5=e0892147bb9e9380cc4cc13a6708746c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.6506-10.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.6506-10.2011%26sid%3Dliteratum%253Aachs%26aulast%3DMieda%26aufirst%3DM.%26aulast%3DHasegawa%26aufirst%3DE.%26aulast%3DKisanuki%26aufirst%3DY.%2BY.%26aulast%3DSinton%26aufirst%3DM.%2BC.%26aulast%3DYanagisawa%26aufirst%3DM.%26aulast%3DSakurai%26aufirst%3DT.%26atitle%3DDifferential%2520Roles%2520of%2520Orexin%2520Receptor-1%2520and%2520-2%2520in%2520the%2520Regulation%2520of%2520non-REM%2520and%2520REM%2520Sleep%26jtitle%3DJ.%2520Neurosci.%26date%3D2011%26volume%3D31%26spage%3D6518%26epage%3D6526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Bonaventure, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonson, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shekhar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitz, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shireman, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebold, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nepomuceno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wnnerholm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugovic, C.</span><span> </span><span class="NLM_article-title">A Selective Origin-1 Receptor Antagonist Attenuates Stress-Induced Hyperarousal without Hypnotic Effects</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">590</span><span class="NLM_x">–</span> <span class="NLM_lpage">601</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.1124%2Fjpet.114.220392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=25583879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Omuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=590-601&author=P.+Bonaventureauthor=S.+Yunauthor=P.+L.+Jonsonauthor=A.+Shekharauthor=S.+D.+Fitzauthor=B.+T.+Shiremanauthor=T.+P.+Leboldauthor=D.+Nepomucenoauthor=B.+Lordauthor=M.+Wnnerholmauthor=J.+Sheltonauthor=N.+Carruthersauthor=T.+Lovenbergauthor=C.+Dugovic&title=A+Selective+Origin-1+Receptor+Antagonist+Attenuates+Stress-Induced+Hyperarousal+without+Hypnotic+Effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects</span></div><div class="casAuthors">Bonaventure, Pascal; Yun, Sujin; Johnson, Philip L.; Shekhar, Anantha; Fitz, Stephanie D.; Shireman, Brock T.; Lebold, Terry P.; Nepomuceno, Diane; Lord, Brian; Wennerholm, Michelle; Shelton, Jonathan; Carruthers, Nicholas; Lovenberg, Timothy; Dugovic, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">590-601, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Orexins (OXs) are peptides produced by perifornical (PeF) and lateral hypothalamic neurons that exert a prominent role in arousal-related processes, including stress.  A crit. role for the orexin-1 receptor (OX1R) in complex emotional behavior is emerging, such as overactivation of the OX1R pathway being assocd. with panic or anxiety states.  Here we characterize a brain-penetrant, selective, and high-affinity OX1R antagonist, compd. 56 [N-({3-[(3-ethoxy-6-methylpyridin-2-yl)carbonyl]-3-azabicyclo[4.1.0]hept-4-yl}methyl)-5-(trifluoromethyl)pyrimidin-2-amine].  Ex vivo receptor binding studies demonstrated that, after s.c. administration, compd. 56 crossed the blood-brain barrier and occupied OX1Rs in the rat brain at lower doses than std. OX1R antagonists GSK-1059865 [5-bromo-N-({1-[(3-fluoro-2-methoxyphenyl)carbonyl]-5-methylpiperidin-2-yl}methyl)pyridin-2-amine], SB-334867 [1-(2-methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea], and SB-408124 [1-(6,8-difluoro-2-methylquinolin-4-yl)-3-[4-(dimethylamino)phenyl]urea].  Although compd. 56 did not alter spontaneous sleep in rats and in wild-type mice, its administration in orexin-2 receptor knockout mice selectively promoted rapid eye movement sleep, demonstrating target engagement and specific OX1R blockade.  In a rat model of psychol. stress induced by cage exchange, the OX1R antagonist prevented the prolongation of sleep onset without affecting sleep duration.  In a rat model of panic vulnerability (involving disinhibition of the PeF OX region) to threatening internal state changes (i.e., i.v. sodium lactate infusion), compd. 56 attenuated sodium lactate-induced panic-like behaviors and cardiovascular responses without altering baseline locomotor or autonomic activity.  In conclusion, OX1R antagonism represents a novel therapeutic strategy for the treatment of various psychiatric disorders assocd. with stress or hyperarousal states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobTtYJtwsEh7Vg90H21EOLACvtfcHk0lhDAvK8jPhEWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Omuro%253D&md5=0793591a77a5bf93b9e448cb1381da2a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220392%26sid%3Dliteratum%253Aachs%26aulast%3DBonaventure%26aufirst%3DP.%26aulast%3DYun%26aufirst%3DS.%26aulast%3DJonson%26aufirst%3DP.%2BL.%26aulast%3DShekhar%26aufirst%3DA.%26aulast%3DFitz%26aufirst%3DS.%2BD.%26aulast%3DShireman%26aufirst%3DB.%2BT.%26aulast%3DLebold%26aufirst%3DT.%2BP.%26aulast%3DNepomuceno%26aufirst%3DD.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DWnnerholm%26aufirst%3DM.%26aulast%3DShelton%26aufirst%3DJ.%26aulast%3DCarruthers%26aufirst%3DN.%26aulast%3DLovenberg%26aufirst%3DT.%26aulast%3DDugovic%26aufirst%3DC.%26atitle%3DA%2520Selective%2520Origin-1%2520Receptor%2520Antagonist%2520Attenuates%2520Stress-Induced%2520Hyperarousal%2520without%2520Hypnotic%2520Effects%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D590%26epage%3D601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Etori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujino, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakurai, T.</span><span> </span><span class="NLM_article-title">Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice</span> <span class="citation_source-journal">Front. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=10.3389%2Ffnins.2014.00008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=24550770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;key=1%3ACAS%3A280%3ADC%252BC2cvmt1ynuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=8&author=K.+Etoriauthor=C.+Y.+Saitoauthor=N.+Tsujinoauthor=T.+Sakurai&title=Effects+of+a+newly+developed+potent+orexin-2+receptor-selective+antagonist%2C+compound+1+m%2C+on+sleep%2Fwakefulness+states+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice</span></div><div class="casAuthors">Etori Keishi; Saito Yuki C; Tsujino Natsuko; Sakurai Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">Orexins (also known as hypocretins) play critical roles in the regulation of sleep/wakefulness states by activating two G-protein coupled receptors (GPCRs), orexin 1 (OX1R) and orexin 2 receptors (OX2R).  In order to understand the differential contribution of both receptors in regulating sleep/wakefulness states we compared the pharmacological effects of a newly developed OX2R antagonist (2-SORA), Compound 1 m (C1 m), with those of a dual orexin receptor antagonist (DORA), suvorexant, in C57BL/6J mice.  After oral administration in the dark period, both C1m and suvorexant decreased wakefulness time with similar efficacy in a dose-dependent manner.  While C1m primarily increased total non-rapid eye movement (NREM) sleep time without affecting episode durations and with minimal effects on REM sleep, suvorexant increased both total NREM and REM sleep time and episode durations with predominant effects on REM sleep.  Fos-immunostaining showed that both compounds affected the activities of arousal-related neurons with different patterns.  The number of Fos-IR noradrenergic neurons in the locus coeruleus was lower in the suvorexant group as compared with the control and C1m-treated groups.  In contrast, the numbers of Fos-IR neurons in histaminergic neurons in the tuberomamillary nucleus and serotonergic neurons in the dorsal raphe were reduced to a similar extent in the suvorexant and C1m groups as compared with the vehicle-treated group.  Together, these results suggest that an orexin-mediated suppression of REM sleep via potential activation of OX1Rs in the locus coeruleus may possibly contribute to the differential effects on sleep/wakefulness exerted by a DORA as compared to a 2-SORA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQakzy_Ia1EjwaK-_ZudimnfW6udTcc2eZ4xu2u1vho6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvmt1ynuw%253D%253D&md5=d7bc4732cd4e8c93eaf65b7bd4a9a84e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2014.00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2014.00008%26sid%3Dliteratum%253Aachs%26aulast%3DEtori%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DC.%2BY.%26aulast%3DTsujino%26aufirst%3DN.%26aulast%3DSakurai%26aufirst%3DT.%26atitle%3DEffects%2520of%2520a%2520newly%2520developed%2520potent%2520orexin-2%2520receptor-selective%2520antagonist%252C%2520compound%25201%2520m%252C%2520on%2520sleep%252Fwakefulness%2520states%2520in%2520mice%26jtitle%3DFront.%2520Neurosci.%26date%3D2014%26volume%3D8%26spage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Mori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takatsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuda-Tsukimoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kume, T.</span><span> </span><span class="NLM_article-title">Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2009&pages=415-422&author=K.+Moriauthor=H.+Hashimotoauthor=H.+Takatsuauthor=M.+Tsuda-Tsukimotoauthor=T.+Kume&title=Cocktail-substrate+assay+system+for+mechanism-based+inhibition+of+CYP2C9%2C+CYP2D6%2C+and+CYP3A+using+human+liver+microsomes+at+an+early+stage+of+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DK.%26aulast%3DHashimoto%26aufirst%3DH.%26aulast%3DTakatsu%26aufirst%3DH.%26aulast%3DTsuda-Tsukimoto%26aufirst%3DM.%26aulast%3DKume%26aufirst%3DT.%26atitle%3DCocktail-substrate%2520assay%2520system%2520for%2520mechanism-based%2520inhibition%2520of%2520CYP2C9%252C%2520CYP2D6%252C%2520and%2520CYP3A%2520using%2520human%2520liver%2520microsomes%2520at%2520an%2520early%2520stage%2520of%2520drug%2520development%26jtitle%3DXenobiotica%26date%3D2009%26volume%3D39%26spage%3D415%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i74"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00217">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_62416"></div></div></div></div></div><hr /></hr><p class="last">Synthesis and analytical data of all compounds and intermediates not described in the <a class="ref internalNav" href="#sec3">Experimental Section</a>. The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b00217">10.1021/acs.jmedchem.5b00217</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00217/suppl_file/jm5b00217_si_001.pdf">jm5b00217_si_001.pdf (815.64 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-11%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b00217%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b00217" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799abaff9c83c04","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
